US4419340A
(en)
*
|
1969-03-24 |
1983-12-06 |
University Of Delaware |
Controlled release of anticancer agents from biodegradable polymers
|
US3993073A
(en)
*
|
1969-04-01 |
1976-11-23 |
Alza Corporation |
Novel drug delivery device
|
US3981303A
(en)
*
|
1971-09-09 |
1976-09-21 |
Alza Corporation |
Bioerodible ocular device
|
US3986510A
(en)
*
|
1971-09-09 |
1976-10-19 |
Alza Corporation |
Bioerodible ocular device
|
US3993071A
(en)
*
|
1971-09-09 |
1976-11-23 |
Alza Corporation |
Bioerodible ocular device
|
US3960150A
(en)
*
|
1971-09-09 |
1976-06-01 |
Alza Corporation |
Bioerodible ocular device
|
BE793246A
(fr)
*
|
1971-12-30 |
1973-06-22 |
Xerox Corp |
Procede d'encapsulation
|
US3962414A
(en)
*
|
1972-04-27 |
1976-06-08 |
Alza Corporation |
Structured bioerodible drug delivery device
|
US4351337A
(en)
*
|
1973-05-17 |
1982-09-28 |
Arthur D. Little, Inc. |
Biodegradable, implantable drug delivery device, and process for preparing and using the same
|
US3991766A
(en)
*
|
1973-05-31 |
1976-11-16 |
American Cyanamid Company |
Controlled release of medicaments using polymers from glycolic acid
|
US4001388A
(en)
*
|
1973-06-14 |
1977-01-04 |
Alza Corporation |
Ophthalmological bioerodible drug dispensing formulation
|
US3914402A
(en)
*
|
1973-06-14 |
1975-10-21 |
Alza Corp |
Ophthalmic dosage form, for releasing medication over time
|
US3976071A
(en)
*
|
1974-01-07 |
1976-08-24 |
Dynatech Corporation |
Methods of improving control of release rates and products useful in same
|
US4054138A
(en)
*
|
1974-12-30 |
1977-10-18 |
Louis Bucalo |
Implants for acting on living beings
|
US3982537A
(en)
*
|
1974-12-30 |
1976-09-28 |
Louis Bucalo |
Dynamic implants and method for implanting the same
|
US4076798A
(en)
*
|
1975-05-29 |
1978-02-28 |
American Cyanamid Company |
High molecular weight polyester resin, the method of making the same and the use thereof as a pharmaceutical composition
|
US4011312A
(en)
*
|
1975-06-25 |
1977-03-08 |
American Home Products Corporation |
Prolonged release drug form for the treatment of bovine mastitis
|
US4115544A
(en)
*
|
1976-08-18 |
1978-09-19 |
Alza Corporation |
Ocular system made of bioerodible esters having linear ether
|
HU174057B
(hu)
*
|
1976-09-17 |
1979-10-28 |
Richter Gedeon Vegyeszet |
Sostav dlja pokrytij obespechivajuhhij uregulirovannuju otdachy aktivnogo vehhestva biologicheski aktivnykh preparatov i sposob poluchenija takikh preparatov s uregulirovannoj otdachej aktivnogo vehhestva
|
US4328204A
(en)
*
|
1977-03-02 |
1982-05-04 |
Ethicon, Inc. |
Absorbable polymer-drug compounds and method for making same
|
WO1978000011A1
(en)
*
|
1977-06-07 |
1978-12-21 |
Garching Instrumente |
Form of implant medicament and preparation process
|
CH644768A5
(de)
*
|
1977-08-25 |
1984-08-31 |
Sandoz Ag |
Verfahren zur herstellung von mikrokugeln.
|
US4186189A
(en)
*
|
1977-09-28 |
1980-01-29 |
Ethicon, Inc. |
Absorbable pharmaceutical compositions based on poly(alkylene oxalates)
|
US4148871A
(en)
*
|
1977-10-11 |
1979-04-10 |
Pitt Colin G |
Sustained subdermal delivery ofdrugs using poly(ε-caprolactone) and its copolymers
|
DE2843963A1
(de)
*
|
1978-10-09 |
1980-04-24 |
Merck Patent Gmbh |
Im koerper resorbierbare geformte masse auf basis von kollagen und ihre verwendung in der medizin
|
US4159322A
(en)
*
|
1978-06-26 |
1979-06-26 |
A. H. Robins Company, Inc. |
Anticoccidium implants
|
GB2026862A
(en)
*
|
1978-08-04 |
1980-02-13 |
Robins Co Inc A H |
Filaricide implants containing diethylcarbamazine
|
US4272398A
(en)
*
|
1978-08-17 |
1981-06-09 |
The United States Of America As Represented By The Secretary Of Agriculture |
Microencapsulation process
|
CA1143289A
(en)
*
|
1978-10-17 |
1983-03-22 |
Lee R. Beck |
Microparticle drug delivery system
|
US4585651A
(en)
*
|
1978-10-17 |
1986-04-29 |
Stolle Research & Development Corporation |
Active/passive immunization of the internal female reproductive organs
|
US4732763A
(en)
*
|
1978-10-17 |
1988-03-22 |
Stolle Research And Development Corporation |
Active/passive immunization of the internal female reproductive organs
|
US4622244A
(en)
*
|
1979-09-04 |
1986-11-11 |
The Washington University |
Process for preparation of microcapsules
|
US4333919A
(en)
*
|
1979-09-12 |
1982-06-08 |
Eli Lilly And Company |
Growth promotant controlled release formulations and method of treatment
|
NZ194900A
(en)
*
|
1979-09-12 |
1983-04-12 |
Lilly Co Eli |
Controlled release growth promoting formulations
|
US4273920A
(en)
*
|
1979-09-12 |
1981-06-16 |
Eli Lilly And Company |
Polymerization process and product
|
US4293539A
(en)
*
|
1979-09-12 |
1981-10-06 |
Eli Lilly And Company |
Controlled release formulations and method of treatment
|
AU539868B2
(en)
*
|
1979-09-12 |
1984-10-18 |
Eli Lilly And Company |
Device for drug delivery to ruminants
|
US4331652A
(en)
*
|
1979-09-12 |
1982-05-25 |
Eli Lilly And Company |
Controlled release parasitic formulations and method
|
US4384975A
(en)
*
|
1980-06-13 |
1983-05-24 |
Sandoz, Inc. |
Process for preparation of microspheres
|
US4389330A
(en)
*
|
1980-10-06 |
1983-06-21 |
Stolle Research And Development Corporation |
Microencapsulation process
|
US4675189A
(en)
*
|
1980-11-18 |
1987-06-23 |
Syntex (U.S.A.) Inc. |
Microencapsulation of water soluble active polypeptides
|
PH19942A
(en)
*
|
1980-11-18 |
1986-08-14 |
Sintex Inc |
Microencapsulation of water soluble polypeptides
|
DE3045135A1
(de)
*
|
1980-11-29 |
1982-06-09 |
Sandoz-Patent-GmbH, 7850 Lörrach |
Pharmazeutische kompositionen enthaltende bioabbaubare polymere
|
GB2091554B
(en)
*
|
1981-01-13 |
1984-09-12 |
Mitsui Toatsu Chemicals |
Rod like moulded drug
|
US5366734A
(en)
*
|
1981-02-16 |
1994-11-22 |
Zeneca Limited |
Continuous release pharmaceutical compositions
|
IE52535B1
(en)
*
|
1981-02-16 |
1987-12-09 |
Ici Plc |
Continuous release pharmaceutical compositions
|
DE3360633D1
(en)
*
|
1982-02-12 |
1985-10-03 |
Unitika Ltd |
Anti-cancer device
|
WO1983003061A1
(en)
*
|
1982-03-04 |
1983-09-15 |
Battelle Development Corp |
Dual microcapsules
|
US4532123A
(en)
*
|
1982-03-04 |
1985-07-30 |
Battelle Development Corporation |
Dual Microcapsules and process for their preparation
|
US4637905A
(en)
*
|
1982-03-04 |
1987-01-20 |
Batelle Development Corporation |
Process of preparing microcapsules of lactides or lactide copolymers with glycolides and/or ε-caprolactones
|
DE3378250D1
(en)
*
|
1982-04-22 |
1988-11-24 |
Ici Plc |
Continuous release formulations
|
US5248700A
(en)
*
|
1982-05-14 |
1993-09-28 |
Akzo Nv |
Active agent containing solid structures for prolonged release of active agents
|
DE3218151A1
(de)
*
|
1982-05-14 |
1983-11-17 |
Akzo Gmbh, 5600 Wuppertal |
Mikroporoese, pulverfoermige polylactide und verfahren zu deren herstellung
|
DE3218150C2
(de)
*
|
1982-05-14 |
1986-09-25 |
Akzo Gmbh, 5600 Wuppertal |
Wirkstoff enthaltender Körper für die Langzeitabgabe sowie Verfahren zu dessen Herstellung
|
US4530840A
(en)
*
|
1982-07-29 |
1985-07-23 |
The Stolle Research And Development Corporation |
Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
|
AT382076B
(de)
*
|
1982-10-15 |
1987-01-12 |
Chemie Linz Ag |
Verfahren zur herstellung von presslingen mit retardierter wirkstofffreisetzung
|
US4523591A
(en)
*
|
1982-10-22 |
1985-06-18 |
Kaplan Donald S |
Polymers for injection molding of absorbable surgical devices
|
US4539981A
(en)
*
|
1982-11-08 |
1985-09-10 |
Johnson & Johnson Products, Inc. |
Absorbable bone fixation device
|
US4550449A
(en)
*
|
1982-11-08 |
1985-11-05 |
Johnson & Johnson Products Inc. |
Absorbable bone fixation device
|
FR2537980B1
(fr)
*
|
1982-12-17 |
1986-12-19 |
Sandoz Sa |
Derives d'acides hydroxycarboxyliques oligomeres, leur preparation et leur utilisation
|
CA1196864A
(en)
*
|
1983-06-10 |
1985-11-19 |
Mattheus F.A. Goosen |
Controlled release of injectable and implantable insulin compositions
|
CH656884A5
(de)
*
|
1983-08-26 |
1986-07-31 |
Sandoz Ag |
Polyolester, deren herstellung und verwendung.
|
CH661206A5
(fr)
*
|
1983-09-23 |
1987-07-15 |
Debiopharm Sa |
Procede pour la preparation d'un medicament destine au traitement de maladies hormonodependantes.
|
JPS60100516A
(ja)
*
|
1983-11-04 |
1985-06-04 |
Takeda Chem Ind Ltd |
徐放型マイクロカプセルの製造法
|
US4530920A
(en)
*
|
1983-11-07 |
1985-07-23 |
Syntex (U.S.A.) Inc. |
Nonapeptide and decapeptide analogs of LHRH, useful as LHRH agonist
|
FR2557459B1
(fr)
*
|
1984-01-02 |
1986-05-30 |
Lhd Lab Hygiene Dietetique |
Matrice inerte a base de polycaprolactone pour administration orale d'un medicament, et procede de preparation de la forme galenique comprenant cette matrice
|
US4578384A
(en)
*
|
1984-02-15 |
1986-03-25 |
The United States Of America As Represented By The Secretary Of The Army |
Polylactic-polyglycolic acids combined with an acidic phospholipid-lysozyme complex for healing osseous tissue
|
ES2091185T3
(es)
*
|
1984-03-06 |
1996-11-01 |
United States Surgical Corp |
Un procedimiento para la preparacion de composiciones bifasicas para dispositivos quirurgicos absorbibles.
|
US6217911B1
(en)
|
1995-05-22 |
2001-04-17 |
The United States Of America As Represented By The Secretary Of The Army |
sustained release non-steroidal, anti-inflammatory and lidocaine PLGA microspheres
|
USRE40786E1
(en)
|
1984-03-16 |
2009-06-23 |
The United States Of America As Represented By The Secretary Of The Army |
Vaccines against intracellular pathogens using antigens encapsulated within biodegradable-biocompatible microspheres
|
US6309669B1
(en)
|
1984-03-16 |
2001-10-30 |
The United States Of America As Represented By The Secretary Of The Army |
Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
|
US4659693A
(en)
*
|
1984-04-30 |
1987-04-21 |
Syntex (U.S.A.) Inc. |
N,N'-dialkyl substituted guanidino amino acyl residue substituted GRF-analog peptides
|
GB8416234D0
(en)
*
|
1984-06-26 |
1984-08-01 |
Ici Plc |
Biodegradable amphipathic copolymers
|
DE3428640A1
(de)
*
|
1984-08-03 |
1986-02-06 |
Akzo Gmbh, 5600 Wuppertal |
Mikroporoese, pulverfoermige polylactide
|
US4880635B1
(en)
*
|
1984-08-08 |
1996-07-02 |
Liposome Company |
Dehydrated liposomes
|
US4666704A
(en)
*
|
1985-05-24 |
1987-05-19 |
International Minerals & Chemical Corp. |
Controlled release delivery system for macromolecules
|
GB8609537D0
(en)
*
|
1986-04-18 |
1986-05-21 |
Ici Plc |
Polyesters
|
ATE97929T1
(de)
*
|
1986-05-15 |
1993-12-15 |
Hoechst Ag |
Biologisch abbaubare polymere fuer depotzubereitungen mit kontrollierter wirkstoffabgabe.
|
US5160745A
(en)
*
|
1986-05-16 |
1992-11-03 |
The University Of Kentucky Research Foundation |
Biodegradable microspheres as a carrier for macromolecules
|
US4962091A
(en)
*
|
1986-05-23 |
1990-10-09 |
Syntex (U.S.A.) Inc. |
Controlled release of macromolecular polypeptides
|
US4744365A
(en)
*
|
1986-07-17 |
1988-05-17 |
United States Surgical Corporation |
Two-phase compositions for absorbable surgical devices
|
US4758435A
(en)
*
|
1986-08-11 |
1988-07-19 |
American Cyanamid Company |
Estradiol implant composition and method for preparation
|
US4981696A
(en)
*
|
1986-12-22 |
1991-01-01 |
E. I. Du Pont De Nemours And Company |
Polylactide compositions
|
DE3700128A1
(de)
*
|
1987-01-03 |
1988-07-14 |
Hoechst Ag |
Biologisch abbaubare poly- (hydroxyalkyl)- aminodicarbonsaeure-derivate, verfahren zu ihrer herstellung und verwendung derselben fuer depotzubereitungen mit kontrollierter wirkstoffabgabe
|
DE3701625A1
(de)
*
|
1987-01-21 |
1988-08-04 |
Boehringer Ingelheim Kg |
Perorale arzneimittelzubereitung mit verzoegerter wirkstofffreigabe
|
DE3710175A1
(de)
*
|
1987-02-12 |
1988-08-25 |
Hoechst Ag |
Mehrteilige implantierbare arzneizubereitung mit langzeitwirkung
|
AU606383B2
(en)
*
|
1987-03-06 |
1991-02-07 |
Research Triangle Institute |
Polymer blends for selective biodegradability
|
DE3712095A1
(de)
*
|
1987-04-10 |
1988-10-20 |
Lentia Gmbh |
Bindemittelfreies granulat mit verzoegerter wirkstoffabgabe
|
FR2618674B1
(fr)
*
|
1987-07-30 |
1990-06-15 |
Ire Celltarg Sa |
Microparticules comportant un polymere biodegradable controlant la liberation d'un principe actif antimalarique, compositions pharmaceutiques en comprenant et procede de preparation
|
US4897268A
(en)
*
|
1987-08-03 |
1990-01-30 |
Southern Research Institute |
Drug delivery system and method of making the same
|
US5212154A
(en)
*
|
1987-08-14 |
1993-05-18 |
Akzo N.V. |
Preparation for treating complications in diabetes
|
GB2209937B
(en)
*
|
1987-09-21 |
1991-07-03 |
Depiopharm S A |
Water insoluble polypeptides
|
AU2810189A
(en)
*
|
1987-10-30 |
1989-05-23 |
Stolle Research & Development Corporation |
Low residual solvent microspheres and microencapsulation process
|
DE3738228A1
(de)
*
|
1987-11-11 |
1989-05-24 |
Hoechst Ag |
Verfahren zur herstellung von bioabbaubaren mikrokapseln wasserloeslicher peptide und proteine sowie nach diesem verfahren erhaltene mikrokapseln
|
DE3744329A1
(de)
*
|
1987-12-28 |
1989-07-06 |
Schwarz Pharma Gmbh |
Verfahren zur herstellung einer mindestens einen wirkstoff und einen traeger umfassenden zubereitung
|
WO1989007451A1
(en)
|
1988-02-10 |
1989-08-24 |
Abbott Laboratories |
Reduced size lhrh analogs
|
US4902515A
(en)
*
|
1988-04-28 |
1990-02-20 |
E. I. Dupont De Nemours And Company |
Polylactide compositions
|
US5502158A
(en)
*
|
1988-08-08 |
1996-03-26 |
Ecopol, Llc |
Degradable polymer composition
|
US6323307B1
(en)
|
1988-08-08 |
2001-11-27 |
Cargill Dow Polymers, Llc |
Degradation control of environmentally degradable disposable materials
|
US5444113A
(en)
*
|
1988-08-08 |
1995-08-22 |
Ecopol, Llc |
End use applications of biodegradable polymers
|
US5424346A
(en)
*
|
1988-08-08 |
1995-06-13 |
Ecopol, Llc |
Biodegradable replacement of crystal polystyrene
|
US5180765A
(en)
*
|
1988-08-08 |
1993-01-19 |
Biopak Technology, Ltd. |
Biodegradable packaging thermoplastics from lactides
|
DE3826915A1
(de)
*
|
1988-08-09 |
1990-02-15 |
Henkel Kgaa |
Neue werkstoffe fuer den knochenersatz und knochen- bzw. prothesenverbund
|
US4990336A
(en)
*
|
1989-02-08 |
1991-02-05 |
Biosearch, Inc. |
Sustained release dosage form
|
US5116964A
(en)
|
1989-02-23 |
1992-05-26 |
Genentech, Inc. |
Hybrid immunoglobulins
|
US6797270B1
(en)
*
|
1989-03-16 |
2004-09-28 |
Center For Blood Research, Inc. |
Functional derivatives of the intercellular adhesion molecule ICAM-1 in anti-viral therapy
|
US5491131A
(en)
*
|
1989-04-14 |
1996-02-13 |
Applied Research Systems Ars Holding Nv |
Somatostatin-active polypeptide composition
|
HU221294B1
(en)
*
|
1989-07-07 |
2002-09-28 |
Novartis Ag |
Process for producing retarde compositions containing the active ingredient in a polymeric carrier
|
US5232707A
(en)
*
|
1989-07-10 |
1993-08-03 |
Syntex (U.S.A.) Inc. |
Solvent extraction process
|
US5268178A
(en)
*
|
1989-09-25 |
1993-12-07 |
The Board Of Regents, The University Of Texas System |
Biodegradable antibiotic implants and methods of their use in treating and preventing infections
|
DE59003337D1
(de)
*
|
1989-10-16 |
1993-12-09 |
Danubia Petrochem Polymere |
Pressling mit retardierter Wirkstofffreisetzung.
|
FR2654337B1
(fr)
*
|
1989-11-15 |
1994-08-05 |
Roussel Uclaf |
Nouvelles microspheres injectables biodegradables procede de preparation et suspensions injectables les renfermant.
|
DE4002736A1
(de)
*
|
1990-01-31 |
1991-08-01 |
Hoechst Ag |
Biologisch abbaubare polymere, verfahren zu ihrer herstellung und verwendung derselben fuer depotzubereitungen mit kontrollierter wirkstoffabgabe
|
FR2663223B1
(fr)
*
|
1990-06-14 |
1994-12-02 |
Af Aplicaciones Far Lab |
Forme galenique parenterale.
|
FR2663224B1
(fr)
*
|
1990-06-14 |
1995-01-20 |
Applicationes Farmaceuticas Sa |
Forme galenique parenterale.
|
CA2046830C
(en)
*
|
1990-07-19 |
1999-12-14 |
Patrick P. Deluca |
Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
|
US6353030B1
(en)
*
|
1990-08-01 |
2002-03-05 |
Novartis Ag |
Relating to organic compounds
|
US5149543A
(en)
*
|
1990-10-05 |
1992-09-22 |
Massachusetts Institute Of Technology |
Ionically cross-linked polymeric microcapsules
|
US5562099A
(en)
*
|
1990-10-05 |
1996-10-08 |
Massachusetts Institute Of Technology |
Polymeric microparticles containing agents for imaging
|
DE4041563A1
(de)
*
|
1990-12-22 |
1992-06-25 |
Sanol Arznei Schwarz Gmbh |
Verfahren zur herstellung wirkstoffhaltiger mikropartikel aus hydrolytisch abbaubaren polymeren
|
US6228954B1
(en)
|
1991-02-12 |
2001-05-08 |
United States Surgical Corporation |
Blends of glycolide and/or lactide polymers and caprolactone and/or trimethylene carbonate polymers and absorabable surgical devices made therefrom
|
US5320624A
(en)
*
|
1991-02-12 |
1994-06-14 |
United States Surgical Corporation |
Blends of glycolide and/or lactide polymers and caprolactone and/or trimethylene carbonate polymers and absorbable surgical devices made therefrom
|
US5153002A
(en)
*
|
1991-03-04 |
1992-10-06 |
University Of Montreal |
Biocompatible gradient controlled release implant
|
AU8303691A
(en)
|
1991-04-24 |
1992-12-21 |
United States Of America, As Represented By The Secretary Of The Army, The |
Oral-intestinal vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
|
EP0514790A2
(de)
*
|
1991-05-24 |
1992-11-25 |
Hoechst Aktiengesellschaft |
Polykondensate, die Weinsäurederivate enthalten, Verfahren zu ihrer Herstellung und Verwendung derselben
|
ZA924811B
(en)
*
|
1991-06-28 |
1993-12-29 |
Endorecherche Inc |
Controlled release systems and low dose androgens
|
HU222501B1
(hu)
*
|
1991-06-28 |
2003-07-28 |
Endorecherche Inc. |
MPA-t vagy MGA-t tartalmazó nyújtott hatóanyag-felszabadulású gyógyászati készítmény és eljárás előállítására
|
AU2572692A
(en)
|
1991-09-09 |
1993-04-05 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
Methods and devices for treating hemophilia and aids
|
US6063910A
(en)
*
|
1991-11-14 |
2000-05-16 |
The Trustees Of Princeton University |
Preparation of protein microparticles by supercritical fluid precipitation
|
US5258488A
(en)
*
|
1992-01-24 |
1993-11-02 |
Cargill, Incorporated |
Continuous process for manufacture of lactide polymers with controlled optical purity
|
US5142023A
(en)
*
|
1992-01-24 |
1992-08-25 |
Cargill, Incorporated |
Continuous process for manufacture of lactide polymers with controlled optical purity
|
US5247059A
(en)
*
|
1992-01-24 |
1993-09-21 |
Cargill, Incorporated |
Continuous process for the manufacture of a purified lactide from esters of lactic acid
|
US6326458B1
(en)
|
1992-01-24 |
2001-12-04 |
Cargill, Inc. |
Continuous process for the manufacture of lactide and lactide polymers
|
US5247058A
(en)
*
|
1992-01-24 |
1993-09-21 |
Cargill, Incorporated |
Continuous process for manufacture of lactide polymers with controlled optical purity
|
US6005067A
(en)
*
|
1992-01-24 |
1999-12-21 |
Cargill Incorporated |
Continuous process for manufacture of lactide polymers with controlled optical purity
|
US6013853A
(en)
*
|
1992-02-14 |
2000-01-11 |
The University Of Texas System |
Continuous release polymeric implant carrier
|
US5876452A
(en)
*
|
1992-02-14 |
1999-03-02 |
Board Of Regents, University Of Texas System |
Biodegradable implant
|
FR2689400B1
(fr)
*
|
1992-04-03 |
1995-06-23 |
Inoteb |
Materiau pour prothese osseuse contenant des particules de carbonate de calcium dispersees dans une matrice polymere bioresorbable.
|
US5518730A
(en)
*
|
1992-06-03 |
1996-05-21 |
Fuisz Technologies Ltd. |
Biodegradable controlled release flash flow melt-spun delivery system
|
CA2099476A1
(en)
*
|
1992-07-13 |
1994-01-14 |
Akira Ohneda |
Medicaments comprising glicentin as active ingredient
|
FR2693905B1
(fr)
*
|
1992-07-27 |
1994-09-02 |
Rhone Merieux |
Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues.
|
US5922340A
(en)
*
|
1992-09-10 |
1999-07-13 |
Children's Medical Center Corporation |
High load formulations and methods for providing prolonged local anesthesia
|
US5338822A
(en)
*
|
1992-10-02 |
1994-08-16 |
Cargill, Incorporated |
Melt-stable lactide polymer composition and process for manufacture thereof
|
US6005068A
(en)
|
1992-10-02 |
1999-12-21 |
Cargill Incorporated |
Melt-stable amorphous lactide polymer film and process for manufacture thereof
|
ATE199944T1
(de)
*
|
1992-10-02 |
2001-04-15 |
Cargill Inc |
Schmelzstabiles lactidpolymergewebe und verfahren zu seiner herstellung
|
BR9305658A
(pt)
*
|
1992-10-02 |
1996-11-26 |
Cargill Inc |
Papel tendo um polímero de lactideo estável em fusao e processo para sua produçao
|
CA2148823C
(en)
*
|
1992-11-17 |
1999-03-09 |
Welfide Corporation |
Sustained release microsphere preparation containing antipsychotic drug and production process thereof
|
TW333456B
(en)
*
|
1992-12-07 |
1998-06-11 |
Takeda Pharm Ind Co Ltd |
A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
|
US6387363B1
(en)
|
1992-12-31 |
2002-05-14 |
United States Surgical Corporation |
Biocompatible medical devices
|
US6221958B1
(en)
|
1993-01-06 |
2001-04-24 |
Societe De Conseils De Recherches Et D'applications Scientifiques, Sas |
Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
|
CA2114290C
(en)
*
|
1993-01-27 |
2006-01-10 |
Nagabushanam Totakura |
Post-surgical anti-adhesion device
|
US6124259A
(en)
*
|
1993-01-28 |
2000-09-26 |
Celtrix Pharmaceuticals, Inc. |
Method for treating ophthalmic disorders with IGFBP
|
US5340614A
(en)
*
|
1993-02-11 |
1994-08-23 |
Minnesota Mining And Manufacturing Company |
Methods of polymer impregnation
|
GB9310030D0
(en)
*
|
1993-05-15 |
1993-06-30 |
Scras |
Dry processed particles and process for the preparation of the same
|
US6939546B2
(en)
|
1993-05-21 |
2005-09-06 |
The United States Of America As Represented By The Secretary Of The Army |
Model for testing immunogenicity of peptides
|
US6440457B1
(en)
*
|
1993-05-27 |
2002-08-27 |
Alza Corporation |
Method of administering antidepressant dosage form
|
US6638905B2
(en)
*
|
1993-06-18 |
2003-10-28 |
The Salk Institute For Biological Studies |
Cloning and recombinant production of CFR receptor(s)
|
US6495343B1
(en)
|
1993-06-18 |
2002-12-17 |
The Salk Institute For Biological Studies |
Cloning and recombinant production of CRF receptor(s)
|
CA2163860A1
(en)
*
|
1993-06-30 |
1995-01-12 |
Chung C. Hsu |
Method for preparing liposomes
|
JP3822232B2
(ja)
|
1993-08-30 |
2006-09-13 |
ベイラー・カレッジ・オブ・メディシン |
老化細胞由来dna合成阻害因子
|
US5500161A
(en)
*
|
1993-09-21 |
1996-03-19 |
Massachusetts Institute Of Technology And Virus Research Institute |
Method for making hydrophobic polymeric microparticles
|
JP3841309B2
(ja)
*
|
1993-10-22 |
2006-11-01 |
ジェネンテック・インコーポレーテッド |
流動床乾燥工程を含んでなるミクロスフェアの製造方法
|
US5339766A
(en)
|
1993-11-03 |
1994-08-23 |
Embrex, Inc. |
Method of introducing material into eggs during early embryonic development
|
EP0732933B1
(en)
*
|
1993-11-15 |
2002-10-09 |
Celtrix Pharmaceuticals, Inc. |
Use of igf-1 and igfbp-3 in the manufacture of a medicament for treating a renal disorder
|
NZ276088A
(en)
|
1993-11-19 |
1999-07-29 |
Janssen Pharmaceutica Nv |
[(1,2-benzisoxazol-3-yl)-1-piperidinyl-alkyl-6,7,8,9-tetrahydro-4h- pyrido[1,2-a]-pyrimidin-4-one derivatives (ie risperidone)
|
DE4406172C2
(de)
*
|
1994-02-25 |
2003-10-02 |
Sanol Arznei Schwarz Gmbh |
Polyester
|
DE4407898A1
(de)
*
|
1994-03-09 |
1995-09-14 |
Hoechst Ag |
Nanopartikel, enthaltend einen Wirkstoff und ein Polyketalweinsäureamid, Verfahren zu ihrer Herstellung und Verwendung derselben
|
US5877016A
(en)
|
1994-03-18 |
1999-03-02 |
Genentech, Inc. |
Human trk receptors and neurotrophic factor inhibitors
|
JPH09511666A
(ja)
*
|
1994-04-08 |
1997-11-25 |
アトリックス・ラボラトリーズ・インコーポレイテッド |
医療装置で使用する付随的ポリマー系
|
US6447796B1
(en)
|
1994-05-16 |
2002-09-10 |
The United States Of America As Represented By The Secretary Of The Army |
Sustained release hydrophobic bioactive PLGA microspheres
|
US6855331B2
(en)
|
1994-05-16 |
2005-02-15 |
The United States Of America As Represented By The Secretary Of The Army |
Sustained release hydrophobic bioactive PLGA microspheres
|
US5708142A
(en)
|
1994-05-27 |
1998-01-13 |
Genentech, Inc. |
Tumor necrosis factor receptor-associated factors
|
DE4423131A1
(de)
*
|
1994-07-01 |
1996-01-04 |
Bayer Ag |
Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4
|
US6339130B1
(en)
*
|
1994-07-22 |
2002-01-15 |
United States Surgical Corporation |
Bioabsorbable branched polymers containing units derived from dioxanone and medical/surgical devices manufactured therefrom
|
US5578662A
(en)
|
1994-07-22 |
1996-11-26 |
United States Surgical Corporation |
Bioabsorbable branched polymers containing units derived from dioxanone and medical/surgical devices manufactured therefrom
|
US5595760A
(en)
*
|
1994-09-02 |
1997-01-21 |
Delab |
Sustained release of peptides from pharmaceutical compositions
|
AUPM897594A0
(en)
*
|
1994-10-25 |
1994-11-17 |
Daratech Pty Ltd |
Controlled release container
|
US6093697A
(en)
*
|
1994-11-07 |
2000-07-25 |
The University Of Virginia Patent Foundation |
Synthetic insulin mimetic substances
|
US5660817A
(en)
*
|
1994-11-09 |
1997-08-26 |
Gillette Canada, Inc. |
Desensitizing teeth with degradable particles
|
US7033608B1
(en)
|
1995-05-22 |
2006-04-25 |
The United States Of America As Represented By The Secretary Of The Army |
“Burst-free” sustained release poly-(lactide/glycolide) microspheres
|
US5599535A
(en)
*
|
1995-06-07 |
1997-02-04 |
Regents Of The University Of California |
Methods for the cyto-protection of the trabecular meshwork
|
US5674888A
(en)
*
|
1995-06-07 |
1997-10-07 |
University Of California |
Method for the treatment of a trabecular meshwork whose cells are subject to inhibition of cell division
|
US5641502A
(en)
*
|
1995-06-07 |
1997-06-24 |
United States Surgical Corporation |
Biodegradable moldable surgical material
|
US5942241A
(en)
|
1995-06-09 |
1999-08-24 |
Euro-Celtique, S.A. |
Formulations and methods for providing prolonged local anesthesia
|
US5955574A
(en)
|
1995-07-13 |
1999-09-21 |
Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. |
Analogs of parathyroid hormone
|
US5925351A
(en)
|
1995-07-21 |
1999-07-20 |
Biogen, Inc. |
Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
|
US7005505B1
(en)
|
1995-08-25 |
2006-02-28 |
Genentech, Inc. |
Variants of vascular endothelial cell growth factor
|
US6020473A
(en)
*
|
1995-08-25 |
2000-02-01 |
Genentech, Inc. |
Nucleic acids encoding variants of vascular endothelial cell growth factor
|
DE19537415A1
(de)
*
|
1995-10-09 |
1997-04-10 |
New Standard Gmbh |
Micro Wirkstoff-Perlen
|
US5942253A
(en)
*
|
1995-10-12 |
1999-08-24 |
Immunex Corporation |
Prolonged release of GM-CSF
|
SE505146C2
(sv)
*
|
1995-10-19 |
1997-06-30 |
Biogram Ab |
Partiklar för fördröjd frisättning
|
US5968543A
(en)
*
|
1996-01-05 |
1999-10-19 |
Advanced Polymer Systems, Inc. |
Polymers with controlled physical state and bioerodibility
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
US5980945A
(en)
*
|
1996-01-16 |
1999-11-09 |
Societe De Conseils De Recherches Et D'applications Scientifique S.A. |
Sustained release drug formulations
|
US6004572A
(en)
*
|
1996-01-25 |
1999-12-21 |
Triangle Laboratories, Inc. |
Time release delivery system
|
HUP0000732A3
(en)
*
|
1996-04-23 |
2000-11-28 |
Ipsen Mfg Ireland Ltd |
Acidic polylactic polymers
|
IE960308A1
(en)
*
|
1996-04-23 |
1997-11-05 |
Kinerton Ltd |
Sustained release ionic conjugate
|
FR2748205A1
(fr)
|
1996-05-06 |
1997-11-07 |
Debio Rech Pharma Sa |
Compositions pharmaceutiques pour la liberation controlee de principes actifs insolubles
|
US5792477A
(en)
|
1996-05-07 |
1998-08-11 |
Alkermes Controlled Therapeutics, Inc. Ii |
Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
|
US6100071A
(en)
|
1996-05-07 |
2000-08-08 |
Genentech, Inc. |
Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
|
US5766877A
(en)
*
|
1996-05-10 |
1998-06-16 |
Amgen Inc. |
Genes encoding art, an agouti-related transcript
|
AU733867B2
(en)
|
1996-06-24 |
2001-05-31 |
Euro-Celtique S.A. |
Methods for providing safe local anesthesia
|
US5756651A
(en)
*
|
1996-07-17 |
1998-05-26 |
Chronopol, Inc. |
Impact modified polylactide
|
US5851984A
(en)
*
|
1996-08-16 |
1998-12-22 |
Genentech, Inc. |
Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
|
US6159462A
(en)
*
|
1996-08-16 |
2000-12-12 |
Genentech, Inc. |
Uses of Wnt polypeptides
|
AU4196697A
(en)
*
|
1996-09-16 |
1998-04-14 |
Dalhousie University |
Use of igf-i for the treatment of polycystic kidney disease and related indications
|
US6046187A
(en)
|
1996-09-16 |
2000-04-04 |
Children's Medical Center Corporation |
Formulations and methods for providing prolonged local anesthesia
|
KR20050004269A
(ko)
|
1996-10-25 |
2005-01-12 |
휴먼 게놈 사이언시즈, 인코포레이티드 |
뉴트로킨 알파
|
ES2221019T3
(es)
|
1996-10-31 |
2004-12-16 |
Takeda Chemical Industries, Ltd. |
Preparacion de liberacion mantenida.
|
US6156728A
(en)
*
|
1996-11-01 |
2000-12-05 |
Genentech, Inc. |
Treatment of inner ear hair cells
|
US6593290B1
(en)
|
1996-11-01 |
2003-07-15 |
Genentech, Inc. |
Treatment of inner ear hair cells
|
US6919373B1
(en)
|
1996-11-12 |
2005-07-19 |
Alza Corporation |
Methods and devices for providing prolonged drug therapy
|
US7390891B1
(en)
|
1996-11-15 |
2008-06-24 |
Amgen Inc. |
Polynucleotides encoding a telomerase component TP2
|
US5919656A
(en)
*
|
1996-11-15 |
1999-07-06 |
Amgen Canada Inc. |
Genes encoding telomerase protein 1
|
US20020111603A1
(en)
*
|
1996-12-02 |
2002-08-15 |
Societe De Conseils De Recherches Et D'application |
Device for local administration of solid or semi-solid formulations and delayed-release formulations for proposal parental administration and preparation process
|
US6171788B1
(en)
|
1997-01-28 |
2001-01-09 |
The Regents Of The University Of California |
Methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
|
US7138511B1
(en)
|
1997-01-28 |
2006-11-21 |
The Regents Of The University Of California |
Nucleic acids, kits and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
|
US6475724B1
(en)
|
1997-01-28 |
2002-11-05 |
The Regents Of The University Of California |
Nucleic acids, kits, and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
|
US6126919A
(en)
|
1997-02-07 |
2000-10-03 |
3M Innovative Properties Company |
Biocompatible compounds for pharmaceutical drug delivery systems
|
US5945126A
(en)
*
|
1997-02-13 |
1999-08-31 |
Oakwood Laboratories L.L.C. |
Continuous microsphere process
|
SI1325932T1
(ko)
|
1997-04-07 |
2005-08-31 |
Genentech Inc |
|
DE69841815D1
(de)
|
1997-04-07 |
2010-09-16 |
Genentech Inc |
Anti-VEGF Antikörper
|
AU737106B2
(en)
*
|
1997-04-18 |
2001-08-09 |
Biogen, Inc. |
Type II TGF-beta receptor/immunoglobulin constant region fusion proteins
|
DK1015477T3
(da)
|
1997-05-30 |
2011-02-07 |
Human Genome Sciences Inc |
32 humane sekreterede proteiner
|
US6867181B1
(en)
|
1997-06-02 |
2005-03-15 |
Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. |
Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
|
US6113947A
(en)
*
|
1997-06-13 |
2000-09-05 |
Genentech, Inc. |
Controlled release microencapsulated NGF formulation
|
FR2764514B1
(fr)
*
|
1997-06-13 |
1999-09-03 |
Biopharmex Holding Sa |
Implant injectable en sous-cutane ou intradermique a bioresorbabilite controlee pour la chirurgie reparatrice ou plastique et la dermatologie esthetique
|
US6663899B2
(en)
*
|
1997-06-13 |
2003-12-16 |
Genentech, Inc. |
Controlled release microencapsulated NGF formulation
|
WO1999001114A1
(en)
*
|
1997-07-02 |
1999-01-14 |
Euro-Celtique, S.A. |
Prolonged anesthesia in joints and body spaces
|
US6342220B1
(en)
|
1997-08-25 |
2002-01-29 |
Genentech, Inc. |
Agonist antibodies
|
US6635443B1
(en)
|
1997-09-17 |
2003-10-21 |
Human Genome Sciences, Inc. |
Polynucleotides encoding a novel interleukin receptor termed interleukin-17 receptor-like protein
|
ATE409225T1
(de)
|
1997-10-29 |
2008-10-15 |
Genentech Inc |
Durch wnt-1 induzierbare gene
|
CA2306183A1
(en)
|
1997-10-29 |
1999-05-06 |
Genentech, Inc. |
Wnt-1 induced secreted polypeptides: wisp-1, -2 and -3
|
WO1999024061A1
(en)
|
1997-11-07 |
1999-05-20 |
Chiron Corporation |
Method for producing igf-1 sustained-release formulations
|
US8088386B2
(en)
|
1998-03-20 |
2012-01-03 |
Genentech, Inc. |
Treatment of complement-associated disorders
|
US7192589B2
(en)
|
1998-09-16 |
2007-03-20 |
Genentech, Inc. |
Treatment of inflammatory disorders with STIgMA immunoadhesins
|
EP1481990B1
(en)
|
1997-11-21 |
2007-06-06 |
Genentech, Inc. |
A-33 related antigens and their pharmacological uses
|
DE69841751D1
(en)
*
|
1997-11-21 |
2010-08-12 |
Human Genome Sciences Inc |
Chemokin alpha-5
|
EP1947119A3
(en)
|
1997-12-12 |
2012-12-19 |
Genentech, Inc. |
Treatment of cancer with anti-erb2 antibodies in combination with a chemotherapeutic agent
|
KR100289471B1
(ko)
*
|
1998-01-19 |
2001-09-17 |
김충섭 |
휀타닐계마취제의이식형서방성제제
|
KR19990065921A
(ko)
*
|
1998-01-19 |
1999-08-16 |
김충섭 |
항생제의서방성제제
|
US5906979A
(en)
*
|
1998-01-27 |
1999-05-25 |
Insmed Pharmaceuticals, Inc. |
Compositions and methods for treating metabolic diseases characterized by hyperandrogenism and/or anovulation and/or infertility
|
EP2050762A3
(en)
|
1998-03-10 |
2009-07-08 |
Genentech, Inc. |
Human cornichon-like protein and nucleic acids encoding it
|
US20030180368A1
(en)
*
|
1998-03-14 |
2003-09-25 |
Cenes Drug Delivery Limited |
Production of microparticles
|
ES2313778T3
(es)
|
1998-03-17 |
2009-03-01 |
Genentech, Inc. |
Polipeptidos homologos de vegf y de bmp1.
|
CA2323776C
(en)
|
1998-03-19 |
2010-04-27 |
Human Genome Sciences, Inc. |
Cytokine receptor common gamma chain like
|
EP1941905A1
(en)
|
1998-03-27 |
2008-07-09 |
Genentech, Inc. |
APO-2 Ligand-anti-her-2 antibody synergism
|
US7157083B2
(en)
*
|
1998-04-17 |
2007-01-02 |
Surrogate Pharmaceutical Pathways, Llc |
Compositions and methods for treating retroviral infections
|
EP3112468A1
(en)
|
1998-05-15 |
2017-01-04 |
Genentech, Inc. |
Il-17 homologous polypeptides and therapeutic uses thereof
|
EP2333069A3
(en)
|
1998-05-15 |
2011-09-14 |
Genentech, Inc. |
Therapeutic uses of IL-17 homologous polypeptides
|
US5973119A
(en)
*
|
1998-06-05 |
1999-10-26 |
Amgen Inc. |
Cyclin E genes and proteins
|
US7700353B2
(en)
*
|
1998-07-22 |
2010-04-20 |
E-P Therapeutics, Inc. |
Compositions and methods for inducing apoptosis in tumor cells
|
US20020172678A1
(en)
|
2000-06-23 |
2002-11-21 |
Napoleone Ferrara |
EG-VEGF nucleic acids and polypeptides and methods of use
|
US6344541B1
(en)
|
1998-09-25 |
2002-02-05 |
Amgen Inc. |
DKR polypeptides
|
DE69931944T2
(de)
*
|
1998-10-09 |
2007-02-08 |
Biogen Idec Ma Inc., Cambridge |
Umkehr des viral-induzierten systemischen schocks und des atemnotsyndroms durch blockierung des lymphotoxin-beta- aktivierungsweges
|
US6270802B1
(en)
|
1998-10-28 |
2001-08-07 |
Oakwood Laboratories L.L.C. |
Method and apparatus for formulating microspheres and microcapsules
|
US6143314A
(en)
*
|
1998-10-28 |
2000-11-07 |
Atrix Laboratories, Inc. |
Controlled release liquid delivery compositions with low initial drug burst
|
EP1950300A3
(en)
|
1998-11-18 |
2011-03-23 |
Genentech, Inc. |
Antibody variants with higher binding affinity compared to parent antibodies
|
CA2351734A1
(en)
|
1998-11-20 |
2000-06-02 |
University Of Connecticut |
Generic integrated implantable potentiostat telemetry unit for electrochemical sensors
|
US20030099682A1
(en)
*
|
1998-11-20 |
2003-05-29 |
Francis Moussy |
Apparatus and method for control of tissue/implant interactions
|
AU1740900A
(en)
*
|
1998-11-20 |
2000-06-13 |
Genentech Inc. |
Method of inhibiting angiogenesis
|
AUPP785098A0
(en)
|
1998-12-21 |
1999-01-21 |
Victor Chang Cardiac Research Institute, The |
Treatment of heart disease
|
EP1820859B9
(en)
|
1998-12-22 |
2009-10-28 |
Genentech, Inc. |
Methods and compositions for inhibiting neoplastic cell growth
|
DE69926536T3
(de)
|
1998-12-22 |
2013-09-12 |
Genentech, Inc. |
Antagonisten von vaskular-endothelialen zellwachstumsfaktoren und ihre anwendung
|
US6194006B1
(en)
|
1998-12-30 |
2001-02-27 |
Alkermes Controlled Therapeutics Inc. Ii |
Preparation of microparticles having a selected release profile
|
US6498153B1
(en)
*
|
1998-12-31 |
2002-12-24 |
Akzo Nobel N.V. |
Extended release growth promoting two component composition
|
KR101077001B1
(ko)
|
1999-01-15 |
2011-10-26 |
제넨테크, 인크. |
효과기 기능이 변화된 폴리펩티드 변이체
|
US6303749B1
(en)
|
1999-01-29 |
2001-10-16 |
Amgen Inc. |
Agouti and agouti-related peptide analogs
|
US7708993B2
(en)
*
|
1999-02-03 |
2010-05-04 |
Amgen Inc. |
Polypeptides involved in immune response
|
EP2332976B1
(en)
|
1999-02-03 |
2014-04-02 |
Amgen, Inc |
Novel polypeptides involved in immune response
|
US8624010B1
(en)
|
1999-02-03 |
2014-01-07 |
Steven K. Yoshinaga |
Nucleic acids encoding B7RP1
|
US7435796B1
(en)
|
1999-02-03 |
2008-10-14 |
Amgen Inc. |
Antibodies which bind B7RP1
|
EP1161451A4
(en)
|
1999-02-26 |
2006-05-17 |
Human Genome Sciences Inc |
HUMAN ALPHA ENDOKIN AND METHOD FOR ITS USE
|
EP1574210B1
(en)
|
1999-02-26 |
2016-04-06 |
Novartis Vaccines and Diagnostics, Inc. |
Microemulsions with adsorbed macromolecules
|
WO2000058479A1
(en)
|
1999-03-26 |
2000-10-05 |
Amgen Inc. |
Beta secretase genes and polypeptides
|
US6306425B1
(en)
|
1999-04-09 |
2001-10-23 |
Southern Research Institute |
Injectable naltrexone microsphere compositions and their use in reducing consumption of heroin and alcohol
|
US6635249B1
(en)
*
|
1999-04-23 |
2003-10-21 |
Cenes Pharmaceuticals, Inc. |
Methods for treating congestive heart failure
|
US20040229779A1
(en)
*
|
1999-05-14 |
2004-11-18 |
Ramesh Kekuda |
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
US6974684B2
(en)
*
|
2001-08-08 |
2005-12-13 |
Curagen Corporation |
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
US20040023874A1
(en)
*
|
2002-03-15 |
2004-02-05 |
Burgess Catherine E. |
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
US20040067490A1
(en)
*
|
2001-09-07 |
2004-04-08 |
Mei Zhong |
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
NZ530701A
(en)
*
|
1999-06-04 |
2005-09-30 |
Alza Corp |
Implantable gel compositions comprising compressed particles including the active agent in a bioerodible gel
|
EP1953173B1
(en)
|
1999-06-15 |
2009-11-18 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids endoding the same
|
US20030166561A1
(en)
*
|
1999-06-18 |
2003-09-04 |
Cooper Garth J. S. |
Peptide
|
EP2112167A3
(en)
|
1999-06-25 |
2010-12-22 |
Genentech, Inc. |
Humanized ANTI-ERBB2 antibodies and treatment with ANTI-ERBB2 antibodies
|
DK2283866T3
(en)
|
1999-06-25 |
2015-05-18 |
Genentech Inc |
METHODS OF TREATMENT USING ANTI-ERBB ANTIBODY-MAYTANSINOID CONJUGATES
|
MXPA01013236A
(es)
|
1999-06-28 |
2002-06-21 |
Genentech Inc |
Metodos para hacer ligando apo-2 mediante el uso de iones metalicos divalentes.
|
US7713739B1
(en)
*
|
2000-11-17 |
2010-05-11 |
Novartis Vaccines And Diagnostics, Inc. |
Microparticle-based transfection and activation of dendritic cells
|
JP2003508185A
(ja)
*
|
1999-08-03 |
2003-03-04 |
スミス アンド ネフュー インコーポレーテッド |
埋め込み型制御放出装置
|
ATE438411T1
(de)
|
1999-08-27 |
2009-08-15 |
Genentech Inc |
Dosierung für die behandlung mit anti erbb2- antikörpern
|
US20040214783A1
(en)
|
2002-05-08 |
2004-10-28 |
Terman David S. |
Compositions and methods for treatment of neoplastic disease
|
US7408047B1
(en)
*
|
1999-09-07 |
2008-08-05 |
Amgen Inc. |
Fibroblast growth factor-like polypeptides
|
US7459540B1
(en)
|
1999-09-07 |
2008-12-02 |
Amgen Inc. |
Fibroblast growth factor-like polypeptides
|
US7078382B1
(en)
|
1999-11-02 |
2006-07-18 |
Genentech, Inc. |
Modulation of eNOS activity and therapeutic uses thereof
|
US6331317B1
(en)
*
|
1999-11-12 |
2001-12-18 |
Alkermes Controlled Therapeutics Ii Inc. |
Apparatus and method for preparing microparticles
|
US6495166B1
(en)
|
1999-11-12 |
2002-12-17 |
Alkermes Controlled Therapeutics Inc. |
Apparatus and method for preparing microparticles using in-line solvent extraction
|
US6705757B2
(en)
*
|
1999-11-12 |
2004-03-16 |
Alkermes Controlled Therapeutics, Inc. Ii |
Method and apparatus for preparing microparticles using in-line solvent extraction
|
EP1666495A1
(en)
|
1999-12-01 |
2006-06-07 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
ES2169980B1
(es)
|
1999-12-17 |
2003-11-01 |
Lipotec Sa |
Microcapsulas para la liberacion prolongada de farmacos.
|
EP2258848B1
(en)
|
1999-12-23 |
2014-03-05 |
Genentech, Inc. |
Il-17 homologous polypeptide and therapeutic uses thereof
|
EP1246917B1
(en)
*
|
2000-01-13 |
2009-03-04 |
Genentech, Inc. |
Human stra6 polypeptides
|
ES2267593T3
(es)
|
2000-02-16 |
2007-03-16 |
Genentech, Inc. |
Anticuerpos anti-april y celulas hibridomas.
|
US20030103978A1
(en)
|
2000-02-23 |
2003-06-05 |
Amgen Inc. |
Selective binding agents of osteoprotegerin binding protein
|
US6689747B2
(en)
*
|
2000-03-24 |
2004-02-10 |
Genentech, Inc. |
Use of insulin for the treatment of cartilagenous disorders
|
US7514239B2
(en)
|
2000-03-28 |
2009-04-07 |
Amgen Inc. |
Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
|
DK2857516T3
(en)
|
2000-04-11 |
2017-08-07 |
Genentech Inc |
Multivalent antibodies and uses thereof
|
CA2405709A1
(en)
|
2000-04-12 |
2001-10-25 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
JP5356636B2
(ja)
|
2000-04-21 |
2013-12-04 |
タフツ メディカル センター インコーポレイテッド |
Gタンパク質共役型受容体(gpcr)のアゴニストおよびアンタゴニスト、および、それらを用いてgpcrを活性化および阻害する方法
|
AR023940A1
(es)
|
2000-05-03 |
2002-09-04 |
Eriochem Sa |
Procedimiento para la produccion de microcapsulas de liberacion prolongada de peptidos solubles en agua
|
US6264987B1
(en)
*
|
2000-05-19 |
2001-07-24 |
Alkermes Controlled Therapeutics Inc. Ii |
Method for preparing microparticles having a selected polymer molecular weight
|
ATE441433T1
(de)
|
2000-05-19 |
2009-09-15 |
Genentech Inc |
Gennachweisverfahren zur verbesserung der wahrscheinlichkeit einer wirkungsvollen antwort auf eine krebstherapie mit einem erbb- antagonisten
|
NZ522951A
(en)
*
|
2000-05-24 |
2004-11-26 |
Jordan Loyal Holtzman |
Biphenylmethane compounds as agents for increasing brain chaperonin levels
|
US6495164B1
(en)
*
|
2000-05-25 |
2002-12-17 |
Alkermes Controlled Therapeutics, Inc. I |
Preparation of injectable suspensions having improved injectability
|
US20040170665A1
(en)
*
|
2000-06-02 |
2004-09-02 |
Allergan, Inc. |
Intravitreal botulinum toxin implant
|
US20050214327A1
(en)
*
|
2000-06-02 |
2005-09-29 |
Allergan, Inc. |
Neurotoxin-containing suppositories and related methods
|
US6306423B1
(en)
|
2000-06-02 |
2001-10-23 |
Allergan Sales, Inc. |
Neurotoxin implant
|
US20040033241A1
(en)
*
|
2000-06-02 |
2004-02-19 |
Allergan, Inc. |
Controlled release botulinum toxin system
|
AU2001282856A1
(en)
|
2000-06-15 |
2001-12-24 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor delta and epsilon
|
EP2052742A1
(en)
|
2000-06-20 |
2009-04-29 |
Biogen Idec Inc. |
Treatment of B-cell associated diseases such as malignancies and autoimmune diseases using a cold anti-CD20 antibody/radiolabeled anti-CD22 antibody combination
|
US20020068691A1
(en)
*
|
2000-06-21 |
2002-06-06 |
Susana Salceda |
Method of diagnosing, monitoring, staging, imaging and treating breast cancer
|
CA2709771A1
(en)
|
2000-06-23 |
2002-01-03 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
DK2042597T3
(da)
|
2000-06-23 |
2014-08-11 |
Genentech Inc |
Sammensætninger og fremgangsmåder til diagnose og behandling af sygdomme, der involverer angiogenese
|
CA2413547A1
(en)
*
|
2000-06-28 |
2002-01-03 |
Amgen, Inc. |
B7-like molecules and uses thereof
|
ES2317917T3
(es)
|
2000-06-28 |
2009-05-01 |
Amgen Inc. |
Moleculas de receptor de linfopoyetina estromal timica y sus usos de las mismas.
|
US20040023259A1
(en)
*
|
2000-07-26 |
2004-02-05 |
Luca Rastelli |
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
CA2415473A1
(en)
|
2000-07-27 |
2002-02-07 |
Genentech, Inc. |
Apo-2l receptor agonist and cpt-11 synergism
|
UA81743C2
(uk)
|
2000-08-07 |
2008-02-11 |
Центокор, Инк. |
МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
|
US7288390B2
(en)
|
2000-08-07 |
2007-10-30 |
Centocor, Inc. |
Anti-dual integrin antibodies, compositions, methods and uses
|
US6902734B2
(en)
|
2000-08-07 |
2005-06-07 |
Centocor, Inc. |
Anti-IL-12 antibodies and compositions thereof
|
EP1310517B2
(en)
*
|
2000-08-07 |
2010-11-17 |
Wako Pure Chemical Industries, Ltd. |
Lactic acid polymer and process for producing the same
|
AU2001290515B2
(en)
|
2000-08-16 |
2007-02-01 |
Covidien Lp |
High consistency absorbable polymeric resin
|
WO2002013701A1
(en)
*
|
2000-08-17 |
2002-02-21 |
Tyco Healthcare Group Lp |
Sutures and coatings made from therapeutic absorbable glass
|
ATE412009T1
(de)
|
2000-08-24 |
2008-11-15 |
Genentech Inc |
Methode zur inhibierung von il-22 induziertem pap1
|
EP1944317A3
(en)
|
2000-09-01 |
2008-09-17 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
US6824822B2
(en)
|
2001-08-31 |
2004-11-30 |
Alkermes Controlled Therapeutics Inc. Ii |
Residual solvent extraction method and microparticles produced thereby
|
US6471995B1
(en)
|
2000-09-27 |
2002-10-29 |
Alkermes Controlled Therapeutics, Inc. Ii |
Apparatus and method for preparing microparticles using liquid-liquid extraction
|
ES2367891T3
(es)
|
2000-09-29 |
2011-11-10 |
Schering Corporation |
Interleucina-10 pegilada.
|
JP4296341B2
(ja)
*
|
2000-10-13 |
2009-07-15 |
独立行政法人産業技術総合研究所 |
リポソームの製造方法およびその装置
|
CA2429625C
(en)
|
2000-10-18 |
2012-05-01 |
Robert Sackstein |
Hematopoietic cell e-selectin/l-selectin ligand polypeptides and methods of use thereof
|
DE10055742B4
(de)
*
|
2000-11-10 |
2006-05-11 |
Schwarz Pharma Ag |
Neue Polyester, Verfahren zu ihrer Herstellung und aus den Polyestern hergestellte Depot-Arzneiformen
|
CA2429599A1
(en)
|
2000-11-28 |
2002-06-06 |
Amgen Inc. |
Use of b7rp1 antagonists in ige-mediated disorders
|
US6989247B2
(en)
|
2000-11-28 |
2006-01-24 |
Celltech R & D, Inc. |
Compositions and methods for diagnosing or treating psoriasis
|
US20060014674A1
(en)
*
|
2000-12-18 |
2006-01-19 |
Dennis Keith |
Methods for preparing purified lipopeptides
|
NZ554405A
(en)
*
|
2000-12-18 |
2009-04-30 |
Cubist Pharm Inc |
Method for preparing crystalline and crystal-like forms of purified lipopeptides
|
WO2002059145A1
(en)
*
|
2000-12-18 |
2002-08-01 |
Cubist Pharmaceuticals, Inc. |
Methods for preparing purified lipopeptides
|
US20020114843A1
(en)
*
|
2000-12-27 |
2002-08-22 |
Ramstack J. Michael |
Preparation of microparticles having improved flowability
|
US6964849B2
(en)
|
2001-01-11 |
2005-11-15 |
Curagen Corporation |
Proteins and nucleic acids encoding same
|
US20040043928A1
(en)
*
|
2001-08-02 |
2004-03-04 |
Ramesh Kekuda |
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
KR20080087184A
(ko)
|
2001-01-31 |
2008-09-30 |
바이오겐 아이덱 인크. |
종양질환 치료를 위한 cd23 길항제의 용도
|
US20020159996A1
(en)
|
2001-01-31 |
2002-10-31 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
US7087726B2
(en)
|
2001-02-22 |
2006-08-08 |
Genentech, Inc. |
Anti-interferon-α antibodies
|
GB0111628D0
(en)
*
|
2001-05-11 |
2001-07-04 |
Scancell Ltd |
Binding member
|
EP1390067A1
(en)
*
|
2001-05-11 |
2004-02-25 |
Novartis AG |
Compositions for use in treating ige-associated disorders
|
CN101653604A
(zh)
|
2001-05-30 |
2010-02-24 |
基因技术股份有限公司 |
抗ngf抗体用于治疗各种疾病
|
AUPR546801A0
(en)
|
2001-06-05 |
2001-06-28 |
Commonwealth Scientific And Industrial Research Organisation |
Recombinant antibodies
|
US20070160576A1
(en)
|
2001-06-05 |
2007-07-12 |
Genentech, Inc. |
IL-17A/F heterologous polypeptides and therapeutic uses thereof
|
ES2372321T3
(es)
|
2001-06-20 |
2012-01-18 |
Genentech, Inc. |
Composiciones y métodos para el diagnóstico y tratamiento de un tumor de pulmón.
|
CA2451187C
(en)
|
2001-06-22 |
2012-08-14 |
Southern Biosystems, Inc. |
Zero-order prolonged release coaxial implants
|
EP1414517A4
(en)
*
|
2001-06-26 |
2008-02-06 |
Photomed Technologies Inc |
MULTIPLE WAVELENGTH ILLUMINATOR
|
CN1547486A
(zh)
|
2001-06-26 |
2004-11-17 |
|
抗opgl抗体
|
TW200526267A
(en)
*
|
2001-06-29 |
2005-08-16 |
Takeda Chemical Industries Ltd |
Controlled release composition and method of producing the same
|
CN1194688C
(zh)
*
|
2001-07-03 |
2005-03-30 |
山东绿叶制药股份有限公司 |
石杉碱甲及其衍生物或其盐的注射用缓释微球及其制备方法
|
US20040029790A1
(en)
*
|
2001-07-05 |
2004-02-12 |
Meera Patturajan |
Novel human proteins, polynucleotides encoding them and methods of using the same
|
US20030087274A1
(en)
*
|
2001-07-05 |
2003-05-08 |
Anderson David W. |
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
GB0117057D0
(en)
*
|
2001-07-12 |
2001-09-05 |
Ferring Bv |
Pharmaceutical composition
|
AUPR673001A0
(en)
|
2001-07-31 |
2001-08-23 |
Prince Henry's Institute Of Medical Research |
Pregnancy-related enzyme activity
|
US20040030096A1
(en)
*
|
2001-08-02 |
2004-02-12 |
Linda Gorman |
Novel human proteins, polynucleotides encoding them and methods of using the same
|
MXPA04001050A
(es)
*
|
2001-08-03 |
2004-07-08 |
Genentech Inc |
Polipeptidos tacis y br3 y usos de los mismos.
|
EP2382982A3
(en)
|
2001-08-24 |
2012-02-22 |
Neuren Pharmaceuticals Limited |
Neural regeneration peptide and methods for their use in treatment of brain damage
|
NZ530985A
(en)
|
2001-08-29 |
2006-03-31 |
Genentech Inc |
Bv8 nucleic acids and polypeptides with mitogenic activity
|
US20040235068A1
(en)
*
|
2001-09-05 |
2004-11-25 |
Levinson Arthur D. |
Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
|
US20080085283A1
(en)
*
|
2001-09-05 |
2008-04-10 |
Levinson Arthur D |
Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
|
GB0121709D0
(en)
*
|
2001-09-07 |
2001-10-31 |
Imp College Innovations Ltd |
Food inhibition agent
|
GB0122318D0
(en)
*
|
2001-09-14 |
2001-11-07 |
Novartis Ag |
Organic compounds
|
KR101008758B1
(ko)
|
2001-09-18 |
2011-01-14 |
제넨테크, 인크. |
종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
|
AU2002332054B2
(en)
|
2001-09-24 |
2007-11-08 |
Imperial Innovations Limited |
Modification of feeding behavior
|
WO2003029420A2
(en)
|
2001-10-02 |
2003-04-10 |
Genentech, Inc. |
Apo-2 ligand variants and uses thereof
|
AR045702A1
(es)
|
2001-10-03 |
2005-11-09 |
Chiron Corp |
Composiciones de adyuvantes.
|
US20030199442A1
(en)
*
|
2001-10-09 |
2003-10-23 |
Alsobrook John P. |
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
US7138370B2
(en)
|
2001-10-11 |
2006-11-21 |
Amgen Inc. |
Specific binding agents of human angiopoietin-2
|
US7521053B2
(en)
|
2001-10-11 |
2009-04-21 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
EP2316485A1
(en)
|
2001-10-12 |
2011-05-04 |
Schering Corporation |
Use of bispecific antibodies to regulate immune responses
|
US7349733B2
(en)
*
|
2001-11-02 |
2008-03-25 |
Ceramatel, Inc. |
Iontophoretic drug delivery systems
|
US20030119000A1
(en)
*
|
2001-11-05 |
2003-06-26 |
Jon Polansky |
Methods to screen and treat individuals with glaucoma or the propensity to develop glaucoma
|
ATE482716T1
(de)
|
2001-11-13 |
2010-10-15 |
Genentech Inc |
Zusammensetzungen basierend auf apo2-ligand/ trail und ihre verwendung
|
PT2308888T
(pt)
|
2001-11-14 |
2017-05-03 |
Janssen Biotech Inc |
Anticorpos anti-il-6, composições, métodos e utilizações
|
DE60232987D1
(de)
*
|
2001-11-14 |
2009-08-27 |
Durect Corp |
Injizierbare depotzusammensetzungen
|
MXPA04003689A
(es)
*
|
2001-11-30 |
2004-07-23 |
Pfizer Prod Inc |
Composiciones farmaceuticas y procedimientos para administrar agonistas selectivos del receptor ep2.
|
CA2471363C
(en)
|
2001-12-21 |
2014-02-11 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
KR100623128B1
(ko)
|
2002-01-02 |
2006-09-14 |
제넨테크, 인크. |
종양의 진단 및 치료 방법 및 이를 위한 조성물
|
AU2003201998C1
(en)
|
2002-01-10 |
2012-10-25 |
Imperial Innovations Limited |
Modification of feeding behavior
|
US8058233B2
(en)
*
|
2002-01-10 |
2011-11-15 |
Oregon Health And Science University |
Modification of feeding behavior using PYY and GLP-1
|
AU2003217693A1
(en)
*
|
2002-02-22 |
2003-09-09 |
Board Of Trustees Of The University Of Illinois |
Beta chain-associated regulator of apoptosis
|
CA2476518A1
(en)
|
2002-02-22 |
2003-09-04 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
US7662924B2
(en)
*
|
2002-02-22 |
2010-02-16 |
The Board Of Trustees Of The University Of Illinois |
Beta chain-associated regulator of apoptosis
|
US20070122406A1
(en)
|
2005-07-08 |
2007-05-31 |
Xencor, Inc. |
Optimized proteins that target Ep-CAM
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
US20090042291A1
(en)
*
|
2002-03-01 |
2009-02-12 |
Xencor, Inc. |
Optimized Fc variants
|
US7662925B2
(en)
|
2002-03-01 |
2010-02-16 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
US20100311954A1
(en)
*
|
2002-03-01 |
2010-12-09 |
Xencor, Inc. |
Optimized Proteins that Target Ep-CAM
|
EA011853B1
(ru)
|
2002-03-13 |
2009-06-30 |
Байоджен Айдек Ма Инк. |
АНТИТЕЛА ПРОТИВ αβ
|
US7264822B2
(en)
*
|
2002-04-03 |
2007-09-04 |
Poly-Med, Inc. |
Conjugated drug-polymer coated stent
|
EP1494714A4
(en)
*
|
2002-04-05 |
2008-03-05 |
Amgen Inc |
HUMAN ANTI-OPGL NEUTRALIZING ANTIBODIES AS SELECTIVE OPGL PATH HEMMER
|
SI2289942T1
(sl)
|
2002-04-10 |
2013-11-29 |
Genentech, Inc. |
Variante protitelesa proti HER2
|
JP4386741B2
(ja)
|
2002-04-15 |
2009-12-16 |
中外製薬株式会社 |
scDbライブラリーの作成方法
|
EP2011886A3
(en)
|
2002-04-16 |
2009-02-11 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
EP1499367A1
(en)
*
|
2002-04-24 |
2005-01-26 |
Poly-Med, Inc. |
Multifaceted endovascular stent coating for preventing restenosis
|
US7732149B2
(en)
|
2002-04-26 |
2010-06-08 |
Chugai Seiyaku Kabushiki Kaisha |
Methods of screening agonistic antibodies
|
AU2002304965A1
(en)
*
|
2002-05-24 |
2003-12-12 |
Zensun (Shanghai) Sci-Tech.Ltd |
Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
|
WO2005056606A2
(en)
*
|
2003-12-03 |
2005-06-23 |
Xencor, Inc |
Optimized antibodies that target the epidermal growth factor receptor
|
EP2305710A3
(en)
|
2002-06-03 |
2013-05-29 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
AU2003251397B2
(en)
|
2002-06-05 |
2009-10-01 |
Genentech, Inc. |
Compositions and methods for liver growth and liver protection
|
AU2003243400B2
(en)
*
|
2002-06-07 |
2009-10-29 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
AU2003247609A1
(en)
|
2002-06-24 |
2004-01-06 |
Genentech, Inc. |
Apo-2 ligand/trail variants and uses thereof
|
AU2003280130B2
(en)
|
2002-06-28 |
2009-06-11 |
Centocor, Inc. |
Mammalian CH1 deleted mimetibodies, compositions, methods and uses
|
WO2004004649A2
(en)
|
2002-07-08 |
2004-01-15 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
MX337052B
(es)
|
2002-07-15 |
2016-02-11 |
Univ Texas |
Peptidos que se enlazan a fosfatidiletanolamina y sus usos en el tratamiento de infecciones virales y del cancer.
|
MXPA05000403A
(es)
|
2002-07-15 |
2005-07-22 |
Genentech Inc |
Metodos para identificar tumores que responden al tratamiento con anticuerpos contra erbb2.
|
MXPA05000940A
(es)
*
|
2002-07-25 |
2005-05-16 |
Genentech Inc |
Anticuerpos taci y su uso.
|
US20050232995A1
(en)
|
2002-07-29 |
2005-10-20 |
Yam Nyomi V |
Methods and dosage forms for controlled delivery of paliperidone and risperidone
|
US20040142393A1
(en)
*
|
2002-08-01 |
2004-07-22 |
Cooper Garth James Smith |
Methods of use of compounds with preptin function
|
US20050271639A1
(en)
*
|
2002-08-22 |
2005-12-08 |
Penn Marc S |
Genetically engineered cells for therapeutic applications
|
WO2007068784A1
(en)
|
2005-12-14 |
2007-06-21 |
Licentia Ltd |
Novel neurotrophic factor protein and uses thereof
|
EA018072B1
(ru)
|
2002-09-06 |
2013-05-30 |
Амджен Инк. |
Антитело к рецептору интерлейкина-1 типа 1 (il-1r1) и его применение
|
CA2497661A1
(en)
|
2002-09-11 |
2004-03-25 |
Genentech, Inc. |
Compositions and methods for the diagnosis of immune related diseases using pro71061
|
EP1539228B1
(en)
|
2002-09-11 |
2010-12-29 |
Genentech, Inc. |
Novel composition and methods for the treatment of immune related diseases
|
CA2497334A1
(en)
|
2002-09-11 |
2004-03-25 |
Genentech, Inc. |
Novel compositions and methods for the treatment of immune related diseases
|
AU2003265994B2
(en)
|
2002-09-11 |
2010-04-01 |
Genentech, Inc. |
Protein purification
|
JP2006515165A
(ja)
|
2002-09-16 |
2006-05-25 |
ジェネンテック・インコーポレーテッド |
免疫関連疾患の治療のための新規組成物と方法
|
JP2006513700A
(ja)
|
2002-09-25 |
2006-04-27 |
ジェネンテック・インコーポレーテッド |
乾癬の治療のための新規組成物と方法
|
US20040062778A1
(en)
*
|
2002-09-26 |
2004-04-01 |
Adi Shefer |
Surface dissolution and/or bulk erosion controlled release compositions and devices
|
CN101987871A
(zh)
|
2002-09-27 |
2011-03-23 |
赞科股份有限公司 |
优化的Fc变体及其产生方法
|
WO2004032852A2
(en)
*
|
2002-10-04 |
2004-04-22 |
Rinat Neuroscience Corp. |
Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists
|
UA80447C2
(en)
*
|
2002-10-08 |
2007-09-25 |
|
Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
|
PT1556083E
(pt)
*
|
2002-10-08 |
2011-03-17 |
Rinat Neuroscience Corp |
Métodos para tratar a dor pós-cirúrgica pela administração de um anticorpo contra o factor de crescimento nervoso e composições que contêm o mesmo
|
WO2005000194A2
(en)
|
2002-10-08 |
2005-01-06 |
Rinat Neuroscience Corp. |
Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
|
AU2003285874A1
(en)
|
2002-10-16 |
2004-05-04 |
Amgen Inc. |
HUMAN ANTI-IFN-Gamma NEUTRALIZING ANTIBODIES AS SELECTIVE IFN-Gamma PATHWAY INHIBITORS
|
EP1576137A4
(en)
|
2002-10-29 |
2010-06-30 |
Genentech Inc |
COMPOSITIONS AND METHODS FOR TREATING DISEASES RELATED TO THE IMMUNE SYSTEM
|
US20040086532A1
(en)
*
|
2002-11-05 |
2004-05-06 |
Allergan, Inc., |
Botulinum toxin formulations for oral administration
|
EP2364716A3
(en)
|
2002-11-08 |
2012-01-11 |
Genentech, Inc. |
Compositions and methods for the treatment of natural killer cell related diseases
|
US20040097419A1
(en)
*
|
2002-11-19 |
2004-05-20 |
Holger Petersen |
Organic compounds
|
AU2003302386B2
(en)
|
2002-11-26 |
2010-04-01 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
RU2377253C2
(ru)
|
2002-12-02 |
2009-12-27 |
Амген Фремонт,Инк. |
Антитела, специфичные к фактору некроза опухолей, и их применение
|
US7569364B2
(en)
*
|
2002-12-24 |
2009-08-04 |
Pfizer Inc. |
Anti-NGF antibodies and methods using same
|
SI2263692T1
(sl)
|
2002-12-24 |
2020-10-30 |
Rinat Neuroscience Corp. |
Anti-NGF protitelesa in postopki, v katerih se le-ta uporabljajo
|
US9498530B2
(en)
|
2002-12-24 |
2016-11-22 |
Rinat Neuroscience Corp. |
Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
|
JP2006517191A
(ja)
|
2002-12-30 |
2006-07-20 |
アムジエン・インコーポレーテツド |
共刺激因子を用いた併用療法
|
US7060299B2
(en)
*
|
2002-12-31 |
2006-06-13 |
Battelle Memorial Institute |
Biodegradable microparticles that stabilize and control the release of proteins
|
GB0300571D0
(en)
*
|
2003-01-10 |
2003-02-12 |
Imp College Innovations Ltd |
Modification of feeding behaviour
|
EP1585768A2
(en)
*
|
2003-01-23 |
2005-10-19 |
Genentech, Inc. |
Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
|
CA2514117A1
(en)
|
2003-01-24 |
2004-08-12 |
Elan Pharmaceuticals, Inc. |
Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
|
EP1594517B1
(en)
|
2003-01-28 |
2007-06-20 |
Microbia, Inc. |
Compositions for the treatment of gastrointestinal disorders
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
JP4764334B2
(ja)
|
2003-02-01 |
2011-08-31 |
タノックス インコーポレーテッド |
高親和性抗ヒトIgE抗体
|
DE602004030535D1
(de)
|
2003-02-19 |
2011-01-27 |
Rinat Neuroscience Corp |
Verfahren zur behandlung von schmerzen durch verabreichung eines nervenwachstumsfaktor-antagonisten und eines nsaid und diese enthaltende zusammensetzung
|
GB0304726D0
(en)
*
|
2003-03-01 |
2003-04-02 |
Ardana Bioscience Ltd |
New Process
|
US20090010920A1
(en)
*
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
US8388955B2
(en)
*
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
US9445901B2
(en)
*
|
2003-03-12 |
2016-09-20 |
Deger C. Tunc |
Prosthesis with sustained release analgesic
|
EP2526960A1
(en)
|
2003-03-12 |
2012-11-28 |
Genentech, Inc. |
Use of BV8 and/or EG-VEGF to promote hematopoiesis
|
DK1613750T3
(en)
|
2003-03-19 |
2016-01-18 |
Amgen Fremont Inc |
ANTIBODIES TO T CELL AND MUCINDO immunoglobulin-binding domain 1 (TIM-1) antigen and uses thereof
|
US8431396B2
(en)
|
2003-03-21 |
2013-04-30 |
The Cleveland Clinic Foundation |
Anti-angiogenic peptides
|
ES2431548T3
(es)
|
2003-04-04 |
2013-11-26 |
Université de Lausanne |
Proteínas inhibidoras de una proteasa y su uso
|
ZA200507757B
(en)
|
2003-04-04 |
2007-01-31 |
Genentech Inc |
High concentration antibody and protein formulations
|
WO2004091657A2
(en)
|
2003-04-09 |
2004-10-28 |
Genentech, Inc. |
Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor
|
CN101052726A
(zh)
|
2003-05-09 |
2007-10-10 |
森托科尔公司 |
IL-23p40特异性免疫球蛋白衍生蛋白、组合物、方法和用途
|
JP4884224B2
(ja)
|
2003-05-09 |
2012-02-29 |
ディアデクサス インコーポレーテッド |
Ovr110抗体組成物および使用方法
|
US7259234B2
(en)
|
2003-05-15 |
2007-08-21 |
Trustees Of Tufts College |
Stable analogs of peptide and polypeptide therapeutics
|
US7375076B2
(en)
*
|
2003-05-20 |
2008-05-20 |
The Regents Of The University Of Michigan |
Methods of reducing vascular permeability in tissue by inhibition of tissue plasminogen activator (tPA) and tPA inhibitors useful therein
|
KR20060006975A
(ko)
|
2003-05-30 |
2006-01-20 |
제넨테크, 인크. |
항-vegf 항체를 사용한 치료
|
WO2005000896A2
(en)
*
|
2003-05-30 |
2005-01-06 |
Genentech, Inc. |
Polypeptides that bind an anti-tissue factor antibody and uses thereof
|
PT1631313E
(pt)
*
|
2003-06-05 |
2015-07-02 |
Genentech Inc |
Terapêutica de combinação para distúrbios de células b
|
US20050163775A1
(en)
*
|
2003-06-05 |
2005-07-28 |
Genentech, Inc. |
Combination therapy for B cell disorders
|
ES2323425T3
(es)
|
2003-06-06 |
2009-07-15 |
Genentech, Inc. |
Modulacion de la interaccion entre la cadena beta de hgf y c-met.
|
KR20130065723A
(ko)
*
|
2003-06-27 |
2013-06-19 |
암젠 프레몬트 인코포레이티드 |
상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그 용도
|
WO2005020886A2
(en)
*
|
2003-06-27 |
2005-03-10 |
New England Biolabs, Inc. |
Identification and use of cofactor independent phosphoglycerate mutase as a drug target
|
US7939058B2
(en)
*
|
2003-07-03 |
2011-05-10 |
University Of Southern California |
Uses of IL-12 in hematopoiesis
|
NZ544317A
(en)
|
2003-07-08 |
2009-05-31 |
Genentech Inc |
IL-17 A/F heterologous polypeptides and therapeutic uses thereof
|
PL1648998T3
(pl)
|
2003-07-18 |
2015-03-31 |
Amgen Inc |
Specyficzne czynniki wiążące czynnik wzrostu hepatocytów
|
DK1660039T3
(en)
|
2003-07-18 |
2017-01-16 |
Oakwood Laboratories L L C |
PREVENTION OF REDUCTION OF THE POLYMER MOLECULE WEIGHT, THE PREPARATION OF PURPOSES AND GELING IN POLYMER COMPOSITIONS
|
JP2007501011A
(ja)
*
|
2003-08-01 |
2007-01-25 |
ジェネンテック・インコーポレーテッド |
制限多様性配列を有する結合型ポリペプチド
|
WO2005019258A2
(en)
|
2003-08-11 |
2005-03-03 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
WO2005020933A2
(en)
*
|
2003-09-02 |
2005-03-10 |
University Of South Florida |
Nanoparticles for drug-delivery
|
ES2541673T3
(es)
|
2003-09-12 |
2015-07-23 |
Ipsen Biopharmaceuticals, Inc. |
Métodos para el tratamiento de la deficiencia de factor 1 de crecimiento similar a la insulina (IGF-1)
|
US9714282B2
(en)
|
2003-09-26 |
2017-07-25 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
US8101720B2
(en)
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
UA89481C2
(uk)
|
2003-09-30 |
2010-02-10 |
Центокор, Инк. |
Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування
|
AU2003271174A1
(en)
|
2003-10-10 |
2005-04-27 |
Chugai Seiyaku Kabushiki Kaisha |
Double specific antibodies substituting for functional protein
|
AU2003271186A1
(en)
|
2003-10-14 |
2005-04-27 |
Chugai Seiyaku Kabushiki Kaisha |
Double specific antibodies substituting for functional protein
|
WO2005037235A2
(en)
|
2003-10-16 |
2005-04-28 |
Imclone Systems Incorporated |
Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof
|
CA2543484C
(en)
|
2003-10-27 |
2014-02-04 |
Amgen Inc. |
Modulation of immune response to an immunogen with ctla-4 and tnfbp
|
WO2005040163A1
(en)
*
|
2003-10-28 |
2005-05-06 |
Dr. Reddy's Laboratories Ltd |
Heterocyclic compounds that block the effects of advanced glycation end products (age)
|
ES2383525T3
(es)
|
2003-11-05 |
2012-06-21 |
Sarcode Bioscience Inc. |
Moduladores de la adhesión celular
|
LT2380911T
(lt)
|
2003-11-05 |
2018-07-10 |
Roche Glycart Ag |
Antigeną surišančios molekulės, pasižyminčios padidintu fc receptoriaus surišimo afiniškumu ir efektoriaus funkcija
|
ES2472690T3
(es)
|
2003-11-17 |
2014-07-02 |
Genentech, Inc. |
Anticuerpo contra CD22 para el tratamiento de tumores de origen hematopoy�tico
|
US20050125914A1
(en)
*
|
2003-11-18 |
2005-06-16 |
Gerard Malle |
Hair shaping composition comprising at least one- non-hydroxide base
|
CN1914226B
(zh)
*
|
2003-11-25 |
2012-02-01 |
达纳-法伯癌症研究院有限公司 |
SARS-CoV抗体及其使用方法
|
US20080220049A1
(en)
*
|
2003-12-05 |
2008-09-11 |
Adnexus, A Bristol-Myers Squibb R&D Company |
Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins
|
EP1711196A4
(en)
|
2003-12-05 |
2011-09-14 |
Bristol Myers Squibb Co |
INHIBITORS OF TYPE-2 VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTORS
|
WO2005065015A2
(en)
|
2003-12-10 |
2005-07-21 |
Novimmune Sa |
Neutralizing antibodies and methods of use thereof
|
US7312320B2
(en)
|
2003-12-10 |
2007-12-25 |
Novimmune Sa |
Neutralizing antibodies and methods of use thereof
|
EP2336178A1
(en)
|
2003-12-11 |
2011-06-22 |
Genentech, Inc. |
Methods and compositions for inhibiting C-Met dimerization and activation
|
PL1718677T3
(pl)
|
2003-12-19 |
2012-09-28 |
Genentech Inc |
Jednowartościowe fragmenty przeciwciała stosowane jako środki lecznicze
|
KR20070001932A
(ko)
*
|
2003-12-23 |
2007-01-04 |
리나트 뉴로사이언스 코퍼레이션 |
작용물질 항 티알케이씨 항체 및 그의 사용 방법
|
JP2007530015A
(ja)
*
|
2004-01-05 |
2007-11-01 |
バイオテック・スタジオ・リミテッド・ライアビリティ・カンパニー |
生物治療学的、診断および研究試薬
|
HUE026132T2
(en)
|
2004-01-07 |
2016-05-30 |
Novartis Vaccines & Diagnostics Inc |
M-CSF-specific monoclonal antibody and its uses
|
EP1703915A2
(en)
*
|
2004-01-13 |
2006-09-27 |
Vasogenix Pharmaceuticals, Inc. |
Methods of using cgrp for cardiovascular and renal indications
|
JP2007517913A
(ja)
*
|
2004-01-13 |
2007-07-05 |
バソジェニックス ファーマシューティカルズ, インコーポレイテッド |
カルシトニン遺伝子関連ペプチドを投与することによって急性心筋梗塞を処置するための方法およびカルシトニン遺伝子関連ペプチドを含有する組成物
|
CA2552677A1
(en)
*
|
2004-01-13 |
2005-07-28 |
Vasogenix Pharmaceuticals, Inc. |
Controlled release cgrp delivery composition for cardiovascular and renal indications
|
NZ548871A
(en)
|
2004-01-30 |
2009-06-26 |
Shire Pharmaceuticals Ireland |
Use of arylsulfatase A for treating metachromatic leukodystrophy
|
MXPA06008496A
(es)
|
2004-02-02 |
2007-01-30 |
Ambrx Inc |
Polipeptidos de interferon humano modificados y sus usos.
|
MXPA06008746A
(es)
|
2004-02-06 |
2007-01-23 |
Elan Pharm Inc |
Metodos y composiciones para tratamiento de tumores y enfermedad metastatica.
|
EP2168986A3
(en)
|
2004-02-19 |
2010-07-28 |
Genentech, Inc. |
CDR-repaired antibodies
|
WO2005082401A1
(en)
*
|
2004-02-20 |
2005-09-09 |
Rinat Neuroscience Corp. |
Methods of treating obesity or diabetes using nt-4/5
|
US20100028995A1
(en)
*
|
2004-02-23 |
2010-02-04 |
Anaphore, Inc. |
Tetranectin Trimerizing Polypeptides
|
EP1732947B1
(en)
*
|
2004-03-05 |
2011-04-27 |
Vegenics Pty Ltd |
Growth factor binding constructs materials and methods
|
JP4705026B2
(ja)
|
2004-03-19 |
2011-06-22 |
ジェノミディア株式会社 |
血管内皮増殖促進遺伝子
|
JP2008507257A
(ja)
|
2004-03-19 |
2008-03-13 |
アムゲン・インコーポレーテッド |
V遺伝子の操作を介したヒト抗ヒト抗体の危険性の低減
|
CA2560889A1
(en)
*
|
2004-03-23 |
2005-10-13 |
Sanjay D. Khare |
Monoclonal antibodies specific for human ox40l (cd 134l)
|
KR20070004078A
(ko)
*
|
2004-03-31 |
2007-01-05 |
센토코 인코포레이티드 |
인간 glp-1 모방체, 조성물, 방법 및 용도
|
MY162179A
(en)
|
2004-04-01 |
2017-05-31 |
Elan Pharm Inc |
Steroid sparing agents and methods of using same
|
NZ549990A
(en)
*
|
2004-04-07 |
2009-08-28 |
Rinat Neuroscience Copr |
Methods for treating bone cancer pain by administering a nerve growth factor antagonist
|
US7794713B2
(en)
|
2004-04-07 |
2010-09-14 |
Lpath, Inc. |
Compositions and methods for the treatment and prevention of hyperproliferative diseases
|
EP1737489B1
(en)
|
2004-04-08 |
2012-01-11 |
David B Agus |
ErbB2 antagonists for tumor pain therapy
|
MXPA06011924A
(es)
*
|
2004-04-15 |
2007-06-11 |
Alkermes Inc |
Dispositivo de liberacion continua base polimeros.
|
WO2005113003A2
(en)
*
|
2004-04-16 |
2005-12-01 |
Genentech, Inc. |
Method for augmenting b cell depletion
|
ATE483981T1
(de)
|
2004-04-20 |
2010-10-15 |
Galapagos Nv |
Verfahren, zusammensetzungen und verbindungstests zur hemmung der amyloid-beta-proteinproduktion
|
MXPA06012162A
(es)
|
2004-04-27 |
2007-03-30 |
Galapagos Nv |
Metodos, agentes y ensayos de seleccion de compuestos para inducir diferenciacion de celulas de mamifero no diferenciadas, en osteoblastos.
|
GB0410627D0
(en)
|
2004-05-12 |
2004-06-16 |
Scancell Ltd |
Specific binding members
|
CA2566647A1
(en)
*
|
2004-05-13 |
2005-12-22 |
Imclone Systems Incorporated |
Inhibition of macrophage-stimulating protein receptor (ron)
|
EP1789453A2
(en)
*
|
2004-05-18 |
2007-05-30 |
Genentech, Inc. |
M13 virus major coat protein variants for c-terminal and bi-terminal display of a heterologous protein
|
EP1598428A1
(en)
|
2004-05-18 |
2005-11-23 |
Georg Dewald |
Methods and kits to detect Hereditary angioedema type III
|
AU2005249490B2
(en)
|
2004-06-01 |
2010-07-29 |
Genentech, Inc. |
Antibody drug conjugates and methods
|
AU2005249566B2
(en)
|
2004-06-04 |
2010-11-11 |
Genentech, Inc. |
Method for treating multiple sclerosis
|
WO2005120462A2
(en)
*
|
2004-06-07 |
2005-12-22 |
Callisyn Pharmaceuticals, Inc. |
Biodegradable and biocompatible crosslinked polymer hydrogel prepared from pva and/or peg macromer mixtures
|
WO2005121778A2
(en)
|
2004-06-14 |
2005-12-22 |
Galapagos N.V. |
Methods for identification, and compounds useful for the treatment of degenerative & inflammatory diseases
|
SV2006002143A
(es)
|
2004-06-16 |
2006-01-26 |
Genentech Inc |
Uso de un anticuerpo para el tratamiento del cancer resistente al platino
|
MXPA06014684A
(es)
|
2004-06-18 |
2007-02-12 |
Ambrx Inc |
Novedosos polipeptidos de enlace antigeno y sus usos.
|
EP2360474B1
(en)
|
2004-06-21 |
2013-07-24 |
Galapagos N.V. |
Methods and means for treatment of osteoarthritis
|
ATE501252T1
(de)
|
2004-06-22 |
2011-03-15 |
Univ Illinois |
Verfahren zur inhibierung von tumorzellwachstum mit foxm1 sirns
|
DK2801583T3
(en)
|
2004-07-10 |
2018-07-16 |
Fox Chase Cancer Center |
Genetically modified human natural killer cell lines
|
AU2005272993B2
(en)
|
2004-07-15 |
2010-02-11 |
Xencor, Inc |
Optimized Fc variants
|
ME00226B
(me)
|
2004-07-15 |
2011-02-10 |
Medarex Llc |
Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
|
ATE456579T1
(de)
|
2004-07-20 |
2010-02-15 |
Genentech Inc |
Angiopoietin-like 4 protein hemmer kombinationen und deren verwendung
|
WO2009100255A2
(en)
|
2008-02-08 |
2009-08-13 |
Ambrx, Inc. |
Modified leptin polypeptides and their uses
|
KR20070039593A
(ko)
|
2004-07-21 |
2007-04-12 |
암브룩스, 인코포레이티드 |
비천연적으로 코딩된 아미노산을 이용한 생합성 폴리펩티드
|
ES2414460T3
(es)
|
2004-08-04 |
2013-07-19 |
Amgen Inc. |
Anticuerpos para Dkk-1
|
AU2005325213B2
(en)
|
2004-08-04 |
2010-10-07 |
Evonik Corporation |
Methods for manufacturing delivery devices and devices thereof
|
AU2005277384B2
(en)
|
2004-08-17 |
2011-11-17 |
The Johns Hopkins University |
PDE5 inhibitor compositions and methods for treating cardiac indications
|
SI1784426T1
(sl)
|
2004-09-03 |
2012-03-30 |
Genentech Inc |
Humanizirani antagonisti proti beta in njihove uporabe
|
US7393662B2
(en)
*
|
2004-09-03 |
2008-07-01 |
Centocor, Inc. |
Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
|
US20100111856A1
(en)
|
2004-09-23 |
2010-05-06 |
Herman Gill |
Zirconium-radiolabeled, cysteine engineered antibody conjugates
|
PL1791565T3
(pl)
|
2004-09-23 |
2016-10-31 |
|
Modyfikowane cysteiną przeciwciała i koniugaty
|
WO2006037182A1
(en)
|
2004-10-06 |
2006-04-13 |
Agri-Biotech Pty Ltd |
Antibody production method
|
US8034345B2
(en)
|
2004-10-15 |
2011-10-11 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-PCI antibody for regulating liver regeneration/repair
|
US7485468B2
(en)
|
2004-10-15 |
2009-02-03 |
Galapagos Bv |
Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
|
NZ596663A
(en)
|
2004-10-21 |
2013-07-26 |
Genentech Inc |
Use of vegf antagonists in intraocular neovascular disease treatment
|
CA2586344C
(en)
|
2004-11-04 |
2013-05-28 |
New England Medical Center Hospitals, Inc. |
G protein coupled receptor agonists and antagonists and methods of use
|
EP1817055B1
(en)
|
2004-11-10 |
2012-12-26 |
Diadexus, Inc. |
Ovr110 antibody compositions and methods of use
|
US8546543B2
(en)
|
2004-11-12 |
2013-10-01 |
Xencor, Inc. |
Fc variants that extend antibody half-life
|
DK2325207T3
(en)
|
2004-11-12 |
2017-06-06 |
Xencor Inc |
Fc variants with altered binding to FcRn
|
US8802820B2
(en)
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US8367805B2
(en)
*
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
DE602005025525D1
(de)
|
2004-11-17 |
2011-02-03 |
Amgen Inc |
Vollständige humane monoklonale antikörper gegen il-13
|
EP1817059A2
(en)
|
2004-12-01 |
2007-08-15 |
Genentech, Inc. |
Conjugates of 1,8-bis-naphthalimides with an antibody
|
CA2590962A1
(en)
|
2004-12-06 |
2006-06-15 |
Siga Technologies, Inc. |
Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses
|
AU2005319404B2
(en)
|
2004-12-20 |
2011-10-20 |
Amgen Fremont Inc. |
Binding proteins specific for human Matriptase
|
PL1838733T3
(pl)
|
2004-12-21 |
2012-02-29 |
Medimmune Ltd |
Przeciwciała skierowane przeciwko angiopoetynie-2 i ich zastosowania
|
KR101224781B1
(ko)
|
2004-12-22 |
2013-01-21 |
암브룩스, 인코포레이티드 |
비천연적으로 코딩된 아미노산을 포함하는 인간 성장호르몬의 조제물
|
BRPI0518661A2
(pt)
|
2004-12-22 |
2008-12-02 |
Ambrx Inc |
mÉtodos para expressço e purificaÇço do hormânio do crescimento humano recombinante
|
MX2007007580A
(es)
|
2004-12-22 |
2007-12-11 |
Ambrx Inc |
Hormona del crecimiento humana modificada.
|
ATE541934T1
(de)
*
|
2004-12-22 |
2012-02-15 |
Ambrx Inc |
Zusammensetzungen von aminoacyl-trna-synthetase und verwendungen davon
|
US7638491B2
(en)
|
2004-12-22 |
2009-12-29 |
Ambrx, Inc. |
Therapies using non-natural amino acids and polypeptides
|
DE602006013275D1
(de)
|
2005-01-07 |
2010-05-12 |
Diadexus Inc |
Ovr110-antikörperzusammensetzungen und verwendungsverfahren dafür
|
JP2008526998A
(ja)
*
|
2005-01-13 |
2008-07-24 |
ジェネンテック・インコーポレーテッド |
治療方法
|
CN101141981A
(zh)
|
2005-01-21 |
2008-03-12 |
健泰科生物技术公司 |
Her抗体的固定剂量给药
|
CA2590164A1
(en)
|
2005-01-26 |
2006-08-03 |
Amgen Fremont Inc. |
Antibodies against interleukin-1 beta
|
US11246913B2
(en)
|
2005-02-03 |
2022-02-15 |
Intarcia Therapeutics, Inc. |
Suspension formulation comprising an insulinotropic peptide
|
PL1871805T3
(pl)
|
2005-02-07 |
2020-03-31 |
Roche Glycart Ag |
Cząsteczki wiążące antygen, które wiążą egfr, wektory kodujące te cząsteczki oraz ich zastosowania
|
DK1853718T3
(en)
|
2005-02-15 |
2015-11-09 |
Univ Duke |
ANTI-CD19 ANTIBODIES AND THEIR USE IN ONCOLOGY
|
US8329178B2
(en)
|
2005-02-18 |
2012-12-11 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against CXCR4 and methods of use thereof
|
EP2399605A1
(en)
|
2005-02-23 |
2011-12-28 |
Genentech, Inc. |
Extending time to disease progression or survival in cancer patients
|
TW200714289A
(en)
*
|
2005-02-28 |
2007-04-16 |
Genentech Inc |
Treatment of bone disorders
|
RU2007137489A
(ru)
|
2005-03-10 |
2009-04-20 |
Дженентек, Инк. (Us) |
Способы и композиции для модуляции целостности сосудов
|
WO2006105325A2
(en)
*
|
2005-03-31 |
2006-10-05 |
The University Of Chicago |
Compositions comprising wnt-3 peptide for modulating medial-lateral neuronal topographic maps
|
US20100003254A1
(en)
|
2005-04-08 |
2010-01-07 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody Substituting for Function of Blood Coagulation Factor VIII
|
CA2604036A1
(en)
|
2005-04-09 |
2006-10-19 |
Fusion Antibodies Limited |
Cathepsin s antibody
|
US20090054320A1
(en)
*
|
2005-04-20 |
2009-02-26 |
Protemix Discovery Limited |
Vesiculins
|
JO3058B1
(ar)
|
2005-04-29 |
2017-03-15 |
Applied Molecular Evolution Inc |
الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها
|
WO2006121852A2
(en)
|
2005-05-05 |
2006-11-16 |
Duke University |
Anti-cd19 antibody therapy for autoimmune disease
|
US20080009546A1
(en)
|
2005-05-06 |
2008-01-10 |
Chevron U.S.A. Inc. |
Diamondoid derivatives possessing therapeutic activity in the treatment of neurologic disorders
|
ES2561628T3
(es)
|
2005-05-06 |
2016-02-29 |
Zymogenetics, Inc. |
Anticuerpos monoclonales IL-31 y métodos de uso
|
RU2007145509A
(ru)
*
|
2005-05-09 |
2009-06-20 |
Гликарт Биотехнологи Аг (Ch) |
Антигенсвязывающие молекулы, имеющие модифицированные fc-участки и измененное связывание с fc-рецепторами
|
WO2006124627A2
(en)
*
|
2005-05-12 |
2006-11-23 |
Biogen Idec Ma Inc. |
Methods of treating conditions involving neuronal degeneration
|
WO2006124699A2
(en)
*
|
2005-05-12 |
2006-11-23 |
Wisconsin Alumni Research Foundation |
Blockade of pin1 prevents cytokine production by activated immune cells
|
NZ581779A
(en)
|
2005-05-17 |
2011-09-30 |
Univ Connecticut |
Composition and methods for immunomodulation in an organism comprising interleukin-15 polypeptide and interleukin-15 receptor subunit A polypeptide complex
|
PT1881823E
(pt)
*
|
2005-05-17 |
2015-03-02 |
Sarcode Bioscience Inc |
Composições e métodos para o tratamento de transtornos oculares
|
EP1893229B1
(en)
*
|
2005-06-03 |
2011-10-19 |
Ambrx, Inc. |
Improved human interferon molecules and their uses
|
NZ563341A
(en)
|
2005-06-06 |
2009-10-30 |
Genentech Inc |
Methods for identifying agents that modulate a gene that encodes for a PRO1568 polypeptide
|
CA2610987C
(en)
|
2005-06-10 |
2013-09-10 |
Chugai Seiyaku Kabushiki Kaisha |
Stabilizer for protein preparation comprising meglumine and use thereof
|
EP3348639A3
(en)
|
2005-06-10 |
2018-10-31 |
Chugai Seiyaku Kabushiki Kaisha |
Sc(fv)2 site-directed mutant
|
GB0511986D0
(en)
*
|
2005-06-13 |
2005-07-20 |
Imp College Innovations Ltd |
Novel compounds and their effects on feeding behaviour
|
EA012801B1
(ru)
|
2005-06-14 |
2009-12-30 |
Эмджен Инк. |
Самобуферирующиеся композиции белков
|
SI1899378T1
(sl)
|
2005-06-21 |
2010-02-26 |
Xoma Technology Ltd |
IL-1Beta vezavna protitelesa in njihovi fragmenti
|
WO2007005955A2
(en)
|
2005-06-30 |
2007-01-11 |
Centocor, Inc. |
Anti-il-23 antibodies, compositions, methods and uses
|
CN102875681A
(zh)
|
2005-07-08 |
2013-01-16 |
拜奥根Idec马萨诸塞公司 |
抗-αvβ6抗体及其用途
|
US20090062909A1
(en)
|
2005-07-15 |
2009-03-05 |
Micell Technologies, Inc. |
Stent with polymer coating containing amorphous rapamycin
|
JP5756588B2
(ja)
|
2005-07-15 |
2015-07-29 |
ミセル テクノロジーズ、インコーポレイテッド |
制御されたモルホロジーの薬剤粉末を含むポリマーコーティング
|
NO345593B1
(no)
|
2005-07-18 |
2021-05-03 |
Amgen Inc |
Humane anti-B7RP1 nøytraliserende antistoffer
|
JP2009502954A
(ja)
|
2005-07-27 |
2009-01-29 |
ユニバーシティ オブ フロリダ リサーチ ファウンデーション,インコーポレイティド |
タンパク質のミスフォールディングを修正する小分子及びその使用
|
WO2007016285A2
(en)
*
|
2005-07-28 |
2007-02-08 |
Novartis Ag |
M-csf specific monoclonal antibody and uses thereof
|
ES2538036T3
(es)
*
|
2005-07-28 |
2015-06-16 |
Novartis Ag |
Uso de anticuerpo a M-CSF
|
CA2618796C
(en)
|
2005-08-11 |
2018-01-02 |
Arpi Matossian-Rogers |
Peptides for treatment and diagnosis of autoimmune disease
|
JP2009504183A
(ja)
|
2005-08-15 |
2009-02-05 |
ジェネンテック・インコーポレーテッド |
遺伝子破壊、それに関連する組成物および方法
|
AU2005335491B2
(en)
*
|
2005-08-18 |
2010-11-25 |
Ambrx, Inc. |
Compositions of tRNA and uses thereof
|
CA2619298C
(en)
|
2005-08-26 |
2017-07-04 |
Glycart Biotechnology Ag |
Modified antigen binding molecules with altered cell signaling activity
|
CN101262874A
(zh)
|
2005-09-08 |
2008-09-10 |
塔夫茨大学信托人 |
稳定化的glp-1类似物
|
JP5554496B2
(ja)
*
|
2005-09-19 |
2014-07-23 |
ニューロナセント インコーポレイテッド |
神経発生を刺激するための、およびニューロン変性を阻害するための方法および組成物
|
ES2740108T3
(es)
|
2005-09-29 |
2020-02-05 |
Ipsen Pharma |
Composición para uso en el tratamiento de dismotilidad gastrointestinal
|
WO2007041635A2
(en)
|
2005-10-03 |
2007-04-12 |
Xencor, Inc. |
Fc variants with optimized fc receptor binding properties
|
EP3037544A1
(en)
|
2005-10-13 |
2016-06-29 |
Human Genome Sciences, Inc. |
Methods and compositions for use in treatment of systemic lupus erythematosus (sle) patients with autoantibody positive diseases
|
JP5014143B2
(ja)
|
2005-10-14 |
2012-08-29 |
学校法人福岡大学 |
膵島移植における移植膵島障害抑制剤
|
BRPI0617664B8
(pt)
|
2005-10-21 |
2021-05-25 |
Chugai Pharmaceutical Co Ltd |
uso de um anticorpo que reconhece a il-6 para a produção de uma composição farmacêutica para tratar o enfarte do miocárdio ou suprimir a remodelagem ventricular esquerda depois do enfarte do miocárdio
|
PT1978993T
(pt)
|
2005-10-31 |
2017-03-17 |
Oncomed Pharm Inc |
Composições e métodos para diagnóstico e tratamento do cancro com base em recetores fzd humanos
|
EP2455100A3
(en)
|
2005-11-07 |
2012-11-07 |
The Rockefeller University |
Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof
|
EP1957531B1
(en)
|
2005-11-07 |
2016-04-13 |
Genentech, Inc. |
Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
|
AU2006311568B2
(en)
*
|
2005-11-08 |
2010-11-11 |
Ambrx, Inc. |
Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides
|
UA96139C2
(uk)
|
2005-11-08 |
2011-10-10 |
Дженентек, Інк. |
Антитіло до нейропіліну-1 (nrp1)
|
EP2548583A3
(en)
|
2005-11-10 |
2013-02-27 |
Curagen Corporation |
Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen
|
EP1945202A2
(en)
*
|
2005-11-11 |
2008-07-23 |
Licentia OY |
Mammalian hedgehog signaling inhiabitors
|
EP1964574B1
(en)
|
2005-11-14 |
2016-09-07 |
Cellmid Limited |
Method for treatment or prevention of disease associated with functional disorder of regulatory t cell
|
EP3069731A1
(en)
|
2005-11-14 |
2016-09-21 |
Labrys Biologics Inc. |
Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
|
TW200736277A
(en)
|
2005-11-14 |
2007-10-01 |
Amgen Inc |
RANKL antibody-PTH/PTHrP chimeric molecules
|
MY149159A
(en)
|
2005-11-15 |
2013-07-31 |
Hoffmann La Roche |
Method for treating joint damage
|
PT2090575E
(pt)
|
2005-11-15 |
2011-06-06 |
Array Biopharma Inc |
Inibidores de erbb
|
AR057582A1
(es)
|
2005-11-15 |
2007-12-05 |
Nat Hospital Organization |
Agentes para suprimir la induccion de linfocitos t citotoxicos
|
PT2339014E
(pt)
*
|
2005-11-16 |
2015-10-13 |
Ambrx Inc |
Métodos e composições compreendendo aminoácidos não-naturais
|
CA2629715C
(en)
|
2005-11-18 |
2016-05-03 |
Glenmark Pharmaceuticals S.A. |
Anti-alpha2 integrin antibodies and their uses
|
WO2007081608A2
(en)
|
2005-11-21 |
2007-07-19 |
Genentech, Inc. |
Novel gene disruptions, compositions and methods relating thereto
|
CA2629306A1
(en)
*
|
2005-11-23 |
2007-05-31 |
Genentech, Inc. |
Methods and compositions related to b cell assays
|
WO2007061029A1
(ja)
|
2005-11-25 |
2007-05-31 |
Keio University |
前立腺癌治療剤
|
CA2632797A1
(en)
|
2005-12-01 |
2007-06-07 |
The Provost, Fellows And Scholars Of The College Of The Holy And Undivid Ed Trinity Of Queen Elizabeth Near Dublin |
Compositions and methods relating to treatment of cancer and infectious diseases using toll like receptor agonists
|
CA2631327C
(en)
*
|
2005-12-02 |
2015-10-13 |
Genentech, Inc. |
Her2 binding polypeptides and uses thereof
|
US20070213264A1
(en)
|
2005-12-02 |
2007-09-13 |
Mingdong Zhou |
Neuregulin variants and methods of screening and using thereof
|
WO2007126439A2
(en)
|
2005-12-02 |
2007-11-08 |
Genentech, Inc. |
Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
|
US8466263B2
(en)
*
|
2005-12-02 |
2013-06-18 |
Dana-Farber Cancer Institute, Inc. |
Carbonic anhydrase IX (G250) anitbodies
|
EP1973951A2
(en)
*
|
2005-12-02 |
2008-10-01 |
Genentech, Inc. |
Binding polypeptides with restricted diversity sequences
|
WO2008024128A2
(en)
*
|
2005-12-05 |
2008-02-28 |
Simon Delagrave |
Loop-variant pdz domains as biotherapeutics, diagnostics and research reagents
|
JP2009518387A
(ja)
|
2005-12-05 |
2009-05-07 |
ザ・プロウボウスト・フェロウズ・アンド・スカラーズ・オブ・ザ・カレッジ・オブ・ザ・ホリー・アンド・アンデバイデッド・トリニティ・オブ・クイーン・エリザベス・ニア・ダブリン |
免疫反応を調節する組成物および方法
|
PL2347775T3
(pl)
|
2005-12-13 |
2020-11-16 |
President And Fellows Of Harvard College |
Rusztowania do przeszczepiania komórek
|
RS52357B
(en)
|
2005-12-13 |
2012-12-31 |
Medimmune Limited |
BINDING PROTEINS SPECIFIC TO INSULIN SIMILAR GROWTH FACTORS AND THEIR USE
|
EP1968635B1
(en)
*
|
2005-12-14 |
2014-09-17 |
Ambrx, Inc. |
Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
|
EP1973948B1
(en)
|
2005-12-15 |
2015-02-11 |
Genentech, Inc. |
Methods and compositions for targeting polyubiquitin
|
KR101371773B1
(ko)
|
2005-12-15 |
2014-03-07 |
아스트라제네카 아베 |
암 치료를 위한, 안지오포이에틴-2 길항자와 vegf-a,kdr 및/또는 flt1 길항자의 조합물
|
KR20080078075A
(ko)
|
2005-12-20 |
2008-08-26 |
세레우사이언스 아베 |
하지 불안 증후군의 치료 및 진단을 위한 방법 및 조성물
|
PL1968549T3
(pl)
*
|
2005-12-22 |
2014-10-31 |
Novartis Ag |
Preparat o podtrzymywanym uwalnianiu zawierający okterotyd i dwa lub większą liczbę polimerów typu poli(mleczan-co-glikolan)
|
US8138361B2
(en)
*
|
2005-12-28 |
2012-03-20 |
The Trustees Of The University Of Pennsylvania |
C-10 carbamates of taxanes
|
EA035459B1
(ru)
|
2005-12-29 |
2020-06-19 |
Сентокор, Инк. |
Антитело против il-23p19
|
EP1981525B1
(en)
|
2005-12-30 |
2015-01-21 |
Zensun (Shanghai) Science and Technology Limited |
Extended release of neuregulin for improved cardiac function
|
EP1984024A2
(en)
*
|
2006-01-05 |
2008-10-29 |
Novartis AG |
Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
|
SI1973950T1
(sl)
|
2006-01-05 |
2015-01-30 |
Genentech, Inc. |
Anti-EphB4 protitelesa in postopki njihove uporabe
|
US20100167341A1
(en)
|
2006-01-17 |
2010-07-01 |
Dnavec Corporation |
Novel protein expression system
|
EP2264060B1
(en)
|
2006-01-26 |
2014-04-23 |
Recopharma AB |
Compositions and methods for inhibiting viral adhesion
|
ES2685915T3
(es)
|
2006-01-27 |
2018-10-15 |
Keio University |
Agentes terapéuticos para enfermedades que implican neovascularización coroidea
|
US7756524B1
(en)
|
2006-01-31 |
2010-07-13 |
Nextel Communications Inc. |
System and method for partially count-based allocation of vocoder resources
|
WO2007088479A1
(en)
*
|
2006-02-02 |
2007-08-09 |
Rinat Neuroscience Corp. |
Methods for treating obesity by administering a trkb antagonist
|
JP2009528985A
(ja)
*
|
2006-02-02 |
2009-08-13 |
ライナット ニューロサイエンス コーポレイション |
trkBアゴニストを投与することにより望まれない体重減少または摂食障害を治療する方法
|
EP1818395A1
(en)
|
2006-02-08 |
2007-08-15 |
Diatos |
Compositions and methods for treating lysosomal storage diseases
|
US20090221072A1
(en)
*
|
2006-02-15 |
2009-09-03 |
Chen Thomas T |
Compositions and methods for modulating cell differentiation
|
US20080311107A1
(en)
|
2006-02-17 |
2008-12-18 |
Genetech, Inc. |
Novel Gene Disruptions, Compositions and Methods Relating Thereto
|
GB0604187D0
(en)
*
|
2006-03-02 |
2006-04-12 |
Fusion Antibodies Ltd |
Peptide and uses thereof
|
EP2650306A1
(en)
|
2006-03-06 |
2013-10-16 |
Aeres Biomedical Limited |
Humanized Anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
JP2009529047A
(ja)
|
2006-03-07 |
2009-08-13 |
アレイ バイオファーマ、インコーポレイテッド |
ヘテロ二環系ピラゾール化合物およびその使用
|
US7504106B2
(en)
*
|
2006-03-14 |
2009-03-17 |
Boris Skurkovich |
Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis
|
AR059851A1
(es)
|
2006-03-16 |
2008-04-30 |
Genentech Inc |
Anticuerpos de la egfl7 y metodos de uso
|
ES2544957T3
(es)
|
2006-03-21 |
2015-09-07 |
Genentech, Inc. |
Terapia combinada que implica antagonistas alfa5beta1
|
ES2536547T3
(es)
|
2006-03-24 |
2015-05-26 |
Array Biopharma, Inc. |
Análogos de 2-aminopiridina como activadores de glucoquinasa
|
EP2007602A4
(en)
*
|
2006-03-31 |
2010-09-22 |
Centocor Ortho Biotech Inc |
HUMAN EPO MIMETICS IN HINGED CENTRAL REGION, COMPOSITIONS, METHODS AND USES IN THE PREVENTION OR TREATMENT OF GLUCOSE INTOLERANCE OR ANEMIA ASSOCIATED WITH NEPHROPATHY
|
US8426387B2
(en)
*
|
2006-03-31 |
2013-04-23 |
Stephen Carper |
Treatments for cancer
|
WO2007126455A2
(en)
|
2006-04-05 |
2007-11-08 |
Genentech, Inc. |
Method for using boc/cdo to modulate hedgehog signaling
|
EA022780B1
(ru)
|
2006-04-05 |
2016-03-31 |
Дзе Рокфеллер Юниверсити |
СПОСОБ ПОВЫШЕНИЯ ПРОТИВОВОСПАЛИТЕЛЬНОЙ АКТИВНОСТИ И СНИЖЕНИЯ ЦИТОТОКСИЧЕСКОЙ АКТИВНОСТИ ПРЕПАРАТА IgG
|
EP2025346B1
(en)
|
2006-04-07 |
2016-08-10 |
Osaka University |
Muscle regeneration promoter
|
CA2648947A1
(en)
*
|
2006-04-10 |
2007-11-15 |
Fusion Antibodies Limited |
Therapy targeting cathepsin s
|
TW200813091A
(en)
|
2006-04-10 |
2008-03-16 |
Amgen Fremont Inc |
Targeted binding agents directed to uPAR and uses thereof
|
GB0620255D0
(en)
*
|
2006-10-12 |
2006-11-22 |
Fusion Antibodies Ltd |
Antibody and uses thereof
|
US20090288176A1
(en)
|
2006-04-19 |
2009-11-19 |
Genentech, Inc. |
Novel Gene Disruptions, Compositions and Methods Relating Thereto
|
TWI395754B
(zh)
|
2006-04-24 |
2013-05-11 |
Amgen Inc |
人類化之c-kit抗體
|
EP2246354A1
(en)
|
2006-04-26 |
2010-11-03 |
F. Hoffmann-La Roche AG |
Thieno[3,2-d]pyrimidine derivative useful as PI3K inhibitor
|
TWI498332B
(zh)
|
2006-04-26 |
2015-09-01 |
Hoffmann La Roche |
作為pi3k抑制劑之嘧啶衍生物及相關製備方法、醫藥組合物、用途、套組及產物
|
PL2019657T3
(pl)
|
2006-04-26 |
2015-10-30 |
Micell Technologies Inc |
Powłoki zawierające wiele leków
|
US8592149B2
(en)
|
2006-04-27 |
2013-11-26 |
Pikamab, Inc. |
Methods and compositions for antibody therapy
|
US20070259820A1
(en)
*
|
2006-05-03 |
2007-11-08 |
The Regents Of The University Of Michigan |
Methods and reagents for activating heat shock protein 70
|
EP2018184B1
(en)
|
2006-05-17 |
2013-09-11 |
The Ludwig Institute for Cancer Research |
Anti-VEGF-B antibody for the treatment or prophylaxis of diabetes type II or metabolic syndrome
|
US20100022457A1
(en)
|
2006-05-26 |
2010-01-28 |
Bristol-Myers Squibb Company |
Sustained release glp-1 receptor modulators
|
MX2008015132A
(es)
|
2006-05-30 |
2008-12-10 |
Genentech Inc |
Anticuerpos e inmunoconjugados y sus usos.
|
US8796429B2
(en)
*
|
2006-05-31 |
2014-08-05 |
Lpath, Inc. |
Bioactive lipid derivatives, and methods of making and using same
|
US7862812B2
(en)
|
2006-05-31 |
2011-01-04 |
Lpath, Inc. |
Methods for decreasing immune response and treating immune conditions
|
US9274129B2
(en)
*
|
2006-05-31 |
2016-03-01 |
Lpath, Inc. |
Methods and reagents for detecting bioactive lipids
|
EP2035037A4
(en)
|
2006-05-31 |
2010-03-31 |
Thallion Pharmaceuticals Inc |
METHOD, COMPOSITIONS AND KITS FOR TREATING SHIGA-TOXIN ASSOCIATED ILLNESSES
|
US9274130B2
(en)
|
2006-05-31 |
2016-03-01 |
Lpath, Inc. |
Prevention and treatment of pain using antibodies to lysophosphatidic acid
|
US20080138334A1
(en)
*
|
2006-05-31 |
2008-06-12 |
Sabbadini Roger A |
Immune-Derived Moieties Reactive Against Bioactive Lipids, and Methods of Making and Using Same
|
EP2049570B1
(en)
*
|
2006-06-01 |
2016-08-10 |
President and Fellows of Harvard College |
Purification of a bivalently active antibody using a non-chromatographic method
|
JP2010505743A
(ja)
|
2006-06-01 |
2010-02-25 |
ジェネンテック インコーポレイテッド |
CRIg及びC3b:CRIg複合体の結晶構造
|
MY157796A
(en)
|
2006-06-08 |
2016-07-29 |
Chugai Pharmaceutical Co Ltd |
Preventive or remedy for inflammatory disease
|
GB0611405D0
(en)
|
2006-06-09 |
2006-07-19 |
Univ Belfast |
FKBP-L: A novel inhibitor of angiogenesis
|
UA95641C2
(en)
|
2006-07-06 |
2011-08-25 |
Эррей Биофарма Инк. |
Hydroxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
|
WO2008008315A2
(en)
|
2006-07-10 |
2008-01-17 |
Biogen Idec Ma Inc. |
Compositions and methods for inhibiting growth of smad4-deficient cancers
|
CN101511181B
(zh)
|
2006-07-11 |
2013-08-21 |
新泽西医科和牙科大学 |
蛋白、编码该蛋白的核酸和相关的应用方法
|
US20080015546A1
(en)
*
|
2006-07-13 |
2008-01-17 |
Casas Jesus W |
Methods and formulations for optimal local delivery of cell therapy via minimally invasive procedures
|
MX2009000487A
(es)
|
2006-07-13 |
2009-01-27 |
Chugai Pharmaceutical Co Ltd |
Inductor de muerte celular.
|
EP2068877A4
(en)
|
2006-07-19 |
2011-09-21 |
Cleveland Clinic Foundation |
COMPOUNDS AND METHODS FOR MODULATING ANGIOGENESIS
|
ES2612383T3
(es)
|
2006-07-19 |
2017-05-16 |
The Trustees Of The University Of Pennsylvania |
WSX-1/IL-27 como una diana para respuestas antiinflamatorias
|
WO2008010556A1
(fr)
|
2006-07-21 |
2008-01-24 |
Chugai Seiyaku Kabushiki Kaisha |
Médicament agissant contre une maladie rénale
|
US20080038258A1
(en)
*
|
2006-07-21 |
2008-02-14 |
Amgen Inc. |
Polypeptides with Reduced Susceptibility to Oxidation and Methods of Making
|
US7666423B2
(en)
|
2006-07-28 |
2010-02-23 |
Children's Memorial Hospital |
Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
|
CL2007002225A1
(es)
|
2006-08-03 |
2008-04-18 |
Astrazeneca Ab |
Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
|
EP2420252A1
(en)
*
|
2006-08-04 |
2012-02-22 |
Novartis AG |
EPHB3-specific antibody and uses thereof
|
EP2054437A2
(en)
*
|
2006-08-07 |
2009-05-06 |
Teva Biopharmaceuticals USA, Inc. |
Albumin-insulin fusion proteins
|
PL2359808T3
(pl)
|
2006-08-09 |
2013-10-31 |
Intarcia Therapeutics Inc |
Osmotyczne systemy dostawcze i zespoły tłokowe
|
AR062223A1
(es)
|
2006-08-09 |
2008-10-22 |
Glycart Biotechnology Ag |
Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
|
ME00588A
(en)
*
|
2006-08-18 |
2011-12-20 |
|
Prlr-specific antibody and uses thereof
|
WO2008023077A2
(en)
*
|
2006-08-25 |
2008-02-28 |
The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin |
Compositions and methods for modulating an immune response
|
CA2661782C
(en)
|
2006-08-28 |
2019-04-16 |
La Jolla Institute For Allergy And Immunology |
Antagonistic human light-specific human monoclonal antibodies
|
EP2471816A1
(en)
|
2006-08-30 |
2012-07-04 |
Genentech, Inc. |
Multispecific antibodies
|
US10568860B2
(en)
*
|
2006-08-30 |
2020-02-25 |
Kowa Co., Ltd. |
Pharmaceutical composition containing statin-encapsulated nanoparticle
|
CA2660175C
(en)
|
2006-09-01 |
2015-05-12 |
Zymogenetics, Inc. |
Variable region sequences of il-31 monoclonal antibodies and methods of use
|
CA2662753C
(en)
*
|
2006-09-08 |
2016-02-23 |
Ambrx, Inc. |
Hybrid suppressor trna for vertebrate cells
|
US8420792B2
(en)
*
|
2006-09-08 |
2013-04-16 |
Ambrx, Inc. |
Suppressor tRNA transcription in vertebrate cells
|
CN106008699A
(zh)
*
|
2006-09-08 |
2016-10-12 |
Ambrx公司 |
经修饰的人类血浆多肽或Fc骨架和其用途
|
US20100008910A1
(en)
|
2006-09-12 |
2010-01-14 |
John Chant |
Methods and compositions for the diagnosis and treatment of cancer
|
EP1905841A1
(en)
*
|
2006-09-25 |
2008-04-02 |
Max Delbrück Centrum für Molekulare Medizin (MDC) Berlin-Buch; |
Trex1 as a marker for lupus erythematosus
|
BRPI0719446A2
(pt)
|
2006-09-28 |
2013-12-10 |
Schering Corp |
Uso de il-10 peguilada para tratar câncer
|
WO2008042236A2
(en)
|
2006-09-29 |
2008-04-10 |
Oncomed Pharmaceuticals, Inc. |
Compositions and methods for diagnosing and treating cancer
|
US7767206B2
(en)
|
2006-10-02 |
2010-08-03 |
Amgen Inc. |
Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
|
KR101161923B1
(ko)
|
2006-10-03 |
2012-07-03 |
유니버시티 오브 메디신 앤드 덴티스트리 오브 뉴 저지 |
Atap 펩티드, 상기 펩티드를 엔코딩하는 핵산 및 이들과 관련된 사용 방법
|
WO2008044068A2
(en)
*
|
2006-10-11 |
2008-04-17 |
Fusion Antibodies Limited |
Combination therapy
|
NZ576032A
(en)
|
2006-10-12 |
2012-03-30 |
Genentech Inc |
Antibodies to lymphotoxin-alpha
|
US8691761B2
(en)
|
2006-10-16 |
2014-04-08 |
Jean E. F. Rivier |
Somatostatin receptor 2 antagonists
|
SI2076535T1
(sl)
|
2006-10-16 |
2013-07-31 |
The Salk Institute For Biological Studies |
Antagonisti somatostatina, selektivni za receptor (SSTR2)
|
MX2009004134A
(es)
*
|
2006-10-20 |
2009-08-12 |
Biogen Idec Inc |
Tratamiento de trastornos de desmielinizacion con el receptor de linfotoxina beta soluble.
|
US8338376B2
(en)
*
|
2006-10-20 |
2012-12-25 |
Biogen Idec Ma Inc. |
Compositions comprising variant LT-B-R-IG fusion proteins
|
ES2636089T3
(es)
|
2006-10-27 |
2017-10-05 |
Genentech, Inc. |
Anticuerpos e inmunoconjugados y usos para los mismos
|
ES2524059T3
(es)
|
2006-10-27 |
2014-12-03 |
Lpath, Inc. |
Composiciones y procedimientos de unión a esfingosina-1-fosfato
|
JP5732182B2
(ja)
|
2006-10-27 |
2015-06-10 |
エルパス・インコーポレイテッドLpath, Inc. |
眼疾患と症状を処置するための組成物および方法
|
PL2097455T3
(pl)
|
2006-11-02 |
2015-04-30 |
Genentech Inc |
Humanizowane przeciwciała przeciw czynnikowi D
|
WO2008061019A2
(en)
|
2006-11-14 |
2008-05-22 |
Genentech, Inc. |
Modulators of neuronal regeneration
|
EP2727936B1
(en)
|
2006-11-22 |
2016-09-07 |
Bristol-Myers Squibb Company |
Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
|
CA2670696A1
(en)
|
2006-11-27 |
2008-06-05 |
Diadexus, Inc. |
Ovr110 antibody compositions and methods of use
|
ES2435437T3
(es)
|
2006-12-07 |
2013-12-19 |
Novartis Ag |
Anticuerpos antagonistas contra Ephb3
|
JP5284977B2
(ja)
|
2006-12-07 |
2013-09-11 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
ホスホイノシチド3−キナーゼ阻害剤化合物及び使用方法
|
MX2009006082A
(es)
|
2006-12-08 |
2009-08-18 |
Lexicon Pharmaceuticals Inc |
Anticuerpos monoclonales contra la proteina 3 similar a angiopoyetina (angptl3).
|
TWI428346B
(zh)
*
|
2006-12-13 |
2014-03-01 |
Imp Innovations Ltd |
新穎化合物及其等對進食行為影響
|
WO2008075762A1
(en)
*
|
2006-12-18 |
2008-06-26 |
Takeda Pharmaceutical Company Limited |
Sustained-release composition and method for producing the same
|
JP5386364B2
(ja)
|
2006-12-18 |
2014-01-15 |
ジェネンテック, インコーポレイテッド |
抗Notch3アンタゴニスト抗体とNotch3関連疾患の予防及び治療におけるその使用
|
MY183404A
(en)
|
2006-12-19 |
2021-02-18 |
Genentech Inc |
Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
|
RU2009123491A
(ru)
*
|
2006-12-20 |
2010-12-27 |
Ринат Ньюросайенс Корпорейшн (Us) |
АГОНИСТЫ TrkB ДЛЯ ЛЕЧЕНИЯ АУТОИММУННЫХ НАРУШЕНИЙ
|
EP2094306A2
(en)
|
2006-12-20 |
2009-09-02 |
XOMA Technology Ltd. |
Treatment of il-1-beta related diseases
|
UY30820A1
(es)
*
|
2006-12-21 |
2008-07-03 |
Centocor Inc |
Uso de agonistas del receptor de glp-1 de accion prolongada para mejorar la sensibilidad a la insulina y los perfiles lipidicos
|
US11426494B2
(en)
|
2007-01-08 |
2022-08-30 |
MT Acquisition Holdings LLC |
Stents having biodegradable layers
|
EP2111184B1
(en)
|
2007-01-08 |
2018-07-25 |
Micell Technologies, Inc. |
Stents having biodegradable layers
|
PL2104682T3
(pl)
|
2007-01-11 |
2017-03-31 |
Michael Bacher |
Diagnostyka i leczenie choroby Alzheimera i innych chorób neurodegeneracyjnych
|
WO2008090901A1
(ja)
|
2007-01-23 |
2008-07-31 |
Shinshu University |
慢性拒絶反応抑制剤
|
US20080177219A1
(en)
*
|
2007-01-23 |
2008-07-24 |
Joshi Ashok V |
Method for Iontophoretic Fluid Delivery
|
EP2125013A4
(en)
*
|
2007-01-26 |
2010-04-07 |
Bioinvent Int Ab |
DLL4 SIGNALING INHIBITOR AND ITS USES
|
US20100144599A1
(en)
|
2007-02-02 |
2010-06-10 |
Bristol-Myers Squibb Company |
Vegf pathway blockade
|
AU2008214386B2
(en)
|
2007-02-02 |
2013-09-19 |
Amgen Inc |
Hepcidin and hepcidin antibodies
|
CA2676766A1
(en)
|
2007-02-09 |
2008-08-21 |
Genentech, Inc. |
Anti-robo4 antibodies and uses therefor
|
AU2008218925A1
(en)
|
2007-02-20 |
2008-08-28 |
Anaptysbio, Inc. |
Somatic hypermutation systems
|
ES2379413T3
(es)
|
2007-02-22 |
2012-04-25 |
Genentech, Inc. |
Procedimientos para detectar la enfermedad inflamatoria del intestino
|
WO2008109440A2
(en)
|
2007-03-02 |
2008-09-12 |
Genentech, Inc. |
Predicting response to a her dimerisation inhibitor based on low her3 expression
|
US8501678B2
(en)
|
2007-03-06 |
2013-08-06 |
Atara Biotherapeutics, Inc. |
Variant activin receptor polypeptides and uses thereof
|
US7947646B2
(en)
|
2007-03-06 |
2011-05-24 |
Amgen Inc. |
Variant activin receptor polypeptides
|
CL2008000719A1
(es)
|
2007-03-12 |
2008-09-05 |
Univ Tokushima Chugai Seiyaku |
Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
|
US7960139B2
(en)
|
2007-03-23 |
2011-06-14 |
Academia Sinica |
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
|
EP2068909B1
(en)
|
2007-03-30 |
2012-04-25 |
Ambrx, Inc. |
Modified fgf-21 polypeptides and their uses
|
CA2682469A1
(en)
|
2007-03-30 |
2008-10-09 |
The Cleveland Clinic Foundation |
Method of treating ischemic disorders
|
CA2683610C
(en)
|
2007-04-23 |
2013-01-08 |
Intarcia Therapeutics, Inc. |
Suspension formulations of insulinotropic peptides and uses thereof
|
TWI570135B
(zh)
|
2007-04-27 |
2017-02-11 |
建南德克公司 |
高效、穩定且非免疫抑制之抗-cd4抗體
|
AU2008247815B2
(en)
*
|
2007-05-02 |
2012-09-06 |
Ambrx, Inc. |
Modified interferon beta polypeptides and their uses
|
CN101861168B
(zh)
|
2007-05-07 |
2014-07-02 |
米迪缪尼有限公司 |
抗-icos抗体及其在治疗肿瘤、移植和自身免疫病中的应用
|
US20110065673A1
(en)
|
2007-05-11 |
2011-03-17 |
Bizen Chemical Co., Ltd. |
Novel leukotriene receptor agonist
|
NZ555163A
(en)
|
2007-05-14 |
2010-05-28 |
Fonterra Co Operative Group |
Methods of immune or hematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer, cancer symptoms, or the symptoms of cancer treatments
|
PE20090387A1
(es)
|
2007-05-24 |
2009-04-28 |
Novartis Ag |
Formulacion de pasireotida
|
EP1994927A1
(en)
|
2007-05-24 |
2008-11-26 |
Chevron USA, Inc. |
Diamondoid derivatives possessing therapeutic activity in the treatment of viral disorders
|
EP1995227A1
(en)
|
2007-05-24 |
2008-11-26 |
Chevron USA, Inc. |
Spiro and other derivatives of diamondoids posessing therapeutic activity in the treatment of viral disorders
|
US9163091B2
(en)
*
|
2007-05-30 |
2015-10-20 |
Lpath, Inc. |
Compositions and methods for binding lysophosphatidic acid
|
CA2693053C
(en)
|
2007-05-30 |
2021-01-05 |
Xencor, Inc. |
Methods and compositions for inhibiting cd32b expressing cells
|
US8158124B2
(en)
*
|
2007-05-30 |
2012-04-17 |
Lpath, Inc. |
Compositions and methods for binding lysophosphatidic acid
|
WO2008151257A2
(en)
|
2007-06-04 |
2008-12-11 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
PE20090321A1
(es)
|
2007-06-04 |
2009-04-20 |
Genentech Inc |
Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
|
GB0710976D0
(en)
|
2007-06-07 |
2007-07-18 |
Bioalvo |
Am Screening method
|
LT2170390T
(lt)
|
2007-06-14 |
2019-01-10 |
Biogen Ma Inc. |
Natalizumabo antikūnų kompozicijos
|
PE20090368A1
(es)
*
|
2007-06-19 |
2009-04-28 |
Boehringer Ingelheim Int |
Anticuerpos anti-igf
|
US8637257B2
(en)
|
2007-06-20 |
2014-01-28 |
Galapagos Nv |
Molecular targets and compounds, and methods to identify the same, useful in the treatment of bone and joint degenerative diseases
|
DK2170340T3
(en)
|
2007-06-21 |
2016-03-14 |
Neuronascent Inc |
Methods and compositions for Stimulating neurogenesis and inhibition of neuronal degeneration BY USING ISOTHIAZOLOPYRIMIDINONER
|
WO2009002401A2
(en)
|
2007-06-21 |
2008-12-31 |
President And Fellows Of Harvard College |
Scaffolds for cell collection or elimination
|
EP2190448B1
(en)
|
2007-06-22 |
2016-04-20 |
Children's Medical Center Corporation |
Methods and uses thereof of a fragment of saposin a
|
JP2010534195A
(ja)
|
2007-06-27 |
2010-11-04 |
オークランド ユニサーヴィスィズ リミテッド |
アルテミン及び関連するリガンドについてのポリペプチド及びポリヌクレオチド、並びにその使用方法
|
PT2176296E
(pt)
|
2007-07-16 |
2012-05-14 |
Genentech Inc |
Anticorpos e imunoconjugados anti-cd79b e métodos de utilização
|
JP2010533495A
(ja)
|
2007-07-16 |
2010-10-28 |
ジェネンテック, インコーポレイテッド |
ヒト化CD79b抗体およびイムノコンジュゲートならびにそれらの使用
|
JP5424330B2
(ja)
|
2007-07-26 |
2014-02-26 |
国立大学法人大阪大学 |
インターロイキン6受容体阻害剤を有効成分とする眼炎症疾患治療剤
|
CN101835490A
(zh)
|
2007-08-02 |
2010-09-15 |
阿雷斯托生物科学股份有限公司 |
Lox和loxl2抑制剂及其应用
|
US8153112B2
(en)
*
|
2007-08-03 |
2012-04-10 |
Warsaw Orthopedic, Inc. |
Compositions and methods for treating cavity conditions
|
TW200916113A
(en)
|
2007-08-08 |
2009-04-16 |
Sod Conseils Rech Applic |
Method for inhibiting inflammation and pro-inflammatory cytokine/chemokine expression using a ghrelin analogue
|
PE20120259A1
(es)
|
2007-08-09 |
2012-04-04 |
Boehringer Ingelheim Int |
Anticuerpos anti-cd37
|
RS56743B1
(sr)
|
2007-08-21 |
2018-03-30 |
Amgen Inc |
Humani c-fms antigen vezujući proteini
|
CA2697032C
(en)
|
2007-08-22 |
2021-09-14 |
The Regents Of The University Of California |
Activatable binding polypeptides and methods of identification and use thereof
|
JOP20080381B1
(ar)
|
2007-08-23 |
2023-03-28 |
Amgen Inc |
بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
|
EP2615113A3
(en)
|
2007-08-23 |
2013-11-13 |
Amgen Inc. |
Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
|
WO2009028158A1
(en)
|
2007-08-24 |
2009-03-05 |
Oncotherapy Science, Inc. |
Dkk1 oncogene as therapeutic target for cancer and a diagnosing marker
|
KR20100075857A
(ko)
|
2007-08-24 |
2010-07-05 |
온코세라피 사이언스 가부시키가이샤 |
폐암의 치료 및 진단의 표적유전자인 ebi3,dlx5,nptx1 및 cdkn
|
UA117446C2
(uk)
|
2007-08-29 |
2018-08-10 |
Санофі-Авентіс |
Гуманізоване антитіло до cxcr5
|
AU2008295140A1
(en)
|
2007-09-05 |
2009-03-12 |
F. Hoffmann-La Roche Ag |
Combination therapy with type I and type II anti-CD20 antibodies
|
US7982016B2
(en)
|
2007-09-10 |
2011-07-19 |
Amgen Inc. |
Antigen binding proteins capable of binding thymic stromal lymphopoietin
|
US20090156488A1
(en)
*
|
2007-09-12 |
2009-06-18 |
Zensun (Shanghai) Science & Technology Limited |
Use of neuregulin for organ preservation
|
CA2698809C
(en)
|
2007-09-14 |
2023-10-17 |
Amgen Inc. |
Homogeneous antibody populations
|
JP5543920B2
(ja)
|
2007-09-17 |
2014-07-09 |
プレグレム エスアー |
閉経前の女性におけるエストロゲン依存症状の治療
|
TW200918553A
(en)
|
2007-09-18 |
2009-05-01 |
Amgen Inc |
Human GM-CSF antigen binding proteins
|
CA2704711C
(en)
|
2007-09-24 |
2016-07-05 |
Genentech, Inc. |
Thiazolopyrimidine p13k inhibitor compounds and methods of use
|
EP2040075A1
(en)
|
2007-09-24 |
2009-03-25 |
Julius-Maximilians-Universität Würzburg |
Compounds and markers for surface-enhanced raman scattering
|
SG187477A1
(en)
|
2007-09-26 |
2013-02-28 |
U3 Pharma Gmbh |
Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
|
JP5264752B2
(ja)
|
2007-10-02 |
2013-08-14 |
中外製薬株式会社 |
インターロイキン6受容体阻害剤を有効成分とする移植片対宿主病治療剤
|
GB2453589A
(en)
|
2007-10-12 |
2009-04-15 |
King S College London |
Protease inhibition
|
US20090098118A1
(en)
|
2007-10-15 |
2009-04-16 |
Thomas Friess |
Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
|
EP2050764A1
(en)
|
2007-10-15 |
2009-04-22 |
sanofi-aventis |
Novel polyvalent bispecific antibody format and uses thereof
|
ES2565202T3
(es)
|
2007-10-16 |
2016-04-01 |
Zymogenetics, Inc. |
Combinación de activador transmembrana y modulador de calcio e interactor de ligando de ciclofilina (TACI) y agentes anti-CD20 para tratamiento de enfermedades autoinmunitarias
|
MX2010004281A
(es)
|
2007-10-19 |
2010-09-10 |
Sarcode Corp |
Composiciones y metodos para el tratamiento de la retinopatia diabetica.
|
US8361465B2
(en)
*
|
2007-10-26 |
2013-01-29 |
Lpath, Inc. |
Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
|
ES2666170T3
(es)
|
2007-10-30 |
2018-05-03 |
Genentech, Inc. |
Purificación de anticuerpos mediante cromatografía de intercambio catiónico
|
SI2219452T1
(sl)
|
2007-11-05 |
2016-03-31 |
Medimmune, Llc |
Postopki zdravljenja skleroderme
|
MX2010005108A
(es)
|
2007-11-07 |
2010-05-27 |
Genentech Inc |
Composiciones y metodos para el tratamiento de trastornos microbianos.
|
MX2010005115A
(es)
|
2007-11-08 |
2010-05-27 |
Genentech Inc |
Anticuerpos anti-factor b y sus usos.
|
EP2225269A2
(en)
*
|
2007-11-09 |
2010-09-08 |
Anaphore, Inc. |
Fusion proteins of mannose binding lectins for treatment of disease
|
BRPI0820298A8
(pt)
|
2007-11-09 |
2018-05-08 |
Affitech Res As |
composições e métodos de anticorpos anti-vegf
|
WO2009064805A1
(en)
|
2007-11-12 |
2009-05-22 |
Spaltudaq Corporation |
Compositions and methods for the therapy and diagnosis of influenza
|
US20110033476A1
(en)
*
|
2007-11-12 |
2011-02-10 |
Theraclone Sciences Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
EA201000809A1
(ru)
|
2007-11-16 |
2010-12-30 |
Те Рокфеллер Юниверсити |
АНТИТЕЛА, СПЕЦИФИЧЕСКИЕ В ОТНОШЕНИИ ПРОТОФИБРИЛЛЯРНОЙ ФОРМЫ БЕЛКА β-АМИЛОИДА
|
EP2220123A1
(en)
|
2007-11-19 |
2010-08-25 |
Genentech, Inc. |
Compositions and methods for inhibiting tumor progression
|
WO2009067242A2
(en)
*
|
2007-11-20 |
2009-05-28 |
Imclone Llc |
Co-crystal of antibody 11f8 fab fragment and egfr extracellular domain and uses thereof
|
JP5547083B2
(ja)
*
|
2007-11-20 |
2014-07-09 |
アンブルックス,インコーポレイテッド |
修飾されたインスリンポリペプチドおよびそれらの使用
|
UY31478A1
(es)
*
|
2007-11-21 |
2009-07-17 |
|
Inhibicion del receptor para la proteina estimulante del macrofago (ron) y métodos para el tratamiento de lo mismo
|
AR069501A1
(es)
|
2007-11-30 |
2010-01-27 |
Genentech Inc |
Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
|
GB0723797D0
(en)
|
2007-12-05 |
2008-01-16 |
Immunosolv Ltd |
Method
|
AU2008332276B2
(en)
|
2007-12-05 |
2014-02-27 |
Chugai Seiyaku Kabushiki Kaisha |
Therapeutic agent for pruritus
|
ES2585480T3
(es)
|
2007-12-05 |
2016-10-06 |
Chugai Seiyaku Kabushiki Kaisha |
Anticuerpo anti-NR10 y uso del mismo
|
EP2222701B1
(en)
|
2007-12-06 |
2017-11-01 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against influenza virus and methods of use thereof
|
DK2796466T3
(en)
|
2007-12-07 |
2018-02-05 |
Zymogenetics Inc |
HUMANIZED ANTIBODY MOLECULE SPECIFIC TO IL-31
|
WO2009075344A1
(ja)
|
2007-12-12 |
2009-06-18 |
Japan As Represented By Director General Of Agency Of National Cancer Center |
M-csf受容体を分子標的とするmll白血病及びmoz白血病治療剤、およびその利用
|
US20100272679A1
(en)
*
|
2007-12-14 |
2010-10-28 |
Penn Marc S |
Compositions and methods of promoting wound healing
|
CA2709135C
(en)
|
2007-12-17 |
2018-06-05 |
Pfizer Limited |
Treatment of interstitial cystitis
|
CA2710252C
(en)
|
2007-12-20 |
2017-03-28 |
Xoma Technology Ltd. |
Methods for the treatment of gout
|
JP5502751B2
(ja)
|
2007-12-20 |
2014-05-28 |
エボニック コーポレイション |
低残留溶媒濃度を有する微粒子を調製するためのプロセス
|
WO2009085200A2
(en)
|
2007-12-21 |
2009-07-09 |
Amgen Inc. |
Anti-amyloid antibodies and uses thereof
|
EP3825329A1
(en)
|
2007-12-26 |
2021-05-26 |
Xencor, Inc. |
Fc variants with altered binding to fcrn
|
WO2009086514A1
(en)
|
2007-12-28 |
2009-07-09 |
Dana-Farber Cancer Institute, Inc. |
Humanized monoclonal antibodies and methods of use
|
EP2077281A1
(en)
|
2008-01-02 |
2009-07-08 |
Bergen Teknologioverforing AS |
Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
|
US7914785B2
(en)
*
|
2008-01-02 |
2011-03-29 |
Bergen Teknologieverforing As |
B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
|
US20090181068A1
(en)
*
|
2008-01-14 |
2009-07-16 |
Dunn Richard L |
Low Viscosity Liquid Polymeric Delivery System
|
US20090183503A1
(en)
*
|
2008-01-18 |
2009-07-23 |
Alberto Verdesi |
Exhaust apparatus
|
AR070141A1
(es)
*
|
2008-01-23 |
2010-03-17 |
Glenmark Pharmaceuticals Sa |
Anticuerpos humanizados especificos para el factor von willebrand
|
US9175078B2
(en)
|
2008-01-25 |
2015-11-03 |
Amgen Inc. |
Ferroportin antibodies and methods of use
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至her2結構域ii之抗體及其酸性變異體的組合物
|
MY157403A
(en)
|
2008-01-31 |
2016-06-15 |
Genentech Inc |
Anti-cd79b antibodies and immunoconjugates and methods of use
|
JOP20090061B1
(ar)
|
2008-02-11 |
2021-08-17 |
Ferring Int Center Sa |
طريقة معالجة سرطان البروستاتا بمضادات الهرمونات التناسلية GnRH
|
US9370558B2
(en)
|
2008-02-13 |
2016-06-21 |
President And Fellows Of Harvard College |
Controlled delivery of TLR agonists in structural polymeric devices
|
WO2009102465A2
(en)
|
2008-02-13 |
2009-08-20 |
President And Fellows Of Harvard College |
Continuous cell programming devices
|
DK2240155T3
(da)
|
2008-02-13 |
2012-09-17 |
Intarcia Therapeutics Inc |
Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
|
EP2247615B1
(en)
|
2008-02-14 |
2014-07-30 |
Bristol-Myers Squibb Company |
Targeted therapeutics based on engineered proteins that bind egfr
|
JO2913B1
(en)
|
2008-02-20 |
2015-09-15 |
امجين إنك, |
Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
|
WO2009114560A2
(en)
|
2008-03-10 |
2009-09-17 |
Spaltudaq Corporation |
Compositions and methods for the therapy and diagnosis of cytomegalovirus
|
EP2268310B1
(en)
|
2008-03-25 |
2016-07-20 |
Roche Glycart AG |
Use of a type ii anti-cd20 antibody with increased antibody dependent cellular cytotoxicity (adcc) in combination with cyclophosphamide, vincristine and doxorubicine for treating non-hodgkin' s lymphomas
|
US20090258013A1
(en)
|
2008-04-09 |
2009-10-15 |
Genentech, Inc. |
Novel compositions and methods for the treatment of immune related diseases
|
WO2009139817A2
(en)
|
2008-04-15 |
2009-11-19 |
Sarcode Corporation |
Crystalline pharmaceutical and methods of preparation and use thereof
|
JP2011516607A
(ja)
*
|
2008-04-15 |
2011-05-26 |
サーコード コーポレイション |
胃腸系へのlfa−1アンタゴニストの送達
|
MX2010011485A
(es)
|
2008-04-17 |
2011-03-01 |
Micell Technologies Inc |
Stents que contienen capas bioadsorbibles.
|
GB0807018D0
(en)
*
|
2008-04-17 |
2008-05-21 |
Fusion Antibodies Ltd |
Antibodies and treatment
|
US9132087B2
(en)
|
2008-04-21 |
2015-09-15 |
Otonomy, Inc. |
Auris formulations for treating otic diseases and conditions
|
CR20170001A
(es)
|
2008-04-28 |
2017-08-10 |
Genentech Inc |
Anticuerpos anti factor d humanizados
|
JP2011523401A
(ja)
*
|
2008-04-29 |
2011-08-11 |
ワイス・エルエルシー |
炎症を治療するための方法
|
FI20080326A0
(fi)
|
2008-04-30 |
2008-04-30 |
Licentia Oy |
Neurotroofinen tekijä MANF ja sen käytöt
|
MX2010011717A
(es)
|
2008-05-01 |
2010-11-30 |
Amgen Inc |
Anticuerpos anti-hepcidina y metodos de uso.
|
SG190596A1
(en)
|
2008-05-06 |
2013-06-28 |
Genentech Inc |
Affinity matured crig variants
|
AU2009245358A1
(en)
*
|
2008-05-09 |
2009-11-12 |
Recopharma Ab |
Compositions and methods for inhibiting shiga toxin and shiga-like toxin
|
US8093018B2
(en)
|
2008-05-20 |
2012-01-10 |
Otsuka Pharmaceutical Co., Ltd. |
Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same
|
AR071874A1
(es)
|
2008-05-22 |
2010-07-21 |
Bristol Myers Squibb Co |
Proteinas de dominio de armazon basadas en fibronectina multivalentes
|
US20110076723A1
(en)
*
|
2008-05-23 |
2011-03-31 |
Samsung Electronics Co., Ltd. |
Antibody-peptide fused synergibody
|
EP2328910B1
(en)
|
2008-06-04 |
2014-08-06 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
JOP20190083A1
(ar)
|
2008-06-04 |
2017-06-16 |
Amgen Inc |
بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
|
EP2305306B1
(en)
|
2008-06-05 |
2016-02-10 |
National Cancer Center |
Neuroinvasion inhibitor
|
RU2531915C2
(ru)
|
2008-06-09 |
2014-10-27 |
Людвиг-Максимилианс-Универзитет Мюнхен |
Новые лекарственные средства для ингибирования агрегации белков, вовлеченных в заболевания, связанные с агрегацией белков, и нейродегенеративные заболевания
|
WO2009150623A1
(en)
|
2008-06-13 |
2009-12-17 |
Pfizer Inc |
Treatment of chronic prostatitis
|
US20100035875A1
(en)
|
2008-06-20 |
2010-02-11 |
Bing-Yan Zhu |
Triazolopyridine jak inhibitor compounds and methods
|
EP2138508A1
(en)
|
2008-06-26 |
2009-12-30 |
Helmholtz-Zentrum für Infektionsforschung GmbH |
Met agonists
|
AU2009262199B2
(en)
|
2008-06-27 |
2012-08-09 |
Amgen Inc. |
Ang-2 inhibition to treat multiple sclerosis
|
PL2307051T3
(pl)
|
2008-07-08 |
2015-07-31 |
Oncomed Pharm Inc |
Środki wiążące i antagoniści Notch oraz sposoby ich zastosowania
|
CA2730340C
(en)
*
|
2008-07-14 |
2017-02-07 |
Polypid Ltd. |
Sustained-release drug carrier composition
|
EP2303332B1
(en)
|
2008-07-15 |
2014-12-31 |
Genentech, Inc. |
Anthracycline conjugates, process for their preparation and their use as antitumor compounds
|
EP2318832B1
(en)
|
2008-07-15 |
2013-10-09 |
Academia Sinica |
Glycan arrays on ptfe-like aluminum coated glass slides and related methods
|
AU2009270833B2
(en)
|
2008-07-16 |
2015-02-19 |
Bausch Health Ireland Limited |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
|
AU2009270849B2
(en)
|
2008-07-17 |
2013-11-21 |
Micell Technologies, Inc. |
Drug delivery medical device
|
WO2011009096A1
(en)
|
2009-07-16 |
2011-01-20 |
Micell Technologies, Inc. |
Drug delivery medical device
|
US8784870B2
(en)
*
|
2008-07-21 |
2014-07-22 |
Otonomy, Inc. |
Controlled release compositions for modulating free-radical induced damage and methods of use thereof
|
CN102105133B
(zh)
|
2008-07-21 |
2015-06-17 |
奥德纳米有限公司 |
控制释放型耳结构调节和先天性免疫系统调节组合物以及治疗耳部病症的方法
|
US10138283B2
(en)
|
2008-07-23 |
2018-11-27 |
Ambrx, Inc. |
Modified bovine G-CSF polypeptides and their uses
|
EP2172189A1
(en)
|
2008-10-01 |
2010-04-07 |
Novartis AG |
Pharmaceutical Compositions
|
US8652843B2
(en)
|
2008-08-12 |
2014-02-18 |
Oncomed Pharmaceuticals, Inc. |
DDR1-binding agents and methods of use thereof
|
EP2213307A1
(en)
|
2009-02-03 |
2010-08-04 |
Novartis AG |
Injectable depot formulations
|
LT2848625T
(lt)
|
2008-08-14 |
2019-10-10 |
Genentech, Inc. |
Priemaišų pašalinimo būdai, panaudojant reziduojančio baltymo pakeitimą jonų mainų membraninės chromatografijos pagalba
|
EP2328928A2
(en)
|
2008-08-25 |
2011-06-08 |
Dana-Farber Cancer Institute, Inc. |
Conserved influenza hemagglutinin epitope and antibodies thereto
|
US8790642B2
(en)
|
2008-08-29 |
2014-07-29 |
Genentech, Inc. |
Cross-reactive and bispecific anti-IL-17A/F antibodies
|
US8163497B2
(en)
|
2008-09-07 |
2012-04-24 |
Glyconex Inc. |
Anti-extended type I glycosphingolipid antibody, derivatives thereof and use
|
KR20110051245A
(ko)
|
2008-09-10 |
2011-05-17 |
제넨테크, 인크. |
안구 혈관신생의 억제 방법
|
EP2816113A3
(en)
|
2008-09-11 |
2015-03-25 |
Galapagos N.V. |
Method for identifying compounds useful for increasing the functional activity and cell surface expression of cf-associated mutant cystic fibrosis transmembrane conductance regulator
|
TWI516501B
(zh)
|
2008-09-12 |
2016-01-11 |
禮納特神經系統科學公司 |
Pcsk9拮抗劑類
|
TW201014605A
(en)
|
2008-09-16 |
2010-04-16 |
Genentech Inc |
Methods for treating progressive multiple sclerosis
|
CA2735900A1
(en)
|
2008-09-19 |
2010-03-25 |
Medimmune, Llc |
Antibodies directed to dll4 and uses thereof
|
CN107022020A
(zh)
|
2008-09-26 |
2017-08-08 |
Ambrx公司 |
修饰的动物促红细胞生成素多肽和其用途
|
WO2010037041A2
(en)
|
2008-09-26 |
2010-04-01 |
Oncomed Pharmaceuticals, Inc. |
Frizzled-binding agents and uses thereof
|
MX348657B
(es)
|
2008-09-26 |
2017-06-21 |
Ambrx Inc |
Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales.
|
AU2009303304A1
(en)
*
|
2008-10-10 |
2010-04-15 |
Anaphore, Inc. |
Polypeptides that bind TRAIL-RI and TRAIL-R2
|
EA201990619A1
(ru)
|
2008-10-10 |
2019-07-31 |
Амген Инк. |
Fgf21 мутанты и их применение
|
EP3524620A1
(en)
|
2008-10-14 |
2019-08-14 |
Genentech, Inc. |
Immunoglobulin variants and uses thereof
|
AU2009308293B2
(en)
|
2008-10-22 |
2015-02-05 |
Genentech, Inc. |
Modulation of axon degeneration
|
US8871202B2
(en)
|
2008-10-24 |
2014-10-28 |
Lpath, Inc. |
Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
|
MX345226B
(es)
|
2008-10-29 |
2017-01-20 |
Ablynx Nv |
Formulaciones de moleculas de union a antigeno de dominio sencillo.
|
KR101781907B1
(ko)
|
2008-10-31 |
2017-09-26 |
얀센 바이오테크 인코포레이티드 |
파이브로넥틴 타입 ⅲ 도메인 기반 스캐폴드 조성물, 방법 및 용도
|
JP5775458B2
(ja)
*
|
2008-11-06 |
2015-09-09 |
グレンマーク ファーマシューティカルズ, エセ.アー. |
抗α2インテグリン抗体を使用する処置
|
EP2364368B1
(en)
|
2008-11-07 |
2014-01-15 |
Sequenta, Inc. |
Methods of monitoring conditions by sequence analysis
|
US9528160B2
(en)
|
2008-11-07 |
2016-12-27 |
Adaptive Biotechnolgies Corp. |
Rare clonotypes and uses thereof
|
US8628927B2
(en)
|
2008-11-07 |
2014-01-14 |
Sequenta, Inc. |
Monitoring health and disease status using clonotype profiles
|
US9506119B2
(en)
|
2008-11-07 |
2016-11-29 |
Adaptive Biotechnologies Corp. |
Method of sequence determination using sequence tags
|
US9365901B2
(en)
|
2008-11-07 |
2016-06-14 |
Adaptive Biotechnologies Corp. |
Monitoring immunoglobulin heavy chain evolution in B-cell acute lymphoblastic leukemia
|
US8748103B2
(en)
|
2008-11-07 |
2014-06-10 |
Sequenta, Inc. |
Monitoring health and disease status using clonotype profiles
|
EP2362782A1
(en)
|
2008-11-17 |
2011-09-07 |
The Provost, Fellows, Foundation Scholars, and the other Members of Board, of the College of the Holy and Undivided Trinity of Queen Elizabeth |
A vaccinia virus protein a46 peptide and use thereof
|
JP6041489B2
(ja)
|
2008-11-22 |
2016-12-07 |
ジェネンテック, インコーポレイテッド |
乳癌の治療のための化学療法と併用した抗vegf抗体の使用
|
TWI496582B
(zh)
|
2008-11-24 |
2015-08-21 |
必治妥美雅史谷比公司 |
雙重專一性之egfr/igfir結合分子
|
CA2997971A1
(en)
*
|
2008-11-26 |
2010-06-03 |
Amgen Inc. |
Variants of activin iib receptor polypeptides and uses thereof
|
WO2010065572A1
(en)
|
2008-12-04 |
2010-06-10 |
The Salk Institute For Biological Studies |
Sstr1-selective analogs
|
UY32317A
(es)
|
2008-12-12 |
2010-07-30 |
Boehringer Ingelheim Int |
Anticuerpos anti-igf
|
JP2012512261A
(ja)
|
2008-12-17 |
2012-05-31 |
ジェネンテック, インコーポレイテッド |
C型肝炎ウイルス併用療法
|
WO2010077853A2
(en)
|
2008-12-17 |
2010-07-08 |
Schering Corporation |
Mono- and di-peg il-10 production; and uses
|
WO2010070136A2
(en)
|
2008-12-19 |
2010-06-24 |
Centre de Recherche Public de la Santé |
Novel caviidae allergens and uses thereof
|
EP2367564A1
(en)
|
2008-12-22 |
2011-09-28 |
Universität Regensburg |
Norrin in the treatment of diseases associated with an increased tgf-beta activity
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
JP6039183B2
(ja)
|
2008-12-23 |
2016-12-07 |
ジェネンテック, インコーポレイテッド |
プロテインaに対する結合が変化した免疫グロブリン変異体
|
US20120114667A1
(en)
|
2008-12-23 |
2012-05-10 |
Medimmune Limited |
TARGETED BINDING AGENTS DIRECTED TO a5BETA1 AND USES THEREOF
|
JO3382B1
(ar)
|
2008-12-23 |
2019-03-13 |
Amgen Inc |
أجسام مضادة ترتبط مع مستقبل cgrp بشري
|
US20110142836A1
(en)
*
|
2009-01-02 |
2011-06-16 |
Olav Mella |
B-cell depleting agents for the treatment of chronic fatigue syndrome
|
EP2385955B1
(en)
|
2009-01-12 |
2020-08-12 |
CytomX Therapeutics, Inc. |
Modified antibody compositions, methods of making and using thereof
|
DK2387627T3
(en)
|
2009-01-15 |
2016-07-04 |
Adaptive Biotechnologies Corp |
Adaptive immunity profiling and methods for producing monoclonal antibodies
|
KR101040396B1
(ko)
|
2009-01-20 |
2011-06-09 |
한올바이오파마주식회사 |
변형된 인간 트롬보포이에틴 폴리펩타이드 절편 및 그의 제조방법
|
US20120022000A1
(en)
|
2009-01-30 |
2012-01-26 |
Universite De Lausanne |
Use of a peptide in the treatment or prevention of metastasis
|
WO2010086828A2
(en)
|
2009-02-02 |
2010-08-05 |
Rinat Neuroscience Corporation |
Agonist anti-trkb monoclonal antibodies
|
WO2010093993A2
(en)
|
2009-02-12 |
2010-08-19 |
Human Genome Sciences, Inc. |
Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
|
EP2396011B1
(en)
|
2009-02-12 |
2016-04-13 |
Janssen Biotech, Inc. |
Fibronectin type iii domain based scaffold compositions, methods and uses
|
WO2010092109A2
(en)
|
2009-02-13 |
2010-08-19 |
Novartis Ag |
Nucleic acid molecule of a biosynthetic cluster encoding non ribosomal peptide synthases and uses thereof
|
TW201031436A
(en)
*
|
2009-02-16 |
2010-09-01 |
Univ Nat Taiwan |
Pharmaceutical composition for inhalation delivery and fabrication method thereof
|
US20120004160A1
(en)
|
2009-02-19 |
2012-01-05 |
Glaxo Group Ltd. |
Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation
|
JP2012518181A
(ja)
|
2009-02-19 |
2012-08-09 |
ガラパゴス・ナムローゼ・フェンノートシャップ |
炎症を包含する疾患の診断及び治療に有用な同定方法及び化合物
|
JP2012517821A
(ja)
|
2009-02-19 |
2012-08-09 |
ガラパゴス・ナムローゼ・フェンノートシャップ |
炎症を包含する疾患の診断及び治療に有用な同定方法及び化合物
|
GB0902916D0
(en)
|
2009-02-20 |
2009-04-08 |
Fusion Antibodies Ltd |
Antibody therapy
|
WO2010096838A2
(en)
*
|
2009-02-23 |
2010-08-26 |
Cytomx Therapeutics, Llc |
Proproteins and methods of use thereof
|
MX2011008988A
(es)
|
2009-02-27 |
2011-12-16 |
Siga Technologies Inc |
Derivados de tienopiridina para el tratamiento y prevencion de infecciones por el virus del dengue.
|
JP5667094B2
(ja)
|
2009-03-10 |
2015-02-12 |
エムイーディー ディスカバリー エスエー |
好中球減少症の処置におけるセリンプロテアーゼ阻害剤の使用
|
KR101781654B1
(ko)
|
2009-03-12 |
2017-09-25 |
제넨테크, 인크. |
조혈 악성종양의 치료를 위한 포스포이노시티드 3-키나제 억제제 화합물 및 화학요법제의 조합물
|
JP2010210772A
(ja)
|
2009-03-13 |
2010-09-24 |
Dainippon Screen Mfg Co Ltd |
液晶表示装置の製造方法
|
SI3260136T1
(sl)
|
2009-03-17 |
2021-05-31 |
Theraclone Sciences, Inc. |
Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
|
WO2010108153A2
(en)
|
2009-03-20 |
2010-09-23 |
Amgen Inc. |
Carrier immunoglobulins and uses thereof
|
KR20130080871A
(ko)
|
2009-03-20 |
2013-07-15 |
제넨테크, 인크. |
이중특이적 항-her 항체
|
CA2753988C
(en)
|
2009-03-25 |
2017-04-25 |
Genentech, Inc. |
Novel anti-.alpha.5.beta. integrin antibodies and uses thereof
|
CN104788564A
(zh)
*
|
2009-03-25 |
2015-07-22 |
健泰科生物技术公司 |
抗-fgfr3抗体及其使用方法
|
US20100247484A1
(en)
|
2009-03-31 |
2010-09-30 |
Heinrich Barchet |
Combination therapy of an afucosylated antibody and one or more of the cytokines gm csf, m csf and/or il3
|
WO2010115825A2
(en)
|
2009-03-31 |
2010-10-14 |
Robert Zimmermann |
Modulation of adipose triglyceride lipase for prevention and treatment of cachexia, loss of weight and muscle atrophy and methods of screening therefor
|
SG174963A1
(en)
|
2009-03-31 |
2011-11-28 |
Roche Glycart Ag |
Treatment of cancer with a humanized anti-egfr igg1 antibody and irinotecan
|
EP2236139A1
(en)
|
2009-03-31 |
2010-10-06 |
F. Hoffmann-La Roche AG |
Combination therapy of erlotinib with an anti-IGF-1R antibody, which does not inhibit binding of insulin to the insulin receptor
|
WO2010112569A1
(en)
|
2009-03-31 |
2010-10-07 |
Robert Zimmermann |
Modulation of adipose triglyceride lipase for prevention and treatment of cachexia, loss of weight and muscle atrophy and methods of screening therefor
|
JP2012522977A
(ja)
|
2009-04-01 |
2012-09-27 |
ガラパゴス・ナムローゼ・フェンノートシャップ |
変形性関節症の治療のための方法及び手段
|
JP2012522589A
(ja)
|
2009-04-01 |
2012-09-27 |
ミシェル テクノロジーズ,インコーポレイテッド |
被覆ステント
|
AU2010232692C1
(en)
|
2009-04-01 |
2017-06-01 |
Genentech, Inc. |
Treatment of insulin-resistant disorders
|
JP6132548B2
(ja)
|
2009-04-01 |
2017-05-24 |
ジェネンテック, インコーポレイテッド |
抗FcRH5抗体および免疫接合体および使用方法
|
JP5501439B2
(ja)
|
2009-04-02 |
2014-05-21 |
ロシュ グリクアート アクチェンゲゼルシャフト |
完全長抗体と単鎖Fabフラグメントとを含む多重特異的抗体
|
US9297005B2
(en)
|
2009-04-13 |
2016-03-29 |
President And Fellows Of Harvard College |
Harnessing cell dynamics to engineer materials
|
WO2010121187A2
(en)
|
2009-04-17 |
2010-10-21 |
Micell Techologies, Inc. |
Stents having controlled elution
|
US8362218B2
(en)
|
2009-04-17 |
2013-01-29 |
New York University School Of Medicine |
Peptides targeting TNF family receptors and antagonizing TNF action, compositions, methods and uses thereof
|
US9724337B2
(en)
*
|
2009-04-21 |
2017-08-08 |
University Of Kentucky Research Foundation |
AG-205 for the treatment of breast cancer
|
SG175305A1
(en)
*
|
2009-04-23 |
2011-11-28 |
Theraclone Sciences Inc |
Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
|
EP2424567B1
(en)
*
|
2009-04-27 |
2018-11-21 |
OncoMed Pharmaceuticals, Inc. |
Method for making heteromultimeric molecules
|
MX2011011431A
(es)
*
|
2009-05-01 |
2012-02-23 |
Ferring Bv |
Composicion para el tratamiento de cancer de prostata.
|
AU2010246038A1
(en)
|
2009-05-05 |
2011-12-01 |
Amgen Inc. |
FGF21 mutants and uses thereof
|
US8188040B2
(en)
|
2009-05-05 |
2012-05-29 |
Amgen Inc. |
FGF21 mutants and uses thereof
|
MX348013B
(es)
|
2009-05-05 |
2017-05-23 |
Novimmune Sa |
Anticuerpos anti il-17f y metodos de uso de los mismos.
|
TW201043221A
(en)
*
|
2009-05-06 |
2010-12-16 |
Ferring Int Ct Sa |
Kit and method for preparation of a Degarelix solution
|
US8858948B2
(en)
|
2009-05-20 |
2014-10-14 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
EP2435438A1
(en)
|
2009-05-27 |
2012-04-04 |
Genentech, Inc. |
Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
|
EP2260857A1
(en)
|
2009-06-11 |
2010-12-15 |
Alfact Innovation |
Novel applications of HIP/PAP or derivatives thereof
|
WO2010144797A2
(en)
|
2009-06-12 |
2010-12-16 |
Vaccine Technologies, Incorporated |
Influenza vaccines with enhanced immunogenicity and uses thereof
|
IN2012DN00352A
(ko)
|
2009-06-16 |
2015-08-21 |
Bikam Pharmaceuticals Inc |
|
WO2010146059A2
(en)
|
2009-06-16 |
2010-12-23 |
F. Hoffmann-La Roche Ag |
Biomarkers for igf-1r inhibitor therapy
|
WO2010146511A1
(en)
|
2009-06-17 |
2010-12-23 |
Pfizer Limited |
Treatment of overactive bladder
|
AU2010262927A1
(en)
|
2009-06-17 |
2012-01-19 |
Amgen Inc. |
Chimeric FGF19 polypeptides and uses thereof
|
EP2446052B1
(en)
|
2009-06-25 |
2018-08-08 |
Fred Hutchinson Cancer Research Center |
Method of measuring adaptive immunity
|
EP2450055B1
(en)
|
2009-06-30 |
2018-01-03 |
Obshestvo S OgranichennoyOtvetstvennostiu"OncoMax" |
Method for suppressing renal tumor growth by blocking fibroblast growth factor receptor
|
US20110039787A1
(en)
*
|
2009-07-06 |
2011-02-17 |
Ferring International Center S.A. |
Compositions, kits and methods for treating benign prostate hyperplasia
|
CN102471382A
(zh)
|
2009-07-10 |
2012-05-23 |
依奈特制药公司 |
Tlr3 结合剂
|
US20130029970A1
(en)
|
2009-07-10 |
2013-01-31 |
Ironwood Pharmaceuticals, Inc |
CB Receptor Agonists
|
AU2010273585B2
(en)
|
2009-07-13 |
2015-04-23 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of cancer
|
US8992979B2
(en)
|
2009-07-14 |
2015-03-31 |
Polypid Ltd. |
Sustained-release drug carrier composition
|
MY161541A
(en)
|
2009-07-31 |
2017-04-28 |
Shin Maeda |
Cancer metastasis inhibitor
|
CA2768552A1
(en)
|
2009-07-31 |
2011-02-03 |
President And Fellows Of Harvard College |
Programming of cells for tolerogenic therapies
|
EP2459184A1
(en)
|
2009-07-31 |
2012-06-06 |
The Brigham and Women's Hospital, Inc. |
Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses
|
WO2011015573A1
(en)
|
2009-08-03 |
2011-02-10 |
Galapagos Nv |
Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
|
WO2011015572A1
(en)
|
2009-08-03 |
2011-02-10 |
Galapagos Nv |
Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
|
CN102575298A
(zh)
|
2009-08-14 |
2012-07-11 |
霍夫曼-拉罗奇有限公司 |
用于监测患者对vegf拮抗剂的响应的生物学标志物
|
JP2013501741A
(ja)
|
2009-08-14 |
2013-01-17 |
ロシュ グリクアート アーゲー |
アフコシル化cd20抗体とフルダラビン及び/又はミトキサントロンの併用療法
|
TWI409079B
(zh)
|
2009-08-14 |
2013-09-21 |
Roche Glycart Ag |
非典型岩藻醣化cd20抗體與苯達莫斯汀(bendamustine)之組合療法
|
RU2576027C2
(ru)
|
2009-08-15 |
2016-02-27 |
Дженентек, Инк. |
Антиангиогенная терапия для лечения ранее подвергавшегося лечению рака молочной железы
|
WO2011024114A1
(en)
|
2009-08-25 |
2011-03-03 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Targeting extracellular matrix molecules for the treatment of cancer
|
EP2473196B1
(en)
|
2009-08-28 |
2017-05-31 |
The Cleveland Clinic Foundation |
Sdf-1 delivery for treating ischemic tissue
|
WO2011028753A1
(en)
|
2009-09-01 |
2011-03-10 |
Genentech, Inc. |
Enhanced protein purification through a modified protein a elution
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
JP2013504595A
(ja)
|
2009-09-11 |
2013-02-07 |
ジェネンテック, インコーポレイテッド |
抗癌剤に対する応答の可能性が増加した患者を同定するための方法
|
WO2011034605A2
(en)
|
2009-09-16 |
2011-03-24 |
Genentech, Inc. |
Coiled coil and/or tether containing protein complexes and uses thereof
|
TW201118166A
(en)
|
2009-09-24 |
2011-06-01 |
Chugai Pharmaceutical Co Ltd |
HLA class I-recognizing antibodies
|
KR101823699B1
(ko)
|
2009-09-28 |
2018-01-30 |
인타르시아 세라퓨틱스 인코포레이티드 |
실질 항정상태 약물 전달의 신속 확립 및/또는 종결
|
PL2483278T3
(pl)
|
2009-09-28 |
2014-05-30 |
Hoffmann La Roche |
Związki benzoksazepinowe stanowiące inhibitor pi3k i ich zastosowanie w leczeniu nowotworu
|
MX2012003641A
(es)
|
2009-09-28 |
2012-04-30 |
Hoffmann La Roche |
Compuestos de benzoxepina inhibidores de la pi3x y metodos de uso.
|
EP2305285A1
(en)
|
2009-09-29 |
2011-04-06 |
Julius-Maximilians-Universität Würzburg |
Means and methods for treating ischemic conditions
|
KR20120095371A
(ko)
*
|
2009-10-01 |
2012-08-28 |
에보닉 데구사 코포레이션 |
노화 황반변성 치료용 극미립자 조성물들 및 노화 황반변성 치료방법
|
EP2305810A1
(en)
|
2009-10-02 |
2011-04-06 |
Technische Universität München |
miRNAs in the treatment of fibrosis
|
US20110195987A1
(en)
|
2009-10-05 |
2011-08-11 |
Thomas Najarian |
Treatment with cholinergic agonists
|
CN102686606A
(zh)
*
|
2009-10-09 |
2012-09-19 |
阿纳福公司 |
结合il-23r的多肽
|
TW201117824A
(en)
|
2009-10-12 |
2011-06-01 |
Amgen Inc |
Use of IL-17 receptor a antigen binding proteins
|
JP6016636B2
(ja)
*
|
2009-10-15 |
2016-10-26 |
ジェネンテック, インコーポレイテッド |
改変したレセプター特異性を持つキメラ線維芽細胞増殖因子
|
DK2488204T3
(en)
|
2009-10-16 |
2016-06-06 |
Oncomed Pharm Inc |
Therapeutic combination and use of DLL4 antagonist antibodies and blood pressure lowering agents
|
US20120282266A1
(en)
|
2009-10-16 |
2012-11-08 |
Auckland Uniservices Limited |
Anti-neoplastic uses of artemin antagonists
|
EP2492281B1
(en)
|
2009-10-19 |
2018-04-11 |
HanAll Biopharma Co., Ltd. |
Modified human tumor necrosis factor receptor-1 polypeptide or fragment thereof, and method for preparing same
|
CN102791739B
(zh)
|
2009-10-19 |
2014-10-15 |
霍夫曼-拉罗奇有限公司 |
肝细胞生长因子激活剂的调控物
|
WO2011050175A1
(en)
|
2009-10-21 |
2011-04-28 |
Sarcode Corporation |
Crystalline pharmaceutical and methods of preparation and use thereof
|
AR078716A1
(es)
|
2009-10-22 |
2011-11-30 |
Genentech Inc |
Anticuerpos antihepsina y metodos para su uso
|
ES2564207T3
(es)
|
2009-10-22 |
2016-03-18 |
F. Hoffmann-La Roche Ag |
Métodos y composiciones para modular la activación con hepsina de la proteína estimuladora de macrófagos
|
JP2013508401A
(ja)
|
2009-10-22 |
2013-03-07 |
ジェネンテック, インコーポレイテッド |
軸索変性の調節
|
WO2011056502A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Bone morphogenetic protein receptor type ii compositions and methods of use
|
WO2011056494A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
|
WO2011056497A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor type iib compositions and methods of use
|
US8729058B2
(en)
*
|
2009-10-27 |
2014-05-20 |
Michael Zasloff |
Methods and compositions for treating and preventing viral infections
|
KR102378465B1
(ko)
|
2009-11-02 |
2022-03-28 |
유니버시티 오브 워싱톤 스루 이츠 센터 포 커머셜리제이션 |
치료학적 뉴클레아제 조성물 및 방법
|
US20110165648A1
(en)
|
2009-11-04 |
2011-07-07 |
Menno Van Lookeren Campagne |
Co-crystal structure of factor D and anti-factor D antibody
|
SI2496601T1
(sl)
|
2009-11-05 |
2017-09-29 |
F. Hoffmann-La Roche Ag |
Tehnike in sestavek za sekrecijo heterolognih polipeptidov
|
WO2011058027A2
(en)
|
2009-11-12 |
2011-05-19 |
F. Hoffmann-La Roche Ag |
N-9-substituted purine compounds, compositions and methods of use
|
BR112012011147A2
(pt)
|
2009-11-12 |
2021-09-08 |
F.Hoffmann-La Roche Ag |
Composto, composição farmacêutica e uso de um composto.
|
WO2011060371A2
(en)
|
2009-11-13 |
2011-05-19 |
Puget Sound Blood Center |
Factor viii t cell epitope variants having reduced immunogenicity
|
JP2013511279A
(ja)
|
2009-11-20 |
2013-04-04 |
アムジエン・インコーポレーテツド |
抗Orai1抗原結合蛋白及びその使用
|
ES2646863T3
(es)
|
2009-11-24 |
2017-12-18 |
Medimmune Limited |
Agentes de unión específica contra B7-H1
|
WO2011066260A2
(en)
*
|
2009-11-25 |
2011-06-03 |
Michael Zasloff |
Formulations comprising aminosterols
|
EP3002297B1
(en)
|
2009-11-30 |
2020-04-08 |
F. Hoffmann-La Roche AG |
Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211)
|
US8491927B2
(en)
|
2009-12-02 |
2013-07-23 |
Nimble Epitech, Llc |
Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
|
AU2010326024A1
(en)
*
|
2009-12-02 |
2012-07-05 |
Amgen Inc. |
Binding proteins that bind to human FGFR1c, human beta-Klotho and both human FGFR1c and human beta-Klotho
|
US11377485B2
(en)
|
2009-12-02 |
2022-07-05 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
US10087236B2
(en)
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
CA2781682A1
(en)
|
2009-12-04 |
2011-06-09 |
Genentech, Inc. |
Multispecific antibodies, antibody analogs, compositions, and methods
|
UA109888C2
(uk)
|
2009-12-07 |
2015-10-26 |
|
ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
|
US20130109721A1
(en)
|
2009-12-08 |
2013-05-02 |
Ironwood Pharmaceuticals, Inc. |
FAAH Inhibitors
|
JP5997053B2
(ja)
|
2009-12-09 |
2016-09-21 |
オークランド ユニサービシーズ リミティド |
殺真菌性化合物及びその使用方法
|
AR078377A1
(es)
|
2009-12-11 |
2011-11-02 |
Genentech Inc |
Anticuerpos anti-vegf-c (factor de crecimiento endotelial anti-vascular aislado c) y sus metodos de uso
|
AU2010339794B2
(en)
|
2009-12-17 |
2016-09-22 |
Children's Medical Center Corporation |
Saposin-A derived peptides and uses thereof
|
AU2010341516B2
(en)
|
2009-12-21 |
2014-01-16 |
Ambrx, Inc. |
Modified bovine somatotropin polypeptides and their uses
|
CA2784800A1
(en)
|
2009-12-21 |
2011-07-21 |
Ambrx, Inc. |
Modified porcine somatotropin polypeptides and their uses
|
EA201200855A1
(ru)
|
2009-12-23 |
2013-04-30 |
Айронвуд Фармасьютикелз, Инк. |
Модуляторы crth2
|
HUE028629T2
(en)
|
2009-12-23 |
2016-12-28 |
Synimmune Gmbh |
Anti-FLT3 antibodies and ways of their use
|
GB0922553D0
(en)
|
2009-12-23 |
2010-02-10 |
Fusion Antibodies Ltd |
Prognostic marker
|
EP2516465B1
(en)
|
2009-12-23 |
2016-05-18 |
F.Hoffmann-La Roche Ag |
Anti-bv8 antibodies and uses thereof
|
WO2011082187A1
(en)
|
2009-12-30 |
2011-07-07 |
Genentech, Inc. |
Methods for modulating a pdgf-aa mediated biological response
|
CN102686235A
(zh)
|
2010-01-04 |
2012-09-19 |
Mapi医药公司 |
包含格拉默或其药用盐的储药系统
|
USRE49251E1
(en)
|
2010-01-04 |
2022-10-18 |
Mapi Pharma Ltd. |
Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
|
US8377885B2
(en)
|
2010-01-04 |
2013-02-19 |
Mapi Pharma Ltd. |
Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
|
WO2011085216A2
(en)
|
2010-01-08 |
2011-07-14 |
Ironwood Pharmaceuticals, Inc. |
Use of faah inhibitors for treating parkinson's disease and restless legs syndrome
|
TWI535445B
(zh)
|
2010-01-12 |
2016-06-01 |
安可美德藥物股份有限公司 |
Wnt拮抗劑及治療和篩選方法
|
EP2523682B1
(en)
|
2010-01-13 |
2015-12-16 |
Oncomed Pharmaceuticals, Inc. |
Notch1 binding agents and methods of use thereof
|
US8936804B2
(en)
|
2010-01-15 |
2015-01-20 |
Rutgers, The State University Of New Jersey |
Use of vanadium compounds to accelerate bone healing
|
US8795726B2
(en)
|
2010-01-19 |
2014-08-05 |
Polypid Ltd. |
Sustained-release nucleic acid matrix compositions
|
EP2525792A1
(en)
|
2010-01-19 |
2012-11-28 |
Medizinische Universität Wien |
Pharmaceutical compositions comprising lignans and their derivatives for the medical management of angiogenesis and hypovascularity
|
WO2011089211A1
(en)
|
2010-01-22 |
2011-07-28 |
Synimmune Gmbh |
Anti-cd133 antibodies and methods of using the same
|
WO2011094430A2
(en)
|
2010-01-27 |
2011-08-04 |
Children's Medical Center Corporation |
Pro-angiogenic fragments of prominin-1 and uses thereof
|
CN102753575A
(zh)
|
2010-01-28 |
2012-10-24 |
诺沃—诺迪斯克保健股份有限公司 |
因子vii融合多肽
|
US11369498B2
(en)
|
2010-02-02 |
2022-06-28 |
MT Acquisition Holdings LLC |
Stent and stent delivery system with improved deliverability
|
WO2011098644A2
(es)
|
2010-02-09 |
2011-08-18 |
Proyecto De Biomedicina Cima, S.L. |
Composiciones para el tratamiento de enfermedades infecciosas y tumorales
|
US20130196960A1
(en)
|
2010-02-09 |
2013-08-01 |
Ironwood Pharmaceuticals, Inc. |
Cannabinoid Receptor Agonists
|
WO2011100359A1
(en)
|
2010-02-09 |
2011-08-18 |
Ironwood Pharmaceuticals, Inc. |
Cannabinoid agonists
|
WO2011099007A1
(en)
|
2010-02-10 |
2011-08-18 |
Nayacure Therapeutics Ltd. |
Pharmaceutical compositions and methods for the treatment and prevention of cancer
|
SA111320200B1
(ar)
|
2010-02-17 |
2014-02-16 |
ديبيوفارم اس ايه |
مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة
|
WO2011101328A2
(en)
|
2010-02-18 |
2011-08-25 |
Roche Glycart Ag |
Treatment with a humanized igg class anti egfr antibody and an antibody against insulin like growth factor 1 receptor
|
CA2790500A1
(en)
|
2010-02-19 |
2011-08-25 |
Lynn K. Gordon |
Epithelial membrane protein 2 (emp2) binding reagents and their therapeutic uses in ocular diseases
|
US9233087B2
(en)
|
2010-02-19 |
2016-01-12 |
Siga Technologies, Inc |
Inhibitors and methods of inhibiting bacterial and viral pathogens
|
MX2012009059A
(es)
|
2010-02-22 |
2012-09-07 |
Hoffmann La Roche |
Compuestos inhibidores de fosfoinositida 3-cinasa delta (pi3k) pirido [3,2-d]pirimidina y metodos de uso.
|
CN103237810A
(zh)
|
2010-02-23 |
2013-08-07 |
霍夫曼-拉罗奇有限公司 |
用于治疗卵巢癌的抗血管发生疗法
|
JP5972176B2
(ja)
|
2010-02-23 |
2016-08-17 |
サノフイ |
抗アルファ2インテグリン抗体及びそれらの使用
|
KR20130004579A
(ko)
|
2010-02-23 |
2013-01-11 |
제넨테크, 인크. |
종양의 진단 및 치료를 위한 조성물 및 방법
|
AR080291A1
(es)
|
2010-02-24 |
2012-03-28 |
Rinat Neuroscience Corp |
Anticuerpos antagonistas anti receptor de il-7 y procedimientos
|
WO2011106703A2
(en)
|
2010-02-26 |
2011-09-01 |
Anchor Therapeutics, Inc. |
Cxcr4 receptor compounds
|
EP2544688B1
(en)
|
2010-03-02 |
2016-09-07 |
President and Fellows of Harvard College |
Methods and compositions for treatment of angelman syndrome
|
US9610328B2
(en)
|
2010-03-05 |
2017-04-04 |
President And Fellows Of Harvard College |
Enhancement of skeletal muscle stem cell engraftment by dual delivery of VEGF and IGF-1
|
WO2011112516A1
(en)
|
2010-03-08 |
2011-09-15 |
Ico Therapeutics Inc. |
Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides
|
SA111320266B1
(ar)
|
2010-03-11 |
2015-06-21 |
رينات نيوروساينس كوربوريشن |
أجسام مضادة مع ارتباط مولد مضاد يعتمد على الأس الهيدروجيني
|
EP2550289A4
(en)
|
2010-03-12 |
2013-11-27 |
Childrens Medical Center |
NEW IMMUNOGENS AND METHODS FOR DISCOVERY AND SCREENING THEREOF
|
WO2011115804A1
(en)
|
2010-03-17 |
2011-09-22 |
Ironwood Pharmaceuticals, Inc. |
Sgc stimulators
|
KR101878369B1
(ko)
|
2010-03-22 |
2018-07-16 |
제넨테크, 인크. |
단백질-함유 제제의 안정화에 유용한 조성물 및 방법
|
WO2011118804A1
(ja)
|
2010-03-26 |
2011-09-29 |
国立大学法人徳島大学 |
新規抗cd98抗体とその用途
|
WO2011119906A1
(en)
|
2010-03-26 |
2011-09-29 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
HUMAN POLYOMAVIRUS 6 (HPyV6) AND HUMAN POLYOMAVIRUS 7 (HPyV7)
|
TW201138821A
(en)
|
2010-03-26 |
2011-11-16 |
Roche Glycart Ag |
Bispecific antibodies
|
MX341925B
(es)
|
2010-03-29 |
2016-09-07 |
Zymeworks Inc |
Anticuerpos con funcion efectora suprimida o mejorada.
|
US20130224151A1
(en)
|
2010-03-31 |
2013-08-29 |
United States Of America |
Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain
|
AU2011237936A1
(en)
|
2010-04-07 |
2012-10-11 |
F. Hoffmann-La Roche Ag |
Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
|
EP2374816B1
(en)
|
2010-04-07 |
2016-09-28 |
Agency For Science, Technology And Research |
Binding molecules against Chikungunya virus and uses thereof
|
US10338069B2
(en)
|
2010-04-12 |
2019-07-02 |
Academia Sinica |
Glycan arrays for high throughput screening of viruses
|
CA2796055A1
(en)
|
2010-04-15 |
2011-10-20 |
Amgen Inc. |
Human fgf receptor and .beta.-klotho binding proteins
|
CA2793892A1
(en)
|
2010-04-16 |
2011-10-20 |
Elizabeth Punnoose |
Foxo3a as predictive biomarker for pi3k/akt kinase pathway inhibitor efficacy
|
WO2011131626A1
(en)
|
2010-04-19 |
2011-10-27 |
Medizinische Universität Innsbruck |
Tmem195 encodes for tetrahydrobiopterin-dependent alkylglycerol monooxygenase activity
|
CA2797110C
(en)
|
2010-04-22 |
2020-07-21 |
Micell Technologies, Inc. |
Stents and other devices having extracellular matrix coating
|
RU2624027C2
(ru)
|
2010-04-23 |
2017-06-30 |
Дженентек, Инк. |
Получение гетеромультимерных белков
|
AU2011248625B2
(en)
|
2010-04-26 |
2017-01-05 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-tRNA synthetase
|
RU2585489C2
(ru)
|
2010-04-27 |
2016-05-27 |
Рош Гликарт Аг |
КОМБИНИРОВАННАЯ ТЕРАПИЯ АФУКОЗИЛИРОВАННЫМ АНТИТЕЛОМ CD20 И ИНГИБИТОРОМ mTOR
|
JP6294074B2
(ja)
|
2010-04-27 |
2018-03-14 |
エータイアー ファーマ, インコーポレイテッド |
イソロイシルtRNA合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
|
EP2563911B1
(en)
|
2010-04-28 |
2021-07-21 |
aTyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases
|
WO2011139854A2
(en)
|
2010-04-29 |
2011-11-10 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases
|
WO2011139907A2
(en)
|
2010-04-29 |
2011-11-10 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases
|
ES2623805T3
(es)
|
2010-05-03 |
2017-07-12 |
Atyr Pharma, Inc. |
Descubrimiento innovador de composiciones terapéuticas, de diagnóstico y de anticuerpos relacionadas con fragmentos de proteínas de fenilalanil-alfa-ARNt sintetasas
|
JP2013525484A
(ja)
|
2010-05-03 |
2013-06-20 |
ジェネンテック, インコーポレイテッド |
タンパク質含有製剤の粘度を低減させるために有用な組成物及び方法
|
WO2011139986A2
(en)
|
2010-05-03 |
2011-11-10 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-trna synthetases
|
RU2636461C2
(ru)
|
2010-05-03 |
2017-11-23 |
Дженентек, Инк. |
Композиции и способы для диагностики и лечения опухоли
|
WO2011140135A2
(en)
|
2010-05-03 |
2011-11-10 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-trna synthetases
|
EP2566499B1
(en)
|
2010-05-04 |
2017-01-25 |
aTyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-trna synthetase complex
|
GB201007531D0
(en)
|
2010-05-05 |
2010-06-23 |
Imp Innovations Ltd |
Composition
|
CN103038233B
(zh)
|
2010-05-07 |
2017-06-20 |
吉利德康涅狄格有限公司 |
吡啶酮和氮杂吡啶酮化合物及使用方法
|
WO2011138457A1
(en)
|
2010-05-07 |
2011-11-10 |
Technische Universität Graz |
Ucp1 (thermogenin) - inducing agents for use in the treatment of a disorder of the energy homeostasis
|
AU2011250970B2
(en)
|
2010-05-10 |
2016-12-15 |
Sinica, Academia |
Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
|
WO2011141891A1
(en)
|
2010-05-12 |
2011-11-17 |
Debio Recherche Pharmaceutique S.A. |
Use of cycloundecadepsipeptide compounds
|
US8945541B2
(en)
|
2010-05-14 |
2015-02-03 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-tRNA synthetases
|
CA2800348C
(en)
|
2010-05-18 |
2020-07-21 |
Lena A. Basile |
Il-12 formulations for enhancing hematopoiesis
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
EP3190187A1
(en)
|
2010-05-21 |
2017-07-12 |
Peptimed, Inc. |
Reagents and methods for treating cancer
|
US10285936B2
(en)
|
2010-05-31 |
2019-05-14 |
Laboratorios Farmacéuticos Rovi, S.A. |
Injectable composition with aromatase inhibitor
|
US10335366B2
(en)
|
2010-05-31 |
2019-07-02 |
Laboratorios Farmacéuticos Rovi, S.A. |
Risperidone or paliperidone implant formulation
|
US10350159B2
(en)
|
2010-05-31 |
2019-07-16 |
Laboratories Farmacéuticos Rovi, S.A. |
Paliperidone implant formulation
|
US9562089B2
(en)
|
2010-05-26 |
2017-02-07 |
Bristol-Myers Squibb Company |
Fibronectin based scaffold proteins having improved stability
|
JP6046607B2
(ja)
|
2010-05-27 |
2016-12-21 |
エータイアー ファーマ, インコーポレイテッド |
グルタミニルtRNA合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
|
JP6051049B2
(ja)
|
2010-05-28 |
2016-12-21 |
中外製薬株式会社 |
抗腫瘍t細胞応答増強剤
|
EP2578233B1
(en)
|
2010-05-28 |
2017-04-26 |
National Cancer Center |
Therapeutic agent for pancreatic cancer
|
US10881605B2
(en)
|
2010-05-31 |
2021-01-05 |
Laboratorios Farmaceuticos Rovi, S.A. |
Methods for the preparation of injectable depot compositions
|
US10463607B2
(en)
|
2010-05-31 |
2019-11-05 |
Laboratorios Farmaceutics Rofi S.A. |
Antipsychotic Injectable Depot Composition
|
PT2394663T
(pt)
|
2010-05-31 |
2021-11-26 |
Farm Rovi Lab Sa |
Composições para implantes biodegradáveis injectáveis
|
ES2589106T3
(es)
|
2010-05-31 |
2016-11-10 |
Laboratorios Farmaceuticos Rovi, S.A. |
Composición inyectable antipsicótica de liberación controlada
|
JP5906237B2
(ja)
|
2010-06-01 |
2016-04-20 |
エータイアー ファーマ, インコーポレイテッド |
リジルtRNA合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
|
WO2011153243A2
(en)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Anti-angiogenesis therapy for treating gastric cancer
|
WO2011153224A2
(en)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of cancer
|
SG185430A1
(en)
|
2010-06-03 |
2012-12-28 |
Genentech Inc |
Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
|
US20130115237A1
(en)
|
2010-06-09 |
2013-05-09 |
Vaccine Technologies, Incorporated |
Therapeutic immunization in hiv infected subjects to augment antiretroviral treatment
|
RU2012157399A
(ru)
|
2010-06-18 |
2014-07-27 |
КсайберСайенс ГмбХ |
Пептиды в качестве активных агентов для стабилизации биологических барьеров
|
EP4269563A3
(en)
|
2010-06-19 |
2024-01-10 |
Memorial Sloan-Kettering Cancer Center |
Anti-gd2 antibodies
|
MY161390A
(en)
|
2010-06-24 |
2017-04-14 |
Genentech Inc |
Compositions and methods containing alkylglycosides for stabilizing protein-containing formulations
|
WO2011163669A2
(en)
|
2010-06-25 |
2011-12-29 |
President And Fellows Of Harvard College |
Co-delivery of stimulatory and inhibitory factors to create temporally stable and spatially restricted zones
|
AR088020A1
(es)
|
2010-06-30 |
2014-05-07 |
Ironwood Pharmaceuticals Inc |
Compuestos heterociclicos como estimuladores de sgc
|
CA2804416C
(en)
|
2010-07-12 |
2020-04-28 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases
|
WO2012009137A1
(en)
|
2010-07-12 |
2012-01-19 |
Ironwood Pharmaceuticals, Inc. |
Crth2 modulators
|
WO2012009134A1
(en)
|
2010-07-12 |
2012-01-19 |
Ironwood Pharmaceuticals, Inc. |
Crth2 modulators
|
SG186451A1
(en)
|
2010-07-12 |
2013-01-30 |
Covx Technologies Ireland Ltd |
Multifunctional antibody conjugates
|
KR101531117B1
(ko)
|
2010-07-14 |
2015-06-23 |
에프. 호프만-라 로슈 아게 |
Pi3k p110 델타에 대해 선택적인 퓨린 화합물, 및 사용 방법
|
CA2805572A1
(en)
|
2010-07-16 |
2012-01-19 |
Martin Hegen |
Modified single domain antigen binding molecules and uses thereof
|
CA2805631C
(en)
|
2010-07-16 |
2018-07-31 |
Micell Technologies, Inc. |
Drug delivery medical device
|
US20120189618A1
(en)
|
2010-07-16 |
2012-07-26 |
Boehringer Ingelheim International Gmbh |
Superior efficacy of cd37 antibodies in cll blood samples
|
KR20150013949A
(ko)
|
2010-07-19 |
2015-02-05 |
에프. 호프만-라 로슈 아게 |
항암요법에 반응할 가능성이 증가된 환자를 확인하는 방법
|
EP2596362A1
(en)
|
2010-07-19 |
2013-05-29 |
F. Hoffmann-La Roche AG |
Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
|
US9458509B2
(en)
|
2010-07-22 |
2016-10-04 |
President And Fellows Of Harvard College |
Multiple input biologic classifier circuits for cells
|
EP2596026B1
(en)
|
2010-07-23 |
2020-04-08 |
Trustees of Boston University |
Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
|
WO2012016227A2
(en)
|
2010-07-29 |
2012-02-02 |
Xencor, Inc. |
Antibodies with modified isoelectric points
|
WO2012016918A1
(en)
|
2010-08-02 |
2012-02-09 |
Université de Lausanne |
Use of a peptide enhancing the ability of radiation therapy to kill cancer cells
|
US8900590B2
(en)
|
2010-08-12 |
2014-12-02 |
Theraclone Sciences, Inc. |
Anti-hemagglutinin antibody compositions and methods of use thereof
|
EP2603525A1
(en)
|
2010-08-13 |
2013-06-19 |
F.Hoffmann-La Roche Ag |
Antibodies to il-1beta and il-18, for treatment of disease
|
US9567386B2
(en)
|
2010-08-17 |
2017-02-14 |
Ambrx, Inc. |
Therapeutic uses of modified relaxin polypeptides
|
SG10201506443TA
(en)
|
2010-08-17 |
2015-10-29 |
Ambrx Inc |
Modified relaxin polypeptides and their uses
|
EP2606358B1
(en)
|
2010-08-17 |
2018-12-26 |
Universite De Geneve |
Bard1 isoforms in lung and colorectal cancer and use thereof
|
TW201208703A
(en)
|
2010-08-17 |
2012-03-01 |
Roche Glycart Ag |
Combination therapy of an afucosylated CD20 antibody with an anti-VEGF antibody
|
WO2012025530A1
(en)
|
2010-08-24 |
2012-03-01 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies comprising a disulfide stabilized - fv fragment
|
CN103108650A
(zh)
|
2010-08-25 |
2013-05-15 |
Atyr医药公司 |
与酪氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
|
CA2812063A1
(en)
|
2010-08-30 |
2012-06-07 |
President And Fellows Of Harvard College |
Shear controlled release for stenotic lesions and thrombolytic therapies
|
CA3109036C
(en)
|
2010-08-31 |
2023-08-01 |
Theraclone Sciences, Inc. |
Human immunodeficiency virus (hiv)-neutralizing antibodies
|
US9249123B2
(en)
|
2010-09-01 |
2016-02-02 |
Genentech, Inc. |
Pyridinones/pyrazinones, method of making, and method of use thereof
|
CA2809662C
(en)
|
2010-09-01 |
2019-04-16 |
Gilead Connecticut, Inc. |
Pyridazinones, method of making, and method of use thereof
|
WO2012030919A2
(en)
|
2010-09-01 |
2012-03-08 |
Thomas Jefferson University |
Composition and method for muscle repair and regeneration
|
US8551479B2
(en)
|
2010-09-10 |
2013-10-08 |
Oncomed Pharmaceuticals, Inc. |
Methods for treating melanoma
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
EP2616554A1
(en)
|
2010-09-17 |
2013-07-24 |
President and Fellows of Harvard College |
Functional genomics assay for characterizing pluripotent stem cell utility and safety
|
EP2725034B1
(en)
|
2010-09-22 |
2019-04-03 |
Amgen Inc. |
Carrier immunoglobulins with no specificity for human tissues and uses thereof
|
AR083006A1
(es)
|
2010-09-23 |
2013-01-23 |
Lilly Co Eli |
Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
|
NZ609154A
(en)
|
2010-09-28 |
2014-10-31 |
Sekisui Chemical Co Ltd |
Antihuman ccr7 antibodies, hybridoma, nucleic acid, vector, cell, medicinal composition, and antibody-immobilized carrier
|
EP2621516B1
(en)
|
2010-10-01 |
2016-06-22 |
Biogen MA Inc. |
Interferon-beta for use as monotherapy or in combination with other cancer therapies
|
CA2813665A1
(en)
|
2010-10-04 |
2012-04-12 |
Elro Pharma |
Compositions comprising multivalent synthetic ligands of surface nucleolin and glycosaminoglycans
|
JP6104806B2
(ja)
|
2010-10-06 |
2017-03-29 |
プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ |
材料に基づく細胞治療のための注射可能孔形成性ハイドロゲル
|
US9364505B2
(en)
|
2010-10-25 |
2016-06-14 |
Regents Of The University Of Minnesota |
Therapeutic composition for treatment of glioblastoma
|
TW201307385A
(zh)
|
2010-10-25 |
2013-02-16 |
Genentech Inc |
胃腸炎症和銀屑病以及哮喘的治療
|
ES2617336T3
(es)
|
2010-10-27 |
2017-06-16 |
Ferring B.V. |
Procedimiento para la fabricación de degarelix y sus productos intermedios
|
EP2447276A1
(en)
|
2010-10-27 |
2012-05-02 |
Ferring B.V. |
Process for the manufacture of Degarelix and its intermediates
|
MX354481B
(es)
|
2010-10-27 |
2018-03-07 |
Amgen Inc |
Anticuerpos dkk1 y métodos de uso.
|
AU2011323508B2
(en)
|
2010-11-01 |
2017-04-27 |
Peptimed, Inc. |
Compositions of a peptide targeting system for treating cancer
|
CN104998254A
(zh)
|
2010-11-08 |
2015-10-28 |
基因技术公司 |
皮下施用的抗-il-6受体抗体
|
WO2012064697A2
(en)
|
2010-11-08 |
2012-05-18 |
President And Fellows Of Harvard College |
Materials presenting notch signaling molecules to control cell behavior
|
CN107266433A
(zh)
|
2010-11-09 |
2017-10-20 |
铁木医药有限公司 |
sGC刺激剂
|
PT2644698T
(pt)
|
2010-11-17 |
2018-01-31 |
Chugai Pharmaceutical Co Ltd |
Molécula multiespecífica de ligação ao antigénio com uma função alternativa à função do fator viii de coagulação do sangue
|
GB201019467D0
(en)
|
2010-11-17 |
2010-12-29 |
Biotecnol Sa |
Therapeutic agent
|
US9023791B2
(en)
|
2010-11-19 |
2015-05-05 |
Novartis Ag |
Fibroblast growth factor 21 mutations
|
PT2643019T
(pt)
|
2010-11-24 |
2019-04-23 |
Lexicon Pharmaceuticals Inc |
Anticorpos para notum pectinacetilesterase
|
AU2011336727B2
(en)
|
2010-11-30 |
2016-11-03 |
The Johns Hopkins University |
Hybrid cyclic libraries and screens thereof
|
EP2646470B1
(en)
|
2010-11-30 |
2017-03-01 |
F. Hoffmann-La Roche AG |
Low affinity anti-transferrin receptor antibodies and their use to transfer therapeutic scfv across the blood brain barrier
|
US10208129B2
(en)
|
2010-12-06 |
2019-02-19 |
National Research Council Of Canada |
Antibodies selective for cells presenting ErbB2 at high density
|
MX2013006739A
(es)
|
2010-12-16 |
2013-07-17 |
Roche Glycart Ag |
Terapia combinada de anticuerpo cd20 afucosilado con inhibidor de mdm2.
|
EP3053925A1
(en)
|
2010-12-16 |
2016-08-10 |
F. Hoffmann-La Roche AG |
Tricyclic pi3k inhibitor compounds and methods of use
|
MA34836B1
(fr)
|
2010-12-17 |
2014-01-02 |
Hoffmann La Roche |
Composes heterocycliques azotes 6;6- condenses substitues et leurs utilisations
|
EP2656073A4
(en)
|
2010-12-20 |
2014-12-17 |
Univ Rockefeller |
MODULATION AGONISTIC TNFR ANTIBODY
|
WO2012088254A1
(en)
|
2010-12-22 |
2012-06-28 |
Genentech, Inc. |
Autophagy inducer and inhibitor combination therapy for the treatment of neoplasms
|
ES2703499T3
(es)
|
2010-12-22 |
2019-03-11 |
Salk Inst Biological Studies |
Péptidos antagonistas de CRF cíclicos
|
AR084433A1
(es)
|
2010-12-22 |
2013-05-15 |
Ironwood Pharmaceuticals Inc |
Inhibidores de la faah y composiciones farmaceuticas que los contienen
|
JP5766296B2
(ja)
|
2010-12-23 |
2015-08-19 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
|
WO2012088431A1
(en)
|
2010-12-23 |
2012-06-28 |
Ironwood Pharmaceuticals, Inc. |
Faah inhibitors
|
WO2012087017A2
(ko)
|
2010-12-23 |
2012-06-28 |
한올바이오파마주식회사 |
변형된 인간 종양 괴사 인자 수용체-1 폴리펩티드 또는 그의 절편 및 그의 제조방법
|
JOP20210044A1
(ar)
|
2010-12-30 |
2017-06-16 |
Takeda Pharmaceuticals Co |
الأجسام المضادة لـ cd38
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
US8734790B2
(en)
|
2011-01-10 |
2014-05-27 |
Novimmune Sa |
Anti-TLR4 antibodies and methods of use thereof
|
AU2012206614A1
(en)
|
2011-01-12 |
2013-08-01 |
Innate Pharma |
TLR3 binding agents
|
EP2668207A4
(en)
|
2011-01-24 |
2015-06-10 |
Univ Singapore |
LIPOARABINOMANNANE ANTIGEN-BINDING PROTEINS HAVING A MANNOSIS FROM PATHOGENIC MYCOBACTERIAS
|
EP2668209B8
(en)
|
2011-01-24 |
2021-08-11 |
Gilead Sciences, Inc. |
Antibodies selective for cells presenting egfr at high density
|
JO3755B1
(ar)
|
2011-01-26 |
2021-01-31 |
Ferring Bv |
تركيبات تستوستيرون
|
PL2667715T3
(pl)
|
2011-01-27 |
2018-02-28 |
Neuren Pharmaceuticals Limited |
Leczenie zaburzeń spektrum autystycznego z wykorzystaniem kwasu glicylo-l- 2-metyloprolilo-l-glutaminowego
|
WO2012106281A2
(en)
|
2011-01-31 |
2012-08-09 |
The General Hospital Corporation |
Multimodal trail molecules and uses in cellular therapies
|
WO2012104824A1
(en)
|
2011-02-04 |
2012-08-09 |
Ecole polytechnique fédérale de Lausanne (EPFL) |
Therapeutic antibodies targeting app-c99
|
US10689447B2
(en)
|
2011-02-04 |
2020-06-23 |
Genentech, Inc. |
Fc variants and methods for their production
|
MX355255B
(es)
|
2011-02-04 |
2018-04-11 |
Genentech Inc |
Variantes de fc y métodos para su producción.
|
RU2440142C1
(ru)
|
2011-02-07 |
2012-01-20 |
Общество С Ограниченной Ответственностью "Онкомакс" |
Антитело, останавливающее или замедляющее рост опухоли (варианты), способ подавления роста опухоли, способ диагностики злокачественных образований
|
US20140031383A1
(en)
|
2011-02-08 |
2014-01-30 |
Dana-Farber Cancer Institute, Inc. |
Methods for treatment of melanoma
|
CA2825028A1
(en)
|
2011-02-09 |
2012-08-16 |
F. Hoffman-La Roche Ag |
Heterocyclic compounds as pi3 kinase inhibitors
|
KR20140012098A
(ko)
|
2011-02-14 |
2014-01-29 |
테라클론 사이언시스, 아이엔씨. |
인플루엔자의 치료 및 진단을 위한 조성물 및 방법
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
CN102675460B
(zh)
|
2011-02-28 |
2015-08-19 |
珠海市丽珠单抗生物技术有限公司 |
抗肿瘤坏死因子α的人源化抗体
|
US8658171B2
(en)
|
2011-02-28 |
2014-02-25 |
Livzon Mabpharm Inc. |
Humanized anti-TNFα antibodies
|
MX2013010011A
(es)
|
2011-03-01 |
2014-10-24 |
Amgen Inc |
Agentes de unión biespecífica.
|
MX2013010185A
(es)
|
2011-03-10 |
2014-02-17 |
Genentech Inc |
Tratamiento de alteraciones con funcion de barrera vascular alterada.
|
SG193402A1
(en)
|
2011-03-15 |
2013-10-30 |
Theraclone Sciences Inc |
Compositions and methods for the therapy and diagnosis of influenza
|
JP2014508183A
(ja)
|
2011-03-16 |
2014-04-03 |
エフ.ホフマン−ラ ロシュ アーゲー |
6,5−複素環式プロパルギルアルコール化合物及びこれらの使用
|
EP3235508B1
(en)
|
2011-03-16 |
2020-12-30 |
Sanofi |
Compositions comprising a dual v region antibody-like protein
|
CA2830069C
(en)
|
2011-03-20 |
2019-11-12 |
The University Of British Columbia |
Therapeutic agent for emphysema and copd
|
BR112013024122A2
(pt)
|
2011-03-21 |
2019-09-24 |
Hoffmann La Roche |
compostos de benzoxazepina seletivos para p110 delta pi3k e métodos de uso
|
EP2688594B1
(en)
|
2011-03-22 |
2016-12-14 |
The Brigham and Women's Hospital, Inc. |
Compositions and their use in the treatment of cancer
|
CA2831732C
(en)
|
2011-03-31 |
2019-12-31 |
Genentech, Inc. |
Use of a monoclonal anti-beta7 antibody for treating gastrointestinal inflammatory disorders
|
RU2631240C2
(ru)
|
2011-04-01 |
2017-09-20 |
Дженентек, Инк. |
Комбинации соединений-ингибиторов акт и абиратерона, и способы применения
|
MX2013011333A
(es)
|
2011-04-01 |
2014-04-16 |
Genentech Inc |
Combinaciones de compuestos inhibidores de akt y mek, y metodos de uso.
|
KR20140027211A
(ko)
|
2011-04-04 |
2014-03-06 |
유니버시티 오브 아이오와 리써치 파운데이션 |
백신 면역원성의 개선 방법
|
US8628773B2
(en)
|
2011-04-07 |
2014-01-14 |
Amgen Inc. |
Antigen binding proteins
|
US10752664B2
(en)
|
2011-04-08 |
2020-08-25 |
Amgen Inc. |
Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (GDF-15)
|
ES2608835T3
(es)
|
2011-04-13 |
2017-04-17 |
Bristol-Myers Squibb Company |
Proteínas de fusión Fc que comprenden nuevos enlazadores o disposiciones
|
ES2601892T3
(es)
|
2011-04-21 |
2017-02-16 |
Mapi Pharma Limited |
Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes
|
AR086074A1
(es)
|
2011-04-26 |
2013-11-13 |
Genentech Inc |
Composiciones y metodo para tratar enfermedades autoinmunes
|
US10647959B2
(en)
|
2011-04-27 |
2020-05-12 |
President And Fellows Of Harvard College |
Cell-friendly inverse opal hydrogels for cell encapsulation, drug and protein delivery, and functional nanoparticle encapsulation
|
US9675561B2
(en)
|
2011-04-28 |
2017-06-13 |
President And Fellows Of Harvard College |
Injectable cryogel vaccine devices and methods of use thereof
|
WO2012149358A1
(en)
|
2011-04-28 |
2012-11-01 |
President And Fellows Of Harvard College |
Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration
|
KR102161657B1
(ko)
|
2011-04-29 |
2020-10-06 |
유니버시티 오브 워싱톤 스루 이츠 센터 포 커머셜리제이션 |
치료적 뉴클레아제 조성물 및 방법
|
CA2834776A1
(en)
|
2011-05-03 |
2012-11-08 |
Genentech, Inc. |
Therapeutic apo2l/trail polypeptides and death receptor agonist antibodies
|
WO2012151474A2
(en)
|
2011-05-04 |
2012-11-08 |
Trustees Of Boston University |
Proton-motive force stimulation to potentiate aminoglycoside antibiotics against persistent bacteria
|
CN103635446B
(zh)
|
2011-05-04 |
2016-02-03 |
巴兰斯医疗公司 |
戊四唑衍生物
|
MX2013013044A
(es)
|
2011-05-10 |
2014-02-20 |
Amgen Inc |
METODO PARA IDENTIFICAR COMPUESTOS QUE ESPECIFICAMENTE MODULAN LA INTERACCION DE FGFR1 Y ß-KLOTHO.
|
JOP20200043A1
(ar)
|
2011-05-10 |
2017-06-16 |
Amgen Inc |
طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
|
EP3912619A1
(en)
|
2011-05-11 |
2021-11-24 |
Children's Medical Center Corporation |
Modified biotin-binding protein, fusion proteins thereof and applications
|
EP2709450A4
(en)
|
2011-05-20 |
2015-04-15 |
Benjamin Wolozin |
DETECTION OF COMPOUNDS FOR DISPERSING TDP-43 INCLUSIONS
|
WO2012166903A1
(en)
|
2011-06-02 |
2012-12-06 |
President And Fellows Of Harvard College |
Methods and uses for ex vivo tissue culture systems
|
JP6062426B2
(ja)
|
2011-06-03 |
2017-01-18 |
プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ |
インサイチュー抗原生成癌ワクチン
|
JP6305919B2
(ja)
|
2011-06-06 |
2018-04-04 |
プロセナ バイオサイエンシーズ リミテッド |
Mcamアンタゴニスト及び治療の方法
|
US9574002B2
(en)
|
2011-06-06 |
2017-02-21 |
Amgen Inc. |
Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
|
WO2012174064A1
(en)
|
2011-06-14 |
2012-12-20 |
Bikam Pharmaceuticals, Inc. |
Opsin-binding ligands, compositions and methods of use
|
US20140227265A1
(en)
|
2011-06-17 |
2014-08-14 |
Amgen Inc. |
Method of treating or ameliorating metabolic disorders using clec-2
|
AU2012275841A1
(en)
|
2011-06-27 |
2014-01-16 |
The Jackson Laboratory |
Methods and compositions for treatment of cancer and autoimmune disease
|
WO2013003593A1
(en)
|
2011-06-28 |
2013-01-03 |
Alternative Innovative Technologies Llc |
Methods of use of hsp70 for increased performance or hsp70 related disorders
|
US10400029B2
(en)
|
2011-06-28 |
2019-09-03 |
Inhibrx, Lp |
Serpin fusion polypeptides and methods of use thereof
|
RS59368B1
(sr)
|
2011-06-28 |
2019-11-29 |
Inhibrx Lp |
Fuzioni polipeptidi na bazi serpina i postupci za njihovu upotrebu
|
US8986688B2
(en)
|
2011-06-28 |
2015-03-24 |
Inhibrx, Llc |
WAP domain fusion polypeptides and methods of use thereof
|
WO2013003697A1
(en)
|
2011-06-30 |
2013-01-03 |
Trustees Of Boston University |
Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
|
ES2625511T3
(es)
|
2011-07-08 |
2017-07-19 |
Shire Human Genetic Therapies, Inc. |
Métodos para la purificación de arylsulfatasa A
|
BR112014000392A2
(pt)
|
2011-07-14 |
2017-02-21 |
Pfizer |
tratamento com anticorpos anti-pcsk9
|
US10117972B2
(en)
|
2011-07-15 |
2018-11-06 |
Micell Technologies, Inc. |
Drug delivery medical device
|
US20140234330A1
(en)
|
2011-07-22 |
2014-08-21 |
Amgen Inc. |
Il-17 receptor a is required for il-17c biology
|
US20130022551A1
(en)
|
2011-07-22 |
2013-01-24 |
Trustees Of Boston University |
DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS
|
WO2013017656A1
(en)
|
2011-08-02 |
2013-02-07 |
Medizinische Universität Wien |
Antagonists of ribonucleases for treating obesity
|
WO2013022855A1
(en)
|
2011-08-05 |
2013-02-14 |
Xencor, Inc. |
Antibodies with modified isoelectric points and immunofiltering
|
RU2638116C2
(ru)
|
2011-08-12 |
2017-12-15 |
Ф. Хоффманн-Ля Рош Аг |
Пиразоло[3,4-с]пиридины и способы их применения
|
US9745288B2
(en)
|
2011-08-16 |
2017-08-29 |
Indiana University Research And Technology Corporation |
Compounds and methods for treating cancer by inhibiting the urokinase receptor
|
EP2745113B1
(en)
|
2011-08-16 |
2017-03-22 |
Evotec (München) GmbH |
Markers for susceptibility to an inhibitor of an src-family kinase
|
EP3348575A1
(en)
|
2011-08-16 |
2018-07-18 |
Emory University |
Jaml specific binding agents, antibodies, and uses related thereto
|
ES2664224T3
(es)
|
2011-08-19 |
2018-04-18 |
Children's Medical Center Corporation |
Proteína de unión a VEGF para el bloqueo de la angiogénesis
|
SG11201400073SA
(en)
|
2011-08-23 |
2014-03-28 |
Harvard College |
Peptide nanoparticles and uses thereof
|
WO2013033069A1
(en)
|
2011-08-30 |
2013-03-07 |
Theraclone Sciences, Inc. |
Human rhinovirus (hrv) antibodies
|
JP2014526441A
(ja)
|
2011-08-31 |
2014-10-06 |
アムジエン・インコーポレーテツド |
1型糖尿病の治療における使用のためのfgf21
|
WO2013039916A1
(en)
|
2011-09-12 |
2013-03-21 |
The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services |
Compositions for and methods of treatment and enhanced detection of non-pituitary tumors
|
US10385475B2
(en)
|
2011-09-12 |
2019-08-20 |
Adaptive Biotechnologies Corp. |
Random array sequencing of low-complexity libraries
|
KR102007055B1
(ko)
|
2011-09-22 |
2019-08-02 |
암젠 인크 |
Cd27l 항원 결합 단백질
|
EP3485903B1
(en)
|
2011-09-23 |
2022-11-16 |
Mereo BioPharma 5, Inc. |
Vegf/dll4 binding agents and uses thereof
|
TW201315742A
(zh)
|
2011-09-26 |
2013-04-16 |
Novartis Ag |
治療代謝病症之雙功能蛋白質
|
TWI593708B
(zh)
|
2011-09-26 |
2017-08-01 |
諾華公司 |
治療代謝病症之融合蛋白質
|
EP2760857A1
(en)
|
2011-09-27 |
2014-08-06 |
F.Hoffmann-La Roche Ag |
Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
|
WO2013047729A1
(ja)
|
2011-09-30 |
2013-04-04 |
中外製薬株式会社 |
標的抗原に対する免疫応答を誘導する抗原結合分子
|
DE102011114864A1
(de)
|
2011-10-05 |
2013-04-11 |
Acino Ag |
Verfahren zur Herstellung einer homogenen Pulvermischung und Verfahren zur Herstellung eines Implantats sowie Implantat
|
WO2013053076A1
(en)
|
2011-10-10 |
2013-04-18 |
Zensun (Shanghai)Science & Technology Limited |
Compositions and methods for treating heart failure
|
EP2766392B1
(en)
|
2011-10-10 |
2019-07-17 |
Xencor, Inc. |
A method for purifying antibodies
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
WO2013055985A1
(en)
|
2011-10-12 |
2013-04-18 |
Children's Medical Center Corporation |
Combinatorial compositions and methods of treating hemoglobinopathies
|
JP2014534965A
(ja)
|
2011-10-13 |
2014-12-25 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
コンパニオン診断を用いた乳癌の治療
|
WO2013056197A1
(en)
|
2011-10-14 |
2013-04-18 |
Alternative Innovative Technologies Llc |
Degradation resistant hsp70 formulations and uses thereof
|
US20130172265A1
(en)
|
2011-10-14 |
2013-07-04 |
The Board Of Trustees Of The University Of Illinois |
Methods and Compositions for Inhibiting Tumor Cell Proliferation
|
US8906860B2
(en)
|
2011-10-14 |
2014-12-09 |
The Board Of Trustees Of The University Of Illinois |
Methods and compositions inhibiting tumor cell proliferation
|
US10188772B2
(en)
|
2011-10-18 |
2019-01-29 |
Micell Technologies, Inc. |
Drug delivery medical device
|
US9499464B2
(en)
|
2011-10-19 |
2016-11-22 |
Bikam Pharmaceuticals, Inc. |
Opsin-binding ligands, compositions and methods of use
|
US9279159B2
(en)
|
2011-10-21 |
2016-03-08 |
Adaptive Biotechnologies Corporation |
Quantification of adaptive immune cell genomes in a complex mixture of cells
|
US20130122005A1
(en)
|
2011-10-27 |
2013-05-16 |
Paul Adam |
Anticancer combination therapy
|
TW201325613A
(zh)
|
2011-10-28 |
2013-07-01 |
Genentech Inc |
治療黑色素瘤之治療組合及方法
|
CN104039826A
(zh)
|
2011-10-31 |
2014-09-10 |
弗·哈夫曼-拉罗切有限公司 |
抗体制剂
|
JP2015504038A
(ja)
|
2011-10-31 |
2015-02-05 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
低減した免疫原性を有するフィブロネクチン結合ドメイン
|
RU2622391C2
(ru)
|
2011-11-03 |
2017-06-15 |
Ф. Хоффманн-Ля Рош Аг |
Соединения 8-фторфталазин-1(2н)-она в качестве ингибиторов тирозинкиназы брутона
|
UA111756C2
(uk)
|
2011-11-03 |
2016-06-10 |
Ф. Хоффманн-Ля Рош Аг |
Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
|
WO2013065017A2
(en)
|
2011-11-03 |
2013-05-10 |
Centre Hospitalier Universitaire Vaudois (C.H.U.V.) |
Platelet rich plasma (prp) and prominin-1 derived peptide stimulate lymphangiogenesis
|
CN104024255B
(zh)
|
2011-11-03 |
2017-01-18 |
霍夫曼-拉罗奇有限公司 |
作为btk活性的抑制剂的烷基化哌嗪化合物
|
MX2014005285A
(es)
|
2011-11-03 |
2014-05-30 |
Hoffmann La Roche |
Compuestos biciclicos de piperazina.
|
WO2013071049A1
(en)
|
2011-11-10 |
2013-05-16 |
Trustees Of Boston College |
Gramicidin a mutants that function as antibiotics with improved solubility and reduced toxicity
|
SA112330988B1
(ar)
|
2011-11-11 |
2015-07-22 |
رينات نيوروساينس كورب. |
أجسام مضادة تخص trop-2 واستخداماتها
|
AU2012340174A1
(en)
|
2011-11-16 |
2014-05-29 |
Amgen Inc. |
Methods of treating epidermal growth factor deletion mutant VIII related disorders
|
GR1007832B
(el)
|
2011-11-21 |
2013-02-14 |
Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, |
Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη"
|
WO2013078254A1
(en)
|
2011-11-22 |
2013-05-30 |
Array Biopharma Inc. |
Bicyclic heteroaryl derivatives as kinase inhibitors
|
US20130302274A1
(en)
|
2011-11-25 |
2013-11-14 |
Roche Glycart Ag |
Combination therapy
|
US9353063B2
(en)
|
2011-11-30 |
2016-05-31 |
Bikam Pharmaceuticals, Inc. |
Opsin-binding ligands, compositions and methods of use
|
AU2012346537A1
(en)
|
2011-12-01 |
2014-07-17 |
Bikam Pharmaceuticals, Inc. |
Opsin-binding ligands, compositions and methods of use
|
WO2013082511A1
(en)
|
2011-12-02 |
2013-06-06 |
Genentech, Inc. |
Methods for overcoming tumor resistance to vegf antagonists
|
EP2601941A1
(en)
|
2011-12-06 |
2013-06-12 |
Ludwig-Maximilians-Universität München |
Beta-O/S/N fatty acid based compounds as antibacterial and antiprotozoal agents
|
EP2788384B1
(en)
|
2011-12-08 |
2017-08-09 |
Amgen Inc. |
Agonistic human lcat antigen binding proteins and their use in therapy
|
CA2858070C
(en)
|
2011-12-09 |
2018-07-10 |
Adaptive Biotechnologies Corporation |
Diagnosis of lymphoid malignancies and minimal residual disease detection
|
EP2788500A1
(en)
|
2011-12-09 |
2014-10-15 |
F.Hoffmann-La Roche Ag |
Identification of non-responders to her2 inhibitors
|
US9499865B2
(en)
|
2011-12-13 |
2016-11-22 |
Adaptive Biotechnologies Corp. |
Detection and measurement of tissue-infiltrating lymphocytes
|
RU2685867C2
(ru)
|
2011-12-15 |
2019-04-23 |
Алтернатив Инновейтив Текнолоджиз Ллц |
Гибридные белки и белковые конъюгаты на основе белка теплового шока-70 (БТШ70) и способы их применения (варианты)
|
AU2012364736A1
(en)
|
2011-12-19 |
2014-07-24 |
Amgen Inc. |
Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
|
EP2794657B1
(en)
|
2011-12-19 |
2017-10-11 |
Xoma (Us) Llc |
Methods for treating acne
|
WO2013093693A1
(en)
|
2011-12-22 |
2013-06-27 |
Rinat Neuroscience Corp. |
Staphylococcus aureus specific antibodies and uses thereof
|
WO2013091903A1
(en)
|
2011-12-22 |
2013-06-27 |
Novo Nordisk A/S |
Anti-crac channel antibodies
|
WO2013093868A1
(en)
|
2011-12-22 |
2013-06-27 |
Chuv, Centre Hospitalier Universitaire Vaudois |
Selective plasma activation for medical implants and wound healing devices
|
CN104169301A
(zh)
|
2011-12-22 |
2014-11-26 |
瑞纳神经科学公司 |
人生长激素受体拮抗剂抗体及其使用方法
|
EP2794635B8
(en)
|
2011-12-22 |
2018-11-14 |
H. Hoffnabb-La Roche Ag |
Ion exchange membrane chromatography
|
EP3560509B1
(en)
|
2011-12-22 |
2024-01-31 |
Children's Medical Center Corporation |
Saposin-a derived peptides and uses thereof
|
WO2013093809A1
(en)
|
2011-12-23 |
2013-06-27 |
Pfizer Inc. |
Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
|
CN104066731B
(zh)
|
2011-12-27 |
2016-06-15 |
铁木医药有限公司 |
可用作sgc刺激剂的2-苄基、3-(嘧啶-2-基)取代的吡唑类
|
WO2013101771A2
(en)
|
2011-12-30 |
2013-07-04 |
Genentech, Inc. |
Compositions and method for treating autoimmune diseases
|
US9884123B2
(en)
|
2012-01-03 |
2018-02-06 |
Invictus Oncology Pvt. Ltd. |
Ligand-targeted molecules and methods thereof
|
JP6684490B2
(ja)
|
2012-01-09 |
2020-04-22 |
ザ・スクリップス・リサーチ・インスティテュート |
超長相補性決定領域及びその使用
|
EP2802355B1
(en)
|
2012-01-09 |
2018-09-05 |
CovX Technologies Ireland Limited |
Mutant antibodies and conjugation thereof
|
EP3663314A1
(en)
|
2012-01-09 |
2020-06-10 |
The Scripps Research Institute |
Humanized antibodies with ultralong cdr3s
|
US20150119399A1
(en)
|
2012-01-10 |
2015-04-30 |
President And Fellows Of Harvard College |
Beta-cell replication promoting compounds and methods of their use
|
WO2013106572A1
(en)
|
2012-01-11 |
2013-07-18 |
Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University |
Bispecific antibody fragments for neurological disease proteins and methods of use
|
SG11201403980VA
(en)
|
2012-01-13 |
2014-08-28 |
Gen Hospital Corp |
Anesthetic compounds and related methods of use
|
KR20140114415A
(ko)
|
2012-01-13 |
2014-09-26 |
제넨테크, 인크. |
Vegf 길항제로의 치료를 위한 환자를 확인하기 위한 생물학적 마커
|
EP2807266B1
(en)
|
2012-01-26 |
2020-01-15 |
Amgen Inc. |
Growth differentiation factor 15 (gdf-15) polypeptides
|
JP6363020B2
(ja)
|
2012-01-30 |
2018-07-25 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
イソキノリンおよびナフチリジン誘導体
|
NZ628314A
(en)
|
2012-02-06 |
2017-01-27 |
Inhibrx Lp |
Cd47 antibodies and methods of use thereof
|
EP2626066A1
(en)
|
2012-02-10 |
2013-08-14 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Combination therapy comprising selective VEGFR-2 inhibitors and MEK inhibitors
|
MX2014009565A
(es)
|
2012-02-10 |
2014-11-10 |
Genentech Inc |
Anticuerpos monocatenarios y otros heteromultimeros.
|
AU2013221317B2
(en)
|
2012-02-16 |
2017-07-06 |
Pangu Biopharma Limited |
Histidyl-tRNA synthetases for treating autoimmune and inflammatory diseases
|
WO2013120980A1
(en)
|
2012-02-17 |
2013-08-22 |
F. Hoffmann-La Roche Ag |
Tricyclic compounds and methods of use therefor
|
CN110698408B
(zh)
|
2012-02-17 |
2021-01-05 |
奇尼塔病毒性出血热有限责任公司 |
用于治疗沙粒病毒感染的抗病毒药物
|
EP2819689A1
(en)
|
2012-03-01 |
2015-01-07 |
Yeda Research and Development Co. Ltd. |
Regeneration of islet beta cells by hsp60 derived peptides
|
CA2864655A1
(en)
|
2012-03-01 |
2013-09-06 |
Yeda Research And Development Co. Ltd. |
Hsp60 derived peptides and peptide analogs for suppression and treatment of non-autoimmune diabetes
|
DK2823060T3
(en)
|
2012-03-05 |
2018-05-28 |
Adaptive Biotechnologies Corp |
Determination of associated immune receptor chains from frequency-matched subunits
|
EP2822936B1
(en)
|
2012-03-07 |
2021-09-08 |
The McLean Hospital Corporation |
Aminoquinoline derivatives and uses thereof
|
DK2825558T3
(da)
|
2012-03-13 |
2019-07-22 |
Hoffmann La Roche |
Kombinationsterapi til behandling af ovariecancer
|
CA2867444C
(en)
|
2012-03-16 |
2021-04-13 |
University Health Network |
Compositions containing soluble toso protein and uses thereof
|
MX2014010953A
(es)
|
2012-03-16 |
2014-10-13 |
Hoffmann La Roche |
Metodos para tratamiento de melanoma con inhibidores pak1.
|
JP2015510818A
(ja)
|
2012-03-20 |
2015-04-13 |
トラスティーズ オブ タフツ カレッジ |
薬物送達のための絹リザーバー
|
NZ630828A
(en)
|
2012-03-22 |
2016-10-28 |
Univ Michigan |
Compounds and methods for treating aberrant adrenocartical cell disorders
|
US9592289B2
(en)
|
2012-03-26 |
2017-03-14 |
Sanofi |
Stable IgG4 based binding agent formulations
|
BR112014024017A8
(pt)
|
2012-03-27 |
2017-07-25 |
Genentech Inc |
Métodos de tratamento de um tipo de câncer, de tratamento do carcinoma, para selecionar uma terapia e para quantificação e inibidor de her3
|
EP2831277A4
(en)
|
2012-03-29 |
2016-06-29 |
Univ Colorado |
NUCLEIC ACIDS CLICK
|
ES2651692T3
(es)
|
2012-03-29 |
2018-01-29 |
Novimmune Sa |
Anticuerpos anti-TLR4 y sus usos
|
WO2013148288A1
(en)
|
2012-03-30 |
2013-10-03 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of cancer
|
WO2013155346A1
(en)
|
2012-04-11 |
2013-10-17 |
The Regents Of The University Of California |
Diagnostic tools for response to 6-thiopurine therapy
|
US20150080381A1
(en)
|
2012-04-12 |
2015-03-19 |
Ironwood Pharmaceuticals, Inc. |
Methods of treating alopecia and acne
|
US10130714B2
(en)
|
2012-04-14 |
2018-11-20 |
Academia Sinica |
Enhanced anti-influenza agents conjugated with anti-inflammatory activity
|
LT2838515T
(lt)
|
2012-04-16 |
2020-03-10 |
President And Fellows Of Harvard College |
Mezoporinės silico dioksido kompozicijos, skirtos imuninio atsako moduliavimui
|
JP6286757B2
(ja)
|
2012-04-23 |
2018-03-07 |
ジーンフロンティア株式会社 |
抗ヒトcd69抗体、及びその医薬用途
|
JP2015516980A
(ja)
|
2012-04-26 |
2015-06-18 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Cd37抗体とベンダムスチンとの併用
|
CN104540518A
(zh)
|
2012-04-27 |
2015-04-22 |
西托姆克斯治疗公司 |
结合表皮生长因子受体的可活化的抗体其使用方法
|
EA039663B1
(ru)
|
2012-05-03 |
2022-02-24 |
Амген Инк. |
Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
|
WO2013166500A1
(en)
|
2012-05-04 |
2013-11-07 |
Dana-Farber Cancer Institute, Inc. |
Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use
|
ES2582554T3
(es)
|
2012-05-08 |
2016-09-13 |
Adaptive Biotechnologies Corporation |
Composiciones y método para medir y calibrar el sesgo de la amplificación en reacciones de PCR multiplexadas
|
US8992915B2
(en)
|
2012-05-16 |
2015-03-31 |
Boehringer Ingelheim International Gmbh |
Combination of CD37 antibodies with ICE
|
JP2015517512A
(ja)
|
2012-05-16 |
2015-06-22 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Cd37抗体の更なる薬剤との併用
|
UY34813A
(es)
|
2012-05-18 |
2013-11-29 |
Amgen Inc |
Proteínas de unión a antígeno dirigidas contra el receptor st2
|
EP2666775A1
(en)
|
2012-05-21 |
2013-11-27 |
Domain Therapeutics |
Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
|
US20150353639A1
(en)
|
2012-05-21 |
2015-12-10 |
Genentech, Inc. |
Methods for improving safety of blood-brain barrier transport
|
CN104271566B
(zh)
|
2012-05-22 |
2017-05-31 |
霍夫曼-拉罗奇有限公司 |
取代的联吡啶胺及其用途
|
WO2013177187A2
(en)
|
2012-05-22 |
2013-11-28 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
|
SG11201408284VA
(en)
|
2012-05-22 |
2015-02-27 |
Xenon Pharmaceuticals Inc |
N-substituted benzamides and their use in the treatment of pain
|
CA2873984A1
(en)
|
2012-05-23 |
2013-11-28 |
Stemergie Biotechnology Sa |
Inhibitors of the activity of complex (iii) of the mitochondrial electron transport chain and use thereof
|
WO2013178591A1
(en)
|
2012-05-31 |
2013-12-05 |
F. Hoffmann-La Roche Ag |
Aminoquinazoline and pyridopyrimidine derivatives
|
EP2855527B1
(en)
|
2012-05-31 |
2018-08-01 |
Innate Pharma |
Tlr3 binding agents
|
WO2013178788A2
(en)
|
2012-06-01 |
2013-12-05 |
Ferring B.V. |
Manufacture of degarelix
|
CA2871359A1
(en)
|
2012-06-08 |
2013-12-12 |
F. Hoffmann-La Roche Ag |
Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
|
WO2014004676A1
(en)
|
2012-06-26 |
2014-01-03 |
Ironwood Pharmaceuticals, Inc. |
Use of faah inhibitors as neuroprotective agents in the cns
|
WO2014001325A1
(en)
|
2012-06-27 |
2014-01-03 |
F. Hoffmann-La Roche Ag |
Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
|
ES2597228T3
(es)
|
2012-06-27 |
2017-01-17 |
F. Hoffmann-La Roche Ag |
Procedimiento para la selección y la producción de entidades de objetivación, como dianas, altamente selectivas y multiespecíficas, personalizadas, las cuales contienen por lo menos dos entidades de unión diferentes, y utilización de éstas
|
CA2871388A1
(en)
|
2012-06-27 |
2014-01-03 |
F. Hoffmann-La Roche Ag |
5-azaindazole compounds and methods of use
|
WO2014006063A2
(en)
|
2012-07-02 |
2014-01-09 |
Medizinische Universität Wien |
Complement split product c4d for the treatment of inflammatory conditions
|
EP2870138B1
(en)
|
2012-07-06 |
2018-08-22 |
Genentech, Inc. |
N-substituted benzamides and methods of use thereof
|
EP2687225A1
(en)
|
2012-07-19 |
2014-01-22 |
Alfact Innovation |
HIP/PAP protein and derivatives thereof for use in treating cancer
|
EP3715345B8
(en)
|
2012-07-25 |
2024-05-29 |
Bausch + Lomb Ireland Limited |
Preparation of lfa-1 inhibitor
|
US10513540B2
(en)
|
2012-07-31 |
2019-12-24 |
The Brigham And Women's Hospital, Inc. |
Modulation of the immune response
|
WO2014025813A1
(en)
|
2012-08-07 |
2014-02-13 |
Genentech, Inc. |
Combination therapy for the treatment of glioblastoma
|
US8603470B1
(en)
|
2012-08-07 |
2013-12-10 |
National Cheng Kung University |
Use of IL-20 antagonists for treating liver diseases
|
EP2695950A1
(en)
|
2012-08-10 |
2014-02-12 |
Blackfield AG |
Markers for responsiveness to an inhibitor of the fibroblast growth factor receptor
|
WO2014027959A1
(en)
|
2012-08-14 |
2014-02-20 |
Nanyang Technological University |
Angiopoietin-like 4 antibody and a method of its use in cancer treatment
|
US9914956B2
(en)
|
2012-08-18 |
2018-03-13 |
Academia Sinica |
Cell-permeable probes for identification and imaging of sialidases
|
JP2015526471A
(ja)
|
2012-08-21 |
2015-09-10 |
ジェネシス リサーチ インスティチュート |
アントラサイクリン誘発性心毒性を治療または予防するための組成物および方法
|
AU2013305827A1
(en)
|
2012-08-21 |
2015-03-05 |
Academia Sinica |
Benzocyclooctyne compounds and uses thereof
|
RS58928B1
(sr)
|
2012-08-29 |
2019-08-30 |
Hoffmann La Roche |
Transporter za krvno-moždanu barijeru
|
WO2014035474A1
(en)
|
2012-08-30 |
2014-03-06 |
The General Hospital Corporation |
Compositions and methods for treating cancer
|
JP6022691B2
(ja)
|
2012-08-30 |
2016-11-09 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
ジオキシノ−及びオキサジン−[2,3−d]ピリミジンpi3k阻害剤化合物及び使用方法
|
EP3919079A1
(en)
|
2012-09-07 |
2021-12-08 |
Genentech, Inc. |
Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitor
|
TWI660972B
(zh)
|
2012-09-10 |
2019-06-01 |
愛爾蘭商尼歐托普生物科學公司 |
抗mcam抗體及相關使用方法
|
MY172863A
(en)
|
2012-09-13 |
2019-12-13 |
Bristol Myers Squibb Co |
Fibronectin based scaffold domain proteins that bind to myostatin
|
US9309235B2
(en)
|
2012-09-18 |
2016-04-12 |
Ironwood Pharmaceuticals, Inc. |
SGC stimulators
|
US9487508B2
(en)
|
2012-09-19 |
2016-11-08 |
Ironwood Pharmaceuticals, Inc. |
SGC stimulators
|
LT2900657T
(lt)
|
2012-09-26 |
2020-05-25 |
F. Hoffmann-La Roche Ag |
Cikliniai eterio pirazol-4-il-heterociklil-karboksamido junginiai ir jų naudojimo būdai
|
CA2885908A1
(en)
|
2012-09-27 |
2014-04-03 |
F. Hoffmann-La Roche Ag |
Substituted sulfonamide compounds
|
DK2904111T3
(en)
|
2012-10-01 |
2018-03-12 |
Adaptive Biotechnologies Corp |
Immune competence evaluation of adaptive immune receptor diversity and clonality characterization
|
CN107892719B
(zh)
|
2012-10-04 |
2022-01-14 |
达纳-法伯癌症研究所公司 |
人单克隆抗-pd-l1抗体和使用方法
|
RU2015112024A
(ru)
|
2012-10-05 |
2016-11-27 |
Дженентек, Инк. |
Способы диагностики и лечения воспалительного заболевания кишечника
|
WO2014058915A2
(en)
|
2012-10-08 |
2014-04-17 |
St. Jude Children's Research Hospital |
Therapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin axis
|
KR102229873B1
(ko)
|
2012-10-12 |
2021-03-19 |
더 브리검 앤드 우먼즈 하스피털, 인크. |
면역 반응의 향상
|
US9309318B2
(en)
|
2012-10-17 |
2016-04-12 |
Amgen, Inc. |
Compositions relating to anti-IL-21 receptor antibodies
|
LT2908865T
(lt)
|
2012-10-17 |
2019-01-10 |
Vascular Biogenics Ltd. |
Fas-chimerą ekspresuojantis adenovirusas ir jo panaudojimas vėžio gydymo būduose
|
CA2887711A1
(en)
|
2012-10-23 |
2014-05-01 |
Oncomed Pharmaceuticals, Inc. |
Methods of treating neuroendocrine tumors using wnt pathway-binding agents
|
AU2013334493B2
(en)
|
2012-10-26 |
2018-11-29 |
The University Of Queensland |
Use of endocytosis inhibitors and antibodies for cancer therapy
|
KR101911438B1
(ko)
|
2012-10-31 |
2018-10-24 |
삼성전자주식회사 |
이중 특이 항원 결합 단백질 복합체 및 이중 특이 항체의 제조 방법
|
JP6371294B2
(ja)
|
2012-10-31 |
2018-08-08 |
オンコメッド ファーマシューティカルズ インコーポレイテッド |
Dll4アンタゴニストによる処置の方法およびモニタリング
|
EP2914621B1
(en)
|
2012-11-05 |
2023-06-07 |
Foundation Medicine, Inc. |
Novel ntrk1 fusion molecules and uses thereof
|
CN108424453B
(zh)
|
2012-11-09 |
2021-08-06 |
基因先端领域株式会社 |
用于治疗癌症的抗adam28抗体
|
UY35148A
(es)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
CN104813168B
(zh)
|
2012-11-30 |
2017-10-20 |
霍夫曼-拉罗奇有限公司 |
需要pd‑l1抑制剂综合疗法的患者的鉴定
|
JP6392770B2
(ja)
|
2012-12-03 |
2018-09-19 |
ノビミューン エスアー |
抗cd47抗体およびその使用方法
|
WO2014089570A1
(en)
|
2012-12-07 |
2014-06-12 |
The General Hospital Corporation |
Combinations of a pi3k/akt inhibitor compound with an her3/egfr inhibitor compound and use thereof in the treatment of a hyperproliferative disorder
|
TW201425336A
(zh)
|
2012-12-07 |
2014-07-01 |
Amgen Inc |
Bcma抗原結合蛋白質
|
AU2013358968B2
(en)
|
2012-12-13 |
2017-12-21 |
Warsaw Orthopedic, Inc. |
Compositions and methods comprising polyethylene glycol and magnesium for treatment of neuronal injury
|
GB201223053D0
(en)
|
2012-12-20 |
2013-02-06 |
Medical Res Council |
Receptor
|
EP2934588A4
(en)
|
2012-12-20 |
2016-09-28 |
Medimmune Llc |
LIQUID ANTIBODY FORMULATION HAVING ENHANCED AGGREGATION PROPERTIES
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
EP2943511B1
(en)
|
2013-01-14 |
2019-08-07 |
Xencor, Inc. |
Novel heterodimeric proteins
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
WO2014113510A1
(en)
|
2013-01-15 |
2014-07-24 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
WO2014113729A2
(en)
|
2013-01-18 |
2014-07-24 |
Foundation Mecicine, Inc. |
Methods of treating cholangiocarcinoma
|
MX2015009270A
(es)
|
2013-01-18 |
2015-10-30 |
Hoffmann La Roche |
Pirazoles sustituidos en posicion 3 y uso de los mismos como inhibidores de la cinasa cremallera de leucinas dual (dlk).
|
EP2948433B1
(en)
|
2013-01-22 |
2017-04-26 |
Technische Universität Graz |
Atglistatin as lipase inhibitor
|
WO2014116749A1
(en)
|
2013-01-23 |
2014-07-31 |
Genentech, Inc. |
Anti-hcv antibodies and methods of using thereof
|
JO3519B1
(ar)
|
2013-01-25 |
2020-07-05 |
Amgen Inc |
تركيبات أجسام مضادة لأجل cdh19 و cd3
|
ES2728936T3
(es)
|
2013-01-25 |
2019-10-29 |
Amgen Inc |
Anticuerpos dirigidos contra CDH19 para melanoma
|
JP2016508504A
(ja)
|
2013-02-01 |
2016-03-22 |
サンタ マリア バイオセラピューティクス インコーポレイテッド |
対象に対する抗アクチビン−a化合物の投与
|
WO2014120891A2
(en)
|
2013-02-01 |
2014-08-07 |
Bristol-Myers Squibb Company |
Fibronectin based scaffold proteins
|
SG11201506132PA
(en)
|
2013-02-06 |
2015-09-29 |
Inhibrx Llc |
Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
|
CA2900008A1
(en)
|
2013-02-07 |
2014-08-14 |
Children's Medical Center Corporation |
Protein antigens that provide protection against pneumococcal colonization and/or disease
|
JP6367836B2
(ja)
|
2013-02-07 |
2018-08-01 |
ザ ジェネラル ホスピタル コーポレイション |
T制御性細胞の増殖または枯渇方法
|
RU2015140573A
(ru)
|
2013-02-25 |
2017-03-30 |
Дженентек, Инк. |
Способы и композиции для обнаружения и лечения устойчивого к лекарственным средствам мутанта акт
|
WO2014130922A1
(en)
|
2013-02-25 |
2014-08-28 |
Trustees Of Boston University |
Compositions and methods for treating fungal infections
|
JP6499591B2
(ja)
|
2013-02-25 |
2019-04-10 |
シナジー ファーマシューティカルズ インコーポレイテッド |
結腸洗浄において用いるためのグアニル酸シクラーゼ受容体アゴニスト
|
US20140255413A1
(en)
|
2013-03-07 |
2014-09-11 |
Boehringer Ingelheim International Gmbh |
Combination therapy for neoplasia treatment
|
AU2014225307A1
(en)
|
2013-03-08 |
2015-09-24 |
The Curators Of The University Of Missouri |
Methods and compositions for the treatment and/or prevention of type 1 diabetes
|
CN105307597A
(zh)
|
2013-03-12 |
2016-02-03 |
脉胜医疗技术公司 |
可生物吸收的生物医学植入物
|
US9458246B2
(en)
|
2013-03-13 |
2016-10-04 |
Amgen Inc. |
Proteins specific for BAFF and B7RP1
|
JOP20140087B1
(ar)
|
2013-03-13 |
2021-08-17 |
Amgen Inc |
بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
|
WO2014165093A2
(en)
|
2013-03-13 |
2014-10-09 |
Bristol-Myers Squibb Company |
Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
|
JP2016522675A
(ja)
|
2013-03-14 |
2016-08-04 |
ガラパゴス・ナムローゼ・フェンノートシャップGalapagos N.V. |
上皮間葉移行に関連した疾患の治療において有用な分子標的及び前記標的のインヒビター
|
JP6437467B2
(ja)
|
2013-03-14 |
2018-12-19 |
ガラパゴス・ナムローゼ・フェンノートシャップGalapagos N.V. |
線維化疾患治療において有用な分子標的及び化合物、並びにこれらの同定方法
|
US20140271629A1
(en)
|
2013-03-14 |
2014-09-18 |
Amgen Inc. |
Chrdl-1 antigen binding proteins and methods of treatment
|
EP2968280A4
(en)
|
2013-03-14 |
2016-08-10 |
Genentech Inc |
SUBSTITUTED TRIAZOLOPYRIDINES AND METHOD OF USE THEREOF
|
AU2014239903A1
(en)
|
2013-03-14 |
2015-09-17 |
Genentech, Inc. |
Combinations of a MEK inhibitor compound with an HER3/EGFR inhibitor compound and methods of use
|
US9580486B2
(en)
|
2013-03-14 |
2017-02-28 |
Amgen Inc. |
Interleukin-2 muteins for the expansion of T-regulatory cells
|
US9717583B2
(en)
|
2014-03-13 |
2017-08-01 |
Cell and Molecular Tissue Engineering, LLC |
Sensors, cannulas, collars and coated surgical mesh, and corresponding systems and methods
|
JP2016518812A
(ja)
|
2013-03-14 |
2016-06-30 |
ガラパゴス・ナムローゼ・フェンノートシャップGalapagos N.V. |
線維症治療において有用な分子標的及び前記標的のインヒビター
|
DK2968346T3
(da)
|
2013-03-15 |
2024-05-06 |
Cancer Research Tech Llc |
Fremgangsmåder og sammensætninger til modulation af gamma-glutamylcyklus
|
JP6566933B2
(ja)
|
2013-03-15 |
2019-08-28 |
サッター ベイ ホスピタルズ |
ガンを治療するための療法のための標的として使用するためのfalz
|
ES2774295T3
(es)
|
2013-03-15 |
2020-07-20 |
Cyclerion Therapeutics Inc |
Estimuladores de sGC
|
EP2968439A2
(en)
|
2013-03-15 |
2016-01-20 |
Synergy Pharmaceuticals Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
CA2906909A1
(en)
|
2013-03-15 |
2014-09-18 |
Biological Mimetics, Inc. |
Immunogenic human rhinovirus (hrv) composition
|
CA2905438A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
SI2970449T1
(sl)
|
2013-03-15 |
2019-11-29 |
Amgen Res Munich Gmbh |
Enoverižne vezavne molekule, ki vsebujejo N-terminalni ABP
|
EP3689902B1
(en)
|
2013-03-15 |
2023-06-28 |
Dana-Farber Cancer Institute, Inc. |
Flavivirus neutralizing antibodies and methods of use thereof
|
JP6469644B2
(ja)
|
2013-03-15 |
2019-02-13 |
アムジエン・インコーポレーテツド |
抗ccr7抗原結合タンパク質に関係する方法および組成物
|
DK3460054T3
(da)
|
2013-03-15 |
2021-01-18 |
Atyr Pharma Inc |
Histidyl-tRNA-syntetase-Fc-konjugater
|
WO2014140368A1
(en)
|
2013-03-15 |
2014-09-18 |
Amgen Research (Munich) Gmbh |
Antibody constructs for influenza m2 and cd3
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
AU2014236728B2
(en)
|
2013-03-15 |
2018-09-13 |
Amgen Inc. |
Method of treating metabolic disorders using PLA2G12A polypeptides and PLA2G12A mutant polypeptides
|
WO2014144466A1
(en)
|
2013-03-15 |
2014-09-18 |
Biogen Idec Ma Inc. |
Anti-alpha v beta 6 antibodies and uses thereof
|
US10035860B2
(en)
|
2013-03-15 |
2018-07-31 |
Biogen Ma Inc. |
Anti-alpha V beta 6 antibodies and uses thereof
|
US20160331809A1
(en)
|
2013-03-15 |
2016-11-17 |
Juventas Therapeutics, Inc. |
The use of sdf-1 to mitigate scar formation
|
CN110041427B
(zh)
|
2013-03-15 |
2023-05-23 |
本质生命科学有限公司 |
抗铁调素抗体及其用途
|
US9708375B2
(en)
|
2013-03-15 |
2017-07-18 |
Amgen Inc. |
Inhibitory polypeptides specific to WNT inhibitors
|
KR20150132473A
(ko)
|
2013-03-15 |
2015-11-25 |
다이액스 코포레이션 |
항-혈장 칼리크레인 항체
|
JP6482525B2
(ja)
|
2013-03-15 |
2019-03-13 |
メモリアル スローン ケタリング キャンサー センター |
高親和性抗gd2抗体
|
US11376329B2
(en)
|
2013-03-15 |
2022-07-05 |
Trustees Of Tufts College |
Low molecular weight silk compositions and stabilizing silk compositions
|
KR20230021768A
(ko)
|
2013-03-15 |
2023-02-14 |
트러스티즈 오브 터프츠 칼리지 |
저분자량 실크 조성물 및 안정화 실크 조성물
|
MX2015013181A
(es)
|
2013-03-15 |
2015-12-11 |
Amgen Inc |
Anticuerpos humanos pac1.
|
WO2014145654A1
(en)
|
2013-03-15 |
2014-09-18 |
The Trustees Of The University Of Pennsylvania |
Method for the site-specific covalent cross-linking of antibodies to surfaces
|
WO2014144553A1
(en)
|
2013-03-15 |
2014-09-18 |
Amgen Inc. |
Secreted frizzle-related protein 5 (sfrp5) binding proteins and methods of treatment
|
ES2885696T3
(es)
|
2013-03-15 |
2021-12-15 |
Xencor Inc |
Proteínas heterodiméricas
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
CA2903587C
(en)
|
2013-03-15 |
2021-09-28 |
Genentech, Inc. |
Il-22 polypeptides and il-22 fc fusion proteins and methods of use
|
WO2014145907A1
(en)
|
2013-03-15 |
2014-09-18 |
Xencor, Inc. |
Targeting t cells with heterodimeric proteins
|
WO2014153495A2
(en)
|
2013-03-22 |
2014-09-25 |
University Of Hawaii |
Novel stat3 inhibitors
|
SG11201507974RA
(en)
|
2013-03-27 |
2015-10-29 |
Genentech Inc |
Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
|
WO2014160871A2
(en)
|
2013-03-27 |
2014-10-02 |
The General Hospital Corporation |
Methods and agents for treating alzheimer's disease
|
JP6109622B2
(ja)
*
|
2013-04-01 |
2017-04-05 |
株式会社クレハ |
徐放性成形体およびその製造方法
|
WO2014163512A1
(en)
|
2013-04-05 |
2014-10-09 |
Manuka Health New Zealand Limited |
Therapeutic compositions comprising extracts of propolis and uses thereof
|
US20160051594A1
(en)
|
2013-04-05 |
2016-02-25 |
Manuka Health New Zealand Limited |
Therapeutic Compositions and Uses Thereof
|
ITTO20130284A1
(it)
*
|
2013-04-09 |
2014-10-10 |
Fond Istituto Italiano Di Tecnologia |
Procedimento per la produzione di microparticelle polimeriche sagomate
|
EP2991977B1
(en)
|
2013-05-01 |
2020-07-22 |
F.Hoffmann-La Roche Ag |
C-linked heterocycloalkyl substituted pyrimidines and their uses
|
EA029568B8
(ru)
|
2013-05-01 |
2018-08-31 |
Ф.Хоффманн-Ля Рош Аг |
Бигетероарильные соединения и их применения
|
US11293064B2
(en)
|
2013-05-02 |
2022-04-05 |
Thomas Jefferson University |
Human miRNAs for use in diagnosis, prognosis, and therapy of human conditions and diseases
|
US9248189B2
(en)
|
2013-05-07 |
2016-02-02 |
Pfizer Inc. |
Anti-glucagon receptor antibodies and pharmaceutical compositions thereof
|
WO2014186532A1
(en)
|
2013-05-15 |
2014-11-20 |
Micell Technologies, Inc. |
Bioabsorbable biomedical implants
|
CA2908743A1
(en)
|
2013-05-20 |
2014-11-27 |
Genentech, Inc. |
Anti-transferrin receptor antibodies and methods of use
|
EP2805730A1
(en)
|
2013-05-21 |
2014-11-26 |
Bergen Teknologioverforing AS |
Nitric oxide donor for the treatment of chronic fatigue syndrome
|
US10501803B2
(en)
|
2013-05-21 |
2019-12-10 |
Max-Planck Gesellschaft zur Förderung der Wissenschaften e.V. |
Isoforms of GATA6 and NKX2-1 as markers for diagnosis and therapy of cancer and as targets for anti-cancer therapy
|
CA2922704A1
(en)
|
2013-05-24 |
2014-11-27 |
Neil R. Cashman |
Cell senescence markers as diagnostic and therapeutic targets
|
US20160130585A1
(en)
|
2013-05-28 |
2016-05-12 |
The Johns Hopkins University |
Aptamers for the treatment of sickle cell disease
|
SG11201508829QA
(en)
|
2013-05-30 |
2015-12-30 |
Biogen Ma Inc |
Oncostatin m receptor antigen binding proteins
|
KR20160015286A
(ko)
|
2013-05-31 |
2016-02-12 |
제넨테크, 인크. |
항-세포벽 테이코산 항체 및 접합체
|
KR20160015227A
(ko)
|
2013-05-31 |
2016-02-12 |
제넨테크, 인크. |
항-세포벽 테이코산 항체 및 접합체
|
CN116063479A
(zh)
|
2013-06-04 |
2023-05-05 |
西托姆克斯治疗公司 |
用于缀合可活化抗体的组合物和方法
|
EP2810648A1
(en)
|
2013-06-04 |
2014-12-10 |
Daniel Rauh |
Targeting domain-domain interaction for the identification of kinase modulators
|
NZ714765A
(en)
|
2013-06-06 |
2021-12-24 |
Pf Medicament |
Anti-c10orf54 antibodies and uses thereof
|
KR102232650B1
(ko)
|
2013-06-11 |
2021-03-29 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
SC-β 세포 및 조성물 그리고 그 생성 방법
|
WO2014200018A1
(ja)
|
2013-06-11 |
2014-12-18 |
独立行政法人 国立精神・神経医療研究センター |
再発寛解型多発性硬化症(rrms)患者の治療予後予測方法、及び新規治療適応判断方法
|
DK3007704T3
(da)
|
2013-06-13 |
2021-03-29 |
Antisense Therapeutics Ltd |
Kombinationsterapi til akromegali
|
EP2835135A3
(en)
|
2013-06-19 |
2015-06-24 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin |
Means and methods for treating pseudomonas infection
|
US10086054B2
(en)
|
2013-06-26 |
2018-10-02 |
Academia Sinica |
RM2 antigens and use thereof
|
US9981030B2
(en)
|
2013-06-27 |
2018-05-29 |
Academia Sinica |
Glycan conjugates and use thereof
|
CA2916259C
(en)
|
2013-06-28 |
2024-02-20 |
Amgen Inc. |
Methods for treating homozygous familial hypercholesterolemia
|
WO2014207213A1
(en)
|
2013-06-28 |
2014-12-31 |
Medizinische Universität Innsbruck |
Novel inhibitors of protein kinase c epsilon signaling
|
US9708657B2
(en)
|
2013-07-01 |
2017-07-18 |
Adaptive Biotechnologies Corp. |
Method for generating clonotype profiles using sequence tags
|
CN110698481B
(zh)
|
2013-07-03 |
2023-02-28 |
豪夫迈·罗氏有限公司 |
杂芳基吡啶酮和氮杂-吡啶酮酰胺化合物
|
EP3016980B1
(en)
|
2013-07-05 |
2020-05-06 |
Formation Biologics Inc. |
Egfr antibody conjugates
|
JP2016528890A
(ja)
|
2013-07-09 |
2016-09-23 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
CRISPR/Cas系を用いるゲノム編集の治療用の使用
|
US10683353B2
(en)
|
2013-07-11 |
2020-06-16 |
The Scripps Research Institute |
Coiled coil immunoglobulin fusion proteins and compositions thereof
|
US20160168231A1
(en)
|
2013-07-18 |
2016-06-16 |
Fabrus, Inc. |
Antibodies with ultralong complementarity determining regions
|
EP3022221B1
(en)
|
2013-07-18 |
2021-09-15 |
Taurus Biosciences, LLC |
Humanized antibodies with ultralong complementarity determining regions
|
ES2683268T3
(es)
|
2013-07-25 |
2018-09-25 |
Cytomx Therapeutics, Inc. |
Anticuerpos multiespecíficos, anticuerpos activables multiespecíficos y métodos para usar los mismos
|
EA202092386A1
(ru)
|
2013-07-31 |
2021-04-30 |
Эмджен Инк. |
Конструкции на основе фактора дифференцировки и роста 15 (gdf15)
|
PE20211093A1
(es)
|
2013-08-02 |
2021-06-14 |
Pfizer |
Anticuerpos anti-cxcr4 y conjugados de anticuerpo y farmaco
|
EP2835136A1
(en)
|
2013-08-07 |
2015-02-11 |
PregLem S.A. |
Somatostatin Receptor Modulator for the treatment of infertility
|
MX2016001854A
(es)
|
2013-08-12 |
2016-09-06 |
Genentech Inc |
Composiciones y metodo para tratar condiciones asociadas con el complemento.
|
WO2015022326A1
(en)
|
2013-08-12 |
2015-02-19 |
Xiber Science Gmbh |
Peptides as active agents for treating primary graft dysfunction
|
WO2015023851A1
(en)
|
2013-08-14 |
2015-02-19 |
The Governing Council Of The University Of Toronto |
Antibodies against frizzled proteins and methods of use thereof
|
EP3036226B1
(en)
|
2013-08-22 |
2020-01-08 |
The General Hospital Corporation |
Inhibitors of human 12/15-lipoxygenase
|
WO2015031765A2
(en)
|
2013-08-29 |
2015-03-05 |
Trustees Of Boston University |
Intermediate metabolism products to potentiate aminoglycoside antibiotics in bacterial infections
|
US10456470B2
(en)
|
2013-08-30 |
2019-10-29 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of glioblastoma
|
US10617755B2
(en)
|
2013-08-30 |
2020-04-14 |
Genentech, Inc. |
Combination therapy for the treatment of glioblastoma
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
AU2014318017B2
(en)
|
2013-09-05 |
2020-02-06 |
Amgen Inc. |
Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
|
US9782476B2
(en)
|
2013-09-06 |
2017-10-10 |
Academia Sinica |
Human iNKT cell activation using glycolipids with altered glycosyl groups
|
EP3043790B1
(en)
|
2013-09-11 |
2021-05-26 |
The Administrators of the Tulane Educational Fund |
Novel anthranilic amides and the use thereof
|
KR102302634B1
(ko)
|
2013-09-13 |
2021-09-14 |
더 스크립스 리서치 인스티튜트 |
변형된 치료제 및 이의 조성물
|
AR097648A1
(es)
|
2013-09-13 |
2016-04-06 |
Amgen Inc |
Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide
|
US9371570B2
(en)
|
2013-09-16 |
2016-06-21 |
CeMM—FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GmbH |
Mutant calreticulin for the diagnosis of myeloid malignancies
|
EP3047857A4
(en)
|
2013-09-20 |
2017-08-09 |
Chugai Seiyaku Kabushiki Kaisha |
Treatment for hemorrhagic diseases by anti-protein-c antibody
|
CN104436157A
(zh)
|
2013-09-23 |
2015-03-25 |
恩金生物有限公司 |
流感疫苗和治疗
|
MX2016003957A
(es)
|
2013-09-25 |
2017-02-02 |
Cytomx Therapeutics Inc |
Substratos de metaloproteinasas de matriz y otras porciones escindibles y metodos para usar los mismos.
|
EP3521431A1
(en)
|
2013-09-25 |
2019-08-07 |
Cornell University |
Compounds for inducing anti-tumor immunity and methods thereof
|
US20150087649A1
(en)
|
2013-09-26 |
2015-03-26 |
Atterocor, Inc. |
Treating disorders associated with aberrant adrenocortical cell behavior
|
US20150104392A1
(en)
|
2013-10-04 |
2015-04-16 |
Aptose Biosciences Inc. |
Compositions, biomarkers and their use in the treatment of cancer
|
WO2015054427A1
(en)
|
2013-10-10 |
2015-04-16 |
Beth Israel Deaconess Medical Center, Inc. |
Tm4sf1 binding proteins and methods of using same
|
CN106061494A
(zh)
|
2013-10-10 |
2016-10-26 |
辛纳吉制药公司 |
可用于治疗阿片样物质诱导的功能障碍的鸟苷酸环化酶的激动剂
|
WO2015054662A1
(en)
|
2013-10-10 |
2015-04-16 |
Eastern Virginia Medical School |
4-((2-hydroxy-3-methoxybenzyl)amino) benzenesulfonamide derivatives as 12-lipoxygenase inhibitors
|
HUE041652T2
(hu)
|
2013-10-11 |
2019-05-28 |
Hoffmann La Roche |
TRPA1-modulátorokként hasznos szubsztituált heterociklusos szulfonamid-vegyületek
|
CA2926698C
(en)
|
2013-10-15 |
2021-06-22 |
The California Institute For Biomedical Research |
Chimeric antigen receptor t cell switches and uses thereof
|
US20160304622A1
(en)
|
2013-10-15 |
2016-10-20 |
Genefrontier Corporation |
Human antibody against aggrecanase-type adamts species for therapeutics of aggrecanase-related diseases
|
KR102339240B1
(ko)
|
2013-10-15 |
2021-12-15 |
더 스크립스 리서치 인스티튜트 |
펩타이드 키메라 항원 수용체 t 세포 스위치 및 이의 용도
|
US10780070B2
(en)
|
2013-10-18 |
2020-09-22 |
The Schepens Eye Research Institute, Inc. |
Alpha-aminoadipate for treatment of vision loss and restoring sight
|
WO2015058197A1
(en)
|
2013-10-18 |
2015-04-23 |
The Schepens Eye Research Institute, Inc. |
Alpha-aminoadipate for treatment of vision loss and restoring sight
|
EP3057605A1
(en)
|
2013-10-18 |
2016-08-24 |
Novartis AG |
Methods of treating diabetes and related disorders
|
WO2015066279A2
(en)
|
2013-10-30 |
2015-05-07 |
Cytomx Therapeutics, Inc. |
Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
|
US20160250285A1
(en)
|
2013-10-30 |
2016-09-01 |
University Of Western Australia |
Neuroprotective peptides
|
ES2759252T3
(es)
|
2013-10-31 |
2020-05-08 |
Resolve Therapeutics Llc |
Fusiones y métodos terapéuticos de nucleasa-albúmina
|
GB201319374D0
(en)
|
2013-11-01 |
2013-12-18 |
Univ Nottingham |
Glycans as functional cancer targets abd antibodies thereto
|
WO2015063287A1
(en)
|
2013-11-01 |
2015-05-07 |
Bergen Teknologioverføring As |
Activators or stimulators of soluble guanylate cyclase for use in treating chronic fatigue syndrome
|
CA2966352A1
(en)
|
2013-11-26 |
2015-06-04 |
The Brigham And Women's Hospital, Inc. |
Compositions and methods for modulating an immune response
|
CA2929918C
(en)
|
2013-12-05 |
2018-01-23 |
F. Hoffmann-La Roche Ag |
Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality
|
EP3083684A1
(en)
|
2013-12-06 |
2016-10-26 |
NovImmune SA |
Anti-tlr4 antibodies and methods of use thereof
|
WO2015087187A1
(en)
|
2013-12-10 |
2015-06-18 |
Rinat Neuroscience Corp. |
Anti-sclerostin antibodies
|
JP2016540017A
(ja)
|
2013-12-11 |
2016-12-22 |
アイアンウッド ファーマシューティカルズ インコーポレイテッド |
sGC刺激物質
|
US20160333063A1
(en)
|
2013-12-13 |
2016-11-17 |
The General Hospital Corporation |
Soluble high molecular weight (hmw) tau species and applications thereof
|
JP6572497B2
(ja)
|
2013-12-18 |
2019-09-11 |
ザ・スクリップス・リサーチ・インスティテュート |
修飾された治療剤、ステープル留めされたペプチド脂質複合体、及びそれらの組成物
|
US9873724B2
(en)
|
2013-12-20 |
2018-01-23 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Pro-angiogenic peptides and peptide conjugates
|
MX2016008110A
(es)
|
2013-12-20 |
2016-08-19 |
Hoffmann La Roche |
Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos.
|
RU2732032C2
(ru)
|
2013-12-20 |
2020-09-10 |
Дженентек, Инк. |
Антитела с двойной специфичностью
|
CN103965357B
(zh)
|
2013-12-31 |
2016-08-17 |
嘉和生物药业有限公司 |
一种抗人rankl抗体
|
EP3094327A1
(en)
|
2014-01-13 |
2016-11-23 |
Ironwood Pharmaceuticals, Inc. |
USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
|
WO2016114819A1
(en)
|
2015-01-16 |
2016-07-21 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
US10150818B2
(en)
|
2014-01-16 |
2018-12-11 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
KR20160104727A
(ko)
|
2014-01-16 |
2016-09-05 |
아카데미아 시니카 |
암의 치료 및 검출을 위한 조성물 및 방법
|
WO2015110930A1
(en)
|
2014-01-24 |
2015-07-30 |
Pfizer Inc. |
Modified interleukin 21 receptor proteins
|
JP6835586B2
(ja)
|
2014-01-31 |
2021-02-24 |
シトムクス セラピューティクス,インコーポレイティド |
マトリプターゼ及びu‐プラスミノーゲン活性化因子の基質及び他の切断可能部分、並びにその使用方法
|
WO2015116902A1
(en)
|
2014-01-31 |
2015-08-06 |
Genentech, Inc. |
G-protein coupled receptors in hedgehog signaling
|
JP6736467B2
(ja)
|
2014-02-04 |
2020-08-05 |
ジェネンテック, インコーポレイテッド |
平滑化変異体及びその使用方法
|
WO2015120187A1
(en)
|
2014-02-05 |
2015-08-13 |
The University Of Chicago |
Chimeric antigen receptors recognizing cancer-spevific tn glycopeptide variants
|
EP3104873B1
(en)
|
2014-02-13 |
2019-09-04 |
Technische Universität München |
Fgf-8 for use in treating diseases or disorders of energy homeostasis
|
EP3104882B1
(en)
|
2014-02-14 |
2019-06-05 |
Centrose, Llc |
Extracellular targeted drug conjugates
|
JP6619745B2
(ja)
|
2014-02-20 |
2019-12-11 |
アラーガン、インコーポレイテッドAllergan,Incorporated |
補体成分c5抗体
|
EP3110974A4
(en)
|
2014-02-24 |
2018-01-24 |
Celgene Corporation |
Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders
|
BR112016019825A2
(pt)
|
2014-02-27 |
2017-10-17 |
Allergan Inc |
anticorpos do fator bb do complemento
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
AU2015227054A1
(en)
|
2014-03-05 |
2016-09-22 |
Adaptive Biotechnologies Corporation |
Methods using randomer-containing synthetic molecules
|
EP3114109A4
(en)
|
2014-03-07 |
2017-10-18 |
The Johns Hopkins University |
Inhibitors of histone lysine specific demethylase (lsd1) and histone deacetylases (hdacs)
|
US20150252434A1
(en)
|
2014-03-07 |
2015-09-10 |
University Health Network |
Methods and compositions for detection of targets involved in cancer metastasis
|
CA2939848A1
(en)
|
2014-03-18 |
2015-09-24 |
F. Hoffmann-La Roche Ag |
Oxepan-2-yl-pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
|
AU2015231164B2
(en)
|
2014-03-19 |
2020-04-09 |
Dana-Farber Cancer Institute, Inc. |
Immunogenetic restriction on elicitation of antibodies
|
EP3647322B1
(en)
|
2014-03-20 |
2021-10-20 |
Bristol-Myers Squibb Company |
Stabilized fibronectin based scaffold molecules
|
CN106456759A
(zh)
|
2014-03-21 |
2017-02-22 |
泰华制药国际有限公司 |
针对降钙素基因相关肽的拮抗剂抗体及其使用方法
|
EP3119913B1
(en)
|
2014-03-21 |
2021-01-06 |
The Brigham and Women's Hospital, Inc. |
Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
|
EP3129767B1
(en)
|
2014-03-27 |
2021-09-01 |
Academia Sinica |
Reactive labelling compounds and uses thereof
|
CA2939246A1
(en)
|
2014-03-27 |
2015-10-01 |
Genentech, Inc. |
Methods for diagnosing and treating inflammatory bowel disease
|
JP6775422B2
(ja)
|
2014-03-28 |
2020-10-28 |
ゼンコー・インコーポレイテッドXencor、 Inc. |
Cd38及びcd3に結合する二重特異性抗体
|
US10066265B2
(en)
|
2014-04-01 |
2018-09-04 |
Adaptive Biotechnologies Corp. |
Determining antigen-specific t-cells
|
JP6787789B2
(ja)
|
2014-04-04 |
2020-11-18 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
詰め替え可能な薬物送達デバイスおよびその使用方法
|
CA2888068A1
(en)
|
2014-04-15 |
2015-10-15 |
The Hospital For Sick Children |
Cationic antimicrobial peptides
|
EP3132059B1
(en)
|
2014-04-17 |
2020-01-08 |
Adaptive Biotechnologies Corporation |
Quantification of adaptive immune cell genomes in a complex mixture of cells
|
WO2015164865A1
(en)
|
2014-04-25 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof
|
ES2830849T3
(es)
|
2014-04-25 |
2021-06-04 |
Brigham & Womens Hospital Inc |
Ensayo y método para tratar sujetos con enfermedades inmunomediadas
|
CA2983794A1
(en)
|
2014-04-25 |
2015-10-29 |
The Brigham And Women's Hospital, Inc. |
Methods to manipulate alpha-fetoprotein (afp)
|
JP7348708B2
(ja)
|
2014-04-30 |
2023-09-21 |
プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ |
組み合わせワクチン装置および癌細胞を殺滅する方法
|
WO2015168474A1
(en)
|
2014-04-30 |
2015-11-05 |
President And Fellows Of Harvard College |
Fusion proteins for treating cancer and related methods
|
AU2015253422B2
(en)
|
2014-04-30 |
2020-09-03 |
Abbvie Stemcentrx Llc |
Anti-PTK7 antibody-drug conjugates
|
TW201623337A
(zh)
|
2014-05-01 |
2016-07-01 |
建南德克公司 |
抗-因子d抗體變異體及其用途
|
EP3140392B1
(en)
|
2014-05-06 |
2023-07-26 |
F. Hoffmann-La Roche AG |
Production of heteromultimeric proteins using mammalian cells
|
WO2015173398A1
(en)
|
2014-05-15 |
2015-11-19 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Antagonists of slc38a9 and their use in therapy
|
EP3143043B1
(en)
|
2014-05-16 |
2022-12-14 |
Pfizer Inc. |
Bispecific antibodies with engineered ch1-cl interfaces
|
WO2015179415A1
(en)
|
2014-05-19 |
2015-11-26 |
Novartis Ag |
Methods of treating anorexia
|
EA028614B1
(ru)
|
2014-05-22 |
2017-12-29 |
Общество С Ограниченной Ответственностью "Русские Фармацевтические Технологии" |
Селективные ингибиторы, нарушающие взаимодействие рецептора фактора роста фибробластов и frs2, для профилактики и лечения рака
|
EP2947460A1
(en)
|
2014-05-22 |
2015-11-25 |
Medizinische Universität Wien |
Personalized therapy of inflammation-associated cancer using methods of assessing the susceptibility of a subject to the treatment with EGFR inhibitors/antagonists
|
EP3149036A4
(en)
|
2014-05-27 |
2017-12-27 |
Academia Sinica |
Anti-cd20 glycoantibodies and uses thereof
|
KR20170005142A
(ko)
|
2014-05-27 |
2017-01-11 |
아카데미아 시니카 |
증진된 항체 효능을 위한 범용 당형태에 관한 조성물 및 방법
|
EP3149037A4
(en)
|
2014-05-27 |
2018-01-10 |
Academia Sinica |
Anti-her2 glycoantibodies and uses thereof
|
US10118969B2
(en)
|
2014-05-27 |
2018-11-06 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
JP7063538B2
(ja)
|
2014-05-28 |
2022-05-09 |
アカデミア シニカ |
抗TNFα糖操作抗体群およびその使用
|
US11357748B2
(en)
|
2014-05-30 |
2022-06-14 |
The Johns Hopkins University |
Methods for treating mendelian disorders of the epigenetic machinery
|
ES2905777T3
(es)
|
2014-05-30 |
2022-04-12 |
Shanghai Henlius Biotech Inc |
Anticuerpos anti-receptor del factor de crecimiento epidérmico (EGFR)
|
EP3970747A3
(en)
|
2014-06-03 |
2022-10-05 |
XBiotech Inc. |
Compositions and methods for treating and preventing staphylococcus aureus infections
|
CA2949234C
(en)
|
2014-06-09 |
2022-03-22 |
Ultragenyx Pharmaceutical Inc. |
Anti-fgf23 antibody for treatment of hypophosphatemic disorders
|
BR112016028750A2
(pt)
|
2014-06-11 |
2017-11-14 |
Gilead Sciences Inc |
?métodos para tratar, prevenir, ou melhorar pelo menos um sintoma associado e para diagnosticar e monitorar insuficiência cardíaca ou fibrilação atrial, inibidor da lisil oxidase ativa ou proteína lisil tipo oxidase, e, composição?
|
CN107074931A
(zh)
|
2014-06-13 |
2017-08-18 |
圣塔玛丽亚生物疗法公司 |
经配制的受体多肽和相关方法
|
TWI695011B
(zh)
|
2014-06-18 |
2020-06-01 |
美商梅爾莎納醫療公司 |
抗her2表位之單株抗體及其使用之方法
|
CN114057857A
(zh)
|
2014-06-20 |
2022-02-18 |
豪夫迈·罗氏有限公司 |
基于chagasin的支架组合物、方法和应用
|
TW201625299A
(zh)
|
2014-06-20 |
2016-07-16 |
Chugai Pharmaceutical Co Ltd |
用於因第viii凝血因子及/或活化的第viii凝血因子的活性降低或欠缺而發病及/或進展的疾病之預防及/或治療之醫藥組成物
|
US9840553B2
(en)
|
2014-06-28 |
2017-12-12 |
Kodiak Sciences Inc. |
Dual PDGF/VEGF antagonists
|
EP3166939B1
(en)
|
2014-07-07 |
2019-06-05 |
Genentech, Inc. |
Therapeutic compounds and methods of use thereof
|
SG11201700207WA
(en)
|
2014-07-11 |
2017-02-27 |
Genentech Inc |
Anti-pd-l1 antibodies and diagnostic uses thereof
|
US10166304B2
(en)
|
2014-07-11 |
2019-01-01 |
Regents Of The University Of Minnesota |
Antibody fragments for detecting cancer and methods of use
|
EP2966085A1
(en)
|
2014-07-11 |
2016-01-13 |
Boehringer Ingelheim International GmbH |
Antibody IgG1 with a modified heavy chain constant region
|
CN106460067A
(zh)
|
2014-07-14 |
2017-02-22 |
豪夫迈·罗氏有限公司 |
诊断方法和用于治疗成胶质细胞瘤的组合物
|
EP2977758A1
(en)
|
2014-07-24 |
2016-01-27 |
Université De Nice Sophia Antipolis |
Methods and kits for monitoring membranous nephropathy
|
EP3172235A2
(en)
|
2014-07-25 |
2017-05-31 |
Cytomx Therapeutics Inc. |
Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
|
EP3174901B1
(en)
|
2014-07-31 |
2019-06-26 |
Amgen Research (Munich) GmbH |
Optimized cross-species specific bispecific single chain antibody constructs
|
UY36245A
(es)
|
2014-07-31 |
2016-01-29 |
Amgen Res Munich Gmbh |
Constructos de anticuerpos para cdh19 y cd3
|
WO2016020799A1
(en)
|
2014-08-06 |
2016-02-11 |
Rinat Neuroscience Corp. |
Methods for reducing ldl-cholesterol
|
EP3193928A1
(en)
|
2014-08-06 |
2017-07-26 |
Rinat Neuroscience Corp. |
Methods for reducing ldl-cholesterol
|
CA3133162C
(en)
|
2014-08-12 |
2024-02-13 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein
|
WO2016025645A1
(en)
|
2014-08-12 |
2016-02-18 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker
|
US11111284B2
(en)
|
2014-08-21 |
2021-09-07 |
The General Hospital Corporation |
Tumor necrosis factor superfamily and TNF-like ligand muteins and methods of preparing
|
CN107109410B
(zh)
|
2014-08-22 |
2021-11-02 |
奥克兰联合服务有限公司 |
通道调节剂
|
US10111898B2
(en)
|
2014-08-27 |
2018-10-30 |
Peptimed, Inc. |
Anti-tumor compositions and methods
|
TWI691597B
(zh)
|
2014-09-01 |
2020-04-21 |
中央研究院 |
延長壽命與抑制腫瘤發生的動物模型
|
WO2016034968A1
(en)
|
2014-09-02 |
2016-03-10 |
Pfizer Inc. |
Therapeutic antibody
|
TWI745275B
(zh)
|
2014-09-08 |
2021-11-11 |
中央研究院 |
使用醣脂激活人類iNKT細胞
|
WO2016040767A2
(en)
|
2014-09-12 |
2016-03-17 |
Amgen Inc. |
Chrdl-1 epitopes and antibodies
|
TW201620938A
(zh)
|
2014-09-15 |
2016-06-16 |
安美基公司 |
雙特異性抗cgrp受體/pac1受體抗原結合蛋白質及其用途
|
JP2017527604A
(ja)
|
2014-09-17 |
2017-09-21 |
アイアンウッド ファーマシューティカルズ インコーポレイテッド |
sGC刺激剤
|
CN107406422B
(zh)
|
2014-09-17 |
2022-02-01 |
赛科理音医疗有限公司 |
作为sGC刺激剂的吡唑衍生物
|
US20170298055A1
(en)
|
2014-09-17 |
2017-10-19 |
Ironwood Pharmaceuticals, Inc. |
sGC STIMULATORS
|
JP7095990B2
(ja)
|
2014-09-18 |
2022-07-05 |
シーダーズ-サイナイ メディカル センター |
線維症を治療するための組成物及び方法
|
AU2015321462B2
(en)
|
2014-09-22 |
2020-04-30 |
Intrinsic Lifesciences Llc |
Humanized anti-hepcidin antibodies and uses thereof
|
EP3197492A1
(en)
|
2014-09-23 |
2017-08-02 |
Pfizer Inc |
Treatment with anti-pcsk9 antibodies
|
EP3000814A1
(en)
|
2014-09-26 |
2016-03-30 |
Domain Therapeutics |
Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
|
US9889085B1
(en)
|
2014-09-30 |
2018-02-13 |
Intarcia Therapeutics, Inc. |
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
|
CN111303159A
(zh)
|
2014-10-02 |
2020-06-19 |
豪夫迈·罗氏有限公司 |
用于治疗由布鲁顿酪氨酸激酶(btk)介导的疾病的吡唑甲酰胺化合物
|
CN107250159A
(zh)
|
2014-10-03 |
2017-10-13 |
达纳-法伯癌症研究所公司 |
糖皮质激素诱导的肿瘤坏死因子受体(gitr)抗体及其使用方法
|
EP3699196A1
(en)
|
2014-10-06 |
2020-08-26 |
Dana Farber Cancer Institute, Inc. |
Humanized cc chemokine receptor 4 (ccr4) antibodies and methods of use thereof
|
EP3206707B1
(en)
|
2014-10-13 |
2020-12-02 |
University of Maryland, Baltimore |
Fc-ela-32 and its use in the treatment of cardiac conditions
|
SG11201702558VA
(en)
|
2014-10-21 |
2017-05-30 |
Sciclone Pharmaceuticals Inc |
Treatment of cancer with immune stimulators
|
LT3412302T
(lt)
|
2014-10-24 |
2021-07-26 |
Bristol-Myers Squibb Company |
Modifikuoti fgf-21 polipeptidai ir jų panaudojimai
|
ES2784343T3
(es)
|
2014-10-29 |
2020-09-24 |
Adaptive Biotechnologies Corp |
Detección simultánea altamente multiplexada de ácidos nucleicos que codifican heterodímeros de receptores inmunes adaptativos emparejados de muchas muestras
|
AU2015338974B2
(en)
|
2014-10-31 |
2021-08-26 |
Oncomed Pharmaceuticals, Inc. |
Combination therapy for treatment of disease
|
WO2016069889A1
(en)
|
2014-10-31 |
2016-05-06 |
Resolve Therapeutics, Llc |
Therapeutic nuclease-transferrin fusions and methods
|
WO2016077083A1
(en)
|
2014-11-05 |
2016-05-19 |
University Of The Sciences In Philadelphia |
A high molecular weight biodegradable gelatin-doxorubicin conjugate
|
RU2017119185A
(ru)
|
2014-11-05 |
2018-12-05 |
Дженентек, Инк. |
Антитела против fgfr2/3 и способы их применения
|
US20160168640A1
(en)
|
2014-11-10 |
2016-06-16 |
Genentech, Inc. |
Therapeutic and diagnostic methods for il-33-mediated disorders
|
US10246701B2
(en)
|
2014-11-14 |
2019-04-02 |
Adaptive Biotechnologies Corp. |
Multiplexed digital quantitation of rearranged lymphoid receptors in a complex mixture
|
WO2016081423A1
(en)
|
2014-11-18 |
2016-05-26 |
Janssen Pharmaceutica Nv |
Cd47 antibodies, methods, and uses
|
EP3221362B1
(en)
|
2014-11-19 |
2019-07-24 |
F.Hoffmann-La Roche Ag |
Anti-transferrin receptor antibodies and methods of use
|
EP3221361B1
(en)
|
2014-11-19 |
2021-04-21 |
Genentech, Inc. |
Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
|
WO2016079321A1
(en)
|
2014-11-20 |
2016-05-26 |
Cemm Forschungszentrum Für Molekulare Medizin Gmbh |
Antagonists of setdb2 for use in the therapy of infectious diseases
|
AU2015353573B2
(en)
|
2014-11-25 |
2020-09-03 |
Bristol-Myers Squibb Company |
Novel PD-L1 binding polypeptides for imaging
|
MA41019A
(fr)
|
2014-11-26 |
2021-05-05 |
Xencor Inc |
Anticorps hétérodimériques se liant aux antigènes cd3 et cd38
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
CA2969145A1
(en)
|
2014-11-26 |
2016-06-02 |
The Regents Of The University Of California |
Therapeutic compositions comprising transcription factors and methods of making and using the same
|
EP3223845B1
(en)
|
2014-11-26 |
2021-05-19 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cd20
|
US20160176969A1
(en)
|
2014-11-26 |
2016-06-23 |
Xencor, Inc. |
Heterodimeric antibodies including binding to cd8
|
MX2017007231A
(es)
|
2014-12-03 |
2017-11-08 |
Genentech Inc |
Conjugados de rifamicina y anticuerpos contra el staphylococcuss aureus y usos de estos.
|
BR112017011325A2
(pt)
|
2014-12-03 |
2020-07-21 |
Genentech, Inc. |
?composto de conjugado anticorpo?antibiótico, composição, método de tratamento de uma infecção, método para matar staph aureus, processo para produzir o conjugado, kit para o tratamento de uma infecção, intermediários antibiótico-ligante e ligante-droga?
|
PL3227332T3
(pl)
|
2014-12-03 |
2020-06-15 |
F. Hoffmann-La Roche Ag |
Wielospecyficzne przeciwciała
|
US20170369474A1
(en)
|
2014-12-05 |
2017-12-28 |
Aquinnah Pharmaceuticals, Inc. |
Compounds, compositions and methods of use
|
CA2969756A1
(en)
|
2014-12-05 |
2016-06-09 |
Aquinnah Pharmaceuticals, Inc. |
Sulfonamide derivatives, compositions and methods of use in the treatment of neurodegenerative diseases
|
TWI595006B
(zh)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗pd-1抗體類和使用彼等之方法
|
SG11201703750XA
(en)
|
2014-12-10 |
2017-06-29 |
Genentech Inc |
Blood brain barrier receptor antibodies and methods of use
|
EP3333191B1
(en)
|
2014-12-11 |
2020-09-09 |
Pierre Fabre Medicament |
Anti-c10orf54 antibodies and uses thereof
|
TW201702218A
(zh)
|
2014-12-12 |
2017-01-16 |
美國杰克森實驗室 |
關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
|
CN117865872A
(zh)
|
2014-12-18 |
2024-04-12 |
豪夫迈·罗氏有限公司 |
四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
|
EP3237449A2
(en)
|
2014-12-22 |
2017-11-01 |
Xencor, Inc. |
Trispecific antibodies
|
AU2015371312B2
(en)
|
2014-12-24 |
2022-01-27 |
Genentech, Inc. |
Therapeutic, diagnostic and prognostic methods for cancer of the bladder
|
EP3085709B1
(en)
|
2014-12-28 |
2019-08-21 |
Genor Biopharma Co., Ltd |
Humanized anti-human rankl antibody, pharmaceutical composition and use thereof
|
CN107530423B
(zh)
|
2015-01-14 |
2022-04-05 |
布里格姆及妇女医院股份有限公司 |
用抗lap单克隆抗体治疗癌症
|
US9975965B2
(en)
|
2015-01-16 |
2018-05-22 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
US10495645B2
(en)
|
2015-01-16 |
2019-12-03 |
Academia Sinica |
Cancer markers and methods of use thereof
|
MA41374A
(fr)
|
2015-01-20 |
2017-11-28 |
Cytomx Therapeutics Inc |
Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
|
EP3247386A4
(en)
|
2015-01-20 |
2018-10-03 |
The Children's Medical Center Corporation |
Anti-net compounds for treating and preventing fibrosis and for facilitating wound healing
|
WO2016118961A1
(en)
|
2015-01-24 |
2016-07-28 |
Academia Sinica |
Cancer markers and methods of use thereof
|
AU2015378564A1
(en)
|
2015-01-24 |
2017-07-13 |
Academia Sinica |
Novel glycan conjugates and methods of use thereof
|
US20180170992A1
(en)
|
2015-01-26 |
2018-06-21 |
The University Of Chicago |
CAR T CELLS RECOGNIZING CANCER-SPECIFIC IL 13Ra2
|
JP7264592B2
(ja)
|
2015-01-26 |
2023-04-25 |
ザ ユニバーシティー オブ シカゴ |
IL13Rα2結合剤及び癌治療におけるその使用
|
WO2016123329A2
(en)
|
2015-01-28 |
2016-08-04 |
Genentech, Inc. |
Gene expression markers and treatment of multiple sclerosis
|
US11786457B2
(en)
|
2015-01-30 |
2023-10-17 |
President And Fellows Of Harvard College |
Peritumoral and intratumoral materials for cancer therapy
|
EP3250590B1
(en)
|
2015-01-30 |
2021-09-15 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced anti-ssea4 antibody efficacy
|
CA2975875A1
(en)
|
2015-02-04 |
2016-08-11 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
US10383945B2
(en)
|
2015-02-18 |
2019-08-20 |
The United States of America as Represented by the Department of Verterans Affairs |
Methods for DNA-dependent targeting of a cell permeant antibody
|
WO2016134333A1
(en)
|
2015-02-19 |
2016-08-25 |
Compugen Ltd. |
Anti-pvrig antibodies and methods of use
|
DK3259597T3
(da)
|
2015-02-19 |
2022-05-09 |
Compugen Ltd |
Pvrig-polypeptider og fremgangsmåder til behandling
|
WO2016135137A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Substituted 4-(phenylamino)quinoline derivatives as mth1 inhibitors for the therapy of cancer
|
CA2976593A1
(en)
|
2015-02-23 |
2016-09-01 |
Seagull Therapeutics Sas |
Non-natural semaphorins 3 and their medical use
|
WO2016135140A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
4-aminoquinazoline derivatives as mth1 inhibitors for the therapy of cancer
|
WO2016135138A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Oxoquinoline derivatives as mth1 inhibitors for the therapy of cancer
|
WO2016135139A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
2,3-dihydrocyclopenta[b]quinoline derivatives as mth1 inhibitors for the therapy of cancer
|
EP3262035A1
(en)
|
2015-02-25 |
2018-01-03 |
F. Hoffmann-La Roche AG |
Alkynyl alcohols and methods of use
|
MA41599A
(fr)
|
2015-02-26 |
2018-01-02 |
Array Biopharma Inc |
Formes cristallines d'un composé pyrrolopyridine
|
KR20170120601A
(ko)
|
2015-02-26 |
2017-10-31 |
제넨테크, 인크. |
인테그린 베타7 길항제 및 크론병을 치료하는 방법
|
BR112017014067B1
(pt)
|
2015-02-27 |
2021-01-12 |
Chugai Seiyaku Kabushiki Kaisha |
usos de um anticorpo receptor de il-6 para no tratamento de doenças relacionadas a il-6
|
CN114504651A
(zh)
|
2015-03-03 |
2022-05-17 |
科马布有限公司 |
抗体、用途和方法
|
MA41629A
(fr)
|
2015-03-04 |
2018-01-09 |
Center For Human Reproduction |
Compositions et méthodes d'utilisation de l'hormone anti-müllérienne pour le traitement de l'infertilité
|
US10227411B2
(en)
|
2015-03-05 |
2019-03-12 |
Xencor, Inc. |
Modulation of T cells with bispecific antibodies and FC fusions
|
WO2016144860A1
(en)
|
2015-03-06 |
2016-09-15 |
Ironwood Pharmaceuticals, Inc. |
Faah inhibitors for the treatment or prevention of nausea
|
EP3268373B1
(en)
|
2015-03-09 |
2022-04-27 |
F. Hoffmann-La Roche AG |
Tricyclic dlk inhibitors and uses thereof
|
AU2016233495B2
(en)
|
2015-03-13 |
2022-02-24 |
Cytomx Therapeutics, Inc |
Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof
|
IL296062A
(en)
|
2015-03-17 |
2022-10-01 |
Memorial Sloan Kettering Cancer Center |
Antibodies against muc16 and their uses
|
AR104068A1
(es)
|
2015-03-26 |
2017-06-21 |
Hoffmann La Roche |
Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
|
WO2016154621A1
(en)
|
2015-03-26 |
2016-09-29 |
The California Institute For Biomedical Research |
SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF
|
KR20170132793A
(ko)
|
2015-04-03 |
2017-12-04 |
유레카 쎄라퓨틱스, 인코포레이티드 |
Afp 펩티드/mhc 복합체를 표적화하는 구축물 및 그의 용도
|
US9758575B2
(en)
|
2015-04-06 |
2017-09-12 |
Yung Shin Pharmaceutical Industrial Co. Ltd. |
Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof
|
WO2016164476A2
(en)
|
2015-04-06 |
2016-10-13 |
Millendo Therapeutics, Inc. |
Combination therapy for treating disorders associated with excess cortisol production
|
WO2016164480A1
(en)
|
2015-04-07 |
2016-10-13 |
Genentech, Inc. |
Antigen binding complex having agonistic activity and methods of use
|
CN107750253B
(zh)
|
2015-04-08 |
2022-10-04 |
达纳-法伯癌症研究所公司 |
人源化流感单克隆抗体及其使用方法
|
EP3280464A4
(en)
|
2015-04-10 |
2018-09-26 |
President and Fellows of Harvard College |
Immune cell trapping devices and methods for making and using the same
|
IL283764B2
(en)
|
2015-04-10 |
2024-01-01 |
Amgen Inc |
Interleukin for the expansion of myotonic control T-2 cells
|
TWI703159B
(zh)
|
2015-04-13 |
2020-09-01 |
美商輝瑞股份有限公司 |
Bcma特異性治療性抗體及其用途
|
EP3283113A4
(en)
|
2015-04-15 |
2018-12-05 |
The California Institute for Biomedical Research |
Optimized pne-based chimeric receptor t cell switches and uses thereof
|
SG10201909308XA
(en)
|
2015-04-17 |
2019-11-28 |
Amgen Res Munich Gmbh |
Bispecific antibody constructs for cdh3 and cd3
|
CN107708718B
(zh)
|
2015-04-22 |
2022-01-11 |
西达-赛奈医疗中心 |
用于治疗2型糖尿病的肠内递送的苦味寡肽
|
EP3085366A1
(en)
|
2015-04-22 |
2016-10-26 |
Institut du Cerveau et de la Moelle Epiniere-ICM |
Nmda antagonists for the treatment of mental disorders with occurrence of aggressive and/or impulsive behavior
|
EP3285753A1
(en)
|
2015-04-22 |
2018-02-28 |
CeMM - Forschungszentrum für Molekulare Medizin GmbH |
Combination of an antiandrogen with a vitamin k antagonist or with a gamma -glutamyl carboxylase inhibitor for the therapy of androgen receptor positive cancer
|
SG11201708441RA
(en)
|
2015-04-24 |
2017-11-29 |
Viiv Healthcare Uk (No 5) Ltd |
Polypeptides targeting hiv fusion
|
WO2016172485A2
(en)
|
2015-04-24 |
2016-10-27 |
Genentech, Inc. |
Multispecific antigen-binding proteins
|
WO2016179120A1
(en)
|
2015-05-01 |
2016-11-10 |
Mir Imran |
Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
|
EP3292151A1
(en)
|
2015-05-04 |
2018-03-14 |
Cytomx Therapeutics Inc. |
Anti-itga3 antibodies, activatable anti-itga3 antibodies, and methods of use thereof
|
EA201792414A1
(ru)
|
2015-05-04 |
2018-06-29 |
Сайтомкс Терапьютикс, Инк. |
Антитела против cd166, активируемые антитела против cd166 и способы их применения
|
LT3292149T
(lt)
|
2015-05-04 |
2022-03-10 |
Cytomx Therapeutics, Inc. |
Aktyvinami antikūnai prieš cd71 ir jų naudojimo būdai
|
EP4059514A1
(en)
|
2015-05-08 |
2022-09-21 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and tumor antigens
|
IL255312B
(en)
|
2015-05-12 |
2022-08-01 |
Genentech Inc |
Therapeutic and diagnostic methods for cancer containing a pd–l1 binding antagonist
|
WO2016186977A1
(en)
|
2015-05-15 |
2016-11-24 |
The Johns Hopkins University |
Novel fluoride prenatal dietary supplement
|
WO2016191312A1
(en)
|
2015-05-22 |
2016-12-01 |
Genentech, Inc. |
Substituted benzamides and methods of use thereof
|
EP3708681A1
(en)
|
2015-05-29 |
2020-09-16 |
F. Hoffmann-La Roche AG |
Therapeutic and diagnostic methods for cancer
|
CA2984638A1
(en)
|
2015-05-29 |
2016-12-08 |
Genentech, Inc. |
Pd-l1 promoter methylation in cancer
|
EP3303286B1
(en)
|
2015-06-01 |
2023-10-04 |
Cedars-Sinai Medical Center |
Compounds that bind to rela of nf-kb for use in treating cancer
|
MX2017015504A
(es)
|
2015-06-03 |
2018-05-15 |
Intarcia Therapeutics Inc |
Sistemas de colocacion y remoción de implante.
|
WO2016193496A1
(en)
|
2015-06-04 |
2016-12-08 |
Ospedale San Raffaele Srl |
Igfbp3 and uses thereof
|
NZ738389A
(en)
|
2015-06-04 |
2019-02-22 |
Ospedale San Raffaele Srl |
Inhibitor of igfbp3/tmem219 axis and diabetes
|
US20160361380A1
(en)
|
2015-06-12 |
2016-12-15 |
Nymox Corporation |
Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations
|
EP3310376A4
(en)
|
2015-06-17 |
2019-01-23 |
The California Institute for Biomedical Research |
MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
|
RU2020124105A
(ru)
|
2015-06-24 |
2020-09-18 |
Ф. Хоффманн-Ля Рош Аг |
Антитела против трансферринового рецептора, обладающие индивидуализированной аффинностью
|
US20160375033A1
(en)
|
2015-06-29 |
2016-12-29 |
Genentech, Inc. |
Methods of treatment with taselisib
|
CN112047960A
(zh)
|
2015-07-02 |
2020-12-08 |
豪夫迈·罗氏有限公司 |
苯并氧氮杂*噁唑烷酮化合物及其使用方法
|
CN111848643A
(zh)
|
2015-07-02 |
2020-10-30 |
豪夫迈·罗氏有限公司 |
苯并氧氮杂*噁唑烷酮化合物及其使用方法
|
US10676490B2
(en)
|
2015-07-07 |
2020-06-09 |
Florida Southwestern State College |
Use of amine carboxyboranes as therapeutic delivery of carbon monoxide and as general drug delivery system in the presence of reactive oxygen species
|
HUE044139T2
(hu)
|
2015-07-07 |
2019-09-30 |
Hoffmann La Roche |
Kombinált terápia egy HER2-ellenes antitest-gyógyszer konjugátummal és bcl-2 inhibitorral
|
KR20180040138A
(ko)
|
2015-07-13 |
2018-04-19 |
싸이톰스 테라퓨틱스, 인크. |
항pd-1 항체, 활성화 가능한 항pd-1 항체, 및 이들의 사용 방법
|
CA2991980A1
(en)
|
2015-07-13 |
2017-01-19 |
Compugen Ltd. |
Hide1 compositions and methods
|
EP3325516B1
(en)
|
2015-07-21 |
2021-12-15 |
Takeda Pharmaceutical Company Limited |
A monoclonal antibody inhibitor of factor xiia
|
WO2017017631A2
(en)
|
2015-07-28 |
2017-02-02 |
Vyome Biosciences Pvt. Ltd. |
Antibacterial therapeutics and prophylactics
|
KR20180037994A
(ko)
|
2015-07-28 |
2018-04-13 |
오토노미, 인코포레이티드 |
TrkB 또는 TrkC 아고니스트 조성물 및 귀 병태의 치료 방법
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究(慕尼黑)公司 |
Msln及cd3抗體構築體
|
CA2994162A1
(en)
|
2015-07-31 |
2017-02-09 |
The Johns Hopkins University |
Glutamine antagonists for the treatment of cognitive deficits
|
TWI717375B
(zh)
|
2015-07-31 |
2021-02-01 |
德商安美基研究(慕尼黑)公司 |
Cd70及cd3抗體構築體
|
TW202346349A
(zh)
|
2015-07-31 |
2023-12-01 |
德商安美基研究(慕尼黑)公司 |
Dll3及cd3抗體構築體
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究(慕尼黑)公司 |
Egfrviii及cd3抗體構築體
|
HRP20231163T1
(hr)
|
2015-07-31 |
2024-03-15 |
The Johns Hopkins University |
Prolijekovi glutaminskih analoga
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究(慕尼黑)公司 |
Flt3及cd3抗體構築體
|
CA2994256A1
(en)
|
2015-07-31 |
2017-02-09 |
The Johns Hopkins University |
Methods and compositions for treating metabolic reprogramming disorders
|
US10842763B2
(en)
|
2015-07-31 |
2020-11-24 |
The Johns Hopkins University |
Methods for cancer and immunotherapy using prodrugs of glutamine analogs
|
JO3620B1
(ar)
|
2015-08-05 |
2020-08-27 |
Amgen Res Munich Gmbh |
مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
|
DK3331902T3
(da)
|
2015-08-07 |
2021-07-26 |
Alx Oncology Inc |
Konstruktioner med et sirp-alpha-domæne eller en variant deraf
|
EA034582B1
(ru)
|
2015-08-07 |
2020-02-21 |
АЭлЭкс ОНКОЛОДЖИ ИНК. |
Конструкции варианта sirp-альфа и их применение
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
JP2018526371A
(ja)
|
2015-08-27 |
2018-09-13 |
ジェネンテック, インコーポレイテッド |
治療化合物及びその使用方法
|
CN108350605A
(zh)
|
2015-09-04 |
2018-07-31 |
台湾浩鼎生技股份有限公司 |
聚糖阵列以及使用方法
|
CA2996716A1
(en)
|
2015-09-04 |
2017-03-09 |
The California Institute For Biomedical Research |
Insulin immunoglobulin fusion proteins
|
IL258121B2
(en)
|
2015-09-15 |
2024-01-01 |
Scholar Rock Inc |
Antipro/latent myostatin antibodies and their uses
|
EP3350216A1
(en)
|
2015-09-15 |
2018-07-25 |
Amgen Inc. |
Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof
|
CN109071644B
(zh)
|
2015-09-23 |
2023-09-19 |
昂考梅德药品有限公司 |
治疗癌症的方法和组合物
|
ES2809125T3
(es)
|
2015-09-23 |
2021-03-03 |
Bristol Myers Squibb Co |
Moléculas de armazón a base de fibronectina de unión a glipicano-3
|
WO2017058828A1
(en)
|
2015-09-28 |
2017-04-06 |
Children's Hospital Los Angeles |
Methods for treating diseases mediated by erbb4-positive pro-inflammatory macrophages
|
JP2018529729A
(ja)
|
2015-10-01 |
2018-10-11 |
アムジエン・インコーポレーテツド |
胆汁酸障害の処置
|
WO2017055966A1
(en)
|
2015-10-01 |
2017-04-06 |
Pfizer Inc. |
Low viscosity antibody compositions
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
CR20180149A
(es)
|
2015-10-02 |
2018-04-05 |
Hoffmann La Roche |
Anticuerpos biespecíficos contra el cd20 humano y el receptor de transferrina humano y métodos de uso
|
CN108431038A
(zh)
|
2015-10-06 |
2018-08-21 |
豪夫迈·罗氏有限公司 |
治疗多发性硬化的方法
|
WO2017069958A2
(en)
|
2015-10-09 |
2017-04-27 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
US20180305334A1
(en)
|
2015-10-14 |
2018-10-25 |
Aquinnah Pharmaceuticals, Inc. |
Compounds, compositions and methods of use against stress granules
|
WO2017066714A1
(en)
|
2015-10-16 |
2017-04-20 |
Compugen Ltd. |
Anti-vsig1 antibodies and drug conjugates
|
ES2846848T3
(es)
|
2015-10-26 |
2021-07-29 |
Harvard College |
Polisacáridos reducidos y oxidados y métodos de uso de los mismos
|
WO2017075037A1
(en)
|
2015-10-27 |
2017-05-04 |
Scholar Rock, Inc. |
Primed growth factors and uses thereof
|
KR102162324B1
(ko)
|
2015-10-30 |
2020-10-07 |
제넨테크, 인크. |
항-HtrA1 항체 및 이의 사용 방법
|
JP2018536650A
(ja)
|
2015-10-30 |
2018-12-13 |
ジェネンテック, インコーポレイテッド |
抗d因子抗体変異体コンジュゲート及びその使用
|
US10407510B2
(en)
|
2015-10-30 |
2019-09-10 |
Genentech, Inc. |
Anti-factor D antibodies and conjugates
|
AU2016349786B2
(en)
|
2015-11-03 |
2023-11-16 |
Ambrx, Inc. |
Anti-CD3-folate conjugates and their uses
|
US20180320136A1
(en)
|
2015-11-03 |
2018-11-08 |
GlycoMimitics, Inc. |
Methods and compositions for the production of monoclonal antibodies, hematopoietic stem cells, and methods of using the same
|
AU2016354661B2
(en)
|
2015-11-13 |
2020-12-10 |
Domain Therapeutics |
Substituted tricyclic 1,4-benzodiazepinone derivatives as allosteric modulators of group II metabotropic glutamate receptors
|
CN108136022A
(zh)
|
2015-11-19 |
2018-06-08 |
豪夫迈·罗氏有限公司 |
使用b-raf抑制剂和免疫检查点抑制剂治疗癌症的方法
|
WO2017091592A1
(en)
|
2015-11-25 |
2017-06-01 |
Genentech, Inc. |
Substituted benzamides useful as sodium channel blockers
|
CA2949033A1
(en)
|
2015-11-30 |
2017-05-30 |
Pfizer Inc. |
Antibodies and antibody fragments for site-specific conjugation
|
TWI727380B
(zh)
|
2015-11-30 |
2021-05-11 |
美商輝瑞股份有限公司 |
位點專一性her2抗體藥物共軛體
|
KR20180093010A
(ko)
|
2015-12-04 |
2018-08-20 |
더 리전트 오브 더 유니버시티 오브 캘리포니아 |
새로운 암 치료용 항체
|
WO2017096262A1
(en)
|
2015-12-04 |
2017-06-08 |
Jomoco, Corp. |
Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
|
CA3007030A1
(en)
|
2015-12-07 |
2017-06-15 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and psma
|
PT3387019T
(pt)
|
2015-12-09 |
2022-01-14 |
Scripps Research Inst |
Proteínas de fusão de imunoglobulina de relaxina e métodos de uso
|
HRP20211466T1
(hr)
|
2015-12-09 |
2021-12-24 |
Medizinische Universität Wien |
Spojevi platine funkcionalizirani monomaleimidom, namijenjeni terapiji raka
|
AU2016371762A1
(en)
|
2015-12-14 |
2018-06-21 |
Cyclerion Therapeutics, Inc. |
Use of sGC stimulators for the treatment of gastrointestinal sphincter dysfunction
|
EP3390447A1
(en)
|
2015-12-15 |
2018-10-24 |
Amgen Inc. |
Pacap antibodies and uses thereof
|
DK3391902T3
(da)
|
2015-12-18 |
2023-11-20 |
Talengen Int Ltd |
Plasminogen til anvendelse i behandlingen af diabetisk angiokardiopati
|
JP6948330B2
(ja)
|
2015-12-23 |
2021-10-13 |
アムジエン・インコーポレーテツド |
胃抑制ペプチド受容体(gipr)に対する結合タンパク質をglp−1アゴニストと組み合わせて使用する、代謝障害の治療方法または寛解方法
|
US20200270363A1
(en)
|
2015-12-25 |
2020-08-27 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody having enhanced activity, and method for modifying same
|
SG11201805420SA
(en)
|
2015-12-30 |
2018-07-30 |
Kodiak Sciences Inc |
Antibodies and conjugates thereof
|
MX2018008369A
(es)
|
2016-01-08 |
2019-05-15 |
Scholar Rock Inc |
Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos.
|
US10653744B2
(en)
|
2016-01-11 |
2020-05-19 |
Bausch Health Ireland Limited |
Formulations and methods for treating ulcerative colitis
|
AU2017207867A1
(en)
|
2016-01-15 |
2018-08-09 |
Universität Hamburg |
Flavonoide-type compounds bearing an O-rhamnosyl residue
|
JOP20170017B1
(ar)
|
2016-01-25 |
2021-08-17 |
Amgen Res Munich Gmbh |
تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص
|
MA43955B1
(fr)
|
2016-02-03 |
2022-02-28 |
Amgen Inc |
Anticorps anti-bcma et anti-cd3 bispécifiques de format bite
|
UA126656C2
(uk)
|
2016-02-03 |
2023-01-11 |
Емджен Рісерч (Мюнік) Гмбх |
Біспецифічна конструкція антитіла до psma і cd3, яке залучають t-клітини
|
EA039859B1
(ru)
|
2016-02-03 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
CN109071625A
(zh)
|
2016-02-04 |
2018-12-21 |
柯瑞斯公司 |
平滑化突变体和其使用方法
|
US10098909B2
(en)
|
2016-02-05 |
2018-10-16 |
University Of South Florida |
Ionic cocrystal of lithium, lispro, for the treatment of fragile X syndrome
|
CN109072197A
(zh)
|
2016-02-06 |
2018-12-21 |
哈佛学院校长同事会 |
重塑造血巢以重建免疫
|
EP3414573B1
(en)
|
2016-02-10 |
2023-11-08 |
Rutgers, the State University of New Jersey |
Novel anti-lam antibodies
|
US10519442B2
(en)
|
2016-02-11 |
2019-12-31 |
City Of Hope |
Twist signaling inhibitor compositions and methods of using the same
|
MX2018009870A
(es)
|
2016-02-15 |
2018-11-29 |
Cemm Forschungszentrum Fuer Molekulare Medizin Gmbh |
Inhibidores de taf1 para la terapia del cancer.
|
AU2017225854B2
(en)
|
2016-02-29 |
2020-11-19 |
Foundation Medicine, Inc. |
Therapeutic and diagnostic methods for cancer
|
WO2017148880A1
(en)
|
2016-03-01 |
2017-09-08 |
F. Hoffmann-La Roche Ag |
Obinutuzumab variants having altered cell death induction
|
EP3216458A1
(en)
|
2016-03-07 |
2017-09-13 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Modified vascular endothelial growth factor a (vegf-a) and its medical use
|
CA3016170A1
(en)
|
2016-03-08 |
2017-09-14 |
Academia Sinica |
Methods for modular synthesis of n-glycans and arrays thereof
|
MX2018010948A
(es)
|
2016-03-11 |
2019-06-20 |
Scholar Rock Inc |
INMUNOGLOBULINAS DE ENLACE A TGFß1 Y USOS DE LAS MISMAS.
|
CN109310885B
(zh)
|
2016-03-15 |
2022-05-31 |
梅尔莎纳医疗公司 |
NaPi2b靶向抗体-药物缀合物及其使用方法
|
CA3018893A1
(en)
|
2016-03-28 |
2017-10-05 |
Syneurx International (Taiwan) Corp. |
Compositions containing tannic acids and uses thereof
|
US10980894B2
(en)
|
2016-03-29 |
2021-04-20 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
AU2017239637A1
(en)
|
2016-03-29 |
2018-11-15 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
EP3854782A1
(en)
|
2016-03-30 |
2021-07-28 |
Genentech, Inc. |
Substituted benzamides and methods of use thereof
|
CA3020344A1
(en)
|
2016-04-07 |
2017-10-12 |
Case Western Reserve University |
Tdp-43 mitochondrial localization inhibitor for the treatment of neurodegenerative disease
|
CN109154027A
(zh)
|
2016-04-15 |
2019-01-04 |
豪夫迈·罗氏有限公司 |
用于监测和治疗癌症的方法
|
GB2555264A
(en)
|
2016-04-15 |
2018-04-25 |
Univ Oxford Innovation Ltd |
Adenosine receptor modulators for the treatment of circadian rhythm disorders
|
CA3019921A1
(en)
|
2016-04-15 |
2017-10-19 |
Genentech, Inc. |
Methods for monitoring and treating cancer
|
BR112018071683A2
(pt)
|
2016-04-22 |
2019-02-19 |
Obi Pharma, Inc. |
método para tratar um câncer de mama, método para tratamento de um tumor em um paciente, método para tratar um indivíduo sofrendo com câncer por imunoterapia, método para induzir/melhorar uma resposta imune em um indivíduo, método para melhorar a vacina obi-822 induzida pela resposta imune em um indivíduo necessitando da mesma, método para identificar um paciente adequado para terapia do câncer e método para determinar o prognóstico do tratamento do câncer ou resposta do fármaco de um paciente
|
EP3808764A1
(en)
|
2016-05-04 |
2021-04-21 |
Amgen Inc. |
Interleukin-2 muteins for the expansion of t-regulatory cells
|
EP3455364A2
(en)
|
2016-05-10 |
2019-03-20 |
H. Hoffnabb-La Roche Ag |
Methods of decreasing trisulfide bonds during recombinant production of polypeptides
|
EP3458070A4
(en)
*
|
2016-05-16 |
2020-01-08 |
Amag Pharmaceuticals, Inc. |
PROLONGED RELEASE POLYMER COMPOSITIONS BASED ON HYDROXYPROGESTERONE CAPROATE AND METHODS OF USE THEREOF
|
AU2017268161B2
(en)
|
2016-05-16 |
2020-03-12 |
Intarcia Therapeutics, Inc. |
Glucagon-receptor selective polypeptides and methods of use thereof
|
USD860451S1
(en)
|
2016-06-02 |
2019-09-17 |
Intarcia Therapeutics, Inc. |
Implant removal tool
|
USD840030S1
(en)
|
2016-06-02 |
2019-02-05 |
Intarcia Therapeutics, Inc. |
Implant placement guide
|
DK3468997T3
(da)
|
2016-06-08 |
2023-10-02 |
Xencor Inc |
Behandling af IgG4-relaterede sygdomme med anti-CD9-antistoffer med tværbinding til CD32B
|
WO2017222834A1
(en)
|
2016-06-10 |
2017-12-28 |
City Of Hope |
Compositions and methods for mitochondrial genome editing
|
RU2022104399A
(ru)
|
2016-06-14 |
2022-05-05 |
Ксенкор, Инк. |
Биспецифические антитела-ингибиторы контрольных точек
|
WO2017216280A1
(en)
|
2016-06-16 |
2017-12-21 |
F. Hoffmann-La Roche Ag |
TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
|
JP7018026B2
(ja)
|
2016-06-16 |
2022-02-09 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
ヘテロアリールエストロゲン受容体モジュレーター及びその使用
|
US10183058B2
(en)
|
2016-06-17 |
2019-01-22 |
Nymox Corporation |
Method of preventing or reducing the progression of prostate cancer
|
CN116063545A
(zh)
|
2016-06-28 |
2023-05-05 |
Xencor股份有限公司 |
结合生长抑素受体2的异源二聚抗体
|
CA3029281A1
(en)
|
2016-06-29 |
2018-01-04 |
Otonomy, Inc. |
Triglyceride otic formulations and uses thereof
|
CA3029627A1
(en)
|
2016-07-01 |
2018-01-04 |
Resolve Therapeutics, Llc |
Optimized binuclease fusions and methods
|
JP7033583B2
(ja)
|
2016-07-13 |
2022-03-10 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
ゲノム編集効率を高めるための方法、組成物及びキット
|
WO2018013797A1
(en)
|
2016-07-13 |
2018-01-18 |
President And Fellows Of Harvard College |
Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
|
CN109715670A
(zh)
|
2016-07-15 |
2019-05-03 |
波赛达治疗公司 |
对muc1特异性的嵌合抗原受体(car)及其使用方法
|
WO2018014038A1
(en)
|
2016-07-15 |
2018-01-18 |
Poseida Therapeutics, Inc. |
Chimeric antigen receptors and methods for use
|
US10300145B2
(en)
|
2016-07-15 |
2019-05-28 |
Massachusetts Institute Of Technology |
Synthetic nanoparticles for delivery of immunomodulatory compounds
|
CA3030834A1
(en)
|
2016-07-15 |
2018-01-18 |
Takeda Pharmaceutical Company Limited |
Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies
|
JP6975515B2
(ja)
|
2016-07-20 |
2021-12-01 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
Trpa1モデュレーターとしてのスルホニルシクロアルキルカルボキサミド化合物
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
EP3487853B1
(en)
|
2016-07-20 |
2022-06-08 |
F. Hoffmann-La Roche AG |
Bicyclic proline compounds
|
US11339178B2
(en)
|
2016-07-21 |
2022-05-24 |
The University Of North Carolina At Chapel Hill |
Inhibitors of microbial beta-glucuronidase enzymes and uses thereof
|
WO2018015466A1
(en)
|
2016-07-22 |
2018-01-25 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Virucidal metallic nanoparticles and uses thereof
|
KR102534568B1
(ko)
|
2016-07-22 |
2023-05-18 |
다나-파버 캔서 인스티튜트 인크. |
글루코코르티코이드-유도된 종양 괴사 인자 수용체 (gitr) 항체 및 이의 이용 방법
|
US20190275073A1
(en)
|
2016-07-22 |
2019-09-12 |
Ecole polytechnique fédérale de Lausanne (EPFL) |
Virucidal compounds and uses thereof
|
WO2018022933A1
(en)
|
2016-07-27 |
2018-02-01 |
Obi Pharma, Inc. |
Immunogenic/therapeutic glycan compositions and uses thereof
|
US10172910B2
(en)
|
2016-07-28 |
2019-01-08 |
Nymox Corporation |
Method of preventing or reducing the incidence of acute urinary retention
|
US11643456B2
(en)
|
2016-07-29 |
2023-05-09 |
Obi Pharma, Inc. |
Human antibodies, pharmaceutical compositions and methods
|
EP3493848B1
(en)
|
2016-08-02 |
2021-09-29 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Heterocyclic diamidines
|
EP3494139B1
(en)
|
2016-08-05 |
2022-01-12 |
F. Hoffmann-La Roche AG |
Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
|
JP2019527710A
(ja)
|
2016-08-08 |
2019-10-03 |
アムジエン・インコーポレーテツド |
抗スクレロスチン抗体を用いた結合組織付着の改善方法
|
EP3497093B1
(en)
|
2016-08-12 |
2021-09-15 |
F. Hoffmann-La Roche AG |
Sulfonyl pyridyl trp inhibitors
|
CA3034057A1
(en)
|
2016-08-22 |
2018-03-01 |
CHO Pharma Inc. |
Antibodies, binding fragments, and methods of use
|
JP2019526559A
(ja)
|
2016-08-23 |
2019-09-19 |
ジェネンテック, インコーポレイテッド |
膵がん治療のための組み合わせ治療薬
|
JP7140751B2
(ja)
|
2016-08-24 |
2022-09-21 |
エフ.ホフマン-ラ ロシュ アーゲー |
2-アザビシクロ[3.1.0]ヘキサン-3-オン誘導体及び使用方法
|
JP7138093B2
(ja)
|
2016-08-24 |
2022-09-15 |
エフ.ホフマン-ラ ロシュ アーゲー |
2-アザビシクロ[3.1.0]ヘキサン-3-オン誘導体及び使用方法
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
SI3506921T1
(sl)
|
2016-08-31 |
2023-10-30 |
Mapi Pharma Ltd. |
Depojski sistemi, ki vsebujejo glatiramer acetat
|
WO2018044970A1
(en)
|
2016-08-31 |
2018-03-08 |
University Of Rochester |
Human monoclonal antibodies to human endogenous retrovirus k envelope (herv-k) and uses thereof
|
PT3507291T
(pt)
|
2016-09-02 |
2021-08-30 |
Cyclerion Therapeutics Inc |
Estimulantes de sgc bicíclicos fundidos
|
SG11201901961SA
(en)
|
2016-09-06 |
2019-04-29 |
Chugai Pharmaceutical Co Ltd |
Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x
|
US10532081B2
(en)
|
2016-09-07 |
2020-01-14 |
Nymox Corporation |
Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
|
WO2018049275A1
(en)
|
2016-09-09 |
2018-03-15 |
Genentech, Inc. |
Selective peptide inhibitors of frizzled
|
US11236177B2
(en)
|
2016-09-14 |
2022-02-01 |
The Trustees Of The University Of Pennsylvania |
Proximity-based sortase-mediated protein purification and ligation
|
EP3512832B1
(en)
|
2016-09-16 |
2021-05-19 |
Research Triangle Institute |
Tetrahydroisoquinoline kappa opioid antagonists
|
WO2018052818A1
(en)
|
2016-09-16 |
2018-03-22 |
Henlix, Inc. |
Anti-pd-1 antibodies
|
EP3515488A1
(en)
|
2016-09-23 |
2019-07-31 |
Teva Pharmaceuticals International GmbH |
Treating cluster headache
|
CN109952314A
(zh)
|
2016-09-23 |
2019-06-28 |
泰瓦制药国际有限公司 |
治疗难治性偏头痛
|
KR20190072528A
(ko)
|
2016-10-06 |
2019-06-25 |
제넨테크, 인크. |
암에 대한 치료 및 진단 방법
|
US20200016202A1
(en)
|
2016-10-07 |
2020-01-16 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
KR102649972B1
(ko)
|
2016-10-14 |
2024-03-22 |
젠코어 인코포레이티드 |
IL15/IL15Rα 이종이량체 Fc-융합 단백질
|
CN109843886B
(zh)
|
2016-10-17 |
2022-04-19 |
豪夫迈·罗氏有限公司 |
二环吡啶酮内酰胺及其使用方法
|
US10738338B2
(en)
|
2016-10-18 |
2020-08-11 |
The Research Foundation for the State University |
Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
|
EP3529268A1
(en)
|
2016-10-19 |
2019-08-28 |
The Scripps Research Institute |
Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
|
WO2018078031A1
(en)
|
2016-10-28 |
2018-05-03 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Methods of derivation and/or propagation of epithelial cells
|
WO2018083248A1
(en)
|
2016-11-03 |
2018-05-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
MX2019004775A
(es)
|
2016-11-03 |
2019-08-05 |
Squibb Bristol Myers Co |
Anticuerpos anti antigeno 4 del linfocito t citotoxico (ctla-4) activables y sus usos.
|
CA3040812A1
(en)
|
2016-11-04 |
2018-05-11 |
Novimmune Sa |
Anti-cd19 antibodies and methods of use thereof
|
US11180493B2
(en)
|
2016-11-08 |
2021-11-23 |
Cyclerion Therapeutics, Inc. |
SGC stimulators
|
EA201991147A1
(ru)
|
2016-11-08 |
2019-11-29 |
|
ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ ЦЕНТРАЛЬНОЙ НЕРВНОЙ СИСТЕМЫ С ПОМОЩЬЮ СТИМУЛЯТОРОВ sGC
|
US20200024347A1
(en)
|
2016-11-10 |
2020-01-23 |
Iomx Therapeutics Ag |
Or10h1 antigen binding proteins and uses thereof
|
JP2020511401A
(ja)
|
2016-11-14 |
2020-04-16 |
チェム−フォルシュングスツェントルン フュル モレクラーレ メディツィン ゲゼルシャフト ミット ベシュレンクテル ハフツング |
癌の治療法のためのbrd4阻害剤と葉酸代謝拮抗薬との組み合わせ物
|
US20230137351A1
(en)
|
2016-11-14 |
2023-05-04 |
Amgen Inc. |
Bispecific or biparatopic antigen binding proteins and uses thereof
|
US10646540B2
(en)
|
2016-11-18 |
2020-05-12 |
City Of Hope |
Peptide inhibitors of twist
|
WO2018094414A1
(en)
|
2016-11-21 |
2018-05-24 |
Obi Pharma, Inc. |
Conjugated biological molecules, pharmaceutical compositions and methods
|
JP7126500B2
(ja)
|
2016-11-22 |
2022-08-26 |
エフ.ホフマン-ラ ロシュ アーゲー |
抗体薬物コンジュゲート
|
EP3544979B1
(en)
|
2016-11-28 |
2021-08-04 |
F. Hoffmann-La Roche AG |
Oxadiazolones as transient receptor potential channel inhibitors
|
EP3548488A1
(en)
|
2016-11-30 |
2019-10-09 |
Oncotyrol Center for Personalized Cancer Medicine GmbH |
3-amino-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-ones as cyclin dependent kinase inhibitors
|
CN110023313B
(zh)
|
2016-12-02 |
2022-10-25 |
豪夫迈·罗氏有限公司 |
二环酰胺化合物及其使用方法
|
WO2018111795A2
(en)
|
2016-12-13 |
2018-06-21 |
Ironwood Pharmaceuticals, Inc. |
Use of sgc stimulators for the treatment of esophageal motility disorders
|
CN117045784A
(zh)
|
2016-12-14 |
2023-11-14 |
比奥拉治疗股份有限公司 |
使用利用可摄入装置释放的il-12/il-23抑制剂治疗胃肠道疾病
|
WO2018112256A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor
|
MX2019006864A
(es)
|
2016-12-14 |
2019-10-15 |
Progenity Inc |
Tratamiento de una enfermedad del tracto gastrointestinal con un inhibidor de factor de necrosis tumoral (tnf).
|
BR112019012062A2
(pt)
|
2016-12-14 |
2019-11-12 |
Progenity Inc |
tratamento de uma doença do trato gastrointestinal com um inibidor de jak e dispositivos
|
WO2018112264A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
|
EP3554346B1
(en)
|
2016-12-14 |
2024-01-31 |
Biora Therapeutics, Inc. |
Treatment of a disease of the gastrointestinal tract with an immunosuppressant
|
WO2018112235A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with a smad7 inhibitor
|
WO2018112237A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor
|
WO2018112223A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with a tlr modulator
|
KR20190095936A
(ko)
|
2016-12-14 |
2019-08-16 |
프로제너티, 인크. |
인테그린 저해제로의 위장관 질환의 치료
|
CN110114079A
(zh)
|
2016-12-15 |
2019-08-09 |
泰伦基国际有限公司 |
一种预防和治疗肥胖症的方法和药物
|
CN110366427A
(zh)
|
2016-12-15 |
2019-10-22 |
泰伦基国际有限公司 |
一种预防和治疗病理性肾组织损伤的方法
|
WO2018107687A1
(zh)
|
2016-12-15 |
2018-06-21 |
深圳瑞健生命科学研究院有限公司 |
一种预防和治疗高脂血症的方法
|
JP7313058B2
(ja)
|
2016-12-15 |
2023-07-24 |
タレンゲン インターナショナル リミテッド |
組織器官の繊維化を予防及び治療するための方法
|
CN110402150A
(zh)
|
2016-12-15 |
2019-11-01 |
泰伦基国际有限公司 |
一种预防和治疗骨质疏松的药物及其用途
|
CA3047175A1
(en)
|
2016-12-15 |
2018-06-21 |
Talengen International Limited |
Method for mitigating heart disease
|
EP3556384B1
(en)
|
2016-12-15 |
2024-04-10 |
Talengen International Limited |
Plasminogen for use in treating diabetes
|
PE20191501A1
(es)
|
2016-12-16 |
2019-10-22 |
Pfizer |
Agonistas receptores de glp-1 y sus usos de los mismos
|
US11072607B2
(en)
|
2016-12-16 |
2021-07-27 |
Genentech, Inc. |
Inhibitors of RIP1 kinase and methods of use thereof
|
WO2018119395A1
(en)
|
2016-12-23 |
2018-06-28 |
Aquinnah Pharmaceuticals, Inc. |
Compouns, compositions and methods of use
|
AU2018206539A1
(en)
|
2017-01-03 |
2019-07-18 |
Intarcia Therapeutics, Inc. |
Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
|
WO2018129395A1
(en)
|
2017-01-06 |
2018-07-12 |
Scholar Rock, Inc. |
Methods for treating metabolic diseases by inhibiting myostatin activation
|
WO2018128454A1
(ko)
|
2017-01-06 |
2018-07-12 |
에이비엘바이오 주식회사 |
항 α-SYN 항체 및 그 용도
|
WO2018129329A1
(en)
|
2017-01-06 |
2018-07-12 |
Scholar Rock, Inc. |
ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFβ1 INHIBITORS AND USE THEREOF
|
DK3565592T3
(da)
|
2017-01-06 |
2023-05-01 |
Scholar Rock Inc |
Behandling af stofskiftesygdomme ved inhibering af myostatinaktivering
|
US11529391B2
(en)
|
2017-01-09 |
2022-12-20 |
The Board Of Trustees Of The Leland Stanford Junior University |
Reversing deficient hedgehog signaling restores deficient skeletal regeneration
|
WO2018129522A1
(en)
|
2017-01-09 |
2018-07-12 |
Torch Therapeutics |
Conditionally effective bispecific therapeutics
|
US20190328792A1
(en)
|
2017-01-11 |
2019-10-31 |
Paracelsus Medizinische Privatuniversität Salzburg - Privatstiftung |
Mesenchymal stem cell-derived extracellular vesicles and their medical use
|
TW201831517A
(zh)
|
2017-01-12 |
2018-09-01 |
美商優瑞科生物技術公司 |
靶向組織蛋白h3肽/mhc複合體之構築體及其用途
|
JOP20190177A1
(ar)
|
2017-01-17 |
2019-07-16 |
Amgen Inc |
طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
|
CN111356456A
(zh)
|
2017-01-23 |
2020-06-30 |
夏威夷大学 |
2-芳基磺酰胺基-iV-芳基乙酰胺衍生的Stat3抑制剂
|
EP3574016A2
(en)
|
2017-01-24 |
2019-12-04 |
Innate Pharma |
NKp46 BINDING AGENTS
|
CA3051484A1
(en)
|
2017-01-27 |
2018-08-02 |
Memorial Sloan Kettering Cancer Center |
Bispecific her2 and cd3 binding molecules
|
CN110234351A
(zh)
|
2017-01-30 |
2019-09-13 |
詹森生物科技公司 |
用于治疗活动性银屑病关节炎的抗tnf抗体、组合物和方法
|
JOP20190189A1
(ar)
|
2017-02-02 |
2019-08-01 |
Amgen Res Munich Gmbh |
تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
|
JP2020506947A
(ja)
|
2017-02-07 |
2020-03-05 |
ヤンセン バイオテツク,インコーポレーテツド |
活動性強直性脊椎炎を治療するための抗tnf抗体、組成物、及び方法
|
US10266578B2
(en)
|
2017-02-08 |
2019-04-23 |
Bristol-Myers Squibb Company |
Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
|
US11028166B2
(en)
|
2017-02-16 |
2021-06-08 |
Sonnet Bio Therapeutics |
Albumin binding domain fusion proteins
|
WO2018152496A1
(en)
|
2017-02-17 |
2018-08-23 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Compositions and methods for the diagnosis and treatment of zika virus infection
|
WO2018160538A1
(en)
|
2017-02-28 |
2018-09-07 |
Mersana Therapeutics, Inc. |
Combination therapies of her2-targeted antibody-drug conjugates
|
US10335453B2
(en)
|
2017-03-01 |
2019-07-02 |
Nymox Corporation |
Compositions and methods for improving sexual function
|
TW201837467A
(zh)
|
2017-03-01 |
2018-10-16 |
美商建南德克公司 |
用於癌症之診斷及治療方法
|
AU2018226646A1
(en)
|
2017-03-03 |
2019-09-19 |
Rinat Neuroscience Corp. |
Anti-GITR antibodies and methods of use thereof
|
US11021529B2
(en)
|
2017-03-03 |
2021-06-01 |
Massachusetts Institute Of Technology |
Antimicrobial constructs and uses thereof
|
CN110461838B
(zh)
|
2017-03-07 |
2022-05-06 |
豪夫迈·罗氏有限公司 |
噁二唑瞬时受体电位通道抑制剂
|
KR20190134654A
(ko)
|
2017-03-09 |
2019-12-04 |
싸이톰스 테라퓨틱스, 인크. |
Cd147 항체, 활성화가능한 cd147 항체, 그리고 이를 만들고, 이용하는 방법
|
US10421968B2
(en)
|
2017-03-15 |
2019-09-24 |
Versitech Limited |
Amphiphilic dendrimers complexed with siRNA for treatment of cancer
|
JP2020511511A
(ja)
|
2017-03-24 |
2020-04-16 |
ジェネンテック, インコーポレイテッド |
ナトリウムチャネル阻害剤としての4−ピペリジン−n−(ピリミジン−4−イル)クロマン−7−スルホンアミド誘導体
|
EP3600553A4
(en)
|
2017-03-26 |
2020-09-02 |
Mapi Pharma Ltd. |
GLATIRAMER DEPOT SYSTEMS FOR TREATMENT OF PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS
|
MA48994A
(fr)
|
2017-03-30 |
2020-02-05 |
Hoffmann La Roche |
Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1
|
AU2018244922A1
(en)
|
2017-03-30 |
2019-09-12 |
Biora Therapeutics, Inc. |
Treatment of a disease of the gastrointestinal tract with live biotherapeutics
|
WO2018183929A1
(en)
|
2017-03-30 |
2018-10-04 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
|
EP3600249A1
(en)
|
2017-03-30 |
2020-02-05 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with a chst15 inhibitor
|
CA3054156A1
(en)
|
2017-03-30 |
2018-10-04 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with il-10 or an il-10 agonist
|
WO2018183956A1
(en)
|
2017-03-30 |
2018-10-04 |
Genentech, Inc. |
Naphthyridines as inhibitors of hpk1
|
WO2018183932A1
(en)
|
2017-03-30 |
2018-10-04 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor
|
WO2018183370A2
(en)
|
2017-03-30 |
2018-10-04 |
Albert-Ludwigs-University Freiburg |
Kdm4 inhibitors
|
MY200973A
(en)
|
2017-04-11 |
2024-01-26 |
Inhibrx Inc |
Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same
|
JP2020512825A
(ja)
|
2017-04-12 |
2020-04-30 |
ファイザー・インク |
条件的親和性を有する抗体およびその使用の方法
|
EP3615569A1
(en)
|
2017-04-25 |
2020-03-04 |
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services |
Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
|
KR102663596B1
(ko)
|
2017-04-26 |
2024-05-10 |
유레카 쎄라퓨틱스, 인코포레이티드 |
글리피칸 3을 특이적으로 인식하는 구축물 및 그의 용도
|
WO2018203545A1
(ja)
|
2017-05-02 |
2018-11-08 |
国立研究開発法人国立精神・神経医療研究センター |
Il-6及び好中球の関連する疾患の治療効果の予測及び判定方法
|
MX2019013157A
(es)
|
2017-05-04 |
2020-08-03 |
Helsingin Yliopisto |
Fragmentos de cdnf y manf c-terminales, composiciones farmaceuticas que los comprenden y usos de los mismos.
|
AU2018261951A1
(en)
|
2017-05-05 |
2019-10-31 |
Amgen Inc. |
Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration
|
JP7283699B2
(ja)
|
2017-05-12 |
2023-05-30 |
マックス-プランク-ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ |
黒色腫の治療または予防において使用するためのフェニル-ヘテロ環-フェニル誘導体
|
US11472806B2
(en)
|
2017-05-12 |
2022-10-18 |
Domain Therapeutics |
Substituted heterocyclic compounds as allosteric modulators of group II metabotropic glutamate receptors
|
EP3630167A1
(en)
|
2017-05-26 |
2020-04-08 |
NovImmune SA |
Anti-cd47 x anti-mesothelin antibodies and methods of use thereof
|
JOP20190259A1
(ar)
|
2017-05-31 |
2019-10-31 |
Amgen Inc |
بروتينات ربط مولد ضد مضادة لـ jagged1
|
US11168144B2
(en)
|
2017-06-01 |
2021-11-09 |
Cytomx Therapeutics, Inc. |
Activatable anti-PDL1 antibodies, and methods of use thereof
|
AR111842A1
(es)
|
2017-06-02 |
2019-08-21 |
Amgen Inc |
Antagonistas de péptido pac1
|
CN111344004A
(zh)
|
2017-06-19 |
2020-06-26 |
泰伦基国际有限公司 |
一种调控glp-1/glp-1r 的方法和药物
|
WO2018236904A1
(en)
|
2017-06-19 |
2018-12-27 |
Surface Oncology, Inc. |
COMBINATION OF ANTI-CD47 ANTIBODIES AND CELL DEATH INDUCING AGENTS, AND USES THEREOF
|
PE20200013A1
(es)
|
2017-06-20 |
2020-01-06 |
Amgen Inc |
Metodo para tratar o mejorar trastornos metabolicos con proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1
|
WO2019000223A1
(en)
|
2017-06-27 |
2019-01-03 |
Nanjing Legend Biotech Co., Ltd. |
ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
|
CA3067603A1
(en)
|
2017-06-30 |
2019-01-03 |
Xencor, Inc. |
Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and antigen binding domains
|
TWI820031B
(zh)
|
2017-07-11 |
2023-11-01 |
美商坎伯斯治療有限責任公司 |
結合人類cd137之促效劑抗體及其用途
|
JP2020527558A
(ja)
|
2017-07-13 |
2020-09-10 |
マサチューセッツ インスティテュート オブ テクノロジー |
シナプス機能を増強するためのhdac2−sp3複合体の標的化
|
RS65308B1
(sr)
|
2017-07-14 |
2024-04-30 |
Hoffmann La Roche |
Biciklična ketonska jedinjenja i postupci za njihovu upotrebu
|
EP3655430A1
(en)
|
2017-07-19 |
2020-05-27 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection
|
WO2019018691A1
(en)
|
2017-07-19 |
2019-01-24 |
Auckland Uniservices Limited |
MODULATION OF CYTOKINE
|
TWI823859B
(zh)
|
2017-07-21 |
2023-12-01 |
美商建南德克公司 |
癌症之治療及診斷方法
|
WO2019016784A1
(en)
|
2017-07-21 |
2019-01-24 |
Universidade De Coimbra |
ANTI-NUCLEOLIN ANTIBODIES
|
EP3658584A1
(en)
|
2017-07-26 |
2020-06-03 |
H. Hoffnabb-La Roche Ag |
Combination therapy with a bet inhibitor, a bcl-2 inhibitor and an anti-cd20 antibody
|
EP3658188A1
(en)
|
2017-07-26 |
2020-06-03 |
H. Hoffnabb-La Roche Ag |
Combination therapy with a bet inhibitor and a bcl-2 inhibitor
|
WO2019023661A1
(en)
|
2017-07-28 |
2019-01-31 |
Scholar Rock, Inc. |
SPECIFIC INHIBITORS OF TGF-BETA 1 LTBP COMPLEX AND USES THEREOF
|
EP3665202A1
(en)
|
2017-08-09 |
2020-06-17 |
Massachusetts Institute Of Technology |
Albumin binding peptide conjugates and methods thereof
|
WO2019036363A1
(en)
|
2017-08-14 |
2019-02-21 |
Progenity Inc. |
TREATMENT OF GASTROINTESTINAL TRACT DISEASE WITH GLATIRAMER OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
|
WO2019036605A2
(en)
|
2017-08-17 |
2019-02-21 |
Massachusetts Institute Of Technology |
MULTIPLE SPECIFICITY BINDING AGENTS OF CXC CHEMOKINES AND USES THEREOF
|
AU2018321359B2
(en)
|
2017-08-22 |
2023-11-30 |
Sanabio, Llc |
Soluble interferon receptors and uses thereof
|
BR112020004231A2
(pt)
|
2017-08-30 |
2020-09-08 |
Cytomx Therapeutics, Inc. |
anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos
|
MX2020002901A
(es)
|
2017-09-19 |
2020-07-22 |
Massachusetts Inst Technology |
Composiciones para la terapia con celulas t con receptores de antigeno quimerico y usos de las mismas.
|
US11364303B2
(en)
|
2017-09-29 |
2022-06-21 |
Pfizer Inc. |
Cysteine engineered antibody drug conjugates
|
EP3692061A1
(en)
|
2017-10-04 |
2020-08-12 |
Amgen Inc. |
Transthyretin immunoglobulin fusions
|
MX2020003439A
(es)
|
2017-10-11 |
2020-07-29 |
Hoffmann La Roche |
Compuestos biciclicos para usarse como inhibidores de cinasa de la proteina 1 de interaccion con receptores (rip1).
|
US11912754B2
(en)
|
2017-10-12 |
2024-02-27 |
Immunowake Inc. |
VEGFR-antibody light chain fusion protein
|
CA3078911A1
(en)
|
2017-10-14 |
2019-04-18 |
Cytomx Therapeutics, Inc. |
Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
|
US10336724B2
(en)
|
2017-10-18 |
2019-07-02 |
Syneurx International (Taiwan) Corp. |
D-amino acid oxidase inhibitors and therapeutic uses thereof
|
US11692037B2
(en)
|
2017-10-20 |
2023-07-04 |
Hyogo College Of Medicine |
Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
|
US11897969B2
(en)
|
2017-10-26 |
2024-02-13 |
The Regents Of The University Of California |
Inhibition of oxidation-specific epitopes to treat ischemic reperfusion injury
|
MX2020004381A
(es)
|
2017-10-27 |
2020-08-20 |
Pfizer |
Anticuerpos y conjugados de anticuerpo-farmaco especificos para cd123 y usos de los mismos.
|
MA50536A
(fr)
|
2017-10-30 |
2020-09-09 |
Enterin Inc |
Nouvelles formes solides de squalamine et procédés pour les produire
|
JP7438942B2
(ja)
|
2017-10-30 |
2024-02-27 |
エフ. ホフマン-ラ ロシュ アーゲー |
単一特異性抗体から多重特異性抗体をインビボ生成させるための方法
|
US11718679B2
(en)
|
2017-10-31 |
2023-08-08 |
Compass Therapeutics Llc |
CD137 antibodies and PD-1 antagonists and uses thereof
|
SG11202002877RA
(en)
|
2017-10-31 |
2020-04-29 |
Hoffmann La Roche |
Bicyclic sulfones and sulfoxides and methods of use thereof
|
EP3707510B1
(en)
|
2017-11-06 |
2024-06-26 |
F. Hoffmann-La Roche AG |
Diagnostic and therapeutic methods for cancer
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
AU2018366199A1
(en)
|
2017-11-08 |
2020-05-28 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-PD-1 sequences
|
US11851497B2
(en)
|
2017-11-20 |
2023-12-26 |
Compass Therapeutics Llc |
CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
GB2568526A
(en)
*
|
2017-11-20 |
2019-05-22 |
Rebio Tech Oy |
Composition
|
EP3713545A1
(en)
|
2017-11-22 |
2020-09-30 |
Dauntless 1, Inc. |
Therapeutic compound formulations
|
EP3713660A1
(en)
|
2017-11-22 |
2020-09-30 |
Dauntless 1, Inc. |
Membrane emulsification device for microsphere creation
|
WO2019110139A1
(en)
|
2017-12-05 |
2019-06-13 |
Eth Zurich |
New compounds for use as a therapeutically active substance and in particular for use in the treatment of tumors
|
JP7344206B2
(ja)
|
2017-12-11 |
2023-09-13 |
アムジェン インコーポレイテッド |
二重特異性抗体製品のための連続製造プロセス
|
JP7214245B2
(ja)
|
2017-12-15 |
2023-01-30 |
タレンゲン インターナショナル リミテッド |
骨関節炎を予防または治療するための方法および薬剤
|
BR112020013714A2
(pt)
|
2017-12-15 |
2020-12-01 |
The Australian National University |
compostos para tratamento e prevenção de patologias mediadas por histona extracelular
|
EP3728310A1
(en)
|
2017-12-18 |
2020-10-28 |
VIIV Healthcare UK (No.5) Limited |
Antigen binding polypeptides
|
CA3086199A1
(en)
|
2017-12-19 |
2019-06-27 |
Xencor, Inc. |
Engineered il-2 fc fusion proteins
|
CN111741767A
(zh)
|
2017-12-19 |
2020-10-02 |
麻省理工学院 |
抗原-佐剂偶联剂和使用方法
|
AU2018393110B2
(en)
|
2017-12-20 |
2023-04-27 |
Poseida Therapeutics, Inc. |
VCAR compositions and methods for use
|
TW201930350A
(zh)
|
2017-12-28 |
2019-08-01 |
大陸商南京傳奇生物科技有限公司 |
針對pd-l1之抗體及其變異體
|
KR20200104333A
(ko)
|
2017-12-28 |
2020-09-03 |
난징 레전드 바이오테크 씨오., 엘티디. |
Tigit에 대한 단일-도메인 항체 및 이의 변이체
|
UY38041A
(es)
|
2017-12-29 |
2019-06-28 |
Amgen Inc |
Construcción de anticuerpo biespecífico dirigida a muc17 y cd3
|
EP3737699A1
(en)
|
2018-01-12 |
2020-11-18 |
Amgen Inc. |
Pac1 antibodies and uses thereof
|
CA3084518A1
(en)
|
2018-01-15 |
2019-07-18 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against pd-1
|
AU2019209293B2
(en)
|
2018-01-17 |
2023-07-27 |
Vertex Pharmaceuticals Incorporated |
DNA-PK inhibitors
|
US20200361877A1
(en)
|
2018-01-17 |
2020-11-19 |
Vertex Pharmaceuticals Incorporated |
Quinoxalinone compounds, compositions, methods, and kits for increasing genome editing efficiency
|
EP3728638A1
(en)
|
2018-01-24 |
2020-10-28 |
Genentech, Inc. |
Diagnostic and therapeutic methods for the treatment of rheumatoid arthritis (ra)
|
WO2019147824A1
(en)
|
2018-01-26 |
2019-08-01 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
|
RS63812B1
(sr)
|
2018-01-26 |
2023-01-31 |
Hoffmann La Roche |
Il-22 fc kompozicije i postupci primene
|
EP3743437A1
(en)
|
2018-01-26 |
2020-12-02 |
F. Hoffmann-La Roche AG |
Il-22 fc fusion proteins and methods of use
|
TWI822728B
(zh)
|
2018-01-31 |
2023-11-21 |
加藤元一 |
含有il-6抑制劑的哮喘治療劑
|
EP3749361A1
(en)
|
2018-02-08 |
2020-12-16 |
F. Hoffmann-La Roche AG |
Bispecific antigen-binding molecules and methods of use
|
KR20230142806A
(ko)
|
2018-02-09 |
2023-10-11 |
제넨테크, 인크. |
비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법
|
RU2758378C1
(ru)
|
2018-02-09 |
2021-10-28 |
Галдерма Холдинг СА |
Немолизумаб в лечении атопического дерматита с экскориацией от умеренной до тяжелой
|
AR114585A1
(es)
|
2018-02-20 |
2020-09-23 |
Hoffmann La Roche |
Proceso para preparar compuestos antagonistas de canales potenciales transitorios del receptor de 1-arilsulfonil-pirrolidin-2-carboxamida y formas cristalinas de los mismos
|
WO2019165140A1
(en)
|
2018-02-21 |
2019-08-29 |
Genentech, Inc. |
DOSING FOR TREATMENT WITH IL-22 Fc FUSION PROTEINS
|
TW202000651A
(zh)
|
2018-02-26 |
2020-01-01 |
美商建南德克公司 |
治療性組成物及其使用方法
|
JP2021516045A
(ja)
|
2018-02-28 |
2021-07-01 |
ファイザー・インク |
Il−15バリアントおよびその使用
|
WO2019173771A1
(en)
|
2018-03-09 |
2019-09-12 |
Cytomx Therapeutics, Inc. |
Activatable cd147 antibodies and methods of making and use thereof
|
CN112334484A
(zh)
|
2018-03-14 |
2021-02-05 |
诺维莫尼公司 |
抗-CD3ε抗体及其应用方法
|
JP7037218B2
(ja)
|
2018-03-14 |
2022-03-16 |
サーフィス オンコロジー インコーポレイテッド |
Cd39と結合する抗体及びその使用
|
US10710994B2
(en)
|
2018-03-19 |
2020-07-14 |
Genentech, Inc. |
Oxadiazole transient receptor potential channel inhibitors
|
CA3093740A1
(en)
|
2018-03-22 |
2019-09-26 |
Surface Oncology, Inc. |
Anti-il-27 antibodies and uses thereof
|
EP3774858A1
(en)
|
2018-03-29 |
2021-02-17 |
Helsingin Yliopisto |
C-terminal cdnf fragments, pharmaceutical compositions comprising same and uses thereof
|
EP3774879A1
(en)
|
2018-03-30 |
2021-02-17 |
Amgen Inc. |
C-terminal antibody variants
|
US10947251B2
(en)
|
2018-03-30 |
2021-03-16 |
Genentech, Inc. |
Therapeutic compounds and methods of use thereof
|
US11958903B2
(en)
|
2018-03-30 |
2024-04-16 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies against LAG-3 and uses thereof
|
US10982006B2
(en)
|
2018-04-04 |
2021-04-20 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
WO2019195561A2
(en)
|
2018-04-06 |
2019-10-10 |
BioLegend, Inc. |
Anti-tetraspanin 33 agents and compositions and methods for making and using the same
|
CN112969692A
(zh)
|
2018-04-06 |
2021-06-15 |
兹伦汀公司 |
用于治疗多汗症的布美他尼衍生物
|
US20210163406A1
(en)
|
2018-04-06 |
2021-06-03 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Bumetanide Derivatives for the Therapy of Stroke and Other Neurological Diseases/Disorders Involving NKCCs
|
US20230143988A1
(en)
|
2018-04-09 |
2023-05-11 |
Amgen Inc. |
Growth differentiation factor 15 fusion proteins
|
EP3773913A1
(en)
|
2018-04-11 |
2021-02-17 |
Inhibrx, Inc. |
Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses
|
WO2019200357A1
(en)
|
2018-04-12 |
2019-10-17 |
Surface Oncology, Inc. |
Biomarker for cd47 targeting therapeutics and uses therefor
|
EP3774925A1
(en)
|
2018-04-13 |
2021-02-17 |
Institut national de la santé et de la recherche médicale (INSERM) |
Fc-engineered anti-human ige antibodies and methods of use
|
CN111989092A
(zh)
|
2018-04-18 |
2020-11-24 |
豪夫迈·罗氏有限公司 |
Bet抑制剂和蛋白酶体抑制剂的联合治疗
|
CA3097741A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
|
EP3781599A1
(en)
|
2018-04-18 |
2021-02-24 |
Xencor, Inc. |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
WO2019204743A1
(en)
|
2018-04-19 |
2019-10-24 |
Checkmate Pharmaceuticals, Inc. |
Synthetic rig-i-like receptor agonists
|
EP3781571B1
(en)
|
2018-04-20 |
2024-01-17 |
F. Hoffmann-La Roche AG |
N-[4-oxo-2,3-dihydro-pyrido[3,2-b][1,4]oxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazole-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs)
|
WO2019207051A1
(en)
|
2018-04-25 |
2019-10-31 |
Università Degli Studi Di Torino |
Medical use of combinations of non-natural semaphorins 3 and antimetabolites
|
US20210171610A1
(en)
|
2018-05-02 |
2021-06-10 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
|
WO2019213444A1
(en)
|
2018-05-02 |
2019-11-07 |
Cytomx Therapeutics, Inc. |
Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
|
WO2019217450A1
(en)
|
2018-05-08 |
2019-11-14 |
Rhode Island Hospital |
Anti-chi3l1 antibodies for the detection and/or treatment of nonalcoholic fattly liver disease/nonalcoholic steatohepatitis and subsequent complications
|
EP3790587A4
(en)
|
2018-05-11 |
2022-01-26 |
Janssen Biotech, Inc. |
METHOD OF TREATMENT OF DEPRESSION USING IL-23 ANTIBODIES
|
WO2019226658A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Multispecific antigen-binding compositions and methods of use
|
CA3099308A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Compositions and methods for enhancing the killing of target cells by nk cells
|
TW202003490A
(zh)
|
2018-05-22 |
2020-01-16 |
瑞士商赫孚孟拉羅股份公司 |
治療性化合物及其使用方法
|
AU2019274654B2
(en)
|
2018-05-23 |
2023-07-20 |
Pfizer Inc. |
Antibodies specific for CD3 and uses thereof
|
TWI803637B
(zh)
|
2018-05-23 |
2023-06-01 |
美商輝瑞大藥廠 |
特異性針對gucy2c之抗體及其用途
|
WO2019225787A1
(ko)
|
2018-05-24 |
2019-11-28 |
에이비엘바이오 주식회사 |
항-b7-h3 항체 및 그 용도
|
CN113101364B
(zh)
|
2018-05-29 |
2023-12-01 |
康诺亚生物医药科技(成都)有限公司 |
一种自免疫抑制剂的开发和应用
|
WO2019234680A1
(en)
|
2018-06-08 |
2019-12-12 |
Pfizer Inc. |
Methods of treating iron metabolic disease with a neutralizing antibody binding erhythroferrone
|
CN110577597B
(zh)
|
2018-06-11 |
2021-10-22 |
康诺亚生物医药科技(成都)有限公司 |
一种阻断CD47和SIRPα相互作用的抗体
|
TWI707683B
(zh)
|
2018-06-13 |
2020-10-21 |
美商輝瑞股份有限公司 |
Glp-1受體促效劑及其用途
|
PT3806855T
(pt)
|
2018-06-15 |
2023-05-03 |
Pfizer |
Agonistas dos receptores de glp-1 e suas utilizações
|
US11993661B2
(en)
|
2018-06-18 |
2024-05-28 |
Eureka Therapeutics, Inc. |
Constructs targeting prostate-specific membrane antigen (PSMA) and uses thereof
|
EP3810085A1
(en)
|
2018-06-20 |
2021-04-28 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
|
US20220257600A1
(en)
|
2018-06-20 |
2022-08-18 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor
|
WO2019246313A1
(en)
|
2018-06-20 |
2019-12-26 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
|
EP3810268A1
(en)
|
2018-06-20 |
2021-04-28 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
|
WO2019246317A1
(en)
|
2018-06-20 |
2019-12-26 |
Progenity, Inc. |
Treatment of a disease or condition in a tissue originating from the endoderm
|
WO2019246312A1
(en)
|
2018-06-20 |
2019-12-26 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an immunomodulator
|
WO2020005842A1
(en)
|
2018-06-25 |
2020-01-02 |
Dauntless 2, Inc. |
Membrane emulsification device with impeller for microsphere creation
|
TW202035444A
(zh)
|
2018-06-27 |
2020-10-01 |
台灣浩鼎生技股份有限公司 |
用於糖蛋白工程的糖苷合成酶變體及其使用方法
|
WO2020010079A2
(en)
|
2018-07-02 |
2020-01-09 |
Amgen Inc. |
Anti-steap1 antigen-binding protein
|
BR112020025701A2
(pt)
|
2018-07-06 |
2021-03-16 |
Pfizer Inc. |
Processo de produção e intermediários para um composto de pirrolo[2,3-d]pirimidina e seu uso
|
WO2020011938A1
(en)
|
2018-07-11 |
2020-01-16 |
Medizinische Universität Wien |
Glucocorticoids for the topical treatment of autoimmune gastritis
|
ES2905160T3
(es)
|
2018-07-11 |
2022-04-07 |
Scholar Rock Inc |
Inhibidores selectivos de la isoforma TGFBeta1 y utilización de los mismos
|
JP2021531254A
(ja)
|
2018-07-11 |
2021-11-18 |
スカラー ロック インコーポレイテッドScholar Rock, Inc. |
高親和性のアイソフォーム選択的TGFβ1阻害剤、およびその使用
|
US20210340238A1
(en)
|
2018-07-11 |
2021-11-04 |
Scholar Rock, Inc. |
TGFß1 INHIBITORS AND USE THEREOF
|
US20220275043A1
(en)
|
2018-07-17 |
2022-09-01 |
Massachusetts Institute Of Technology |
Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof
|
CN112740043A
(zh)
|
2018-07-20 |
2021-04-30 |
皮埃尔法布雷医药公司 |
Vista受体
|
CN112601584A
(zh)
|
2018-07-24 |
2021-04-02 |
豪夫迈·罗氏有限公司 |
异喹啉化合物及其用途
|
EP3826721B1
(en)
|
2018-07-24 |
2023-10-11 |
F. Hoffmann-La Roche AG |
Naphthyridine compounds and uses thereof
|
CN112789294A
(zh)
|
2018-07-24 |
2021-05-11 |
印希比股份有限公司 |
含有受限cd3结合结构域和受体结合区的多特异性多肽构建体及其使用方法
|
EP3833443A1
(en)
|
2018-08-09 |
2021-06-16 |
Compass Therapeutics LLC |
Antigen binding agents that bind cd277 and uses thereof
|
WO2020033925A2
(en)
|
2018-08-09 |
2020-02-13 |
Compass Therapeutics Llc |
Antibodies that bind cd277 and uses thereof
|
WO2020033926A2
(en)
|
2018-08-09 |
2020-02-13 |
Compass Therapeutics Llc |
Antibodies that bind cd277 and uses thereof
|
AU2019320072A1
(en)
|
2018-08-10 |
2021-02-25 |
Vertex Pharmaceuticals Incorporated |
Stem cell derived islet differentiation
|
CA3109090A1
(en)
|
2018-08-17 |
2020-02-20 |
F. Hoffmann-La Roche Ag |
Diagnostic and therapeutic methods for the treatment of breast cancer
|
SG11202101875VA
(en)
|
2018-08-28 |
2021-03-30 |
Ambrx Inc |
Anti-cd3 antibody folate bioconjugates and their uses
|
UY38349A
(es)
|
2018-08-30 |
2020-03-31 |
Array Biopharma Inc |
Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met
|
WO2020051099A1
(en)
|
2018-09-03 |
2020-03-12 |
Genentech, Inc. |
Carboxamide and sulfonamide derivatives useful as tead modulators
|
CA3110766A1
(en)
|
2018-09-04 |
2020-03-12 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Virucidal nanoparticles and use thereof against influenza virus
|
CA3111576A1
(en)
|
2018-09-11 |
2020-03-19 |
Ambrx, Inc. |
Interleukin-2 polypeptide conjugates and their uses
|
US20220048888A1
(en)
|
2018-09-12 |
2022-02-17 |
Genentech, Inc. |
Pyrimidinyl-heteroaryloxy-naphthyl compounds and methods of use
|
WO2020053808A1
(en)
|
2018-09-12 |
2020-03-19 |
Georg Dewald |
Method of diagnosing vasoregulatory disorders
|
TWI831829B
(zh)
|
2018-09-12 |
2024-02-11 |
美商建南德克公司 |
苯氧基-吡啶基-嘧啶化合物及使用方法
|
JP7486478B2
(ja)
|
2018-09-19 |
2024-05-17 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
スピロ環状2,3-ジヒドロ-7-アザインドール化合物およびその使用
|
WO2020061060A1
(en)
|
2018-09-19 |
2020-03-26 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
EP3852784A1
(en)
|
2018-09-20 |
2021-07-28 |
Mandalmed, Inc. |
Methods and compositions for preventing, treating, and reversing liver fibrosis
|
CN113365697A
(zh)
|
2018-09-25 |
2021-09-07 |
百进生物科技公司 |
抗tlr9药剂和组合物及其制备方法和使用方法
|
WO2020065409A2
(en)
|
2018-09-28 |
2020-04-02 |
Lyvgen Biopharma Co., Ltd. |
Anti-cd40 binding molecules having engineered fc domains and therapeutic uses thereof
|
US20200102370A1
(en)
|
2018-09-28 |
2020-04-02 |
Massachusetts Institute Of Technology |
Collagen-localized immunomodulatory molecules and methods thereof
|
EP3856724A1
(en)
|
2018-09-30 |
2021-08-04 |
F. Hoffmann-La Roche AG |
Cinnoline compounds and for the treatment of hpk1-dependent disorders such as cancer
|
TW202024053A
(zh)
|
2018-10-02 |
2020-07-01 |
美商建南德克公司 |
異喹啉化合物及其用途
|
WO2020072821A2
(en)
|
2018-10-03 |
2020-04-09 |
Xencor, Inc. |
Il-12 heterodimeric fc-fusion proteins
|
WO2020072695A1
(en)
|
2018-10-03 |
2020-04-09 |
Genentech, Inc. |
8-aminoisoquinoline compounds and uses thereof
|
WO2020070333A1
(en)
|
2018-10-05 |
2020-04-09 |
Fondazione Telethon |
Ezrin inhibitors and uses thereof
|
CN113166695A
(zh)
|
2018-10-10 |
2021-07-23 |
勃林格殷格翰国际公司 |
用于高密度生物反应器培养中的膜气体转移的方法
|
MX2021003976A
(es)
|
2018-10-11 |
2021-05-27 |
Amgen Inc |
Procesamiento posterior de constructos de anticuerpos biespecificos.
|
US11427591B2
(en)
|
2018-10-17 |
2022-08-30 |
Insilico Medicine Ip Limited |
Kinase inhibitors
|
CA3116324A1
(en)
|
2018-10-18 |
2020-04-23 |
Genentech, Inc. |
Diagnostic and therapeutic methods for sarcomatoid kidney cancer
|
EP3867265A1
(en)
|
2018-10-19 |
2021-08-25 |
Ambrx, Inc. |
Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
|
SG11202104010PA
(en)
|
2018-10-23 |
2021-05-28 |
Scholar Rock Inc |
Rgmc-selective inhibitors and use thereof
|
JP7499760B2
(ja)
|
2018-11-02 |
2024-06-14 |
アネクソン,インコーポレーテッド |
脳損傷を治療するための組成物及び方法
|
CN113260383A
(zh)
|
2018-11-02 |
2021-08-13 |
西托姆克斯治疗公司 |
可活化的抗cd166抗体及其使用方法
|
SG11202104864QA
(en)
|
2018-11-13 |
2021-06-29 |
Compass Therapeutics Llc |
Multispecific binding constructs against checkpoint molecules and uses thereof
|
KR20210101235A
(ko)
|
2018-11-16 |
2021-08-18 |
메모리얼 슬로안 케터링 캔서 센터 |
뮤신-16에 대한 항체 및 이의 사용 방법
|
CU20210042A7
(es)
|
2018-11-22 |
2022-01-13 |
Qilu Regor Therapeutics Inc |
Compuestos agonistas de glp-1r y composiciones farmacéuticas que lo contienen
|
WO2020118109A2
(en)
|
2018-12-06 |
2020-06-11 |
Cytomx Therapeutics, Inc. |
Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof
|
KR20210148076A
(ko)
|
2018-12-11 |
2021-12-07 |
큐32 바이오 인크. |
보체 연관 질환을 위한 융합 단백질 작제물
|
EP3898614A1
(en)
|
2018-12-17 |
2021-10-27 |
Tolremo Therapeutics AG |
Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of cancer
|
JP2022514290A
(ja)
|
2018-12-20 |
2022-02-10 |
ジェネンテック, インコーポレイテッド |
改変抗体fcおよび使用方法
|
US20220042038A1
(en)
|
2018-12-20 |
2022-02-10 |
Poseida Therapeutics, Inc. |
Nanotransposon compositions and methods of use
|
US11352445B2
(en)
|
2018-12-31 |
2022-06-07 |
Jecho Laboratories Inc. |
Method for preparing recombinant protein from bacterium and composition containing the same
|
WO2020142612A1
(en)
|
2019-01-03 |
2020-07-09 |
Genentech, Inc. |
Pyrido-pyrimidinone and pteridinone compounds as inhibitors of endoribonuclease inositol requiring enzyme i (ire i alpha) for the treatment of cancer diseases.
|
MX2021008081A
(es)
|
2019-01-04 |
2021-08-05 |
Resolve Therapeutics Llc |
Tratamiento de la enfermedad de sjogren con proteinas de fusion de nucleasa.
|
AU2020206388B2
(en)
|
2019-01-07 |
2022-12-01 |
Vitalixir (Beijing) Co., Ltd |
Novel polypeptide and therapeutic uses thereof
|
CN111499747B
(zh)
|
2019-01-11 |
2022-03-18 |
康诺亚生物医药科技(成都)有限公司 |
一种抗cd73单克隆抗体及其应用
|
CN113302193A
(zh)
|
2019-01-11 |
2021-08-24 |
豪夫迈·罗氏有限公司 |
双环吡咯并三唑酮化合物及其使用方法
|
CA3126654A1
(en)
|
2019-01-15 |
2020-07-23 |
Janssen Biotech, Inc. |
Anti-tnf antibody compositions and methods for the treatment of juvenile idiopathic arthritis
|
US11680105B2
(en)
|
2019-01-17 |
2023-06-20 |
Regents Of The University Of Minnesota |
Antibody fragments for detecting cancer and methods of use
|
JP2022523051A
(ja)
|
2019-01-22 |
2022-04-21 |
マサチューセッツ インスティテュート オブ テクノロジー |
In Vitroのヒト血液脳関門
|
WO2020154032A1
(en)
|
2019-01-23 |
2020-07-30 |
Massachusetts Institute Of Technology |
Combination immunotherapy dosing regimen for immune checkpoint blockade
|
MX2021008871A
(es)
|
2019-01-23 |
2021-08-19 |
Janssen Biotech Inc |
Composiciones de anticuerpos anti-tnf para usarse en metodos para el tratamiento de la artritis psoriasica.
|
JP2020117502A
(ja)
|
2019-01-28 |
2020-08-06 |
ファイザー・インク |
変形性関節症の徴候および症状を処置する方法
|
US11236157B2
(en)
|
2019-01-28 |
2022-02-01 |
Galderma Holding SA |
Treatment of skin lesions and pruritus in prurigo nodularis patients
|
MX2021009175A
(es)
|
2019-01-30 |
2021-09-14 |
Scholar Rock Inc |
Inhibidores especificos del complejo de ltbp de tgf? y usos de los mismos.
|
GB201901305D0
(en)
|
2019-01-30 |
2019-03-20 |
Immunocore Ltd |
Specific binding molecules
|
CA3128081A1
(en)
|
2019-02-12 |
2020-08-20 |
Ambrx, Inc. |
Compositions containing, methods and uses of antibody-tlr agonist conjugates
|
TWI820301B
(zh)
|
2019-02-15 |
2023-11-01 |
美商輝瑞股份有限公司 |
結晶型嘧啶基-3,8-二氮雜雙環〔3.2.1〕辛烷基甲酮化合物及其用途
|
US20220135663A1
(en)
|
2019-02-18 |
2022-05-05 |
Pfizer Inc. |
Method of treatment of Chronic Low Back Pain
|
JP2022521724A
(ja)
|
2019-02-18 |
2022-04-12 |
ジェネンテック, インコーポレイテッド |
ピリド-ピリミジニル化合物及び使用の方法
|
CN113874394B
(zh)
|
2019-02-20 |
2024-01-19 |
和铂抗体有限公司 |
抗体
|
US11739078B2
(en)
|
2019-02-22 |
2023-08-29 |
Insilico Medicine Ip Limited |
Methods of inhibiting kinases
|
EP3930761A1
(en)
|
2019-02-26 |
2022-01-05 |
CytomX Therapeutics, Inc. |
Combined therapies of activatable immune checkpoint inhibitors and conjugated activatable antibodies
|
MX2021010390A
(es)
|
2019-03-01 |
2021-11-17 |
Xencor Inc |
Anticuerpos heterodimericos que se unen a enpp3 y cd3.
|
US11717548B2
(en)
|
2019-03-08 |
2023-08-08 |
Massachusetts Institute Of Technology |
Synthetic oncolytic LNP-replicon RNA and uses for cancer immunotherapy
|
EP3938391A1
(en)
|
2019-03-14 |
2022-01-19 |
Janssen Biotech, Inc. |
Methods for producing anti-tnf antibody compositions
|
JP2022525179A
(ja)
|
2019-03-14 |
2022-05-11 |
ヤンセン バイオテツク,インコーポレーテツド |
抗tnf抗体組成物を産生するための産生方法
|
US20220153829A1
(en)
|
2019-03-14 |
2022-05-19 |
Janssen Biotech, Inc. |
Methods for Producing Anti-TNF Antibody Compositions
|
EP3941511A2
(en)
|
2019-03-20 |
2022-01-26 |
Massachusetts Institute of Technology |
Uses of amphiphiles in immune cell therapy and compositions therefor
|
KR20220004979A
(ko)
|
2019-03-27 |
2022-01-12 |
유엠씨 우트레크트 홀딩 비.브이. |
조작된 iga 항체 및 사용 방법
|
TW202102540A
(zh)
|
2019-03-29 |
2021-01-16 |
日商中外製藥股份有限公司 |
包含抗il-6受體抗體之bbb功能低下之抑制劑
|
TW202102266A
(zh)
|
2019-04-01 |
2021-01-16 |
美商建南德克公司 |
用於穩定含有蛋白質之配方之組合物及方法
|
JP7284830B2
(ja)
|
2019-04-02 |
2023-05-31 |
アレイ バイオファーマ インコーポレイテッド |
タンパク質チロシンホスファターゼ阻害剤
|
KR20220019670A
(ko)
|
2019-04-17 |
2022-02-17 |
고쿠리츠다이가쿠호진 히로시마다이가쿠 |
Il-6 저해제 및 ccr2 저해제를 조합하여 투여하는 것을 특징으로 하는 비뇨기암의 치료제
|
JP7455457B2
(ja)
|
2019-05-10 |
2024-03-26 |
タレンゲン インターナショナル リミテッド |
筋萎縮性側索硬化症を治療するための方法と薬剤
|
EP4386081A2
(en)
|
2019-05-21 |
2024-06-19 |
President and Fellows of Harvard College |
Endocrine differentiation-inducing molecule
|
BR112021023295A2
(pt)
|
2019-05-23 |
2022-02-08 |
Janssen Biotech Inc |
Método de tratamento de doença inflamatória intestinal com uma terapia de combinação de anticorpos para il-23 e tnf-alfa
|
WO2020234445A1
(en)
|
2019-05-23 |
2020-11-26 |
F. Hoffmann-La Roche Ag |
Combination therapy with a bet inhibitor and a bcl-2 inhibitor
|
CN113924119A
(zh)
|
2019-05-31 |
2022-01-11 |
国立大学法人大阪大学 |
新型的消化器官癌治疗剂及其筛选方法
|
US11613564B2
(en)
|
2019-05-31 |
2023-03-28 |
ALX Oncology Inc. |
Methods of treating cancer
|
KR20220030952A
(ko)
|
2019-06-03 |
2022-03-11 |
얀센 바이오테크 인코포레이티드 |
활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
|
WO2020245676A1
(en)
|
2019-06-03 |
2020-12-10 |
Janssen Biotech, Inc. |
Anti-tnf antibody compositions, and methods for the treatment of psoriatic arthritis
|
WO2020252165A1
(en)
|
2019-06-11 |
2020-12-17 |
Genentech, Inc. |
Quinazolinyl compounds and methods of use
|
EP3983520A1
(en)
|
2019-06-13 |
2022-04-20 |
Amgen, Inc |
Automated biomass-based perfusion control in the manufacturing of biologics
|
WO2020257525A1
(en)
|
2019-06-20 |
2020-12-24 |
Cspc Dophen Corporation |
Modified il-2 proteins, peg conjugates, and uses thereof
|
US11642409B2
(en)
|
2019-06-26 |
2023-05-09 |
Massachusetts Insttute of Technology |
Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
|
US20220363673A1
(en)
|
2019-06-28 |
2022-11-17 |
Pfizer Inc. |
5-(Thiophen-2-YL)-1 H-Tetrazole Derivative as BCKDK Inhibitors Useful for Treating Various Diseases
|
MX2021015791A
(es)
|
2019-06-28 |
2022-04-01 |
Amgen Inc |
Proteínas de unión al antígeno biespecificas anti-receptor de cgrp/anti-receptor pac1.
|
TW202115086A
(zh)
|
2019-06-28 |
2021-04-16 |
美商輝瑞大藥廠 |
Bckdk抑制劑
|
CA3140208A1
(en)
|
2019-07-08 |
2021-01-14 |
Amgen Inc. |
Multispecific transthyretin immunoglobulin fusions
|
CN114423787A
(zh)
|
2019-07-19 |
2022-04-29 |
昂科里斯庞斯公司 |
免疫调节性抗体及其使用方法
|
US20220281966A1
(en)
|
2019-07-26 |
2022-09-08 |
Amgen Inc. |
Anti-il13 antigen binding proteins
|
CN112300279A
(zh)
|
2019-07-26 |
2021-02-02 |
上海复宏汉霖生物技术股份有限公司 |
针对抗cd73抗体和变体的方法和组合物
|
GB201910899D0
(en)
|
2019-07-31 |
2019-09-11 |
Scancell Ltd |
Binding members
|
GB201910900D0
(en)
|
2019-07-31 |
2019-09-11 |
Scancell Ltd |
Modified fc-regions to enhance functional affinity of antibodies and antigen binding fragments thereof
|
BR112022002406A2
(pt)
|
2019-08-12 |
2022-07-19 |
Purinomia Biotech Inc |
Métodos e composições para promover e potencializar respostas imunes mediadas por célula t através do alvejamento de adcc de células que expressam cd39
|
AU2020328038A1
(en)
|
2019-08-13 |
2022-03-31 |
Amgen Inc. |
Interleukin-2 muteins for the expansion of T-regulatory cells
|
WO2021028752A1
(en)
|
2019-08-15 |
2021-02-18 |
Janssen Biotech, Inc. |
Anti-tfn antibodies for treating type i diabetes
|
CN114980901A
(zh)
|
2019-08-30 |
2022-08-30 |
挪威西部创新股份有限公司 |
使用针对浆细胞的抑制剂或细胞毒性剂治疗慢性疲劳综合征的方法
|
GB201912657D0
(en)
|
2019-09-03 |
2019-10-16 |
Scancell Ltd |
Binding members
|
KR20220057596A
(ko)
|
2019-09-05 |
2022-05-09 |
포세이다 테라퓨틱스, 인크. |
동종이계 세포 조성물 및 사용 방법
|
GB201912882D0
(en)
|
2019-09-06 |
2019-10-23 |
Scancell Ltd |
Ssea-4 binding members
|
KR20220062500A
(ko)
|
2019-09-16 |
2022-05-17 |
서피스 온콜로지, 인크. |
항-cd39 항체 조성물 및 방법
|
TW202126699A
(zh)
|
2019-09-20 |
2021-07-16 |
美商建南德克公司 |
用於抗類胰蛋白酶抗體之投藥
|
EP4034171A1
(en)
|
2019-09-23 |
2022-08-03 |
Cytomx Therapeutics Inc. |
Anti-cd47 antibodies, activatable anti-cd47 antibodies, and methods of use thereof
|
KR20220066346A
(ko)
|
2019-09-25 |
2022-05-24 |
서피스 온콜로지, 인크. |
항-il-27 항체 및 이의 용도
|
WO2021062092A1
(en)
|
2019-09-26 |
2021-04-01 |
Massachusetts Institute Of Technology |
Trans-activated functional rna by strand displacement and uses thereof
|
WO2021062096A1
(en)
|
2019-09-26 |
2021-04-01 |
Massachusetts Institute Of Technology |
Microrna-based logic gates and uses thereof
|
WO2021064141A1
(en)
|
2019-10-02 |
2021-04-08 |
Tolremo Therapeutics Ag |
Inhibitors of dual specificity tyrosine phosphorylation regulated kinase 1b
|
US20230064948A1
(en)
|
2019-10-02 |
2023-03-02 |
Tolremo Therapeutics Ag |
Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer
|
TWI771766B
(zh)
|
2019-10-04 |
2022-07-21 |
美商輝瑞股份有限公司 |
二醯基甘油醯基轉移酶2 抑制劑
|
CA3153932A1
(en)
|
2019-10-07 |
2021-04-15 |
Jonathan Kipnis |
Modulating lymphatic vessels in neurological disease
|
CN114786731A
(zh)
|
2019-10-10 |
2022-07-22 |
科达制药股份有限公司 |
治疗眼部病症的方法
|
WO2021070885A1
(ja)
|
2019-10-11 |
2021-04-15 |
中外製薬株式会社 |
後天性血友病aの予防および/または治療に用いられる医薬組成物、および当該医薬組成物を含む製品
|
EP4041773A1
(en)
|
2019-10-11 |
2022-08-17 |
Beth Israel Deaconess Medical Center, Inc. |
Anti-tn antibodies and uses thereof
|
WO2021074414A1
(en)
|
2019-10-16 |
2021-04-22 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Oxazole and thioazole-type cullin ring ubiquitin ligase compounds and uses thereof
|
WO2021074418A1
(en)
|
2019-10-16 |
2021-04-22 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Carbazole-type cullin ring ubiquitin ligase compounds and uses thereof
|
AU2020372478A1
(en)
|
2019-10-23 |
2022-06-02 |
Checkmate Pharmaceuticals, Inc. |
Synthetic RIG-I-like receptor agonists
|
US11459389B2
(en)
|
2019-10-24 |
2022-10-04 |
Massachusetts Institute Of Technology |
Monoclonal antibodies that bind human CD161
|
CA3158893A1
(en)
|
2019-10-24 |
2021-04-29 |
Minotaur Therapeutics, Inc. |
Chimeric cytokine modified antibodies and methods of use thereof
|
EP4058485A1
(en)
|
2019-11-13 |
2022-09-21 |
Amgen Inc. |
Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
|
KR20220101138A
(ko)
|
2019-11-13 |
2022-07-19 |
제넨테크, 인크. |
치료적 화합물 및 사용 방법
|
CA3160364A1
(en)
|
2019-11-19 |
2021-05-27 |
Modag Gmbh |
Compounds, and their use for the diagnosis, treatment and prevention of diseases associated with the aggregation of alpha-synuclein
|
EP3831843A1
(en)
|
2019-12-08 |
2021-06-09 |
Royal College Of Surgeons In Ireland |
A hemostatic agent and uses thereof
|
EP4073028A1
(en)
|
2019-12-10 |
2022-10-19 |
Pfizer Inc. |
Solid forms of 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d] [1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d] imidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt
|
KR20220114595A
(ko)
|
2019-12-17 |
2022-08-17 |
암젠 인크 |
치료에서의 사용을 위한 이중 인터류킨-2/tnf 수용체 효현제
|
WO2021127505A1
(en)
|
2019-12-20 |
2021-06-24 |
Poseida Therapeutics, Inc. |
Anti-muc1 compositions and methods of use
|
EP3838912A1
(en)
|
2019-12-20 |
2021-06-23 |
Herantis Pharma Oyj |
Retro-inverso peptides
|
EP3838345A1
(en)
|
2019-12-20 |
2021-06-23 |
Herantis Pharma Oyj |
Macrocyclic peptides
|
WO2021142002A1
(en)
|
2020-01-06 |
2021-07-15 |
Vaccinex, Inc. |
Anti-ccr8 antibodies and uses thereof
|
AU2021205440A1
(en)
|
2020-01-11 |
2022-09-01 |
Scholar Rock,Inc. |
TGF-beta inhibitors and use thereof
|
MX2022008609A
(es)
|
2020-01-11 |
2022-11-10 |
Scholar Rock Inc |
Inhibidores de tgf¿ y uso de los mismos.
|
CN115427447A
(zh)
|
2020-01-17 |
2022-12-02 |
百进生物科技公司 |
抗tlr7药剂和组合物以及制备和使用其的方法
|
US20230066726A1
(en)
|
2020-01-17 |
2023-03-02 |
Talengen International Limited |
Method for treatment of nerve injury and related disease
|
EP4093426A1
(en)
|
2020-01-24 |
2022-11-30 |
University of Virginia Patent Foundation |
Modulating lymphatic vessels in neurological disease
|
CA3167202A1
(en)
|
2020-02-06 |
2021-08-12 |
Jinan Li |
Method and drug for preventing and treating multiple sclerosis
|
CA3167593A1
(en)
|
2020-02-11 |
2021-08-19 |
Jinan Li |
Method and drug for treating viral pneumonia
|
JP2022058085A
(ja)
|
2020-02-24 |
2022-04-11 |
ファイザー・インク |
ジアシルグリセロールアシルトランスフェラーゼ2阻害剤とアセチル-CoAカルボキシラーゼ阻害剤との組合せ
|
WO2021173889A1
(en)
|
2020-02-26 |
2021-09-02 |
Ambrx, Inc. |
Uses of anti-cd3 antibody folate bioconjugates
|
CN115551534A
(zh)
|
2020-02-26 |
2022-12-30 |
泰伦基国际有限公司 |
一种预防和治疗血压异常病症的方法和药物
|
KR20220149588A
(ko)
|
2020-03-04 |
2022-11-08 |
포세이다 테라퓨틱스, 인크. |
대사성 간 장애의 치료를 위한 조성물 및 방법
|
JP2023517044A
(ja)
|
2020-03-09 |
2023-04-21 |
ファイザー・インク |
融合タンパク質およびその使用
|
WO2021180821A2
(en)
|
2020-03-10 |
2021-09-16 |
Tiziana Life Sciences Plc |
Compositions of il-6/il-6r antibodies and methods of use thereof
|
EP4118107A1
(en)
|
2020-03-11 |
2023-01-18 |
Poseida Therapeutics, Inc. |
Chimeric stimulatory receptors and methods of use in t cell activation and differentiation
|
KR20220151202A
(ko)
|
2020-03-11 |
2022-11-14 |
암브룩스, 인코포레이티드 |
인터류킨-2 폴리펩타이드 접합체 및 그의 사용 방법
|
GB202003632D0
(en)
|
2020-03-12 |
2020-04-29 |
Harbour Antibodies Bv |
SARS-Cov-2 (SARS2, COVID-19) antibodies
|
CA3175275A1
(en)
|
2020-03-19 |
2021-09-23 |
Amgen Inc. |
Antibodies against mucin 17 and uses thereof
|
JP2023518812A
(ja)
|
2020-03-23 |
2023-05-08 |
ジェネンテック, インコーポレイテッド |
Covid19肺炎を治療するための、トシリズマブとレムデシビルとの組み合わせ
|
US20230125415A1
(en)
|
2020-03-23 |
2023-04-27 |
Genentech, Inc. |
Biomarkers for predicting response to il-6 antagonist in covid-19 pneumonia
|
JP2023518815A
(ja)
|
2020-03-23 |
2023-05-08 |
ジェネンテック, インコーポレイテッド |
Il6アンタゴニストによるcovid-19肺炎を含む肺炎の治療方法
|
KR20220156935A
(ko)
|
2020-03-24 |
2022-11-28 |
탈렌젠 인터내셔널 리미티드 |
헌팅톤병의 치료 방법 및 약물
|
WO2021190562A1
(zh)
|
2020-03-24 |
2021-09-30 |
泰伦基国际有限公司 |
一种促进错误折叠蛋白及其聚集物降解的方法和药物
|
JP2023518504A
(ja)
|
2020-03-24 |
2023-05-01 |
タレンゲン インターナショナル リミテッド |
アルツハイマー病を治療する方法及び薬剤
|
WO2021190561A1
(zh)
|
2020-03-24 |
2021-09-30 |
泰伦基国际有限公司 |
一种治疗帕金森病的方法和药物
|
CN115348863A
(zh)
|
2020-03-27 |
2022-11-15 |
辉瑞公司 |
以2-[(4-{6-[(4-氰基-2-氟苄基)氧基]吡啶-2-基}哌啶-1-基)甲基]-1-[(2s)-氧杂环丁烷-2-基甲基]-1h-苯并咪唑-6-甲酸或其药学上的盐治疗2型糖尿病或肥胖症或体重过重
|
AU2021248611A1
(en)
|
2020-03-30 |
2022-11-03 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Virucidal compositions and use thereof
|
CN115698717A
(zh)
|
2020-04-03 |
2023-02-03 |
基因泰克公司 |
癌症的治疗和诊断方法
|
AU2021252213A1
(en)
|
2020-04-08 |
2022-11-03 |
Pfizer Inc. |
Crystalline forms of 3-cyano-1-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo(1,5-a)pyrazin-4-yl)-1H-pyrazol-1-yl)cyclobutaneacetonitrile, and use thereof
|
WO2021207662A1
(en)
|
2020-04-10 |
2021-10-14 |
Genentech, Inc. |
Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
|
CA3174777A1
(en)
|
2020-04-14 |
2021-10-21 |
Eric M. Ostertag |
Compositions and methods for use in the treatment of cancer
|
JP2023106635A
(ja)
|
2020-04-17 |
2023-08-02 |
中外製薬株式会社 |
二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法
|
US20230149560A1
(en)
|
2020-04-20 |
2023-05-18 |
Massachusetts Institute Of Technology |
Lipid compositions for delivery of sting agonist compounds and uses thereof
|
WO2021216488A1
(en)
|
2020-04-21 |
2021-10-28 |
Regeneron Pharmaceuticals, Inc. |
Il-2 variants with reduced binding to il-2 receptor alpha and uses thereof
|
WO2021214588A1
(en)
|
2020-04-21 |
2021-10-28 |
Janssen Biotech, Inc. |
Anti-tnf alpha agent for treating coronavirus infections
|
WO2021214587A1
(en)
|
2020-04-21 |
2021-10-28 |
Janssen Biotech, Inc. |
Anti-tnf alpha agent for treating viral infections
|
CA3172880A1
(en)
|
2020-04-27 |
2021-11-04 |
Sotirios Tsimikas |
Isoform-independent antibodies to lipoprotein(a)
|
US20210340524A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
US20210338833A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Chimeric antigen receptor-targeting ligands and uses thereof
|
EP4146688A1
(en)
|
2020-05-06 |
2023-03-15 |
CRISPR Therapeutics AG |
Mask peptides and masked anti-ptk7 antibodies comprising such
|
EP4140498A4
(en)
|
2020-05-11 |
2023-11-01 |
Talengen International Limited |
METHOD AND MEDICINE FOR THE TREATMENT OF SPINAL AMYOTROPHY
|
US11919956B2
(en)
|
2020-05-14 |
2024-03-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
|
WO2021238886A1
(en)
|
2020-05-27 |
2021-12-02 |
Staidson (Beijing) Biopharmaceuticals Co., Ltd. |
Antibodies specifically recognizing nerve growth factor and uses thereof
|
EP4157832B1
(en)
|
2020-05-27 |
2024-06-19 |
Qilu Regor Therapeutics Inc. |
Salt and crystal forms of glp-1r agonists and uses thereof
|
WO2021248081A1
(en)
|
2020-06-05 |
2021-12-09 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Acvr1 (alk2) receptor inhibition to treat neurological diseases
|
GB202101299D0
(en)
|
2020-06-09 |
2021-03-17 |
Avacta Life Sciences Ltd |
Diagnostic polypetides and methods
|
CN116113635A
(zh)
|
2020-06-09 |
2023-05-12 |
辉瑞公司 |
作为黑皮质素4受体拮抗剂的螺环化合物及其用途
|
KR20230023727A
(ko)
|
2020-06-11 |
2023-02-17 |
제넨테크, 인크. |
나노지단백질-폴리펩티드 접합체 및 조성물, 시스템, 및 이의 사용 방법
|
JP2023529853A
(ja)
|
2020-06-17 |
2023-07-12 |
ティジアーナ ライフ サイエンシズ パブリック リミティド カンパニー |
キメラ抗原受容体(car)t細胞療法を増強するための組成物および方法
|
WO2021259227A1
(zh)
|
2020-06-23 |
2021-12-30 |
江苏康缘药业股份有限公司 |
抗cd38抗体及其用途
|
CA3184062A1
(en)
|
2020-06-25 |
2021-12-30 |
Stefanie Fluckiger-Mangual |
Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of fibrotic disease
|
WO2021260577A2
(en)
|
2020-06-26 |
2021-12-30 |
Pfizer Inc. |
Methods of treating inflammatory bowel disease with tl1a antibodies
|
CA3165342A1
(en)
|
2020-06-29 |
2022-01-06 |
James Arthur Posada |
Treatment of sjogren's syndrome with nuclease fusion proteins
|
WO2022006562A1
(en)
|
2020-07-03 |
2022-01-06 |
Dana-Farber Cancer Institute, Inc. |
Multispecific coronavirus antibodies
|
WO2022007805A1
(zh)
|
2020-07-06 |
2022-01-13 |
鸿绪生物医药科技(北京)有限公司 |
新型多肽及其治疗用途
|
EP3939578A1
(en)
|
2020-07-13 |
2022-01-19 |
Novaremed Ltd. |
Compounds for treatment or prevention of an infection resulting from a coronavirus and/or a coronavirus-induced disease
|
TW202216779A
(zh)
|
2020-07-17 |
2022-05-01 |
美商輝瑞股份有限公司 |
治療性抗體類和彼等之用途
|
US11787775B2
(en)
|
2020-07-24 |
2023-10-17 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
US20230295257A1
(en)
|
2020-07-24 |
2023-09-21 |
Strand Therapeutics Inc. |
Lipid nanoparticle comprising modified nucleotides
|
WO2022023335A1
(en)
|
2020-07-30 |
2022-02-03 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Virucidal compositions and use thereof
|
WO2022023292A2
(en)
|
2020-07-31 |
2022-02-03 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Corona virus spike protein-targeting antibodies and use thereof
|
TW202214622A
(zh)
|
2020-08-06 |
2022-04-16 |
大陸商上海齊魯銳格醫藥研發有限公司 |
Glp-1r促效劑及其用途
|
US20220064320A1
(en)
|
2020-08-14 |
2022-03-03 |
Hoffmann-La Roche Inc. |
Methods for treating multiple sclerosis with ocrelizumab
|
JP2023538145A
(ja)
|
2020-08-20 |
2023-09-06 |
泰▲倫▼基国▲際▼有限公司 |
腫瘍を治療する方法及び薬剤
|
US20230302150A1
(en)
|
2020-08-20 |
2023-09-28 |
Ambrx, Inc. |
Antibody-tlr agonist conjugates, methods and uses thereof
|
JP2023539642A
(ja)
|
2020-08-26 |
2023-09-15 |
スキャンセル リミテッド |
ヒトIgG1の改変FC領域 及び少なくとも1つの異種抗原を含むポリペプチドをコードする核酸
|
EP3964497A1
(en)
|
2020-09-04 |
2022-03-09 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Substituted vicinal diamine compounds and their use in the treatment, amelioration or prevention of pain
|
JP2023541921A
(ja)
|
2020-09-17 |
2023-10-04 |
ジェネンテック, インコーポレイテッド |
Covid-19肺炎を有する入院患者におけるトシリズマブの有効性及び安全性を評価するためのランダム化二重盲検プラセボ対照多施設試験(empacta)の結果
|
KR20230079123A
(ko)
|
2020-10-02 |
2023-06-05 |
제넨테크, 인크. |
비헤테로아릴 화합물 및 이의 결정 형태의 제조 공정
|
KR20230104152A
(ko)
|
2020-10-06 |
2023-07-07 |
젠코어 인코포레이티드 |
전신 홍반성 루푸스(sle)를 포함하는 자가면역 질환을 치료하기 위한 바이오마커, 방법 및 조성물
|
CN116710446A
(zh)
|
2020-10-14 |
2023-09-05 |
上海齐鲁锐格医药研发有限公司 |
Glp-1r激动剂的晶型及其用途
|
US20230382978A1
(en)
|
2020-10-15 |
2023-11-30 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
|
WO2022079290A2
(en)
|
2020-10-16 |
2022-04-21 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Cullin ring ubiquitin ligase compounds and uses thereof
|
WO2022087274A1
(en)
|
2020-10-21 |
2022-04-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies that neutralize type-i interferon (ifn) activity
|
WO2022093641A1
(en)
|
2020-10-30 |
2022-05-05 |
BioLegend, Inc. |
Anti-nkg2a agents and compositions and methods for making and using the same
|
WO2022093640A1
(en)
|
2020-10-30 |
2022-05-05 |
BioLegend, Inc. |
Anti-nkg2c agents and compositions and methods for making and using the same
|
AU2021374839A1
(en)
|
2020-11-06 |
2023-06-08 |
Amgen Inc. |
Multitargeting bispecific antigen-binding molecules of increased selectivity
|
JP2023549120A
(ja)
|
2020-11-17 |
2023-11-22 |
泰▲倫▼基国▲際▼有限公司 |
Bdnfレベルを増加させる方法及び薬剤
|
TWI830088B
(zh)
|
2020-11-17 |
2024-01-21 |
大陸商深圳瑞健生命科學研究院有限公司 |
一種提高ngf水平的方法和藥物
|
WO2022140797A1
(en)
|
2020-12-23 |
2022-06-30 |
Immunowake Inc. |
Immunocytokines and uses thereof
|
US20240166707A1
(en)
|
2021-01-08 |
2024-05-23 |
Strand Therapeutics Inc. |
Expression constructs and uses thereof
|
MX2023008485A
(es)
|
2021-01-20 |
2023-07-28 |
Oncoresponse Inc |
Anticuerpos inmunomoduladores y usos de estos.
|
JP2024506844A
(ja)
|
2021-02-03 |
2024-02-15 |
ジェネンテック, インコーポレイテッド |
Cbl-b阻害剤としてのアミド
|
CN116867792A
(zh)
|
2021-02-09 |
2023-10-10 |
基因泰克公司 |
四环氧氮杂䓬化合物及其用途
|
WO2022178255A2
(en)
|
2021-02-19 |
2022-08-25 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies that neutralize sars-cov-2
|
WO2022182797A1
(en)
|
2021-02-23 |
2022-09-01 |
Poseida Therapeutics, Inc. |
Genetically modified induced pluripotent stem cells and methods of use thereof
|
WO2022179528A1
(en)
|
2021-02-24 |
2022-09-01 |
Insilico Medicine Ip Limited |
Analogs for the treatment of disease
|
WO2022187671A1
(en)
|
2021-03-04 |
2022-09-09 |
Poseida Therapeutics, Inc. |
Compositions and methods for the treatment of hemophilia
|
AU2022232375A1
(en)
|
2021-03-09 |
2023-09-21 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cldn6
|
JP2024518013A
(ja)
|
2021-03-10 |
2024-04-24 |
イミュノウェイク インコーポレイテッド |
免疫調節分子及びその使用
|
US11859012B2
(en)
|
2021-03-10 |
2024-01-02 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and GPC3
|
AU2022232856A1
(en)
|
2021-03-12 |
2023-10-26 |
Chugai Seiyaku Kabushiki Kaisha |
Pharmaceutical composition for treatment or prevention of myasthenia gravis
|
WO2022195504A1
(en)
|
2021-03-19 |
2022-09-22 |
Pfizer Inc. |
Method of treating osteoarthritis pain with an anti ngf antibody
|
EP4313309A1
(en)
|
2021-03-22 |
2024-02-07 |
Novimmune S.A. |
Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof
|
US20220315655A1
(en)
|
2021-03-22 |
2022-10-06 |
Novimmune Sa |
Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof
|
WO2022204581A2
(en)
|
2021-03-26 |
2022-09-29 |
Scholar Rock, Inc. |
Tgf-beta inhibitors and use thereof
|
AU2022249223A1
(en)
|
2021-04-03 |
2023-10-12 |
Ambrx, Inc. |
Anti-her2 antibody-drug conjugates and uses thereof
|
KR20230167092A
(ko)
|
2021-04-07 |
2023-12-07 |
톨레모 테라퓨틱스 아게 |
헤테로사이클릭 유도체, 약학 조성물, 및 암의 치료 또는 개선에서의 그들의 용도
|
TW202304510A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商葛德瑪控股公司 |
結節性癢疹之治療
|
AR125304A1
(es)
|
2021-04-08 |
2023-07-05 |
Genentech Inc |
Compuestos de oxazepina acíclicos y usos de los mismos
|
JP2024513520A
(ja)
|
2021-04-11 |
2024-03-25 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
心筋細胞及び組成物ならびにそれらの生産方法
|
WO2022223544A1
(en)
|
2021-04-19 |
2022-10-27 |
Centre National De La Recherche Scientifique (Cnrs) |
COMBINATION THERAPY OF NUCANT AND mTOR INHIBITORS FOR TREATING CANCER
|
EP4329887A1
(en)
|
2021-04-28 |
2024-03-06 |
Minotaur Therapeutics, Inc. |
Humanized chimeric bovine antibodies and methods of use
|
EP4334354A1
(en)
|
2021-05-06 |
2024-03-13 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against alk and methods of use thereof
|
AU2022269312A1
(en)
|
2021-05-06 |
2023-10-19 |
Amgen Research (Munich) Gmbh |
Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
|
CA3215856A1
(en)
|
2021-05-07 |
2022-11-10 |
Alison O'neill |
Anti-il-27 antibodies and uses thereof
|
TW202310868A
(zh)
|
2021-05-14 |
2023-03-16 |
美商克拉里斯生物醫療股份有限公司 |
用於治療眼睛疾病的生長因子組合物
|
WO2022245859A1
(en)
|
2021-05-17 |
2022-11-24 |
Curia Ip Holdings, Llc |
Sars-cov-2 spike protein antibodies
|
WO2022245877A1
(en)
|
2021-05-17 |
2022-11-24 |
Curia Ip Holdings, Llc |
Sars-cov-2 spike protein antibodies
|
WO2022256723A2
(en)
|
2021-06-03 |
2022-12-08 |
Scholar Rock, Inc. |
Tgf-beta inhibitors and therapeutic use thereof
|
WO2022256688A1
(en)
|
2021-06-04 |
2022-12-08 |
Sonnet BioTherapeutics, Inc. |
Methods of treating age-related frailty with interleukin-6
|
IL308597A
(en)
|
2021-06-11 |
2024-01-01 |
Genentech Inc |
A method for treating chronic obstructive pulmonary disease with an ST2 antagonist
|
WO2022265984A1
(en)
|
2021-06-14 |
2022-12-22 |
Curtails Llc |
Use of nep inhibitors for the treatment of gastrointestinal sphincter disorders
|
AU2022299185A1
(en)
|
2021-06-23 |
2024-01-25 |
Scholar Rock, Inc. |
A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders
|
EP4367139A1
(en)
|
2021-07-08 |
2024-05-15 |
Staidson Biopharma Inc. |
Antibodies specifically recognizing tnfr2 and uses thereof
|
US20230040065A1
(en)
|
2021-07-09 |
2023-02-09 |
Janssen Biotech, Inc. |
Manufacturing Methods for Producing Anti-TNF Antibody Compositions
|
CN117957251A
(zh)
|
2021-07-09 |
2024-04-30 |
詹森生物科技公司 |
用于制备抗tnf抗体组合物的制造方法
|
WO2023288277A1
(en)
|
2021-07-14 |
2023-01-19 |
Scholar Rock, Inc. |
Ltbp complex-specific inhibitors of tgfb1 and uses thereof
|
KR20240058075A
(ko)
|
2021-07-14 |
2024-05-03 |
스테이드슨 (베이징) 바이오팔마슈티칼스 캄퍼니 리미티드 |
Cd40을 특이적으로 식별하는 항체 및 이의 응용
|
KR20240064627A
(ko)
|
2021-07-15 |
2024-05-13 |
알스핌 |
Il-23 발현과 관련된 질병을 예방 및/또는 치료하기 위한 조성물 및 방법
|
AU2022316209A1
(en)
|
2021-07-20 |
2024-02-22 |
Regeneron Pharmaceuticals, Inc. |
Butyrophilin-like 2 agents for treating inflammatory disorders
|
WO2023007374A1
(en)
|
2021-07-27 |
2023-02-02 |
Pfizer Inc. |
Method of treatment of cancer pain with tanezumab
|
WO2023018795A1
(en)
|
2021-08-11 |
2023-02-16 |
Curtails Llc |
Nep inhibitors for the treatment of laminitis
|
WO2023019239A1
(en)
|
2021-08-13 |
2023-02-16 |
Genentech, Inc. |
Dosing for anti-tryptase antibodies
|
WO2023028056A1
(en)
|
2021-08-24 |
2023-03-02 |
Genentech, Inc. |
3-amino piperidyl sodium channel inhibitors
|
WO2023028077A1
(en)
|
2021-08-24 |
2023-03-02 |
Genentech, Inc. |
Sodium channel inhibitors and methods of designing same
|
US20230242652A1
(en)
|
2021-08-30 |
2023-08-03 |
Galderma Holding S.A. |
Treatments for atopic dermatitis
|
CA3230347A1
(en)
|
2021-08-31 |
2023-03-09 |
Pfizer Inc. |
Solid forms of 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt
|
WO2023034901A1
(en)
|
2021-09-01 |
2023-03-09 |
The Broad Institute, Inc. |
Tumor avatar vaccine compositions and uses thereof
|
AR126971A1
(es)
|
2021-09-03 |
2023-12-06 |
Univ Of Bern |
Composiciones y métodos para tratar el síndrome de qt largo
|
WO2023036982A1
(en)
|
2021-09-10 |
2023-03-16 |
Harbour Antibodies Bv |
Anti-sars2-s antibodies
|
GB202112935D0
(en)
|
2021-09-10 |
2021-10-27 |
Harbour Antibodies Bv |
Sars-cov-2 (sars2, covid-19) heavy chain only antibodies
|
WO2023039276A1
(en)
|
2021-09-13 |
2023-03-16 |
Curtails Llc |
Use of ibat inhibitors and antimicrobials for the treatment of diseases
|
WO2023056368A1
(en)
|
2021-09-30 |
2023-04-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Cyclic peptides as non-hormonal male contraceptive agents and methods of use thereof
|
WO2023060089A2
(en)
|
2021-10-04 |
2023-04-13 |
Poseida Therapeutics, Inc. |
Transposases and uses thereof
|
AU2022360244A1
(en)
|
2021-10-04 |
2024-04-11 |
Poseida Therapeutics, Inc. |
Transposon compositions and methods of use thereof
|
WO2023064586A1
(en)
|
2021-10-15 |
2023-04-20 |
Tango Therapeutics, Inc. |
Novel modulators of ehmt1 and ehmt2 and therapeutic use thereof
|
CA3237018A1
(en)
|
2021-11-03 |
2023-05-11 |
Joachim Koch |
Bispecific cd16a binders
|
CA3233696A1
(en)
|
2021-11-03 |
2023-05-11 |
Joachim Koch |
Bispecific cd16a binders
|
TW202334122A
(zh)
|
2021-11-05 |
2023-09-01 |
美商建南德克公司 |
作為對c-cbl具選擇性之cbl-b抑制劑的內醯胺
|
AU2022383057A1
(en)
|
2021-11-05 |
2024-05-16 |
Abviro Llc |
Human broadly crossreactive influenza monoclonal antibodies and methods of use thereof
|
CA3236294A1
(en)
|
2021-11-19 |
2023-05-25 |
Mirobio Limited |
Engineered pd-1 antibodies and uses thereof
|
US20230203062A1
(en)
|
2021-11-24 |
2023-06-29 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
WO2023097024A1
(en)
|
2021-11-24 |
2023-06-01 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against ctla-4 and methods of use thereof
|
TW202332429A
(zh)
|
2021-11-24 |
2023-08-16 |
美商建南德克公司 |
治療性化合物及其使用方法
|
WO2023100061A1
(en)
|
2021-12-01 |
2023-06-08 |
Pfizer Inc. |
3-phenyl-1-benzothiophene-2-carboxylic acid derivatives as branched-chain alpha keto acid dehydrogenase kinase inhibitors for the treatment of diabetes, kidney diseases, nash and heart failure
|
AU2022402913A1
(en)
|
2021-12-03 |
2024-06-13 |
Tango Therapeutics, Inc. |
Novel hdac inhibitors and therapeutic use thereof
|
WO2023105387A1
(en)
|
2021-12-06 |
2023-06-15 |
Pfizer Inc. |
Melanocortin 4 receptor antagonists and uses thereof
|
AU2022403854A1
(en)
|
2021-12-08 |
2024-05-23 |
Array Biopharma Inc. |
Crystalline form of n-(2-chloro-3-((5-chloro-3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoroazetidine-1-sulfonamide
|
WO2023114544A1
(en)
|
2021-12-17 |
2023-06-22 |
Dana-Farber Cancer Institute, Inc. |
Antibodies and uses thereof
|
WO2023111817A1
(en)
|
2021-12-17 |
2023-06-22 |
Pfizer Inc. |
Crystalline forms of [(1r,5s,6r)-3-{2-[(2s)-2-methylazetidin-1-yl]-6-(trifluoromethyl) pyrimidin-4-yl}-3-azabicyclo[3.1.0]hex-6-yl]acetic acid
|
WO2023114543A2
(en)
|
2021-12-17 |
2023-06-22 |
Dana-Farber Cancer Institute, Inc. |
Platform for antibody discovery
|
WO2023118150A1
(en)
|
2021-12-22 |
2023-06-29 |
Royal College Of Surgeons In Ireland |
A conjugate for use in localising a molecule to the vascular endothelium.
|
WO2023150552A1
(en)
|
2022-02-04 |
2023-08-10 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treatment of neurological disorders
|
WO2023164573A1
(en)
|
2022-02-23 |
2023-08-31 |
Poseida Therapeutics, Inc. |
Genetically modified cells and methods of use thereof
|
WO2023178357A1
(en)
|
2022-03-18 |
2023-09-21 |
Evolveimmune Therapeutics, Inc. |
Bispecific antibody fusion molecules and methods of use thereof
|
WO2023196866A1
(en)
|
2022-04-06 |
2023-10-12 |
Mirobio Limited |
Engineered cd200r antibodies and uses thereof
|
US20230364031A1
(en)
|
2022-04-19 |
2023-11-16 |
Garth Cooper |
Treatment of brain copper disorders
|
WO2023203174A1
(en)
|
2022-04-20 |
2023-10-26 |
Proxygen Gmbh |
Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
|
WO2023212618A1
(en)
|
2022-04-26 |
2023-11-02 |
Strand Therapeutics Inc. |
Lipid nanoparticles comprising venezuelan equine encephalitis (vee) replicon and uses thereof
|
TW202346368A
(zh)
|
2022-05-12 |
2023-12-01 |
德商安美基研究(慕尼黑)公司 |
具有增加的選擇性的多鏈多靶向性雙特異性抗原結合分子
|
US20240025919A1
(en)
|
2022-05-19 |
2024-01-25 |
Genentech, Inc. |
Aza-tetracyclic oxazepine compounds and uses thereof
|
WO2023228023A1
(en)
|
2022-05-23 |
2023-11-30 |
Pfizer Inc. |
Treatment of type 2 diabetes or weight management control with 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d]imidazole-6-carboxylic acid or a pharmaceutically salt thereof
|
WO2023230128A1
(en)
|
2022-05-25 |
2023-11-30 |
Surface Oncology, Inc. |
Use of anti-il-27 antibodies
|
WO2023230116A1
(en)
|
2022-05-25 |
2023-11-30 |
Surface Oncology, Inc. |
Use of anti-il-27 antibodies
|
WO2023235852A1
(en)
|
2022-06-03 |
2023-12-07 |
Zenas Biopharma, Inc. |
Methods and compositions for treating igg4- related diseases
|
WO2024020407A1
(en)
|
2022-07-19 |
2024-01-25 |
Staidson Biopharma Inc. |
Antibodies specifically recognizing b- and t-lymphocyte attenuator (btla) and uses thereof
|
WO2024020051A1
(en)
|
2022-07-19 |
2024-01-25 |
BioLegend, Inc. |
Anti-cd157 antibodies, antigen-binding fragments thereof and compositions and methods for making and using the same
|
WO2024020564A1
(en)
|
2022-07-22 |
2024-01-25 |
Genentech, Inc. |
Anti-steap1 antigen-binding molecules and uses thereof
|
WO2024036273A1
(en)
|
2022-08-11 |
2024-02-15 |
Poseida Therapeutics, Inc. |
Chimeric cd8-alpha co-receptor compositions and methods of use
|
WO2024039672A2
(en)
|
2022-08-15 |
2024-02-22 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against msln and methods of use thereof
|
WO2024039670A1
(en)
|
2022-08-15 |
2024-02-22 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against cldn4 and methods of use thereof
|
WO2024040114A2
(en)
|
2022-08-18 |
2024-02-22 |
BioLegend, Inc. |
Anti-axl antibodies, antigen-binding fragments thereof and methods for making and using the same
|
WO2024050526A1
(en)
|
2022-09-02 |
2024-03-07 |
Biomarin Pharmaceutical Inc. |
Compositions and methods for treating long qt syndrome
|
WO2024047497A1
(en)
|
2022-09-02 |
2024-03-07 |
Galderma Holding SA |
Treatments for prurigo nodularis
|
WO2024059675A2
(en)
|
2022-09-14 |
2024-03-21 |
Amgen Inc. |
Bispecific molecule stabilizing composition
|
WO2024076995A1
(en)
|
2022-10-03 |
2024-04-11 |
Insigna Inc. |
Compositions for non-surgical prevention of boar taint and aggressive behavior
|
WO2024075051A1
(en)
|
2022-10-07 |
2024-04-11 |
Pfizer Inc. |
Hsd17b13 inhibitors and/or degraders
|
US20240182468A1
(en)
|
2022-10-18 |
2024-06-06 |
Pfizer Inc. |
Compounds for the activation of ampk
|
WO2024084360A1
(en)
|
2022-10-18 |
2024-04-25 |
Pfizer Inc. |
Patatin-like phospholipase domain-containing protein 3 (pnpla3) modifiers
|
WO2024084363A1
(en)
|
2022-10-18 |
2024-04-25 |
Pfizer Inc. |
Use of patatin-like phospholipase domain-containing protein 3 compounds
|
WO2024083168A1
(en)
|
2022-10-19 |
2024-04-25 |
Genentech, Inc. |
Oxazepine compounds comprising a 6-aza moiety and uses thereof
|
WO2024084052A1
(en)
|
2022-10-21 |
2024-04-25 |
Novimmune Sa |
Pd-l1xcd28 bispecific antibodies for immune checkpoint-dependent t cell activation
|
WO2024097767A1
(en)
|
2022-11-02 |
2024-05-10 |
Sonnet BioTherapeutics, Inc. |
Recombinant il-12 albumin binding domain fusion proteins for use in methods for the treatment of cancer
|
WO2024121796A1
(en)
|
2022-12-07 |
2024-06-13 |
Fondazione Matilde Tettamanti E Menotti De Marchi Onlus |
Methods for generating genetically modified cytokine induced killer (cik) cells
|